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ABSTRACT 
Bone remodelling is a dynamic process influenced by factors which effect bone cell 
activity and survival. This thesis details experiments that investigate some of the cellular 
mechanisms influencing the formation and activity of osteoclasts and also osteoblast 
survival and activity. 
The role of growth factors, cytokines and osteotropic hormones on osteoblast 
survival were investigated in vitro. Osteoblast survival was promoted by insulin-like 
growth factor I (IGF-I), IGF-II, insulin and basic fibroblast growth factor (bFGF). Platelet- 
derived growth factor (PDGF) had no effect on osteoblast survival on its own but 
potentiated the survival-promoting effects of insulin and IGFs -I and -II. A similar effect 
occurred when bFGF was added in combination with either IGFs or insulin. The effects of 
the IGF-I and -II were blocked by an antibody to the type I IGF receptor which also 
blocked the potentiating effects of PDGF on IGF-I mediated osteoblast survival. Tumour 
necrosis factor-a (TNF-a) was the only endogenous agent that enhanced programmed cell 
death (PCD) in this study. 
The capability of osteoblasts to support one another's survival in an autocrine 
fashion was investigated in vitro. Osteoblasts survived for 6 days in culture at high cell 
density in the absence of other cell types, serum or exogenous proteins, but died with the 
morphological features of apoptosis in these conditions at low cell density. Addition of 
cysteine to low density cultures enhanced survival during the first 2 days of culture. 
Catalase also protected osteoblasts in low density cultures whereas superoxide dismutase 
had no effect. Conditioned medium from high density osteoblast cultures prevented 
osteoblast apoptosis in low density cultures, as long as antioxidants were present. These 
results indicate that antioxidants are required for osteoblast survival and that they enhance 
growth factor mediated survival. 
The cellular actions of Interleukin (IL)-11 on bone resorption were investigated 
using in vitro bioassays. IL-11 dose-dependently stimulated release of 45Ca from calvarial 
explants and increased osteoblast-mediated type I collagen degradation which was 
prevented by the matrix metalloproteinase (MMP) inhibitor, CT 1166. IL-11 had no effect 
on isolated osteoclast activity even in coculture with primary osteoblasts. In bone marrow 
cultures, IL-11 dose-dependently increased the number of tatrate-resistant acid 
phosphatase-positive osteoclast-like multinucleate cells and the surface area of osteoclast 
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lacunar resorption. The effect of IL-11 on lacunar resorption was prevented by a 
combination of inhibitors of 5-lipoxygenase and cyclooxygenase. In 17-day-old metatarsal 
bones, IL-11 prevented the migration of preosteoclasts to future resorption sites, whereas 
their fusion was unaffected. These results provide evidence that IL-11 stimulates bone 
resorption by enhancing osteoclast formation and osteoblast-mediated osteoid degradation. 
The expression and functional analysis of members of the ADAM (A disintegrin 
and metalloproteinase) family in bone cells were studied by reverse transcriptase- 
polymerase chain reaction (RT-PCR), in situ hybridization and by antisense technology 
using bioassays for osteoclast formation and osteoblast differentiation. RT-PCR analysis 
demonstrated expression of ADAMs -9, -12 and -19 in osteoblasts. In situ hybridization 
studies using DIG-labelled riboprobes revealed expression only of ADAM-12 in isolated 
osteoclasts and in osteoclasts present in 17-day-old fetal mouse metatarsals. Disruption of 
ADAM-12 expression in osteoblasts, using antisense constructs had no effect on osteoblast 
differentiation, assessed by bone nodule formation in vitro. In isolated osteoclast cultures, 
on ivory slices, disruption of ADAM-12 by addition of oligodeoxynucleotides had only 
minor effects on pit formation whereas in bone marrow cultures osteoclast formation was 
inhibited. Addition of a recombinant ADAM-12 cysteine rich domain to M-CSF selected 
bone marrow cells cultured in the presence of M-CSF and RANKL also inhibited 
osteoclast formation. These results provide strong evidence that ADAM-12 may play a key 
role in osteoclastogenesis possibly by mediating fusion of osteoclast precursors. 
The role and sites of action of serine proteinases (SPs) in bone resorption were 
investigated in bioassays for osteoclast formation, activity and migration. The SP 
inhibitors, aprotinin and a2-antiplasmin dose-dependently inhibited 45Ca release from 
neonatal calvarial explants. Neither inhibitor influenced either osteoclast formation or 
resorptive activity. Both inhibitors dose-dependently inhibited the degradation of both type 
I collagen fibres and non-mineralized bone matrix by murine osteoblasts. In 17-day-old 
fetal mouse metatarsal explants aprotinin produced a 55% reduction in the migration of 
osteoclasts from the periosteum to the mineralized matrix after 3 days in culture, however 
after 6 days in culture the inhibitors were without effect on osteoclast migration. In situ 
hybridization studies demonstrated that tPA and uPA are expressed in mature osteoclasts 
disaggregated from 6-day-old murine long bones and uPA is expressed in osteoclasts 
present in 17-day-old fetal metatarsal explants. 
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1. GENERAL INTRODUCTION 
Bone is a highly specialized tissue resulting mainly from the activities of osteoblasts 
and osteoclasts. The functions of bone are (i) mechanical support of soft tissues, (ii) release 
of calcium for the maintenance of a constant ionic environment in the extracellular fluid, and 
(iii) housing and support of haemopoiesis. 
Morphologically two types of bone can be recognized at the macroscopic level: (1) 
trabecular or cancellous bone, also called spongy bone, comprising 20% of the adult 
skeleton and (2) compact or cortical bone comprising 80%. Trabecular bone consists of a 
network of interconnecting bone spicules, the spaces between the network being filled with 
marrow. Trabecular bone is present predominantly in the metaphysis of long bones. In this 
way rigidity of structure is attained with minimum weight. Compact bone consists of a 
dense mass to ensure maximal ability to withstand compression and is found, for example, 
in the diaphysis of long bones. 
Microscopically two types of bone can be recognized: woven bone and lamellar or 
fine bone. Woven bone is laid down initially during intramembraneous ossification and 
during fracture repair and is subsequently replaced by lamellar bone during bone 
remodelling. Compact bone consists of circumferential layers of lamellar bone. The outer 
circumferential lamellae are covered by a layer of dense connective tissue called the 
periosteum while the endosteum covers the inner aspect of bone in juxtaposition to the 
bone marrow cavity. Between the inner and outer lamellar bone are haversian systems each 
comprising of a central canal containing blood vessels. The cellular component of bone 
comprises osteoblasts (bone forming cells), osteocytes, bone lining cells and osteoclasts 
(bone resorbing cells). 
1.1 BONE CELLS 
Skeletal development and subsequent turnover of bone (remodelling) throughout 




Osteoblasts are derived from commited cells of the mesenchymal lineage called 
osteoprogenitor cells (figure 1-1). Friedenstein (1987) demonstrated that the colony- 
forming unit-fibroblast (CFU-F), arising from cultures of bone marrow, when implanted into 
rats in diffusion chambers gave rise to multiple differentiated lineages including osteoblasts 
as well as chondrocytes, adipocytes and fibroblasts. Thus the CFU-F contains populations 
of cells that are restricted to differentiation down specific pathways including the osteogenic 
pathway. Beresford et al. (1994) showed the formation of differentiated lineages in vitro 
from bone marrow stromal cultures. The existence of osteoprogenitors in bone marrow 
stromal cell and calvarial cell cultures that are capable of differentiating into mature 
osteoblasts has been demonstrated by the formation of bone nodules in these cultures. Using 
nodule formation as a bioassay it has been estimated that osteoprogenitors are present at a 
frequency of less than 1% in rat calvarial populations (Bellows and Aubin, 1989). 
Four distinct stages in osteoblast differentiation have been identified based on 
morphological and histochemical criteria: preosteoblasts, mature osteoblasts, osteocytes 
and bone lining cells (Aubin, 1998). Preosteoblasts are present in the adjacent layer of cells 
from the osteoblasts present at the bone forming surface and are considered as the 
precursor of the mature osteoblast. Morphologically active mature osteoblasts are cuboidal 
cells found in contact with the osteoid (Holtrop, 1977). Intracellularly, osteoblasts have a 
well developed, extensive rough endoplasmic reticulum and mitochondria indicative of the 
high metabolic activity of the cell. Mature osteoblasts are characterized by their synthesis 
and secretion of membrane-bound alkaline phosphatase, type I collagen and other organic 
components of the bone matrix such as osteocalcin, osteonectin, osteopontin and bone 
sialoprotein (BSP). In addition osteoblasts express growth factors such as Transforming 
growth factor-ß (TGF-ß), Insulin-like growth factors (IGFs) and possess receptors for 
parathyroid hormone/parathyroid hormone-related peptide (PTH/PTHrP) and 1,25- 
dihydroxyvitamin D3 (1,25-(OH)2D3). 
Current research has focussed on transcriptional control of osteoblast differentiation. 
Core binding factor 1 (Cbfal) has been identified as an osteoblast specific transcription 
factor that acts as a "master" switch for osteoblast differentiation (Ducy et al., 1997). The 
importance of Cbfal in osteogenesis was shown in Cbfal-deficient mice in which osteoblast 
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differentiation never occurs (Komori et al., 1997). These Cbfal-deficient mice have a 
normally patterned skeleton with an absence of ossification. 







Type I collagen 
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Myoblast Osteocyte bone sialoprotein 
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Fig. 1-1 Scheme of osteoblast differentiation. 
In this pathway osteoblasts are derived from pluripotent mesenchymal stem cells under the control 
of the differentiation factor Cbfal. Mesenchymal stem cells are capable of differentiation into the 
lineages shown. Peroxisome proliferator-activated receptor y (PPAR-y) and Myo-U are 
transcription factors that control commitment to adipocytes and myoblasts respectively. 
Commitment to the chondroblast lineage is controlled by bone morphogenetic proteins (IMPs) 
and the transcription factor Sox-9. 
1.1.2 Osteocytes 
Osteocytes represent the terminal and most mature differentiation stage in the 
osteoblastic lineage and arise when osteoblasts incorporate themselves into the newly 
formed bone matrix. Osteocytes are found embedded in small osteocytic lacunae and 
possess many cellular processes forming a network of small canaliculi. This extensive 
network extends throughout the bone matrix forming a communication network between 
osteocytes and osteoblasts. Osteocytes have reduced levels of alkaline phosphatase and 
reduced synthesis of macromolecules compared with osteoblasts. Functionally, it is 
thought that osteocytes may act as sensors of mechanical stress in bone (Kawata and 
Mikuni-Takagaki, 1998) although the precise role for osteocytes has yet to be elucidated. 
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1.1.3 Bone lining cells 
Bone lining cells are flat elongated cells found lining bone surfaces during phases of 
quiescent bone remodelling and are considered to be inactive osteoblasts. Dobnig and 
Turner (1995) proposed that these lining cells can be reactivated by appropriated stimuli 
such as PTH. 
1.1.4 Osteoclasts and bone resorption 
Osteoclasts are the principle cells responsible for bone resorption and have several 
unique ultrastructural characteristics (Holtrop and King, 1977). Osteoclasts are large 
multinucleated giant cells that contain between 2 and 100 nuclei per cell; they have 
abundant mitochondria, a large number of vacuoles and lysosomes and an extensive Golgi 
apparatus. They are rare cells and are found attached to endosteal and periosteal surfaces. 
The most characteristic feature of osteoclasts is the presence of a deeply infolded finger- 
like plasma membrane adjacent to the bone surface known as the ruffled border. In actively 
resorbing osteoclasts the area underneath the ruffled border is known as the sub- 
osteoclastic resorption zone (SORZ), that becomes acidified by transport of protons across 
the ruffled border which is mediated by a vacuolar type proton ATPase pump (Väänänen et 
al., 1990). The ruffled border is surrounded by a clear zone that is organelle-free, 
consisting of numerous cytoplasmic actin filaments, known as the actin ring, that has been 
observed in actively resorbing osteoclasts (Väänänen and Horton, 1995) and mediates 
attachment of the osteoclast to the bone surface. Osteoclasts express abundant aß3 
vitronectin receptors (Nesbitt et al., 1993) present in the clear zone that recognize proteins 
containing the RGD peptide sequence and are essential for inducing osteoclast polarization. 
Biochemical analysis has shown that osteoclasts also express the a2131, collagen integrin 
receptor, and aß1 which is another vitronectin receptor (Nesbitt et al., 1993). 
Osteoclasts express a number of cell surface antigens in common with cells of the 
macrophage/monocyte lineage. Osteoclasts strongly express CD45 (also known as the 
common leukocyte antigen, Athanasou et al., 1987) and a number of other antigens 
including CD 13, CD 15, CD68 and CD54. Osteoclasts do not express CD 11 a, CD 11 b, 
CD 14 or CD 18 (Athanasou and Quinn, 1990). 
Osteoclasts are rich in certain enzymes and enzyme histochemistry is commonly 
used to identify osteoclasts. Osteoclasts are rich in the acid phosphatase isoenzyme, tartrate 
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resistant acid phosphatase (TRAP; Minkin, 1982) which is a convenient cytochemical 
marker for osteoclasts although it is not osteoclast specific. Carbonic anhydrase II is 
expressed at high levels in resorbing osteoclasts and provides the source of hydrogen ions 
for acidification of the SORZ (Väänänen, 1984). Proteolytic enzymes expressed by 
osteoclasts that are more specific markers include cathepsin K (Drake et al., 1996) and 
MMP-9 (Tezuka et al., 1994b). 
Osteoclasts have been shown to express high levels of the tyrosine kinase proto- 
oncogene pp60c-src (Horne et al., 1992) which is expressed only at very low levels in other 
bone cells. Preferential expression of pp60c-src has been demonstrated on the ruffled 
border (Tanaka et al., 1992) and transgenic mice lacking the pp60c-src gene developed 
severe osteopetrosis (Soriano et al., 1991) due to impaired formation of a ruffled border. 
Osteoclasts are derived from cells of the monocyte-macrophage lineage (figure 1-2) 
and investigations have shown that transcription factors play a critical role in osteoclast 
differentiation. The proto-oncogene c-fos is a member of the activator protein-1 (AP-1) 
transcription factor complex (Angel and Karin, 1991) which includes the Fos-related 
proteins (Fra-1, Fra-2 and FosB) and Jun-related proteins (c-Jun, JunB and JunD). Wang et 
al. (1992) demonstrated that c-fos-deficient mice developed severe osteopetrosis caused by 
a defect in osteoclast progenitors. Macrophage differentiation was normal and 
transplantation of normal bone marrow cells into c-fos-defective mice rescued the 
osteopetrosis (Grigoriadis et al., 1994). Osteoclast differentiation was blocked at the point 
between monocyte-macrophages and osteoclasts. Fleischmann et al. (2000) have shown 
that Fra-1 can rescue this block. Recently it has been shown that the myeloid and B-cell 
specific transcription factor PU. 1 is critical for osteoclast differentiation (Tondravi et al., 
1997). PU. 1 deficient mice were osteopetrotic with an absence of both osteoclasts and 
macrophages. These results suggested that PU. 1 regulates the initial stages of macrophage 
differentiation. 
The two most widely accepted means of specifically identifying osteoclasts are the 
demonstration of calcitonin receptors and the ability to form resorption pits or Howship's 
lacunae on a mineralized substrate such as bone or dentin (Chambers et al., 1984). The 
demonstration of receptors that bind calcitonin is considered to be a reliable and highly 
specific marker of mammalian osteoclasts (Hattersley and Chambers, 1989a). 
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Fig. 1-2 Model of osteoclast differentiation. 
The hemopoietic stem cell can give rise to M-CFU and GM-CFU both of which have been 
shown to give rise to osteoclasts in vitro under appropriate conditions. In an alternative 
pathway GM-CFU/M-CFU can give rise to monocytes and macrophage precursors that can 




1.2 ULTRASTRUCTURE OF BONE 
Bone matrix consists of both organic and inorganic components. Type I collagen is 
the most abundant component of the organic phase constituting approximately 90% of the 
total bone protein (Marks and Popoff, 1988). The remaining 10% of the organic matrix 
comprises proteoglycans, adhesive glycoproteins and non-collagenous glycoproteins 
including sialoproteins, osteocalcin and osteonectin. The inorganic component of bone 
consists of crystalline salts of calcium and phosphate in the form of hydroxyapatite. 
1.2.1 Collagens 
Type I collagen provides a framework that binds other bone matrix proteins and 
provides a high degree of tensile strength. Other collagens that are present in trace amounts 
in bone include types III and V, which together with type I collagen are members of the 
group of fibrillar collagens consisting of a continuous triple helix assembled into collagen 
fibrils (Van der Rest and Garrone, 1991). At the molecular level type I collagen has been 
shown to consist of two al chains and one a2 chain each with an N-terminal telopeptide, a 
long helical domain and a C-terminal telopeptide. The amino acid sequence of the helical 
domain of fibrillar collagens has been shown to consist of Gly-X-Y repeats, where X is a 
proline and Y is a hydroxyproline which stabilizes the triple helix (Van der Rest and 
Garrone, 1991). 
1.2.2 Non-collagenous proteins 
Adhesive glycoproteins present within bone matrix are characterized by the presence 
of the amino acid sequence Arg-Gly-Asp (RGD). This confers upon the proteins an ability 
to bind to the integrin class of cell adhesion molecules (Hynes, 1992). Fibronectin is a 400 
kDa adhesive glycoprotein that promotes cell-matrix interactions via the a401 integrin in an 
RGD-independent fashion (Grzesik and Robey, 1994) and has been shown to be 
upregulated in osteoblasts during bone formation. Vitronectin is a 70 kDa cell attachment 
protein that is present in bone matrix at low levels where it interacts with the (43 integrin 
(Grzesik and Robey, 1994). Thrombospondin has been shown to mediate adhesion of bone 
cells and binds to a variety of other matrix proteins such as proteoglycans and fibronectin 
(Robey et al., 1989). 
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The sialoproteins are characterized by the presence of sialic acid. Osteopontin is a 
32 kDa phosphorylated calcium binding protein present in bone matrix. Expression of 
osteopontin by osteoblasts is stimulated by 1,25-(OH)2D3 (Oldberg, 1989) and it is thought 
that osteopontin may have a role in the binding of osteoclasts to the mineralized matrix of 
bone via the aß3 integrin (Miyauchi et al., 1991). Bone sialoprotein-II (BSP-II) is capable 
of promoting cell attachment via the avß3 integrin and has a very high affinity for calcium 
binding; it may play a role in matrix mineralization. 
Osteocalcin (bone gla protein, BGP) is a 5.8 kDa protein which accounts for nearly 
10% of the non-collagenous proteins of bone extracellular matrix and is expressed by 
osteoblasts (Owen et al., 1990). The protein belongs to the family of skeletal gla proteins 
characterized by the presence of three y-carboxy-glutamic acid (gla) residues formed in a 
vitamin K dependent posttranslational modification process that enable gla proteins to bind 
calcium and hydroxyapatite with high affinity. It is thought that the protein functions in the 
assembly of mineralized bone by regulating hydroxyapatite crystal growth. Further insights 
into the function of osteocalcin have come from loss of function studies in transgenic mice 
in which the osteocalcin gene has been deleted (Ducy et al., 1996). These mice show an 
increase in bone mass as a result of increases in cortical and cancellous bone formation. 
Osteocalcin may therefore act as an inhibitor of bone formation in vivo. 
Proteoglycans form part of the remaining 10% of non-collagenous proteins and 
consist of a core protein to which are covalently attached sulfated glycosaminoglycan 
(GAG) side chains (Robey, 1996). The proteoglycans decorin (PG-II) and biglycan (PG-I) 
contain chondroitin sulfate GAGs and have been shown to bind type I collagen and also 
TGF-ß (Takeuchi et al., 1994). 
Osteonectin is a 33 kDa protein that is the most abundant glycoprotein present in 
bone matrix (Tracy et al., 1988). Osteonectin has a high affinity for collagen, calcium and 
hydroxyapatite and may play a role in mineralization (Bolander et al., 1988). 
1.3 BONE REMODELLING 
To accomplish its functions, bone undergoes phases of bone resorption followed by 
bone formation, these two processes constituting bone remodelling (figure 1-3). Bone 
remodelling is modulated by both systemic and locally produced growth factors (Table 1-1) 
that effect osteoclast and osteoblast differentiation, activity and programmed cell death. 
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TABLE 1-1 Hormones, Cytokines and Growth Factors involved in bone remodelling 
Factor Mr (kDa) Effect in vitro 
1,25-(0H)2D3 Stimulates bone resorption 
PTH' 8.5 Stimulates bone resorption 
Calcitonin 3.5 Inhibits bone resorption 
Estrogen Inhibits bone resorption 
IL-la' 7.5 Stimulates bone resorption 
IL-101 17.3 Stimulates bone resorption 
IL-3 14-30 Stimulates osteoclast recruitment 
IL-4 15-20 Inhibits osteoclast formation 
IL-6 23-38 Induces osteoclast formation 
IL-8 6-8 Stimulates osteoclast motilityb 
IL-10 19 Inhibits osteoclast formation` 
IL-11' 11 Induces osteoclast formation 
IL-12 70-75 Inhibits osteoclast formation d 
IL-171 17 Induces osteoclast formations 
IL-18 18 Inhibits osteoclast formation 
IFN-y 20-25 Inhibits osteoclast formation 
TNF-a' 17 Induces osteoclast formation 
LIF 58 Induces osteoclast formation 
OPG 40 Inhibits osteoclast formation 
OPGL2 40-45 Induces osteoclast formation 
TGF-ct 5-7 Stimulates bone resorption 
TGF-ß3 25 Stimulates bone formation and inhibits 
bone resorption 
acidic/basic FGF 16/17 Enhances osteoblast proliferation 
IGF-I 7.5 Enhances osteoblast proliferation and 
IGF-II 7.5 stimulates bone resorption 
PDGF 30 Enhances osteoblast proliferation 
M-CSF (CSF-1) 40-90 Enhances osteoclast survival 
G-CSF 18-22 No effect in bone marrow cultures 
GM-CSF 14-35 Inhibits osteoclast formation 
'Acts via osteoblasts by inducing expression of OPGL 
2Also known as T-cell receptor activator induced cytokine (TRANCE), receptor activator 
of NF-kappaB ligand (RANKL), osteoclast differentiation factor (ODF) 
3 Inhibits osteoclastogenesis by inducing OPG expression and inhibiting OPGL in 
osteoblasts. 
'Riancho et al. (1993); bFuller et al. (1995a); `Owens et al. (1996); dHorwood et al. (2001); 
°Kotake et al. (1999); (Takahashi et al. (1986). 
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Fig. 1-3. Cellular components of bone. 
Interactions between osteoblasts and ostcoclasts are tightly regulated by osteotropic hormones such 
as Pill and 1,25-(OH)2D3 that stimulate expression receptor activator of nuclear factor (NI`)-KB 
ligand (RANKL) by osteoblasts as well as matrix metalloproteinases (MMPs) that degrade 
unmineralized osteoid. 
The resorptive phase involves a complex cascade whereby osteoclasts are recruited 
and subsequently migrate to future sites of bone resorption. Following dissolution of the 
mineralized matrix, osteoclasts may undergo programmed cell death (PCD). Growth 
factors released from the mineralized matrix during bone resorption stimulate bone 
formation by osteoblasts, which subsequently become entrapped in the matrix to form 
osteocytes or may die by PCD. Bone remodelling takes place initially in embryogenesis in 
the formation of the long bones during endochondral ossification. In this process 
osteoclasts present in the periosteum of the primitive long bone migrate through a thin 
layer of osteoid into the calcified cartilage that is partially resorbed to form the future bone 
marrow cavity. Osteoblasts are then recruited and form a collar of woven bone by a 
process of intramembraneous ossification that becomes the future midshaft of the long 
bone. This layer of woven bone is further resorbed later in development and replaced with 
lamellar bone. Bone remodelling continues throughout adult life, the two processes of' 
bone formation and resorption being coupled by growth factors. 
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1.3.1 Systemic Factors regulating bone remodelling 
Bone remodelling is regulated by numerous systemic factors including PTH, 1,25- 
(OH)2D3, insulin, calcitonin and reproductive hormones. 
1.3.1.1 Parathyroid Hormone 
PTH is an 84 amino acid peptide synthesized by the parathyroid gland in response 
to decreases in serum calcium levels and has been shown to be a potent stimulator of bone 
resorption (Raisz, 1965). Takahashi et al. (1988) performed experiments using a murine 
bone marrow culture system and concluded that PTH induces the differentiation of 
immature to mature osteoclast precursors as well as their fusion to form multinucleated 
cells (MNCs). McSheehy and Chambers (1986) showed that isolated osteoclast cultures 
do not respond directly to PTH but do respond to conditioned medium from PTH-treated 
osteoblasts. Hence, a humoral factor produced by osteoblasts mediates the resorptive 
effects of PTH on mature osteoclasts. Rouleau et al. (1988) confirmed the osteoblast as the 
target cell for PTH by showing that '251-PTH binds preferentially to rat osteoblasts and not 
osteoclasts. More recently, Yasuda et al. (1998) have shown that PTH upregulates the 
expression in osteoblasts of RANKL, that can both activate mature osteoclasts and mediate 
osteoclastogenesis. Although PTH receptors have not conclusively been demonstrated on 
osteoclasts, recent studies by Datta et al. (1996) have shown that PTH stimulates 
osteoclasts directly to produce the superoxide radical (02-). 
1.3.1.2 1,25-(OH)2D3 
1,25-(OH)2D3 is the most active metabolite of vitamin D and has been shown to 
stimulate bone resorption in organ culture (Raisz et al., 1972). Subsequent studies showed 
that 1,25-(OH)2D3 stimulates osteoclastogenesis in a murine bone marrow culture system 
(Takahashi et al., 1988a) and in cocultures of spleen cells and osteoblasts (Takahashi et al., 
1988b). In these studies 1,25-(OH)2D3 induced the formation of TRAP +ve MNCs which 
satisfied the major criteria for osteoclasts such as the possession of calcitonin receptors. In 
subsequent studies, Suda et al. (1992) showed that cell-to-cell contact was required for 
1,25-(OH)2D3-induced osteoclast formation in the spleen/osteoblast coculture system and 
suggested that an unknown factor expressed on the plasma membranes of osteoblasts was 
responsible for mediating 1,25-(OH)2D3-induced osteoclastogenesis. Yasuda et al. (1998) 
have shown that RANKL exists in a membrane bound form and that its expression is 
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upregulated by 1,25-(OH)2D3. Although receptors for 1,25-(OH)2D3 have not been 
demonstrated on osteoclasts in vitro, Mee et al. (1996) used a technique called in situ 
reverse transcription polymerase chain reaction in bone sections to demonstrate the 
presence of 1,25-(OH)2D3 receptor transcripts in actively resorbing osteoclasts. 1,25- 
(OH)2D3 acts on cells of the osteoblast lineage to produce several non-collagenous 
proteins, including osteocalcin (Price and Baukol, 1980) and matrix Gla protein (MGP; 
Fraser et al., 1988). 
1.3.1.3 Calcitonin 
Calcitonin is a thyroid peptide hormone consisting of 32 amino acids, the major 
action of which appears to be a direct inhibition of osteoclast-mediated bone resorption 
(Reynolds and Dingle, 1968). High-affinity receptors for calcitonin are found in large 
numbers on the cell membrane of osteoclast precursors and mature osteoclasts (Lee et al., 
1995). Binding of calcitonin to its receptor on osteoclasts results in increased adenylate 
cyclase activity and cAMP accumulation. Calcitonin has been shown to cause detatchment 
of osteoclasts from bone surfaces (Nicholson et al., 1986) and it can inhibit recruitment of 
osteoclasts from bone marrow cultures (Takahashi, 1988a). To examine how calcitonin 
inhibits osteoclast function, Suzuki et al. (1996) investigated calcitonin-induced 
morphological changes of the cytoskeleton of osteoclasts. Calcitonin disrupted actin rings 
and inhibited pit formation by osteoclasts placed on dentin slices. These changes in the 
cytoskeleton were mediated by the protein kinase A signal transduction pathway since 
forskolin, which activates protein kinase A, mimiced the effects of calcitonin. 
1.3.1.4 Insulin 
Insulin is a key systemic regulator of bone formation (Canalis, 1993c). Lack of 
insulin, as exemplified by type I diabetes mellitus, is associated with osteoporosis, delayed 
bone maturation, decreased bone mass, and an overall 2-fold increase in fracture rate 
(Bouillon, 1989). It is known that mature osteoblastic cells are responsive to insulin. In 
vitro studies using primary isolated osteoblasts or clonal osteoblast cell lines have shown 
that insulin induces changes in alkaline phosphatase activity (Levy et al., 1986), collagen 
synthesis (Kream et al., 1985) and cell replication (Hock et al., 1988). Pun et al. (1989) 
showed that the rat clonal osteosarcoma cell line, UMR106 expresses approximately 80 
000 high affinity insulin receptors at the cell surface. Studies have shown heterogeneity of 
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insulin receptor expression within neonatal rat calvaria in vivo, and insulin receptor 
expression and responsiveness is associated with the mature osteoblastic phenotype 
(Thomas et al., 1996) 
1.3.1.5 Reproductive hormones 
Bone cells are major targets of estrogen and to a lesser extent progesterone. These 
hormones play a major role in bone remodelling in the adult skeleton and estrogen 
deficiency following menopause is associated with accelerated loss of bone and 
development of osteoporosis. The importance of estrogen to the maintenance of normal 
bone mineral density has been demonstrated by ovariectomy in rats (Kalu et al., 1991a). In 
this model ovariectomy results in decreased bone density and reduced cancellous bone 
volume which can be suppressed by administration of 17-0-estradiol (Kalu et al., 1991b). In 
vitro studies have demonstrated that bone marrow from ovariectomized mice form 
significantly more TRAP+ve MNCs when cultured with 1,25-(OH)2D3 than cells from 
sham-operated mice (Kalu, 1990). Cytokine production by cells in the local bone 
microenvironment is regulated by estrogen. Pacifici et al. (1987) reported increased 
production of IL-1 by monocytes from patients with osteoporosis and Ralston et al. (1990) 
demonstrated inhibition of TNF-a production by peripheral blood mononuclear cells from 
postmenopasal women following 17 ß-estradiol treatment. Subsequent studies showed that 
treatment of mouse calvarial cells with estrogen inhibits production of IL-6 (Girasole et al., 
1992). Recently, Shevde et al. (2000), demonstrated that estrogen suppresses RANKL- 
induced osteoclast differentiation in murine bone marrow cells which is mediated in part by 
a repression in the level of c-Jun. 
Growth factor expression by osteoblasts has also been shown to be regulated by 
estrogen. Oursler et al. (1991b) demostrated increased expression of TGF-ß by primary 
adult human osteoblasts following estrogen treatment and similarly Slater et al. (1994) 
demonstrated increased expression of TGF-ß and IGF-I in cultures of primary human fetal 
osteoblasts. Recent studies have demonstrated enhanced osteoblastic differentiation, as 
indicated by bone nodule formation, in mouse bone marrow cultures following treatment 
with 17 ß-estradiol (Qu et al., 1999). 
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1.3.2 Local factors regulating bone remodelling 
During bone formation osteoblasts and other cells within the bone 
microenvironment synthesize a variety of growth factors and cytokines that are 
sequestrated by the bone matrix (Canalis, 1993c). A number of polypeptide growth factors 
are found in abundance in the extracellular matrix of bone and when released during phases 
of bone resorption these growth factors have an effect on bone cell survival and regulate 
bone cell function. 
1.3.2.1 Prostaglandins (PGs) 
PGs are cyclopentanoic acids that are biosynthetically derived from the C20 
polyunsaturated fatty acid, arachidonic acid, via the cyclooxygenase pathway. Arachidonic 
acid is present in cell membrane phospholipids and is released primarily through the 
hormonally regulated actions of phospholipase A2 (PLA2; Smith, 1992). It is then converted 
into PGG2 by the enzyme prostaglandin G/H synthase (PGHS) of which there are two 
isoforms, PGHS-1 (Cyclooxygenase-1; COX-1) and PGHS-2 (Cyclooxygenase-2; COX-2). 
PGHS-1 is constitutively expressed in many tissues (Langenbach et al., 1995) and has 
recently been shown to be induced in the bone marrow stromal cell line, ST2, by 1,25- 
(OH)2D3 and dexamethasone (Adams et al., 1999). PGHS-2 is expressed at extremely low 
levels in most tissues and is induced by cytokines (Du Bois et al., 1994). 
The effects of PGs on osteoclasts are varied. Early studies demonstrated that 
prostaglandins were potent activators of bone resorption in organ culture (Dietrich et al., 
1975). However, when added to isolated osteoclasts in vitro it was found that PGs 
transiently inhibited bone resorption (Fuller and Chambers, 1989b). 
Evidence using murine bone marrow cultures indicates that prostaglandins promote 
the differentiation of osteoclasts from haematopoietic precursors (Akatsu et al., 1989a; 
Collins and Chambers, 1991). The effects of PGs in these assays were mimicked by 
dibutyryl-cAMP suggesting a possible role for cAMP in osteoclast differentiation. 
Furthermore Collins and Chambers (1992) showed that osteoclast formation was stimulated 
by PGE2 in cocultures of spleen cells and stromal cell lines. More recent research has shown 
that PGE2 stimulates expression of messenger RNA for RANKL in osteoblasts (Yasuda et 
al., 1998). Furthermore Wani et al. (1999) have shown that PGE2 acts directly on 
precursors synergistically with RANKL in the induction of osteoclast differentiation and 
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maturation but does not synergize with RANKL for resorption-stimulation in mature 
osteoclasts. 
1.3.2.2 Receptor Activator of Nuclear Factor (NF)-icB Ligand 
RANKL, also called osteoprotegerin ligand (OPGL) and TNF-related activation- 
induced cytokine (TRANCE), was recently identified independently by two groups (Lacey 
et al., 1998; Yasuda et al., 1998a) and is an early gene expressed upon stimulation of the 
T-cell receptor (Wong et al., 1997) and a stimulatory factor for dendritic cells (Anderson et 
al., 1997). It is expressed by osteoblasts as a membrane-associated factor and also as a 
soluble factor in response to several osteotropic factors such as 1,25-(OH)2D3, PTH, and 
interleukin-11 (IL-11). RANKL deficient mice exhibit severe osteopetrosis and completely 
lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis (Kong 
et al., 1999). 
In cultures of murine bone marrow and spleen cells RANKL in the presence of 
macrophage colony-stimulating factor (M-CSF) has been shown to be necessary and 
sufficient for differentiation of osteoclast precursors into mature osteoclasts (Yasuda et al., 
1998a; Lacey et al., 1998; Quinn et al., 1998). In addition, RANKL stimulates 4SCa release 
by fetal murine osteoclasts in long bone cultures (Tsukii et al., 1998) and stimulates 
resorption by mature, fully differentiated osteoclasts when cultured on bovine cortical bone 
slices (Burgess et al., 1999). Fuller et al. (1998) have shown that RANKL rapidly 
increased osteoclast motility and spreading and inhibited osteoclast apoptosis. The receptor 
for RANKL, receptor activator of nuclear factor (NF)-KB (RANK) is restricted in bone to 
cells of the osteoclast lineage (Hsu et al., 1999). Signal transduction from RANK may 
involve members of the TNF receptor-associated factor (TRAF) family since TRAF 1, 
TRAF 2, TRAF 3, TRAF 5 and TRAF 6 can interact with the carboxyl terminus of RANK 
(Galibert et al., 1998). However, TRAF 6 deficient mice possess an osteopetrotic 
phenotype which is different to RANKL and similar to that of c-src (Lomaga et al., 1999). 
1.3.2.3 Osteoprotegerin/Osteoclastogenesis Inhibitory Factor (OPG/OCIF) 
Osteoprotegerin was isolated as a decoy receptor for RANKL by two groups 
(Simonet et al., 1997; Yasuda et al., 1998b). High levels of OPG/OCIF are expressed in 
bone and the steady state mRNA levels are higher than those of RANKL. OPG mRNA has 
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been detected in osteoblastic cell lines (Hofbauer et al., 1998) and in marrow stromal cell 
lines (Yasuda et al., 1998b). OPG acts as a soluble decoy receptor for RANKL preventing 
it from binding to RANK. Thus, the effects of OPG on osteoclastogenesis oppose those of 
RANKL. OPG-deficient mice exhibit severe osteoporosis as a result of enhanced osteoclast 
formation and function (Mizuno et al., 1998). It has been shown in bone marrow/stromal 
cell and spleen/stromal cell cocultures that OPG completely inhibits osteoclast 
differentiation at concentrations of 10 to 100 ng/ml (Simonet et al., 1997). In addition to 
inhibiting osteoclast formation OPG has been shown to inhibit osteoclast activity assessed 
by pit formation but at a higher concentration than is required to inhibit osteoclast 
differentiation (Tsukii et al., 1998). 
1.3.2.4 Interleukin-1 
Interleukin-1 (IL-1) is a cytokine produced by monocyte-macrophage cells and 
marrow stromal cells and exists as two functionally related proteins, IL-1 a and IL-10 with 
molecular weights of 17.5 and 17.3 kDa respectively (March et al., 1985). Both IL-la and 
IL-lß are potent osteoclast-activating factors that promote bone resorption both in vitro 
and in vivo. Gowen et al. (1983) and Heath et al. (1985) were the first to show that IL-1 
stimulates bone resorption in bone organ culture and that prostaglandin production is 
partially responsible for mediating the effect of IL-1. Subsequently it was shown that IL-1 
stimulates pit forming activity of isolated rat osteoclasts through a soluble factor secreted 
by osteoblasts. Tsukii et al. (1998) subsequently showed that IL-la stimulated bone 
resorption was suppressed by OPG implicating RANKL as the mediator for IL-1 stimulated 
bone resorption. Boyce et al. (1989) were the first to show that local injections of IL-1 
over the calvaria increase both osteoclastic bone resorption within 24 h and bone formation 
during the following 3-4 weeks. More recently, IL-1 increased osteoclast formation in 
human bone marrow cultures which is mediated by PGE2 (Lader and Flanagan, 1998). 
Several classes of IL-1 receptors have been identified to date. These include the IL-1 type 
I receptor (IL-1RI) which has a molecular weight of 80 kDa (Hannum et al., 1990; 
Eisenberg et al., 1990) and has been shown to be responsible for IL-1 mediated bone 
resorption (Garrett et al., 1993). IL-la has been shown to promote the survival of mouse 
osteoclasts generated in vitro (Jimi et al., 1995) and this was due to activation of the 
transcription factor, NF-KB (Jimi et al., 1998). In addition IL-I induces multinucleation and 
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activation of prefusion osteoclasts in the absence of osteoblasts leading to the conclusion 
that IL-1 is involved in pathological bone resorption (Jimi et al., 1999). It has been shown 
that TNF receptor- associated factor 6 (TRAF 6) is involved in IL-1 signaling leading to 
activation of NF-KB (Cao et al., 1996) and TRAF 6 deficient mice exhibit defective IL-1 
signaling (Lomaga et al., 1999). 
1.3.2.5 Interleukin-6 
Interleukin-6 (IL-6) is a glycoprotein produced by many cells in the bone marrow 
microenvironment including monocyte-macrophages and osteoblasts. Production of IL-6 by 
osteoblasts has been shown to be stimulated by factors that also enhance bone resorption 
such as IL-1 and tumour necrosis factor-a (TNF-a; Ishimi et al., 1990). IL-6 initiates its 
biological response via the IL-6 receptor (IL-6R) complex. IL-6 initially binds to the cell- 
surface IL-6R (also known as gp80) and the resulting complex then associates with a 
second, non-ligand-binding, signal-transducing subunit known as gp130 (Yamasaki et al., 
1988). This leads to homodimerization of gp130 and the activation of signalling pathways 
within the cell. IL-6 belongs to a family of cytokines that share gp130 as a common signal 
transducer; these include interleukin-11 (IL-11), leukaemia inhibitory factor (LIF), 
oncostatin M (OSM), cardiotrophin-1 (CT-1) and ciliary neurotrophic factor (CNTF). IL- 
6R also exists as a soluble form (sIL-6R) that is produced by proteolytic shedding of the 
membrane bound form (Croucher et al., 1999). The in vitro effects of IL-6 on bone 
resorption are variable and seem to depend on the assay used and the species. In cultures of 
newborn murine calvaria IL-6 does not stimulate bone resorption and has inhibitory effects 
on the resorptive response to PTH and 1,25-(OH)2D3 (Al-Humidan et al., 1990). However, 
Ishimi et al. (1990) showed that IL-6 had potent resorptive effects in cultures of 17-day-old 
murine fetal metacarpal and calvaria cultures. Tamura et al. (1993) demostrated that IL-6 is 
a powerful inducer of osteoclast formation in murine bone- marrow cultures in the presence 
of sIL-6R. In a human system, Flanagan et al. (1995) showed that IL-6 could not stimulate 
bone resorption when non-adherent bone marrow cells were cultured on bone marrow 
stromal cells and IL-6 could not replace stromal factors required for osteoclast formation. 
Investigations by Gao et al. (1998) demonstrated expression of IL-6R and gp 130 on 
isolated murine osteoclasts. 
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In vivo studies have shown that IL-6 deficient mice are protected from bone loss 
caused by estogen depletion and exhibit increased bone turnover (Poli et al., 1994) whilst 
overexpression of IL-6 is associated with decreased osteoblast and osteoclast number and 
suppression of bone turnover (Kitamura et al., 1995). Generation of gp 130 deficient mice 
exhibit increased osteoclast number and osteopenia (Kawasaki et al., 1997). 
1.3.2.6 Interleukin-11 
IL-11 is a multifunctional cytokine that was originally identified as the cytokine that 
could induce the proliferation of IL-6 dependent T1165 hemopoietic cells (Paul et al. 
1990). Expression of IL-11 is restricted to certain cells of the mesenchymal lineage, such as 
lung fibroblasts, bone marrow stromal cells, articular chondrocytes and synoviocytes 
(Maier et al., 1993). Whereas the gene structure and amino acid sequence of human IL-1 l 
are unique from those of IL-6 a number of biological actions of IL-11 are shared with IL-6 
Musashi et al., 1991a; Tsuji et al., 1992; Musashi et al., 1991b; Teramura et al., 1992) and 
both cytokines share gp130 as the common signal transducer (Yin et al., 1993; Neuhaus et 
al., 1994). Recent studies have suggested that IL-11 is produced by osteoblasts in response 
to IL-1, TNF, TGF-ß, 1,25-(OH)2D3, and PTH (Girasole et al., 1994). Girasole et al. 
(1994) demonstrated that IL-11 dose-dependently stimulates osteoclast-like MNCs 
formation in cocultures of mouse osteoblasts and bone marrow cells. Morinaga et al. 
(1998) have demonstrated that IL-11 promoted prostaglandin E2 (PGE2) synthesis; thus IL- 
11 may stimulate bone resorption through a PGE2 synthesis dependent mechanism. 
1.3.2.7 Leukemia Inhibitory Factor 
LIF is a single chain glycoprotein that was initially isolated on the basis of its 
capacity to induce differentiation and suppress proliferation of the murine monocytic 
leukemia cell line Ml (Tomida et al., 1984). OSM is closely related to LIF and can mimic 
the activities of LIF in vitro. Receptors for LIF are present on osteoblasts (Allan et al., 
1990; Bellido et al., 1996) and on osteoclast-like cells derived from human giant-cell 
tumour (Gouin et al., 1999). In an in vivo study Metcalf and Gearing (1989) demonstrated 
an increase in bone mass with some evidence of cortical bone resorption in mice injected 
with tumour cells producing high levels of LIF. In vitro studies have shown that LIF 
stimulates bone resorption in neonatal mouse calvariae (Reid et al., 1990). In mouse bone 
35 
marrow assays LIF, OSM and CT-I have been shown to induce TRAP +ve MNCs an effect 
that is synergistically enhanced by dexamethasone (Richards et al., 2000). In long-term 
human bone marrow cultures LIF increases the number of MNCs formed that express the 
macrophage polykaryon phenotype (Heymann et al., 1997). 
1.3.2.8 Tumour Necrosis Factor 
TNF exists as two forms TNF-a and TNF-ß. TNF-a is a cytokine expressed 
mainly by monocytes and macrophages and is the prototype member of the TNF Supergene 
family of ligands (Lotz et al., 1996). It is a hormone like peptide that enters the 
bloodstream to alter the biology of distant tissues or it can behave as a paracrine mediator 
acting locally. TNF-a is a true pleiotropic cytokine with numerous biological effects 
including cytotoxicity. The biological effects of TNF-a are mediated by two 
transmembrane receptors termed TNFRI and TNFR2 (Tartaglia and Goeddel, 1992). TNF- 
ß, previously called lymphotoxin, is expressed by lymphocytes and has similar pleiotropic 
effects to TNF-a. Both TNF-a and TNF-ß have been shown to stimulate bone resorption 
in organ culture (Bertolini et al. 1986). Subsequently, Tashjian et al. (1987) showed that 
TNF induced bone resorption could be blocked by inhibitors of prostaglandin biosynthesis. 
More recently Lader and Flanagan (1998) demonstrated that TNF-a enhances human 
osteoclast formation in a human bone marrow system, an effect mediated by PGE2. 
Hofbauer et al. (1999) have demonstrated that TNF-a increased RANKL mRNA by up to 
two- three-fold in normal human stromal cells. However, Kobayashi et al. (2000) 
demonstrated that TNF-a could induce osteoclast formation from cultures of macrophage 
colony-stimulating factor (M-CSF)-dependent precursors by a mechanism independent of 
RANKL/RANK pathway and dependent on TNFR1-mediated signals. 
1.3.2.9 Transforming Growth Factors 
The transforming growth factors are a family of polypeptide mediators of cell 
proliferation and differentiation and exist in two forms: transforming growth factor a and ß 
(TGFa and TGF-ß). TGF-ß is the prototype member of the TGF-ß supergene family and 
occurs as a homodimeric molecule with a molecular mass of 25 kDa. TGF-ß is produced by 
a number of cell types including bone cells and is the most abundant of the growth factors 
found in bone (Seyedin et al., 1985). To date five isoforms of TGF-ß have been purified 
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from bovine bone matrix (TGF-ß 1-5) with no significant differences in their activity 
(Mohan and Baylink, 1991). TGF-ß is secreted by osteoblasts and stored in the bone matrix 
as a latent high molecular weight complex (100-250 kDa) and upon release from the bone 
matrix becomes activated by the acidic environment beneath bone resorbing osteoclasts 
(Oreffo et al., 1989). The effects of TGF-ß on bone cell function are wide ranging and 
complex. It stimulates cell replication in cultures of primary osteoblast like cells (Centrella, 
1987) and also stimulates bone resorption in neonatal mouse calvarial cultures by a 
prostaglandin synthesis-dependent mechanism (Tashjian et al., 1985). In contrast to these 
findings Chenu et al. (1988) demonstrated that TGF-ß inhibits formation of osteoclast-like 
cells in long-term human bone marrow cultures. TGF-ß 1 negatively regulates 
osteoclastogenesis in murine bone marrow cultures by increasing levels of OPG and 
decreasing the levels of RANKL by bone marrow stromal cells (Takai et al., 1998). In 
cultures of hematopoietic cells containing few stromal cells TGF-ß enhances osteoclast 
formation in the presence of M-CSF and RANKL (Sells Galvin et al., 1999; Fuller et al., 
2000). 
1.3.2.10 Bone Morphogenetic Proteins 
BMPs form part of the TGF-ß superfamily of related peptide growth factors and are 
known to have an osteogenic potential (Wozney et al., 1988). The BMP subfamily consists 
of 15 members and are secreted as 30 kDa homodimers or heterodimers, interconnected by 
seven disulphide bonds (Wozney, 1989). BMW-2, -4, -5, -6, -7 and -9 have been shown to 
induce ectopic bone formation when implanted into subcutaneous or muscular sites in rats 
(Gitelman et al., 1994; Celeste et al., 1994) whilst BMP-13 and -14 have been shown to 
induce ectopic tendon and ligament in rats (Wolfman et al., 1997). 
In vitro studies have demonstrated that osteoprogenitor cells are responsive to the 
effects of BMPs. Asahina et al. (1993) demonstated that cultures of newborn rat calvarial 
cells showed osteogenic differentiation after treatment with recombinant human BMP-7. 
Subsequently Rickard et al. (1994) demonstrated enhanced levels of alkaline phosphatase 
and increased levels of mRNA for osteopontin, osteocalcin and BSP in rat bone marrow 
cultures after stimulation with BMP-2. Fromigue et al. (1998) have demonstrated enhanced 
alkaline phosphatase and osteocalcin levels in cultures of primary human bone marrow 
stromal cells following treatment with recombinant human BMP-2. The effects of BMP-2 
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on osteoclast formation have been investigated in mouse bone marrow cultures (Koide et 
al., 1999). BMP-2 alone had no effect on osteoclast formation though it enhanced 
osteoclast formation in a dose-dependent fashion in the presence of IL-la. Abe et al. 
(2000) have demonstrated the requirement for BMP-2 and -4 in osteoclast formation by 
treating mouse bone marrow cultures with a BMP antagonist called noggin. Addition of 
noggin to these cultures inhibited osteoclast formation which could be reversed by addition 
of exogenous BMP-2. 
1.3.2.11 Fibroblast Growth Factor 
FGF was originally identified as a growth factor for mesenchymal cells (Rifkin and 
Moscatelli, 1989). This activity is due to two proteins, acidic FGF (aFGF; FGF-1) and 
basic FGF (bFGF; FGF-2) that share 55% homology in their amino acid sequences and bind 
to the same receptor (Neufeld and Gospodarowicz, 1986). FGFs also seem to be bone 
regulating factors since they enhance the proliferation of rat osteoblasts in vitro (Canalis et 
al., 1988). However, continuous FGF treatment reduced the synthesis of alkaline 
phosphatase (ALP; Rodan et al., 1989) and type I collagen (Canalis et al., 1988) by 
osteoblasts. Osteoblasts can synthesize two types of FGFs, which persist in the bone matrix 
(Globus et al., 1989) and are released from bone matrix during phases of bone resorption. 
Montero et al. (2000) have examined transgenic mice deficient in FGF-2. These mice 
exhibited significant decreases in trabecular bone volume and bone formation rates, 
providing evidence that FGF-2 helps determine bone mass. 
Jimi et al. (1996) investigated the effects of bFGF on osteoclast-like cell formation 
using cocultured mouse bone marrow cells with the mouse stromal cell line, ST2, or with 
primary osteoblastic cells. In this system bFGF had an inhibitory effect on osteoclast-like 
cell formation induced by 1,25-(OH)2D3 and also PGE2 and IL-11. The effects of bFGF on 
osteoclast formation seem to be varied depending on the culture conditions. Nakagawa et 
al. (1999a) showed that the inhibitory effect of bFGF on 1,25-(OH)2D3-induced osteoclast 
formation was due to suppression of 1,25-(OH)2D3-induced RANKL production. 
However, Hurley et al. (1998) demonstrated osteoclast formation from murine bone 
marrow cultures stimulated with bFGF by a prostaglandin dependent mechanism. 
Subsequently, Nakagawa et al. (1999b) showed an increase in the expression of RANKL 
and COX-2 in bFGF stimulated osteoblasts. 
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1.3.2.12 Platelet Derived Growth Factor 
Platelet derived growth factor (PDGF) is 30 kDa polypeptide first identified as a 
factor in platelets that allowed the growth of fibroblasts in vitro. Further characterization of 
PDGF demonstrated that it is a potent mitogen for all cells of mesenchymal origin including 
osteoblasts (Linkhart et al., 1986). PDGF exists as a dimer comprised of two polypeptide 
chains termed A and B. Independent regulation of the expression of the A and B chains 
allows for the production of at least three different PDGF-related molecules, the AA and 
BB homodimers and the AB heterodimer (Hannink and Donoghue, 1989). Studies on the 
biological activities of PDGF on bone revealed that PDGF stimulates cell replication in 
bone cells derived from neonatal mouse calvariae (Kasperk et al., 1990). PDGF also 
stimulates collagen and non collagen protein synthesis in rat calvaria organ cultures 
(Canalis, 1981). PDGF stimulates bone resorption in mouse calvaria by a mechanism that 
involves prostaglandin synthesis (Tashjian et al., 1982). Zhang et al. (1998) demonstrated 
PDGF receptors on osteoclasts by immunomicroscopy. 
1.3.2.13 Insulin-like Growth Factors 
The insulin like growth factors-I (IGF-I) and II (IGF-II) are 7.5 kDa polypeptides, 
sharing 62% homology, expressed by cells of the osteoblast lineage and found in abundance 
in bone matrix (Mohan et al., 1993). IGFs are fixed in bone by means of IGF binding 
proteins (IGFBPs) of which six have currently been characterized (Bautista et al. 1991). 
These proteins modulate the activity of the IGFs at the local level. Although the IGFs are 
found in abundance in bone matrix the relative concentration of IGF-I is 10 to 15 fold less 
than that of IGF-II. Similarly IGF-I is produced by human bone cells at 50 to 100-fold less 
than that of IGF-II (Mohan et al. 1988). Both IGF-I and IGF-II have been shown to 
stimulate cell proliferation in monolayer cultures of human bone cells (Weregedal et al., 
1990). In addition Hock et al. (1988) showed that IGF-I stimulates matrix synthesis in 21- 
day-old fetal rat calvaria in organ culture. Mochizuki et al. (1992) demonstrated that IGF-I 
but not IGF-II stimulates bone resorption through its direct or indirect action of supporting 
the generation and activation of osteoclasts. More recently Hill et al. (1995a) demonstrated 
that bone resorption induced by IGF-I and IGF-II is mediated by osteoblasts. 
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1.3.3 Colony Stimulating Factors (CSFs) 
The colony stimulating factors are macromolecules that influence the proliferation 
and differentiation of multipotential haemopoietic stem cells into haemopoietic progenitors 
that are commited to a specific lineage. These progenitors further differentiate under 
appropriate signals into terminally differentiated myeloid cells (Metcalf, 1985). The CSFs 
are glycoproteins that have been characterized on the basis of their ability to promote the 
formation of colonies of multipotential stem cells in semi-solid media. The family of CSFs 
include interleukin-3 (IL-3), macrophage colony stimulating factor (M-CSF, also named 
CSF-1), granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte 
colony stimulating factor (G-CSF). Since osteoclasts are derived from progenitors of the 
macrophage/monocyte cell lineage, CSFs are likely to play a role in osteoclast formation as 
shown in Fig. 1-2. 
1.3.3.1 Macrophage colony stimulating factor (M-CSF) 
M-CSF exists in a soluble form and a membrane bound form that are encoded by a 
single gene which undergoes alternative splicing. The biological effects of M-CSF are 
mediated by a high affinity receptor of the tyrosine kinase family which is encoded by the 
protooncogene c-fms (Fixe and Praloran, 1997). Osteoblasts have been shown to produce 
M-CSF in vitro and this is stimulated by PTH, IL-1 and TNF-a (Felix et al., 1989). Using 
murine metatarsals as an in vivo model for osteoclastogenesis, Hofstetter et al. (1995) 
demonstrated that M-CSF production by osteoblasts was associated with the final stages of 
osteoclast formation. 
Evidence implicating M-CSF as an important growth factor in osteoclastogenesis 
has come from studying animal models which have a defect in the M-CSF gene resulting in 
an osteopetrotic phenotype. Such models include the murine op mutation (Felix et al., 
1990b; Wiktor-Jedrzejczak et al., 1990) in which the defect is caused by a point mutation 
within the coding region of the M-CSF gene resulting in a defective protein (Yoshida et al., 
1990). Phenotypically op/op mice are characterized by a virtual absence of osteoclasts 
(Marks and Lane, 1976). Administration of recombinant human M-CSF to op/op mice 
induced osteoclast formation and susequent restoration of bone resorption, thus providing 
unequivocal proof that the defective M-CSF in the op/op mice is the cause of the 
osteopetrosis (Felix et al., 1990b). Takahashi et al. (1991) confirmed that osteoclast 
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formation was dependent on M-CSF and that the op defect was in the stromal cells. In 
coculture experiments, osteoblasts from phenotypically normal animals were able to support 
osteoclast formation when cocultured with precursors from op/op mice. However, 
osteoblasts derived from op/op mice were not able to support osteoclast formation when 
cultured with precursors from either op/op or normal mice. Investigations into the action of 
M-CSF on mature osteoclasts cultured on bone slices have demonstrated an inhibitory 
effect of M-CSF on osteoclast resorptive activity (Hattersley et al., 1988). This was 
subsequently shown to be due to M-CSF inducing spreading and acting as a chemotactic 
agent (Fuller et al., 1993) thus reducing the proportion of resorbing osteoclasts. Confirming 
this Weir et al. (1994) demonstrated that addition of anti-M-CSF antibodies to fetal rat 
long bone cultures led to an increase in PTH-stimulated bone resorption. In cultures of 
isolated human osteoclasts M-CSF increased bone resorption which was attributed to 
increased osteoclast survival (Edwards et al., 1998). 
1.3.3.2 Granulocyte-macrophage colony stimulating factor (GM-CSF) 
GM-CSF is a 124 amino acid cytokine that stimulates the proliferation of 
granulocytes and macrophages and is expressed by various cell types including T- 
lymphocytes, macrophages and endothelial cells. Treatment of whole calvaria and primary 
mouse osteoblasts with PTH or TNF-a stimulates the production of GM-CSF (Felix et al., 
1988; Horowitz et al., 1989). 
The effects of GM-CSF on osteoclast formation are equivocal. MacDonald et al. 
(1986) demonstrated that GM-CSF, when added to human bone marrow cultures, enhanced 
osteoclast formation in the presence of 1,25-(OH)2D3. It was subsequently shown that GM- 
CSF could induce the formation of TRAP-positive MNCs when added to cultures of human 
haemopoietic stem cells (Kurihara et al., 1989). Furthermore Takahashi et al. (1991) 
demonstrated that colonies formed in the presence of GM-CSF contain osteoclast 
precursors. At the same time Abe et al. (1991) showed that GM-CSF present in conditioned 
medium from concanavalin A stimulated spleen cells was an important fusion factor for 
alveolar macrophages. However, other evidence suggests that GM-CSF is not required for 
formation of osteoclasts. GM-CSF cannot support osteoclast formation when substituted 
for M-CSF in coculture of normal spleen cells with op/op osteoblasts (Hattersley et al., 
1991) and injection of GM-CSF into op/op mice cannot reverse the osteopetrotic phenotype 
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(Wiktor Jedrzejczak et al., 1994). Furthermore, a GM-CSF knock-out mouse is not 
osteopetrotic (Dranoff et al., 1994). Subsequent investigations showed that GM-CSF 
inhibited osteoclast formation in bone marrow cultures and suppression of GM-CSF 
production by dexamethasone resulted in a higher number of osteoclasts (Shuto et al., 
1994). Further, Udagawa et al. (1997) showed that GM-CSF mediates the inhibitory effects 
of IL-18 on osteoclast formation. Although GM-CSF has been shown to induce bone 
resorption in fetal long bone organ cultures (Bertolini and Strassman 1991) this may be due 
to the release of PGE2 and other cytokines by activated macrophages. 
1.3.3.3 Granulocyte colony stimulating factor (GCSF) 
G-CSF is a 25 kDa cytokine that stimulates the proliferation and differentiation of 
neutrophils and is expressed by activated macrophages, endothelial cells, fibroblasts and 
osteoblasts. G-CSF has been shown to be produced by calvaria, primary osteoblasts and 
osteoblastic cell lines treated with TNF-a (Felix et al., 1988,1991). 
Granulocyte colony-forming cells (G-CFC) contain multipotential progenitor cells 
and it has been reported that (G-CFC) when injected into osteopetrotic is rats can give rise 
to osteoclasts and thus partially reverse the osteopetrotic phenotype (Schneider and Relfson 
1988). 
1.3.3.4 Interleukin-3 (IL-3) 
IL-3 is a 22-36 kDa glycoprotein that induces the proliferation of early stage 
multipotential haemopoietic stem cells (Sonoda et al., 1988) that are capable of 
differentiating into granuloctes, macrophages and erythroid cells. Murine calvaria have been 
shown to produce IL-3 when treated with lipopolysacharide although primary cultures of 
osteoblasts do not (Felix et al., 1988). 
Cells grown in the presence of IL-3 can differentiate into osteoclasts under a 
microenvironment provided by osteoblasts (Takahashi et al., 1988). Subsequently, Kurihara 
et al. (1989) demonstrated that osteoclast-like cells could be generated from haemopoietic 
progenitors in the presence of IL-3 and 1,25-(OH)2D3 in the absence of any other growth 
factor. At the same time Barton and Mayer (1989) showed that IL-3 could induce 
osteoclast formation in a murine bone marrow assay in the absence of 1,25-(OH)2D3; thus it 
may be that IL-3 can act on later stages in the formation of osteoclasts. However, the 
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culture systems used in these cases does not preclude the involvement of other cytokines 
being produced. 
Contrary to the previous studies, IL-3 can inhibit osteoclast formation induced by 
1,25- (OH)2D3 in murine bone marrow cultures (Hattersley and Chambers, 1990; Shinar et 
al., 1990). Susequently Takahashi et al. (1991) demonstrated that if IL-3 is added at the 
start of the bone marrow culture osteoclast formation was inhibited. However when bone 
marrow cells were cultured in methylcellulose in the presence of IL-3 and the colonies that 
formed were then cocultured with osteoblasts, osteoclasts were formed. 
1.4 PROTEINASES 
Following mineral dissolution during the resorptive phase of bone remodelling 
organic matrix degradation occurs mediated by proteinases. Two major classes of 
proteinases, the matrix metalloproteinases (MMPs) and the cysteine proteinases (CPs) are 
directly involved in digestion of the organic matrix beneath the subosteoclastic resorption 
zone (Hill et al., 1994a, 1994b). Everts et al. (1998) have shown that CPs attack the 
organic matrix initially prior to digestion by MMPs. In addition MMPs also participate in 
the migration of preosteoclasts to sites of bone resorption (Blavier and Delaisse, 1995). 
Members of a fourth family of proteinases the ADAMs (a disintegrin and 
metalloproteinase) have recently been implicated in osteoclast formation by mediating 
fusion of osteoclast precursor cells (Abe et al., 1999). 
1.4.1 Plasminogen Activator /Plasmin pathway 
The plasminogen activator (PA)/plasmin pathway is a highly regulated proteolytic 
pathway that results in the generation of the broad spectrum serine proteinase, plasmin, 
from the zymogen plasminogen. Activation of plasminogen is achieved by the activities of 
the plasminogen activators (PAs) of which there are two types: tissue type plasminogen 
activator (tPA) and urokinase type plasminogen activator (uPA). The PA/plasmin pathway 
is regulated by four members of the serine proteinase inhibitor (serpin) family. Plasminogen 
activator inhibitor-I (PAI-I) and plasminogen activator inhibitor-II (PAI-II) regulate the 
activities of uPA and tPA. A third member of the serpin family, protease nexin-I (PN1) 
regulates thrombin, plasmin and uPA, whilst a2-antiplasmin regulates plasmin. The pathway 
has been implicated in a plasminogen-plasmin-latent metalloproteinase activation cascade in 
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type I collagen degradation (Thomson et al., 1989) and also in the activation of latent 
growth factors such as TGF-ß (Lyons et al., 1990). Thus the PA/plasmin pathway may play 
an important role in bone remodelling and in the coupling of bone resorption and bone 
formation. 
uPA is secreted as a precursor protein of 55 kDa and is activated by cleavage into a 
30 kDa heavy chain and a 24 kDa light chain linked by a disulphide bond, with the active 
site residing in the 30 kDa fragment (Wun et al., 1982). Recent studies have demonstrated 
expression of uPA in osteoclasts by RTPCR of RNA extracted from microisolated mouse 
osteoclasts (Yang et al., 1997). uPA has a domain structure consisting of a Kringle domain, 
a serine proteinase-like active site and a growth factor domain (GFD). The noncatalytic 
NH2-terminal fragment contains the GFD and Kringle domain and is referred to as the 
amino terminal fragment (ATF). The GFD of the ATF is necessary for the binding of uPA 
to its specific receptor. 
The urokinase-type plasminogen activator receptor (uPAR) is a glycosylated GPI- 
linked protein (Ferguson and Williams, 1988) and receptors have been found on fibroblasts 
and the human monocyte-like U937 cells and have been postulated to have a role in 
migration of cells through matrices. The receptor functions in the activation and degradation 
of uPA and pro-uPA bound to its receptor can be activated by plasmin (Cubellis et al., 
1989). The uPA/uPAR complex cannot be internalized and degraded (Cubellis et al., 1990). 
tPA is secreted as a 72-kDa polypeptide and is activated by cleavage into a 39-kDa 
heavy chain and a 33-kDa light chain linked by a disulphide bond. tPA has been found in 
human plasma and tissue extracts as well as in normal and malignant cells. The heavy chain 
has no proteolytic activity but contains two Kringle domains that assist in binding fibrin to 
plasminogen (Banyai et al., 1983), a finger domain involved in fibrin binding (van 
Zonneveld et at., 1986) and a GFD with homology to human and murine EGF. Receptors 
for tPA consist of two populations, a low affinity and a high affinity population (Barnathan 
et al., 1988; Hajjar 1991). 
1.4.1.1 Regulation of the PA system in bone 
Plasminogen activator activity is increased in normal and malignant rat osteoblasts 
and also in murine calvariae by bone resorbing agents such as PTH, PGE2 and 1,25- 
(OH)2D3 (Hamilton et al., 1984,1985; Thomson et al., 1989). Hamilton et al. (1985) 
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demonstrated that increased PA activity in normal and malignant rat osteoblasts in response 
to PTH treatment was due to tPA, as identified by fibrin zymography; there was no 
evidence for the presence of uPA in conditioned medium. Further studies showed that the 
stimulation of PA activity by PTH and PGE2 was mediated by cAMP (Allan et al., 1986). 
Subsequent investigations showed that stimulation of rat osteoblastic UMR106-O1 cells 
with hPTH (1-34) increased the mRNA for both tPA and uPA two fold with a subsequent 
increase in activity and decreased mRNA for PAI-I (Fukumoto et al., 1992). Allan and 
Martin (1995) have shown that PGE2 increased mRNA levels for tPA, uPA and uPAR in 
primary cultures of rat neonatal osteoblast-like cells while mRNA for PAI-I was modulated 
in a biphasic manner and PN1 and PAI-2 were not modulated by PGE2. Thus, in rat 
osteoblasts PTH may increase PA activity by decreasing production of PAI-I. 
1,25-(OH)2D3 has been reported to stimulate plasminogen activator activity in 
normal and malignant rat osteoblasts by a cAMP-independent mechanism and that the 
increase in activity is due to inhibition of PAI-I mRNA (Fukumoto et al., 1994) 
Studies have shown that various growth factors and cytokines expressed by 
osteoblasts modulate components of the PA/plasmin system. Cheng et al. (1990) have 
shown that incubation of fetal rat osteoblastic calvarial cells with either aFGF, bFGF, EGF 
or PDGF elevates the PA activity in the conditioned media as assayed by fibrin zymography. 
Allan et al. (1991) have demonstrated that TGF-ß treatment of rat osteoblast calvarial cells 
or rat osteoblastic UMR 106-01 cells dose dependently inhibited PA activity by increasing 
PAI-I mRNA levels and protein. Similarly LIF inhibits PA activity in rat osteoblasts by 
increasing PAI-I synthesis (Allan et al., 1990). 
1.4.1.2 Role of the PAIPlasmin system in bone remodelling 
The activation of growth factors by plasmin provides a crucial role for the 
PA/plasmin pathway in osteoblast mediated bone formation. Lyons et al. (1990) have 
demonstrated that latent TGF-ß produced by osteoblasts can be activated by plasmin and 
Yee et al. (1993) have shown that treatment of cultures of UMR-106 cells with PTH and 
plasminogen resulted in a 6-fold increase in the concentration of active TGF-ß which was 
plasminogen dependent. In activating TGF-ß the PA/plasmin system provides a mechanism 
for the coupling of bone resorption with bone formation. 
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The osteoblast PA/plasmin pathway is involved in the activation of procollagenase 
secreted by osteoblasts in response to bone resorbing agents (Hamilton et al., 1985). 
Studies by Thompson et al. (1989) found that collagenolysis by mouse calvarial osteoblasts 
grown on Type I collagen films is plasminogen dependent, implicating the PA/plasmin 
system as being of importance in modulating the degradation of the osteoid layer covering 
the bone surfaces. Recent studies have shown that the ability of osteoblasts from tPA: uPA 
deficient knockout mice to degrade nonmineralized matrix is significantly reduced (Daci et 
al., 1999). 
The role of the PA/plasmin system in osteoclast migration and activity has been 
investigated using 17-day-old fetal mouse metatarsal explants (Leloup et al., 1994) and also 
by studying the effects of inactivation of the genes for uPA, tPA and PAT-1 (Leloup et al., 
1996). Leloup et al. (1994) showed that PTH enhanced the activity of tPA in extracts of 
metatarsals but not of uPA. Later work showed that PTH increased the activity of tPA in 
calvariae derived from wild type tPA+/+ and uPA+/+ or deficient uPA-/- and PAI-/- mice; 
no differences were observed for any parameter of bone resorption between tPA+/+, tPA-/-, 
uPA+/+ and uPA-/- calvariae (Leloup et al., 1996). Cultures of metatarsals from uPA-/- 
mice released 45Ca at a slower rate at the beginning of culture. Thus uPA may be important 
in the migration of preosteoclasts from the periosteum into the calcified cartilage. Daci et al. 
(1999) have shown that osteoclast formation and resorption of mineralized matrix is 
unaffected by a combined deficiency of both tPA and uPA although nonmineralized matrix 
digestion is effected. 
1.4.2 Matrix Metalloproteinases 
The matrix metalloproteinases are a family of Zn 2' dependent endopeptidases which 
collectively are capable of degrading the whole spectrum of extracellular matrix 
components (Murphy and Reynolds, 1993a). Four major subgroups have been recognized 
(Table 1-2), the collagenases, gelatinases (type IV collagenases), stromelysins and 
membrane type MMPs. Within each group there is a characteristic domain structure and a 
highly conserved amino acid sequence between members of each group. Six domains have 
been identified and are illustrated in Fig. 1-4. 
All subgroups of M Ps consist of a propeptide of approximately 80 amino acid 
residues, and a catalytic domain of about 160 residues. Within the propeptide is the 
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consensus sequence PRCVNPD forming a cysteine switch mechanism in which the cysteine 
residue ligands with the active site Zn2+ in the catalytic domain, conferring latency on the 
MMPs (Birkedal-Hansen et al., 1993). Within the catalytic domain is the zinc binding motif 
HEXGHXXGXXH in which the three histidine residues bind the catalytic zinc. 
With the exception of matrilysin, all MMPs possess a C-terminal domain which is 
linked to the catalytic domain by a proline rich hinge region. The C-terminal domain 
consists of hemopexin-like repeats which confers substrate, matrix and inhibitor binding 
capabilities upon different MMPs. Gelatinase A and B possess a fourth domain consisting 
of three fibronectin-like repeats confering an ability to bind to gelatin and collagen. The 
MT- M? vlPs possess in addition a transmembrane domain with a cytoplasmic tail. Recently 
Nagasse and Woessner (1999) have identified MMP-23 in which the hemopexin domain 
has been replaced with a cysteine-rich, proline-rich and interleukin/receptor-like region. 
1.4.2.1 Collagenases 
Three members of the collagenase subgroup have been identified which have the 
ability to cleave fibrillar triple helical collagen at neutral pH (Matrisian, 1992). Collagenase- 
1 (MMP-1, also called interstitial or fibroblast collagenase) is synthesized by a wide variety 
of cells including fibroblasts, monocytes and macrophages (Welgus et al., 1985) and 
chondrocytes (Lefebvre et al., 1990). Production of collagenase-1 by osteoblasts has been 
demonstrated and shown to be elevated in response to bone resorbing agents such as PTH 
and 1,25-(OH)2D3 (Heath et al., 1984). Collagenase-2 (MMP-8, also called neutrophil 
collagenase) is expressed by polymorphonuclear leukocytes (Murphy et al., 1980) and has 
also been found to be expressed by human chondrocytes (Cole et al., 1996). Collagenase-3 
(MMP-13) was reported by Freije et al. (1994) to be closely related to the rat and mouse 
interstitial collagenase (Henriet et al., 1992) and has been found to be expressed by human 
chondrocytes (Reboul et al., 1996). Immunohistochemical studies have demonstrated 
collagenase-1 expression in mouse, rat and rabbit osteoclasts (Delaisse et al., 1993; Hill et 
al., 1994b) and in human osteoclasts in vivo (Bord et al., 1996). However, in situ 
hybridization studies could not detect collagenase-1 in osteoclasts and synthetic inhibitors of 
collagenase had no effect on lacunar resorption by isolated osteoclasts (Fuller and 
Chambers, 1995b). 
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A: matrilysin; B: neutrophil collagenase, interstitial collagenase, stromelysin -1, -2, -3, 
metalloelastase; C: gelatinase -A and -B; D: membrane type metalloproteinase. 
Fig. 1-4 Domain structure of matrix metalloproteinases (from Reynolds and Meikle 
2000). 
Six domains can be recognized. A propeptide containing a conserved cysteine residue at the C- 
terminus which ligands with the active site zinc forming a cysteine switch mechanism and 
maintaining the protein in a latent configuration. An N -terminal catalytic domain which contains 
the Zn2+ binding consensus sequence. A C-terminus containing hemopexin-like repeats which are 
involved in sustrate binding. A proline rich hinge region. A gelatin binding domain comprising 
fibronectin-like repeats and a transmembrane domain with a ctoplasmic tail. 
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1.4.2.2 Gelatinases 
Gelatinases (type IV collagenases) are involved in proteolysis and disruption of 
basement membranes by degradation of types IV, V and denatured collagens. There are two 
types of gelatinases, 72 kDa gelatinase A (1VIlVII'-2; Collier ei al., 1988) and 92 kDa 
gelatinase B (MMP-9; Wilhelm et al., 1989). 
In bone, gelatinase A is expressed constitutively by cultured human osteoblasts 
(Rifas et al., 1989,1994; Meikle et al., 1992,1995) and rabbit calvarial osteoblasts (Meikle 
et al., 1994). Immunolocalization studies have demonstrated expression of gelatinase A in 
rabbit osteoclasts (Hill et al., 1994b) though not in human osteoclasts (Wucherpfennig et 
al., 1994). Gelatinase B has been shown to be secreted by the human osteosarcoma cell 
lines (U2OS and MG63; Rifas et al., 1994) but secretion by normal human osteoblasts was 
not detected. Likewise Meikle et al. (1992) found very little immunohistochemical staining 
for gelatinase B in normal human osteoblasts. Expression of gelatinase B has been noted in 
mouse osteoclasts (Reponen et al., 1994) and in human osteoclasts by 
immunohistochemistry and in situ hybridization (Wucherpfennig et al., 1994; Okada et al., 
1995). Hill et al. (1995b) demonstrated, using a synthetic gelatinase inhibitor, that 
gelatinase A and B are likely to play a role in bone resorption. Further studies by Blavier 
and Delaisse (1995) showed that gelatinase B is obligatory for the migration of 
preosteoclasts to the developing bone marrow cavity of primitive long bones. 
1.4.2.3 Stro m elysins 
The stromelysin subgroup of MMPs include stromelysins 1 and 2 (MMP-3 and 
MAP-10), which are highly homologous and exhibit an ability to cleave a broad spectrum 
of matrix components including aggrecan, fibronectin, nidogen, laminin and type IV 
collagen (Murphy et al., 1991; Nagase, 1995). Stromelysin 1 has also been shown to 
degrade types III, IX and X collagen. Stomelysin 3 (MMP-11) shares less homology to 
stromelysin 1 and 2 and displays weak catalytic activity against the same substrates (Murphy 
et al., 1993b). 
Mesenchymal cells such as chondrocytes and fibroblasts are commonly found to 
express stromelysin (Matrisian, 1992). In bone, stromelysin has been shown, by 
immunohistochemistry, to be produced by human osteoblasts (Meikle et al., 1992) upon 
stimulation with PTH or monocyte conditioned medium, as well as by mouse osteoblasts 
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after 1,25-(OH)2D3 treatment (Thomson et al., 1989). Rifas et al. (1994) demonstrated 
secretion of stromelysin by two human osteosarcoma cell lines (MG63 and U2OS) that was 
increased upon stimulation with phorbol myristate acetate (PMA), interleukin-10 and 
tumour necrosis factor a. Expression of stromelysinl has been noted in osteoclasts (Okada 
et al., 1995) and stomelysin 2 has been found strongly associated with human osteoclasts in 
contrast to stromelysin 1 (Bord et al., 1998). 
1.4.2.4 Membrane-type matrix metalloproteinases (MT-MMPs) 
The membrane-type matrix metalloproteinases are a recently described subset of 
metalloproteinases characterized by a transmembrane domain anchoring them into the cell 
membrane. To date five members of the MT-MAP subset have been identified. MT 1-MMP 
(MW-14) was initially discovered on the surface of invasive tumour cells (Sato et al., 
1994; Sato and Seiki 1996) and subsequently found to be expressed in osteoclasts (Sato et 
al., 1997). Other members are widely expressed in a variety of tissues and include MT2- 
MMP (MMP-15; Takino et al., 1995), MT3-MMP (MIVIP-16) and MT4-MMP (MAP-17; 
Puente et al., 1996) while MT5-MM' (MMP-24; Pei, 1999) is expressed in a brain specific 
manner. The MT-MMPs exhibit an ability to cleave a broad spectrum of matrix proteins 
including fibrin, fibronectin, tenascin, nidogen, aggrecan and perlecan, and are also capable 
of processing proTNF-a to its mature form (d'Ortho et al., 1997). 
1.4.2.5 Tissue inhibitors of matrix metalloproteinases (TIMPs) 
TIMPs are the major regulators of MMP activity and to date four members of the 
TIMP family have been identified that possess 12 invariant cysteine residues. TIMP-1 is a 
28 kDa glycosylated protein (Docherty et al., 1985) and is produced by many cell types 
including osteoblasts (Meikle et al., 1992,1995) and osteoclasts (Hill et al., 1993). TIMP-1 
inhibits MMPs by forming a 1: 1, high affinity and irreversible non-covalent complex with 
the active form of MATs (Willenbrook and Murphy, 1994) and can also form a complex 
with progelatinase B (Goldberg et al., 1989). TIMP-2 is a 21 kDa unglycosylated protein 
(Boone et al., 1990) and is constitutively expressed by many cells in culture. TIMP-2 
inhibits MMPs in a similar way to TIMP-1 and also forms a complex with progelatinase A. 
Both TIMP-1 and -2 have been shown to inhibit conversion of progelatinase and 
prostromelysin to their mature forms. TIMP-2 has been shown to be 2 to 10 times more 
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effective than TIMP-1 against gelatinase A and B, whereas TIMP-1 inhibits MMP-1 more 
effectively (Howard et al., 1991). TM-3 is a 21-27 kDa protein originally isolated from 
chicken cells and called ChINT-3 and cloned from human sources (Apte et al., 1994) and 
mouse (Leco et al., 1994). TIMP-3 has a wide tissue distribution, with highest expression in 
the placenta and brain (Apte et al., 1994; Leco et al., 1994) and only low levels found in 
bone (Leco et al., 1994). Knauper et al. (1997) demonstrated that TIMP-3 associates with 
the C-terminal domain of human collagenase-3. TEMP-3 interacts with gelatinases in a 
similar manner to TM-2 and interacts rapidly with both gelatinase A and B and forms 
complexes with both progelatinase A and B (Butler et al., 1999). TINT-4 has recently been 
identified and cloned from human tissue (Greene et al., 1996) and from adult mouse tissues 
(Leco et al., 1997) where it has been shown to be more closely related to TIMP-2 and 
TIMP-3 and expressed in brain, heart, ovary and skeletal muscle. TIMP-4 has been 
demonstrated to bind to gelatinase A and progelatinase A (Bigg et al., 1997). 
1.4.2.6 Activation of MMPs 
Most MMPs are secreted from the cell as inactive zymogens (Sellers and Reynolds, 
1978) and are activated in vitro by proteinases or by exposure to nonproteolytic agents such 
as organomercurial compounds. In vivo, many proMMPs are activated by other MMPs and 
plasma proteins, thus there exists a number of activation cascades involved in MMP 
activation (Murphy and Knauper, 1997). Investigations have implicated plasmin, as being of 
importance in the activation of collaganase, gelatinase B and stromelysin-1 but not 
gelatinase A in in vitro model systems (Murphy et al., 1992). MMP activation by plasmin is 
initiated extracellularly at or near the cell surface where uPA is bound to uPAR. Sato et al. 
(1994) demonstrated that MT1-MMP is an activator of gelatinase A. More recent studies 
demonstrating activation of gelatinase A by MT2-MMP (Butler et al., 1997) suggest that 
other members of the MT-MW family may be involved in the activation of gelatinase A. 
This activation cascade requires active MT1-MMP and TIMP-2 bound MT1-MMP 
(Strongin et al., 1995). MT1-MMP has also been shown to be involved in an activation 
cascade for human procollagenase-3 which is potentiated by the presence of gelatinase A 
(Knauper et al., 1996) and subsequently involved in an activation cascade for gelatinase-A, - 
B and collagenase 3 (Cowell et al., 1998). 
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TABLE 1-2 Subgroups of the matrix metalloproteinase family 
Enzyme MMP No. Mr (kDa) Matrix Substrate 
Proform Active 
Interstitial Collagenase MMP-1 55 45 Native fibrillar collagens, types 
Neutrophil Collagenase MW-8 75 58 I, II, III, VII, VIII, X Gelatins 
Collagenase-3 MMP-13 60 48 
Gelatinase A MW-2 72 66 Type I, IV, V, VII, X, XII, 
XIV collagen. Gelatin, Elastin, 
fibronectin. 
Gelatinase B MW-9 92 86 Type IV, V, VII, X, XIV 
collagen, gelatin, fibronectin 
Stromelysin-1 NMIP-3 57 45 Type III, IV, IX, X collagen, 
aggrecan, laminin, fibronectin 
Stromelysin-2 MMP-l0 57 44 Type III, IV, V collagen, 
aggrecan, gelatins, fibronectin 
Stromelysin-3 MMP-11 51 44 Procollagens I, II, III 
Matrilysin MMP-7 28 19 Type IV, X collagen, gelatin, 
aggrecan, proteoglycan 
laminin, elastin, fibronectin 
Macrophage metalloelastase MW-12 54 45/22 As for matrilysin 
MTl MMP MMP-14 66 56 pro-MW-2, -MW- I3, pro 
MT2 MMP M1113- 15 72 MW-2 
MT3 MMP M W-16 64 52 MMP-2 
MT4 MMP MMP-17 proTNF 
MT5 MMP MW-24 63 MW-2 
MT6 MMP (Leukolysin) MMP-25 34 28 
MMP-19 56 48 Type IV collagen, laminin, 
fibronectin, nidogen 
Enamalysin MMP-20 
MW-23 44 Unknown 
Matrilysin-like MMP-26 29.6 19 
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1.4.2.7 Transcriptional regulation of MMPs 
Expression of MMPs in most tissues is low during phases of quiescent ECM 
remodelling and is induced during periods of active ECM remodelling. MMP gene 
expression is transcriptionally regulated by a variety of extracellular factors such as growth 
factors and cytokines (Shapiro, 1998). The promoter regions of MMP -1, -3, -7, -9, -10, - 
12 and -13 exhibit AP-1 regulatory elements which bind to members of the AP-1 
transcription factor family and polyoma enhancer A binding protein-3 (PEAS) elements that 
interact with members of the Ets transcription factors (Westermark and Kahari, 1999). 
These regulatory elements play an important role in the regulation of MMP gene expression 
in response to stimuli including phorbol ester, cytokines and growth factors (Angel et al., 
1987). Overexpression of c-fos in transgenic mice has been shown to induce expression of 
MMP-13 predominantly in bone although expression of MMP-3, -9 and -10 was not 
affected suggesting that c-fos differently regulates expression of distinct MMP genes in vivo 
(Gack et al., 1994). 
1.4.3 ADAM (A Disintegrin and meta1Ioproteinase) 
The ADAMs or MDCs (metalloproteinase-like, disintegrin-like, ysteine-rich 
proteins) form a large family of multifunctional proteins that fall within the metzincin 
superfamily (Wolfsberg and White, 1996; Primakoff and Myles, 2000). To date 30 
transmembrane glycoproteins have been identified (Table 1-3) which have a characteristic 
multi-domain structure (Fig. 1-5). Tang and Hong, (1999) identified a second group of 
soluble cell associated ADAMs that have C-terminal thrombospondin repeats and have been 
termed ADAMTS (Fig. 1-5). 
All ADAMs isolated to date consist of approximately 750 amino acids and have a 
prodomain, metalloprotease, disintegrin, cysteine-rich, epidermal growth factor (EGF)-like, 
transmembrane and cytoplasmic tail domains. The protease and disintegrin domains of the 
ADAMs share approximately 30% sequence identity with a group of metalloproteinases 
isolated from snake venoms known as the reprolysins. 
Expression studies of the known ADAM genes have shown that they have a 
surprising tissue distribution (Table 1-3). A total of 12 ADAM genes are expressed 
exclusively and 3 ADAM genes predominantly in the testis (Wolfsberg et al., 1995; Hooft 
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van Huijsduijnen, 1998; Zhu et al., 1999; Cerretti et al., 1999). This suggests a special 
relationship between ADAM function and the processes of spermatogenesis and 
fertilization. Cell-cell interactions are believed to play crucial roles in neural function and 
development and 4 ADAM genes have been found to be expressed in brain tissue. ADAM 
--22 and -23 (MDC 2 and 3) are expressed exclusively and ADAM-lI (MDC) 
predominantly in the brain (Sagane et al., 1998). Kuzbanian the Drosophila orthologue of 
ADAM-10 has been shown to be expressed in neurons and to be involved in neurogenesis 
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Fig. 1-5 Domain structure of A: ADAMs and B: ADAMTS. 
The prodomain (P) blocks protease activity via the cysteine switch mechanism; the 
metalloprteinase domain (M) has protease activity; the disintegrin domain (U) has adhesion 
activity; the cysteine rich domain (C) has been shown to have membrane fusion activity in some 
membrane bound members; the F, GIF-like domain (E) and cytoplasmic domain present in membrane 
anchored and absent in ADAMTS. The thrombospondin type I repeat anchors AI)AM'I'S members 
to the extracellular matrix. 
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TABLE 1-3 Membrane anchored ADAMS 
cDNA Other Designations Tissue Distribution Species 
ADAM-1' PH-30 a; Fertilin a Testis predomniant Mouse, Human, Rat 
ADAM-2 PH-30 P-, Fertilin ß Testis specific Mouse, Human, Rat 
ADAM-3 Cyritestin; tMDC I Testis specific Mouse, Human, Rat 
ADAM-4 tMDC V Testis predominant Mouse, Rat 
ADAM-5 tMDC II Testis specific Mouse 
ADAM-6 tMDC IV Testis predominant Rat 
ADAM-7 Epididymal Apical Protein I Testis specific Mouse, Human, Rat 
ADAM-8' Macrophage Surface antigen (MS2) Macrophage Mouse, Human 
ADAM-9' MDC 9; meltrin y Ubiquitous Mouse, Human 
ADAM-10' MADM; kuzbanian in Drosophila Brain, spleen Mouse, Human 
ADAM-11 MDC Brain Mouse, Human 
ADAM-12' Meitrin a Skeletal muscle, bone Mouse, Human 
ADAM-13' Neural Crest Xenopus 
ADAM-14 adm-1 Sperm C. elegans 
ADAM-15' Metargidin; MDC 15 Cartilage, bone Mouse, Human 
ADAM-16' MDC 16 Testis specific Xenopus 
ADAM-17' TACE Ubiquitous Mouse, Human 
ADAM-18 tMDC III Testis specific Mouse, Human 
ADAM-19' Meltrin ß Skeletal muscle, bone Mouse, Human 
ADAM-20' Testis specific Human 
ADAM-21' Testis specific Human 
ADAM-22 MDC 2 Brain Mouse, Human 
ADAM-23 MDC 3 Brain Mouse, Human 
ADAM-24' Testase-1 Testis specific Mouse 
ADAM-25' Testase-2 Testis specific Mouse 
ADAM-26' Testase-3 Testis specific Mouse 
ADAM-27 Testis specific 
ADAM-28' eMDC II Human 
ADAM-29 svphl Testis specific Human 
ADAM-30' svph4 Testis specific Human 
a Contain the metalloproteinase active site sequence f1EXGHXXGXXJ-ID 
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1.4.3.1 Proteinase Activities of ADAMs 
Among the 30 known ADAM genes, 17 have a metalloproteinase active site 
sequence, HEXGHXXGXXHD, and are predicted to be catalytically active (Table 1-3). 
These ADAMs also contain a potential cysteine switch mechanism, and thus their proteinase 
domains may be activated by removal of their prodomains. This has recently been shown in 
the case of ADAM-12 (Loechel et. al., 1999). The physiological substrates for only 4 of 
these ADAMs have been elucidated; ADAM-9, -10, -17 and -19 have been shown to be 
involved in protein ectodomain shedding. 
Kuzbanian (ADAM-10) has been found to release a soluble form of the Notch ligand 
(Qi et. al. 1999) which is a cell surface receptor which regulates cell fate determination in 
neurogenesis. More recently Dallas et al., (1999) have shown colocalization of the 
mammalian orthologue of kuzbanian, ADAM-10, and Notch receptors in osteoblasts and 
osteocytes at locations of active bone formation. Thus ADAM 10 may be involved in cell- 
fate determination of osteoblast progenitor cells, possibly during skeletal development and 
normal bone remodeling. ADAM-10 has also been purified from bovine brain and shown to 
be capable of degrading myelin basic protein (Chantry et al., 1989) and more recently, 
Millichip et al. (1998) has shown that ADAM-10 purified from bovine kidney has type IV 
collagenase activity. Whether myelin basic protein and type IV collagenase are true 
physiological substrates for ADAM-10 is not clear. 
ADAM- 17 (also called TNF-a converting enzyme, TACE) has been shown by direct 
biochemical assay to catalyze the release of the membrane anchored form of TNF-a to its 
soluble form (Moss et al., 1997; Black et al., 1997). Further Peschon et al. (1998) showed 
that TACE-knockout mice were unable to shed TNF-a and were also unable to shed 
embryonic TGF-a resulting in embryonic lethality in most fetuses. TACE-knockout mice 
were also unable to shed the TNF receptor, the adhesion molecule L-selectin or amyloid 
precursor protein (APP), suggesting that TACE has multiple substrates. It has also been 
shown that ADAM-10 is able to shed TNF-a (Lunn et al., 1997). 
ADAM-9 (MDC9) has been reported to shed the heparin-binding EGF-like growth 
factor (Izumi et al., 1998). Both the membrane-anchored and soluble form of this growth 
factor are active but the soluble form can act on cells distant from the site of its release. 
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The remaining 13 proteinases remain `orphan proteinases', lacking an identified 
endogenous substrate. Recent biochemical work has shown that the metalloproteinase 
domain ADAM -12 (meltrin a) is catalytically active. Loechel et al. (1998) used the 
trapping mechanism of a2-macroglobulin to assay for protease activity of wild-type and 
mutant ADAM 12 proteins expressed in a COS cell transfection system. 
1.4.3.2 Cell -adhesion activity 
The disintegrin-like domain of ADAMs shares with PIII snake venom 
metalloproteinases (PIII SVMPs) an amino acid binding loop which protrudes from the core 
structure. In PIII SVMPs this binding loop consists of 13 amino acids with a possible 
integrin binding sequence at its tip consisting of a tripeptide along with an adjacent carboxy- 
terminal cysteine residue. ADAMs share with their PIII SVMIP couterparts the extra 
cysteine carboxy-terminal to the presumed active site tripeptide, but the sequence of the 
predicted 14 amino acid binding loop is a great deal more degenerate among the ADAMs 
(Wolfsberg and White, 1996). The diverse sequences among the ADAMs could reflect that 
not all ADAMs serve as ligands for integrins. A specific interaction between the ADAM 
disintegrin-like domain and a cellular receptor has been demonstrated for three members of 
the ADAMs family. 
Almeida et al. (1995) demonstrated a specific interaction between the disintegrin 
domain of ADAM-2 (fertilin ß) present on sperm and the a6ß 1 integrin present on either 
mouse oocytes or mouse embryonal F9 cells. In sperm-egg or sperm-cultured cell binding 
assays, a synthetic peptide constituting the integrin binding loop of ADAM-2, was able to 
inhibit sperm-egg or sperm-cultured cell binding. Use of a monoclonal antibody to the a6 
subunit also inhibited binding confirming an association between the disintegrin-like domain 
and a6ß1 integrin. 
Another testis-specific sperm surface ADAM (ADAM-3 or cyritestin) has also been 
implicated in sperm-egg binding (Yuan et al., 1997). An eight-residue peptide from the 
cyritestin disintegrin loop sequence inhibits sperm-egg adhesion and subsequent fusion. 
ADAM-15 (metargidin) is the only member of the ADAM family that has an RGD 
sequence in its disintegrin-like domain. Zhang el al. (1998) used recombinant ADAM-15 
expressed in E. coli and investigated its binding activity to Chinese Hamster Ovary (CHO) 
cell lines expressing different recombinant integrins; ADAM-15 specifically interacts with 
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avß3. In addition, Nath et al. (1999) identified integrin ligands for ADAM-15 on 
haemopoietic cells using recombinant ADAM-15 expressed as an Fc fusion protein. 
ADAM- 15 interacted with the avß3 integrin on the monocytic cell line U937 and to the 
(x501 integrin on the T cell line, MOLT-4. Iba et al. (1999) examined the ability of human 
ADAM-15 to support tumour cell adhesion. Using an in vitro binding assay and 
recombinant disintegrin-like domain expressed in E. coli it was found that the disintegrin- 
like domain of ADAM-15 supported adhesion to avß3-expressing A375 melanoma cells. 
Iba et al. (1999) have demonstrated that recombinant polypeptides of the cysteine- 
rich domain of human ADAM-12, but not the disintegrin-like domain supported cell 
adhesion of a panel of carcinoma cell lines. This interaction could be completely inhibited by 
pretreatment of the ADAM-12 cysteine-rich domain with heparin leading to the suggestion 
that ADAM-12 interacts with heparan sulfate chains of the syndecan family of cell surface 
proteoglycans. More recently Zolkiewska el al. (1999) have expressed the disintegrin- 
like/cysteine-rich domain of mouse ADAM-12 and shown that the recombinant protein 
supported adhesion of C2C12 myoblasts and NIH 3T3 fibroblasts. 
1.4.3.3. Cell-fusion activity 
A potential role for members of the ADAM family in cellular fusion was raised by 
the observation that ADAM-1 posesses a potential fusion peptide consisting of 23 amino 
acids within the cysteine rich domain that is similar to the potential fusion sequence of 
rubella virus (Blobel et al., 1992). In addition ADAMS-9, -11 and -12 also possess a 
potential fusion peptide (Wolfsberg and White, 1996). In support of this expression of 
antisense RNA to ADAM-12 in the myoblast cell line, C2, suppressed cellular fusion in this 
cell line and overexpression of ADAM-12 facilitated fusion (Hiromasa et al., 1995). 
Studies by Inoue et al. (1997) demonstrated expression of ADAM-9, -12, -15 and - 
19 in osteoblasts, but the expression of ADAM-12 and -19 was not detected in osteoclasts, 
suggesting that ADAM-12 is not involved in osteoclasts formation. Studies have 
demonstrated, by in situ PCR, that ADAM-12 is expressed in osteoclasts and that addition 
of antisense oligodeoxynucleotides to bone marrow cultures prevents osteoclast formation 
(Abe et al., 1999). Although the evidence suggests that ADAM-12 is involved in cellular 
fusion a definitive role has not been proven. 
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1.4.4 Cvsteine Proteinases 
The lysosomal cysteine proteinases, which include the cathepsins B, L, K and S, function at 
an acidic pH and have been reported to degrade major bone matrix components such as 
type I collagen in vitro (Kirschke et al., 1982; Burleigh el al., 1974). Localization of 
cathepsins B, L and K in osteoclasts has been demonstrated by immunohistochemical 
staining (Sasaki and Ueno-Matsuda, 1993; Goto et al., 1993; Littlewood-Evans et al., 
1997) suggesting that these enzymes are being exported to the subosteoclastic resorption 
zone. Further studies have provided direct evidence for participation of cathepsins during 
bone resorption by the fact that specific cathepsin inhibitors block bone resorption both in 
vitro and in vivo (Delaisse et al., 1984,1987; Hill et al., 1994a) and prevent collagen 
degradation within the subosteoclastic resorption zone (Everts et al., 1988,1992). 
1.4.4.1 Cathepsin B and L 
Cathepsin B is the most abundant cysteine proteinase and is expressed as a 36 kDa 
proform, that is stable at alkaline pH and is converted in the lysosomes to an active 28 kDa 
form. It is capable of cleaving type I collagen in the N-terminal telopeptide region resulting 
in depolymerization of the cross linked collagen fibrils (Burleigh, 1977). Cathepsin B is also 
capable of cleaving collagen types II, IX and XI within the non-helical regions (Maciewicz 
et al., 1991). 
Cathepsin L is synthesized as a proenzyme and processed to an active form of 25 
kDa. It has a similar specificity for collagen degradation as cathepsin B although it has been 
shown to be 20 times more active (Maciewicz, 1987). Kakegawa et al. (1993) showed that 
a specific inhibitor of cathepsin L completely inhibited pit formation by rat osteoclasts 
whereas no inhibition was observed with a specific inhibitor of cathepsin B. In contrast, 
specific inhibitors of cathepsin L do not inhibit human osteoclast resorption in vitro (James 
et al., 2001). 
1.4.4.3 Cathepsin K 
The cDNA encoding cathepsin K was originally cloned from rabbit osteoclasts and 
designated OC2 (Tezuka et al., 1994a) and has since been isolated from human cDNA 
libraries independently by several groups (Bromme and Okamoto, 1995, Inaoka et al., 
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1995; Shi et al., 1995). Bossard et al. (1996) demonstrated that cathepsin K is a highly 
active cysteine proteinase that is capable of hydrolyzing extracellular matrix proteins at pH 
5.5. In situ hybridization studies demostrated that significantly higher levels of cathepsin K 
are expressed in osteoclasts than cathepsins B, L, and S (Drake et al., 1996) implicating 
cathepsin K as having a key role in dissolution of bone matrix during normal bone 
remodelling and in pathological processes such as osteoporosis and osteoarthritis. The view 
that cathepsin K plays a pivotal role in bone resorption was strengthened by the 
identification of mutations in the cathepsin K gene which are linked to pycnodysostosis, a 
hereditary bone disorder characterized by impaired osteoclast function in bone resorption 
(Ho et al., 1999). Furthermore, mice with a targeted disruption of cathepsin K exhibit an 
osteopetrotic phenotype with increased trabecular bone density and retention of cancellous 
bone in the shafts of long bones (Saftig et al., 1998; Gowen et al., 1999). Garnero et al. 
(1998) showed the collagenolytic activity of cathepsin K is directed both outside the helical 
region and also at sites inside the helical region. Thus the activity of cathepsin K is sufficient 
to completely degrade insoluble collagen of cortical bone. 
1.5 IN VITRO BONE RESORPTION ASSAYS 
In vitro assays for bone resorption have been developed over the last three decades 
which have increased our understanding of the role of molecules and local and systemic 
factors in the modulation of bone resorption. 
1.5.1 Bone organ cultures 
Bone organ cultures were developed by Raisz (1965) for fetal long bones and 
subsequently adapted to a variety of bone explants including mouse neonatal calvariae 
(Reynolds and Dingle, 1970) and 17-day-old fetal metatarsal explants (Scheven et al., 
1986a). Resorption in these assays is detected by measuring the release of 45Ca as an 
indicator of mineralized bone resorption or [3H]-proline as an indicator of organic matrix 
dissolution from prelabelled bones. These assays have been useful in the evaluation of the 
effects of osteotropic factors such as PTH (Raisz, 1965), 1,25-(OH)2D3 (Vink-van 
Wijngaarden et al., 1995), PGE2 (Stewart and Stern, 1986) and TNF-a (Votta and 
Bertolini, 1995) on bone resorption. They have also enabled investigators to assess the 
effects of inhibitors such as bisphosphonates (Boonekamp et al., 1986) and MMP inhibitors 
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(Hill et al., 1995b). Other parameters of bone resorption have been assessed in organ 
culture assays including cathepsin release (Delaisse et al., 1984) and release of collagenase 
(Lenaers-Claeys and Vaes, 1979). Bone resorption assessed by the fetal rat long bone assay 
and the mouse calvarial assay involve both activation of osteoclasts and osteoclast 
recruitment making it difficult to assess which phase of bone resorption is being targeted. 
The development of the 17-day-old fetal metatarsal and metacarpal assays have enabled 
assessment of the effects of agents on osteoclast formation and migration since at this age 
mature osteoclasts have not yet developed and only osteoclast precursors are present in the 
periosteum. Upon culture the osteoclast precursors fuse to form mature osteclasts that 
migrate into the calcified cartilage which is resorbed (Scheven et al., 1986a). 
1.5.2 Isolated osteoclast assay 
Methods for the isolation of mature osteoclasts from neonatal rat and rabbit long bones 
were first devised by Chambers and Magnus (1982). The ability of isolated osteoclasts to 
excavate resorption lacunae or pits on a mineralized matrix such as bovine cortical bone, 
dentine or ivory was developed as the basis of a bioassay by Chambers et al. (1985a). The 
assay involved disaggregation of the osteoclasts from the endosteal surface of neonatal rat 
femurs and tibias. The bone cell suspension was allowed to adhere for only 20 minutes 
before washing off nonadherent cells producing what approximated to a purified population 
of osteoclasts although contaminating cells were present. The purity of the osteoclast 
preparation was demonstrated by their lack of response to osteotropic factors such as PTH 
(McSheehy and Chambers, 1986), 1,25-(OH)2D3 (McSheehy and Chambers, 1987), IL-1 
and TNF (Thomson et al., 1986,1987). Subsequently, osteoclasts from a range of sources 
have been used including 6-day-old mouse, embryonic chick (Oursler et al., 1991a), fetal 
human (Murrills et al., 1989) and human osteoclastoma (Chambers et al., 1985b). The main 
disadvantages of this assay are that the osteoclast preparations are impure and the isolated 
osteoclasts are relatively short lived. 
1.5.3 Osteoclast formation assays 
Cellular mechanisms controlling differentiation of osteoclasts from haemopoeitic stem cells 
and commited osteoclast precursor cell populations have been studied using a variety of in 
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vitro bioassays. These assays have provided information on the effects of various 
osteotropic hormones and local factors on osteoclast formation. 
1.5.3.1 Bone marrow cultures 
The generation of MNCs with characteristics of osteoclasts was first demonstrated by 
Testa et al. (1981) from long term feline bone marrow culture. Subsequent studies applied 
this culture system to other animal models including rabbit (Fuller and Chambers, 1989a) 
and human (MacDonald et al., 1987). The MNCs formed in experiments using feline and 
rabbit bone marrow possessed many features characteristic of osteoclasts, including TRAP 
staining, CT receptors and responsivenes to osteotropic hormones such as 1,25-(OH)2D3 
and PTH. In human bone marrow cultures the MNCs formed did not bind calcitonin and 
were unable to form resorption pits on bone slices, leading to the conclusion that they may 
have been macrophage-polykaryons (Flanagan et al., 1992). Sarma and Flanagan, (1996) 
demonstrated that addition of M-CSF to human bone marrow cultures induced large 
numbers of MNCs that were CT receptor positive and that resorbed bone thus implicating 
M-CSF as being of critical importance in the formation of human osteoclasts in vitro. 
Takahashi et al. (1988a) developed an assay for generation of numerous TRAP and 
CT receptor positive MNCs from mouse bone marrow cultured in the presence of 1,25- 
(OH)2D3 in which the MNCs formed within 8 days and had the ability to form pits on 
dentine slices. The effects of various osteotropic and local factors on osteoclast formation 
have been assessed using the mouse bone marrow culture system. Akatsu et al. (1989a, b) 
demonstrated that PGE2 and PTH-related protein (PTH-rP) could stimulate osteoclast 
formation as well as IL-1 (Akatsu et al., 1991). 
1.5.3.2 Coculture of hemopoietic cells with fetal bone rudiments 
Osteoclast formation from hemopoietic stem cell populations was first demonstrated 
by Burger et al. (1982) in which bone marrow or embryonic liver was cocultured with 
periosteum-stripped fetal mouse long bones which are devoid of osteoclast precursors. 
Osteoclasts formed in these cultures that were present in the zone of calcified cartilage. 
This assay was refined by Scheven et al. (1986b) by fractionating mouse bone 
marrow into stem cell populations by equilibrium density centrifugation and fluoescence- 
activated cell sorting (FACS) which were then cocultured with stripped long bones. In this 
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system osteoclast formation increased with increasing stem cell purity although the culture 
time required for osteoclast formation increased. 
Subsequent studies demonstrated that osteoclasts could be generated in experiments 
using a clonal pluripotent hemopoietic stem cell line, FDCP-mix A4, cocultured with fetal 
bone rudiments (Hagenaars et al., 1991). 
1.5.5.3 Coculture of hemopoietic cells with osteoblasts 
Takahashi et al. (1988b) developed a bioassay in which MNCs were generated in 
cocultures of mouse spleen cells and mouse calvarial osteoblasts in the presence of 1,25- 
(OH)2D3. These osteoclast-like MNCs possessed all the characteristics of osteoclasts 
including calcitonin receptors and the ability to form resorption pits on dentine slices. 
Subsequent experiments demonstrated that calvarial osteoblasts could be replaced by the 
bone marrow-derived, preadipocyte cell lines, MC3T3-G2/PA6 and ST2. These cell lines 
could support osteoclast formation in this bioassay in the presence of 1,25-(OH)2D3 and 
glucocorticoids such as dexamethasone (Udagawa et al., 1989). Chambers et al. (1993) 
established stromal cell lines from a transgenic mouse in which the interferon-inducible 
major histocompatibility complex promoter drives the simian virus 40 (SV40) temperature 
sensitive immortalizing gene (tsA58). These immortalized cell lines were capable of 
supporting osteoclast formation in coculture with spleen cells. These cell lines also 
expressed alkaline phosphatase indicative of an osteoblastic phenotype. Matsumoto et al. 
(1995) also established a bone marrow derived cell line, TM8, from an SV40 large T 
antigen transgenic mouse which expressed an osteoblastic phenotype and could support 
osteoclast formation. 
Several cell lines of hemopoietic origin have been shown to have osteoclastic 
potential when cocultured with osteoblasts. Hattersley and Chambers, (1989b) 
demonstrated that the FDCP mix A4 multipotential cell line was capable of generating 
osteoclasts when cocultured with bone marrow stromal cells. Cell lines of hemopoietic 
origin have been derived from the H-2K8tsA58 transgenic mouse (Chambers et al., 1993) 
which when cocultured with stromal cell lines on dentine slices in the presence of 1,25- 
(OH)2D3 resulted in extensive resorption. 
Bioassays analyzing osteoclastic lineage have been developed using a two-step 
coculture system of osteoblasts with hemopoietic cells collected from colonies formed in 
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semi-solid medium in the presence of CSFs (Hattersley and Chambers, 1989b; Hattersley et 
al., 1991; Takahashi et al., 1991; Kerby et al., 1992). Takahashi et al. (1991) demonstrated 
using this system that marrow cells recovered from semosolid cultures supported by M-CSF 
(M-CFU) formed more TRAP-positive and CTR-positive MNCs when cocultured with 
osteoblasts than did GM-CSF, G-CSF or IL-3. In a similar investigation using spleen cells 
as a source of hemopoietic stem cells Kerby et al. (1992) demonstrated that multilineage 
colonies had a greater potential to form osteoclasts as assessed by pit formation than single 
lineage colonies. 
1.6 PROGRAMMED CELL DEATH 
Programmed cell death (PCD) or apoptosis is the process whereby cells activate an 
intrinsic death program and kill themselves. PCD occurs in normal tissue turnover (Wyllie 
et al., 1980b), embryogenesis (Hammar and Mottet, 1971), metamorphosis (Decker, 1976), 
and during tumour growth and regression (Kerr et al., 1972). Cells that die in this manner 
normally undergo a characteristic set of morphological and biochemical changes (Fig 1-6): 
they appear shrunken, with extensive membrane blebbing and nuclear fragmentation (Wyllie 
et al., 1980b). PCD is an energy dependent process requiring ATP and occurs under 
normal physiological conditions. Necrosis occurs in circumstances of wide departure from 
physiological conditions and is not energy dependent. The terminal stages in PCD are 
characterized by the cell fragmenting into a number of membrane bound vessicles called 
apoptotic bodies. These apoptotic bodies contain a variety of cytoplasmic organelles such 
as mitochondria which appear intact and of normal appearance and some also contain 
nuclear fragments. These membrane bound vesicles are eventually phagocytosed by 
macrophages without the involvement of an inflammatory reaction (Wyllie et al., 1980b). 
In contrast, cells undergoing necrosis swell and rupture, releasing their contents and 
thereby eliciting an inflammatory response (Wyllie et al., 1980b). Ultrastructurally, the 
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Fig. 1-6 General overview of apoptosis (from Dragovich et al. 1997). 
Mitochondrial stress caused by growth factor withdrawal (A) induces release of cytochmmr e into 
the cytoplasm which interacts with Apaf-1, ATP and procaspase-9 resulting in the auto-catalytic 
activation of' caspase-9 and subsequent activation of effector caspases-3 and -7. Release of 
cytochrome c is regulated by Bcl-2 family members. In receptor-mediated apoptosis (13) interaction 
of death factor such as 'I'NF-a with 'I'NFRI or Fas ligand with las initiates recruitment of '1'NF- 
receptor associated death domain ('I'RADD) or Fas associated death domain (I"ADD) and 
procaspase-8 molecules with the subsequent catalytic activation of caspase-8. 
Ultrastructural changes in the nucleus are characterized by chromatin condensation 
and margination at the nuclear membrane followed by nuclear fragmentation. Chromatin 
condesation in PCD is associated with the activation of an endogenous deoxyri boll tic lease 
which excises nucleosome chains from nuclear chromatin. This results in an 
oligoonucleosomal ladder-type fragmentation such that the degraded DNA will törm a 200- 
hp ladder pattern when separated by gel electrophoresis (Wyllie el a!., I980b). 
The morphological features observed in cells undergoing apoptosis arise from the 
activities of a family of cysteine proteinases called caspases which form part of an 
evolutionarily conserved mechanism for triggering apoptosis. Fourteen caspases have been 
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identified and are synthesized as proenzymes of 30-50 kDa (Nunez et al., 1998). Caspases 
involved in apoptosis can be divided into two subfamilies: initiator and executor or effector 
caspases. Caspase 8,9 and 10 are initiator caspases activated by forming complexes with 
death factor receptors or Apaf-1 (Fig. 1-6). This is followed by activation of downstream 
effector caspases such as caspase 3 and 6. Effector caspases cleave a number of structural 
and regulatory proteins such as lamins and cytokeratins (Stroh and Schultz-Osthoff, 1998) 
leading to the morphological features of apoptosis. 
Proteins belonging to the Bcl-2 family are major intracellular regulators of apoptosis 
that are evolutionarily conserved. In mammals 15 members of the Bcl-2 family have been 
identified that either suppress or promote apoptosis. Anti-apoptotic Bcl-2 family members 
include the proteins Bcl-2 and Bcl-XL whilst the proapoptotic proteins include Bax, Bid and 
Bad (Adams and Cory, 1998). Proteins of the Bcl-2 family are localized to the membrane of 
mitochondria, the endoplasmic reticulum and the nucleus. Anti-apoptotic proteins are 
believed to inhibit apoptosis by interfering with the release of cytochrome c from the 
mitochondrial membrane (Fig. 1-6). The ratio of pro-apoptotic: anti-apoptotic proteins is 
believed to determine a cells susceptibility to apoptosis (Merry and Korsmeyer, 1997) 
1.6.1 Apoptosis induced by TNF-a 
Tumour necrosis factor-a (TNF-a) and its receptors (TNFR1 and TNFR2) are the 
prototype members of two superfamilies which play an important role in regulating many 
biological processes (Lotz et al., 1996). Over 20 members of the TNF receptor superfamily 
and 9 cognate ligands of the ligand superfamily have been identified thus far in mammalian 
cells (Orlinick and Chao, 1998). Of the members of the TNF ligand family, three are potent 
death factors inducing apoptosis by binding to their cognate receptors thereby signalling the 
cell death pathway (Nagata, 1997). TNF-a has been shown to induce apoptosis in several 
cell lines including the human leukemia cell lines HL-60 and U937 (Greenblatt and Elias, 
1992) and the murine fibrosarcoma cell lines L292 and WEHI (Fulton and Chong, 1992). 
Other death factors include Fas ligand (FasL) also called CD95L or Apo 1L. This ligand 
induces apoptosis by binding to its receptor, Fas, also called CD95 or Apo l. A third 
member known as TRAIL (TNF related apoptosis inducing ligand) also called Apo2L has 
been identified that induces apoptosis in tumorigenic or transformed cells but not in normal 
cells (Wiley et al., 1995). TRAIL can interact with four distinct receptors: DR4, DR5, 
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DcR1 and DcR2. Both DR4 and DR5 are type I transmembrane proteins that contain 
cytoplasmic death domains and upon ligation with TRAIL, mediate apoptosis (Pan et al., 
1997). In contrast neither DcR1 nor DcR2 mediates apoptosis upon ligation with TRAIL. 
Because they lack the ability to directly signal cell death DcR1 and DcR2 have been 
hypothesized as being protective factors, either by acting as "decoy" receptors (Sheridan et 
al., 1997) or by transduction of an antiapoptotic pathway (Degli-Esposti et al., 1997). 
TNF-a induces apoptosis by binding to its cognate receptor TNFRI or TNFR2. 
Although both TNFR1 and TNFR2 can transduce the signal for apoptosis, TNFR1 is 
responsible for these signals in most cases (Vandenabeele et al., 1995). TNFRI contains a 
homologous cytoplasmic sequence (about 80 amino acids) which has been designated a 
"death domain" (Targalia et al., 1993). This sequence, which is also found in the receptors 
which interact with FasL and TRAIL, enables death receptors to engage the cells apoptotic 
machinery (Ashkenazi, 1998) and activation of caspases (Fig. 1-6). 
1.6.2 Ceramide Mediated Apoptosis 
Ceramide is a sphingosine based lipid second messenger molecule that has been 
shown to mediate TNF stimulated apoptosis in the human myeloid leukemia cell line U937 
(Dressler et al., 1992). It has been shown in this cell line that activation of the TNFR1 
receptor promotes rapid breakdown of the phospholipid, sphingomyelin, increasing 
intracellular free ceramide levels within seconds. Gulbins et al. 1995 have demonstrated 
that the sphingomyelin pathway is engaged with similar kinetics following specific ligation 
of Fas in Jurkat T cells. Activation of TNF receptors stimulates neutral and acidic 
sphingomyelinases (N- and A-SMases) which catalyze the hydrolysis of sphingomyelin to 
ceramide and phosphorylcholine. Definitive evidence for the critical role of A-SMase and 
ceramide in initiating apoptotic signaling was provided by studies using genetic models of 
A-SMase deficieny. Lymphoblasts from patients with Niemann-Pick disease, an inherited 
disorder of A-SMase, and A-SMase knockout mice show defects, but not total loss, of the 
apoptotic response (Santana et al., 1996). 
Ceramide has been shown to be an activator of the stress activated protein kinase/c- 
JUN N-terminal kinases (SAPK/JNK) pathway (Verheij, 1996). This pathway is activated 
by many stress stimuli such as irradiation and reactive oxygen species any of which may 
lead to apoptosis (Verheij, 1996). 
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1.6.3 Apoptosis in Bone Cells 
1.6.3.1 Osteoblasts 
Apoptosis has been observed in the murine clonal osteoblast cell line MC3T3-E1 
transfected with the human T-cell leukemia virus type I (HTLV-I) tax gene (Kitajima et al., 
1996a). HTLV-I infection causes adult T-cell leukemia (ATL) which is characterized by 
hypercalcemia-associated bone lysis (Bunn et al., 1983). In studies of HTLV-I transfected 
MC3T3-EI cells, these cells underwent apoptosis in response to TNF-a and this was 
associated with activation of the NF-xB signalling pathway (Kitajima et al., 1996b). It has 
therefore been suggested that the induction of apoptosis by TNF-a and the activation of 
NF-KB in HTLV-I taxexpressing osteoblasts may be involved in the pathogenesis of bone 
lesions in patients with HTLV-I related disease. More recently, Jilka et al., (1998) reported 
that murine osteoblasts undergo apoptosis after serum withdrawal and after addition of 
TNF-a. 
1.6.4.2 Osteoclasts 
Recruitment, differentiation and activity of osteoclasts are tightly controlled by 
systemic and local factors. Vitamin D3, prostaglandins, TGF-ß, IL-1, IL-6 and TNF-a 
stimulate osteoclast differentiation and activity via direct or indirect mechanisms. The fate 
of osteoclasts after bone resorption is largely unknown. A number of factors such as 
bisphosphonates, vitamin K2 and glucocorticoids have been shown to induce apoptosis in 
osteoclasts (Hughes et al., 1995; Kameda et al., 1996; Dempster et al., 1997). It has been 
reported that estrogen promotes apoptosis of murine osteoclast-like cells mediated by TGF- 
ß in a mixed cell population (Hughes et al., 1996). Thus estrogen may prevent excessive 
bone loss before and after the menopause by limiting osteoclast lifespan through promotion 
of apoptosis. It has reported that 17-0-estradiol was able to inhibit osteoclastic bone 
resorption activity in part by targeting osteoclasts directly to undergo apoptosis through 
estrogen receptor mediated mechanisms. In this study 17-0-estradiol induced osteoclast 
apoptosis in a dose- and time-dependent manner (Kameda et al., 1997). Other studies have 
demonstrated apoptosis of osteoclast precursors in bone marrow cultures in response to 
elevated levels of nitric oxide (van't Hof and Ralston, 1997) and osteoclast apoptosis 
following inhibition of vacuolar H+-ATPase (Okahashi et al., 1997). Furthermore, targeting 
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the a,, integrin subunit with oligodeoxynucleotides has been shown to induce osteoclast 
apoptosis (Villanova et al., 1999). 
1.7 AIMS 
The aims of the current study are firstly to investigate the effects of cytokines and 
bone matrix derived growth factors on osteoblast survival in vitro. Secondly to investigate 
the effects of IL-11, serine proteinases and members of the ADAM family on osteoblast and 
osteoclast function using in vitro bioassays. 
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2. Multiple Extracellular Signals Affect Osteoblast 
Survival 
2.1 INTRODUCTION 
Programmed cell death (PCD) has been established as a mechanism for maintaining 
cellular homeostasis during normal tissue turnover (Wyllie et al., 1980b). Skeletal tissue 
undergoes remodelling throughout life, influenced by both systemic and mechanical 
demands. It has been estimated that 65% of osteoblasts present at a remodelling site fail to 
differentiate into bone lining cells or osteocytes and that these cells die by apoptosis (Jilka et 
al., 1998). Recent studies highlight the importance of osteoblast apoptosis in bone diseases 
such as glucocorticoid induced osteoporosis, and the use of bisphosphonates (Plotkin et al., 
1999) and estrogen (Gohel et al., 1999) in preventing apoptosis in osteoblasts. 
In many models of PCD, cells are induced to die as a result of changes in 
environmental stimuli (Jacobson et al., 1994; Elis et al., 1991; Duke and Cohen, 1986). In 
general these studies of PCD suggest that the absence of a "survival factor, " such as a 
particular hormone or growth factor, will induce a cell to initiate its own cell death. Skeletal 
cells and other cells within the bone microenvironment, synthesize a variety of growth 
factors (GFs) and cytokines (Canalis et al., 1993b). The extracellular matrix of bone has 
been shown to be an abundant source of several polypeptide factors, most notably TGF-ß 
(Seyedin et al., 1986), IGF's-I and -II, PDGF, and acidic and basic FGFs (Haushka et al., 
1986). When released and presented to responsive cells during phases of bone resorption, 
these GFs influence bone remodelling in conjunction with IL-1 and TNF-a, cytokines 
produced mainly by bone marrow mononuclear cells. IGFs are important skeletal GFs, not 
only because of their abundance in bone but also because they have important actions on 
bone cell function and are expressed by skeletal cells (Delaney et al., 1994). These various 
GFs and cytokines influence the differentiated function of osteoblasts and bone resorption 
by interacting with cell surface receptors present on osteoblasts. These effects are critical 
for the formation of new bone and for the maintenace of bone matrix. 
Based on the importance of GFs and cytokines in bone remodelling their effects on 
osteoblast survival and apoptosis in vitro have been investigated. 
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2.2 MATERIALS & METHODS 
2.2.1 Materials 
Human recombinant TNF-a was purchased from R&D systems (Abingdon, Oxon, UK). 
ctIR-3, a monoclonal antibody to the type-I IGF receptor was obtained from Oncogene 
Sciences (Cambridge, UK). Terminal deoxynucleotidyl transferase, biotinylated dUTP, 
streptavidin fluorescein, trypsin, dispase and bacterial collagenase A were purchased from 
Boehringer Mannheim (Lewes, East Sussex, UK). Human recombinant IGFs-I and II, 
insulin from bovine pancreas, bFGF, EGF, PDGF, TGF- ß, 3-(4,5-dimethyl-thiazol-2-yl)- 
2,5-diphenyl tetrazolium bromide (MTT), and all cell culture reagents were purchased from 
Sigma Chemical Co. (Poole, Dorset, UK). M-CSF, G-CSF and GM-CSF, interferon-gamma 
(IFN-y) and murine LIF were purchased from British Biotechnology Ltd. (Oxford, UK) 
1,25-(OH)2D3 was a gift from Roche (Welwyn Garden City, UK). Deoxy[5 3H]-cytidine, 
specific activity 888 GBq/mmol, was purchased from Amersham International plc (Little 
Chalfont, Buckinghamshire, U. K). Litters of 1-day-old CD-1 mice were purchased from 
Charles Rivers (Kent, UK). 
2.2.2 Methods 
2.2.2.1 Preparation of osteoblasts from neonatal mouse calvariae 
Calvarial osteoblasts were prepared and characterized as previously described 
(Heath et al., 1984). Briefly, neonatal mouse calvariae were dissected free from adherent 
soft tissue, washed in Ca2+ and Mg2+ free Tyrode's solution (Appendix 1) and sequentially 
digested with 1 mg/ml trypsin (10 min), 2 mg/ml dispase (30 min) and 2 mg/ml bacterial 
collagenase A (3 x 30 min). Cells released by the last two collagenase digestions were 
washed and grown in alpha modification of minimum essential medium (a-MEM) 
containing 10% FBS and antibiotics for 4 days prior to use. All cultures were maintained at 
37°C in a humidified atmosphere of 5% C02/95% air. For survival assays, osteoblasts were 
plated in 100 µl of serum free CMRL-1066 medium containing 10"3 M thymidine to block 
cell proliferation, with or without added cytokines. Osteoblasts were characterized for 
alkaline phosphatase by incubating the cells for 45 min at room temperature in 0.1 M Tris- 
HCI pH 8.3 containing 0.1 mg/ml naphthol AS-MX phosphate and 0.6 mg/ml fast red TR 
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salt. Intracellular accumulation of cyclic AMP in response to PTH was measured by enzyme 
immunoassay (Amersham, UK). 
2.2.2.2 Cell survival assays 
MTT assay. Mitochondrial function was assayed by the ability of viable cells to convert 
soluble MTT into an insoluble dark-blue formazan reaction product (Mosmann, 1983). In 
the bulk cell photometric MTT assay, the bulk conversion of MTT in the well of a 96 well 
plate was measured photometrically as previously described (Mosmann, 1983). MTT was 
dissolved in phosphate buffered saline (PBS, Appendix 1) at a concentration of 5 mg/ml and 
sterilized by passage through a 0.22 µm filter. This stock solution was added (one part to 
10 parts medium) to each well of a 96 well tissue culture plate, and the plate was incubated 
at 37°C for 4 h. Acid-isopropanol (400 . tl of 10 M HCl in 100 ml isopropanol) was added 
to all wells and mixed thoroughly to dissolve the dark blue crystals. After a few min at room 
temperature, to ensure that all the crystals were dissolved, the plates were read on a 
microplate reader (Labsystems EIA reader) at a wavelength of 570 nm-630 nm. A standard 
curve was set up using 200 to 50,000 cells/well and the absorbance was directly 
proportional to the number of cells over this range. The % survival was defined as 
[(experimentalabsorbance - blankabsorbance)/ contro]absorbance-blankabsorbance)] x 100 where the 
controlabsorbance was the value obtained for 10,000 cells/well which is the number plated at the 
start of the experiment and the blankabsorbance was the value obtained in wells containing 
medium and MTT without cells. 
Plasma membrane permeability. Plasma membrane permeability was assessed using the 
membrane-impermeant DNA dye, ethidium homodimer, which labels dead cells. Live cells 
were labelled using the membrane permeant dye calcein AM. (Molecular Probes Inc., 
Leiden, Netherlands) Calcein AM is a non fluorescent dye which is converted into the 
fluorescent dye calcein by intracellular esterases, and is retained only in cells with an intact 
plasma membrane. The concentrated dyes were prepared according to the manufacturers 
instructions, and were added to unwashed cells in culture to final concentrations of 4 tM 
for ethidium homodimer and 2 pM for calcein AM. 
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2.2.2.3 Cell Proliferation assay 
Primary osteoblasts were plated at a density of 1x 104 cells/well of a 96 well plate 
and cultured for 48 h in CMRL-1066 medium with GFs or FCS in the presence or absence 
of non-radioactive thymidine (10'3 M). The cells were pulsed for the last 6h with 1 µCi 
[3H]-cytidine and DNA associated radioactivity was performed at the end of the experiment 
by fixing the cells with 5% TCA at 4°C for 10 min, washing in PBS and the cells were 
detached with trypsin-EDTA solution (0.5%: 0.02%). 
2.2.2.4 Analysis of DNA fragmentation by agarose gel electrophoresis 
DNA fragmentation was analyzed by agarose gel electrophoresis. Primary mouse 
osteoblasts were grown to confluence in 75 cm2 flasks and then cultured in serum free 
CMRL-1066 medium with or without TNF-a. Adherent cells were lysed with 0.1 M NaCl, 
10 mM Tris-HC1(pH 7.5), and 1 mM EDTA in 0.3% SDS and incubated with proteinase K 
(500 µg/ml) at 55°C for 15 h. Samples were extracted with an equal volume of 
phenol: chloroform, and the total DNA contained in the aqueous phase was precipitated with 
a 1/10 volume of sodium acetate (3 M, pH 6.6) and a 2.5 volume of ethanol at -80°C for 
15 h. DNA pellets were obtained by centrifugation at 13,000 xg (Labofuge 400R, Heraeus 
Instruments, Germany) for 15 min and resuspended in 50 pl of 10 mM Tris-HCI (pH 8.0) 
and 1 mM EDTA. Samples were then treated with 10 U/ml of DNAse-free RNAse for 1h 
at 37°C. Electrophoresis was performed on a 1% agarose gel in 1X Tris-Acetate-EDTA 
(Appendix 1) at 50 V for 1.5 h in the presence of 0.5 pg/ml of ethidium bromide. DNA 
bands were visualized on a UV transiluminator (UVP inc., UK). 
2.2.2.5 Terminal Deoxynucleotidyl Transferase-mediated dUTP-Biotin Nick End 
Labeling 
DNA cleavage was assessed by the terminal deoxynucleotidyl transferase- 
mediated dUTP-biotin nick end labelling (TUNEL) reaction, as described by Gavrieli et al. 
1992. Primary mouse osteoblasts were cultured in labtech chamber slides (Life 
Technologies, Paisley, Scotland) in serum free CMRL-1066 medium, containing thymidine 
(10"3 M) and with or without GFs. After 48 h in culture, the cells were fixed in 4% 
paraformaldehyde for 10 min, washed in 10 mM Tris-HCI, pH 8.0, and then permeabilized 
in 0.1% Triton X-100 in 10 mM Tris-HCI, pH 8.0, for 5 min. After washing in 10 mM Tris- 
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HCI, pH 8.0, the cells were preincubated for 10 min at room temperature in the reaction 
buffer for terminal deoxynucleotidyl transferase (200 mM potassium cacodylate, 0.22 mg/ml 
BSA, 25 mM Tris-HCI, pH 6.6). After 10 min the preincubation buffer was removed and 
reaction mixture containing 500 U/ml terminal deoxynucleotidyl transferase, 2.5 mM CoCl2, 
and 40 µM biotinylated dUTP added. After 60 min at 37°C, the reaction was terminated by 
the addition of 300 mM NaCl and 30 mM sodium citrate. After 25 min at room temperature 
cells were washed with PBS, and incubated with streptavidin fluorescein for 60 min at room 
temperature in the dark. After extensive washing in PBS, the cells were examined with a 
Leitz Laborlux fluorescence microscope. 
2.2.2.6 Electron Microscopy 
Primary mouse osteoblasts were plated at 2x 105 cells/ml on glass cover slips that 
had been previously coated with poly-L-lysine. Cells were cultured for 48 h in serum free 
CMRL-1066 medium with or without TNF-a. After 48 h cells were fixed with 2.5% 
glutaraldehyde in 0.2 M phosphate buffer (pH 7.3) at 4°C for 4 h. After washing in PBS, 
the cells were postfixed in 1% osmium tetroxide in phosphate buffer at 4°C for 30 min. The 
cells were then dehydrated in ascending grades of ethyl alcohol and embedded in taab resin. 
After removing the glass cover slip thin sections were cut on a Reichert ultramicrotome. 
The sections were stained with a saturated solution of uranyl acetate and a 4% solution of 
lead citrate and examined using a Hitachi H7000 electron microscope (Tokyo, Japan). 
2.2.2.7 Statistical analysis 
Data are presented as the mean ± SEM of six to twelve cultures per group. Each 
experiment was repeated three times. Differences between control and treatment groups 




2.3.1 Characterization of murine osteoblasts 
Histochemical staining of unstimulated primary cultures for alkaline phosphatase 
was strongly positive; 95.3 ± 3.1% of cells from six separate bone cell preparations 
exhibited positive staining (Fig. 2-1). The intracellular accumulation of cAMP levels in 
response to PTH was determined; treatment with PTH (10"$ M) for 10 min resulted in 
cAMP levels of 12.3 ± 1.2 pmole/ml, compared with control levels of less than 0.125 
pmole/ml. 
2.3.2 Survival of primary osteoblasts in culture 
When osteoblasts were cultured in serum-free and insulin-free CMRL 1066 medium 
containing thymidine (10'3 M) about 67% of cells survived after 24 h whilst only about 28% 
of cells survived in this medium after 48 h (Table 2-1). However, when the osteoblasts were 
cultured with 2% FCS in the presence of thymidine (10"3 M), which blocks cell proliferation 
(Murgo et al., 1980) and therefore permits the assessment of factors on cell survival, there 
was a 100% survival of the cells at both time intervals. 
As can be seen in Table 2-1 bFGF, IGF-I, IGF-II or a concentration of insulin (10"' 
M) high enough to activate IGF-I receptors increased the number of surviving osteoblasts 
after a 48 h culture period but had no effect on their survival after 24 h. In contrast, the 
immunoregulatory cytokine TNF-a induced cell death in the 24 and 48 h osteoblast 
cultures (Table 2-1). A variety of other GFs and osteotropic factors that were tested had no 
effect on either osteoblast survival or cell death, namely PDGF, EGF, TGF-ß, interleukins- 
1, -3, -6, -11, LIF, IFNy, M-CSF, GM-CSF, G-CSF and the osteotropic hormones PTH and 
1,25-(OH)2D3. 
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TABLE 2-1. Effects of cytokines and growth factors on the survival of primary mouse 
osteoblasts under serum free culture conditions. 
% Survival 
Treatment Conc. (M) 
24 11 48 1i 
Control 65±4 28±3 
FCS 2% 98 ± 5° 102 ± 6° 
Insulin 10-6 63 ±4 65 ± 2' 
IGF-I 10"' 71 ±5 72 ± 3° 
IGF-II 10'1 68 ±2 64 ± 4' 
bFGF 20 ng/ml 62 ±2 57 ± 3° 
PDGF 10"9 65±3 32±3 
GM-CSF 10'10 67 ±3 26 ±2 
G-CSF 10"10 60 ±4 31 ±4 
M-CSF 10'10 62 ±3 27 ±I 
ILIa 10"" 68 ±4 36 ±6 
IL3 10"10 62±3 33±3 
LIF 100U/ml 64 ±2 23 ±2 
IL-6 10"9 59±5 21±1 
IL-11 10"9 67±3 25±4 
EGF 10-9 65±3 28±3 
TGF-ß 10"" 61 t2 27 ±3 
TNF-a 10'10 18 t 2° 11 ± 1' 
IFNy 10"11 67±3 32±3 
PT13 2 U/ml 60 ±5 31 ±3 
1,25-(OH)2D3 10$ 69 ±3 28 ±1 
Mouse osteoblasts were cultured at a cell density of 10,000 cells per well of a 96 well plate in 
serum free CMRL-1066 medium in the presence of thymidine (10"3 M) and the above growth 
factors. After incubation for 24 and 48 h cell survival was assessed by MIT survival assay. 
The results are the mean ± SEM of 12 separate cultures. °P < 0.05 significantly different from 
the control. 
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The effects of bFGF, IGF- I, IGF-II and insulin on cell number were due to effects 
on osteoblast survival, rather than on cell proliferation as the addition of thymidine to the 
culture medium at a 10"3 M concentration effectively blocked the proliferative effects of 
these factors. As shown in Table 2-2, these factors both increased the number of surviving 
cells and proportionally decreased the number of dead cells, so that the total numbers of 
cells in the factor-containing microwells were not statistically different from the numbers in 
medium alone, thereby confirming that thymidine had effectively blocked DNA synthesis. 
The addition of thymidine did not induce cell death as the proportion of live/dead cells was 
similar in its presence/ absence (Table 2-2). 
Labelling osteoblast DNA with [3H]-cytidine confirmed that non-radioactive 
thymidine effectively blocked the effects of FCS and the various GF combinations on 
osteoblast proliferation (Table 2-3). 
TABLE 2-2. Effects of IGF-I, IGF-II, bFGF, and insulin on the numbers of live and 
dead osteoblasts. 
Factors added Thymidine 
(10"3 M; +/-) 
No. of cells after 48 h by 
phase contrast 
Live cells Dead cells 
None - 71 ± 15 509 ± 54 
None + 60 ± 18 486 ± 43 
Insulin (10"6 M) + 306 ± 41 278 ± 36 
IGF-I (10"7 M) + 351 ± 39 246 ± 46 
IGF-II (10"' M) + 329 ± 46 229 ± 39 
bFGF (20 ng/ml) + 249 ± 37 254 ± 46 
Primary mouse osteoblasts were cultured at a density of 1000 cells/well of a 96-well plate in 
the presence (+) or absence (-) of thymidine (10-3 M). Approximately 50-60% of the cells 
adhered to the wells. After 48 h, the total numbers of live and dead cells were counted by 
phase contrast microscopy. The results are the mean ± SEM of triplicate cultures. 
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TABLE 2-3. Effects of non-radioactive thymidine (103M) on osteoblast 
proliferation in the presence of IGF-I, bFGF, and PDGF using [3H]cytidine. 
Treatment Non-radioactive thymidine dpm 
(+1-) 
Control + 1987 ± 143 
2% FCS 8123 ± 436 
2% FCS + 1787 ± 129 
IGF-I - 5329 ± 431 
IGF-I + 1601 ± 97 
bFGF - 4097 ± 231 
bFGF + 1585 ± 198 
IGF-I/bFGF/PDGF - 9754 ± 432 
IGF-UbFGF/PDGF + 1768 ± 154 
Primary mouse osteoblasts were cultured at a density of 10,000 cells/well of a 96-well plate in 
CMRL medium with and without non-radioactive thymidine for 48 h. IGF-I, bFGF and PDGF were 
used at 10-6M, 20 ng/ml, and 10"9M respectively. Cells were labelled with [3H]cytidine. The results 
are the mean ± SEM of quadruplicate cultures. 
2.3.3 Mechanism of osteoblast cell death 
The morphology of the cells that died by 24 h in the absence of survival factors and 
in the presence of either TNF-a (10'10 M) or a high concentration (10'6 M) of the protein 
kinase inhibitor staurosporine was consistent with their having died by PCD rather than by 
necrosis. The cells exhibited the typical apoptotic morphology of cell shrinkage and 
membrane blebbing (Fig. 2-2). A characteristic feature of apoptosis is nuclear fragmentation 
(Wyllie et al., 1980b), which can be visualized by fluorescence microscopy using the 
membrane impermeant dye ethidium homodimer and the membrane permeant dye calcein. 
As shown in Fig. 2-3A cells cultured in the presence of 2% FCS for 48 h contained intact 
nuclei, which were identical to nuclei of cells that were cultured in the absence of serum for 
only 2 h. Cells cultured in the absence of serum for 24 h, however, showed extensive 
nuclear fragmentation (Fig. 2-3B). In many cases these fragments were associated with 





FIG. 2-1. Photomicrograph of primary mouse osteoblasts stained for alkaline 
phosphatase. 
Primary mouse osteoblasts were grown to confluence in MEM + 10% serum and 
stained for alkaline phosphatase as described in Materials and Methods. Bar = 10 
µm. Osteoblasts exhibited strong staining for alkaline phosphatase. 
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FIG. 2-2. Phase contrast micrograph of osteoblasts. 
Osteoblasts were maintained in the absence of serum for 24 h. Arrows show 
degenerating cells. Bar = 20 gm. 
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FIG. 2-3. Plasma membrane permeability of osteoblasts 
Osteoblasts (5000 cells/well) were cultured in Lab-Tek slide chambers in the 
presence of 2% FCS (A) or in its absence (B) for 48 h. The cells were then stained 
with ethidium homodimer and calcein and examined by fluorescence microscopy. 
A, Typical appearance of live cells. B, Typical examples of dead cells. Bar = 10 
µm. 
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Many investigators have reported that endogenous deoxyribonucleases are activated 
in cells undergoing PCD (Compton, 1992) with DNA being degraded to form 200 bp 
ladders (Wyllie, 1980a). To assay for DNA degradation, DNA was analyzed by agarose gel 
electrophoresis. As shown in Fig. 2-4 DNA isolated from osteoblasts cultured in the 
absence of serum migrated as a single, high molecular weight band ( Fig. 2-4, lane 3). On 
the other hand, in four separate experiments, DNA extracted from osteoblasts that were 
cultured for 3,6,12, or 24 h in the presence of either TNF-a or staurosporine, an agent 
which induces DNA degradation in many cell types, showed no evidence of DNA 
degradation into oligonucleosome fragments (Fig. 2-4, lanes 1,2 respectively), which is 
often observed in PCD (Wyllie, 1980a). In contrast, U937 leukemia cells cultured under 
identical conditions exhibited the characteristic pattern of DNA degradation in response to 
either TNF-a or staurosporine (Fig. 2-4, lanes 4, and 5) whilst no degradtion was observed 
when the cells were cultured in serum (Fig. 2-4, lane 6). 
Since DNA degradation was not detected by gel electrophoresis, DNA 
fragmentation in individual cells was demonstrated by specific labelling of double-strand 
DNA breaks using terminal deoxyribonucleotidyl transferase, otherwise referred to as the 
TUNEL method (Gavrieli et al., 1992). As shown in Fig. 2-5A osteoblasts cultured in the 
presence of 2% FCS for 48 h demonstrated negligible DNA fragmentation by TUNEL. 
However, TUNEL of osteoblasts cultured with TNF-a for 48 h confirmed that a substantial 
cell death had taken place in accordance with the results obtained with the MTT assay (Fig. 
2-5B). The TUNEL method showed innumerable cells with clear-cut staining indicative of 
chromatin condensation. 
Electron microscopy confirmed that TNF-a induced PCD in osteoblasts, as the 
chromatin was usually seen to be compacted and segregated into sharply defined masses 
under the nuclear membrane (Fig. 2-6A), although margination of chromatin was observed 
in about 50% of these cells (Fig. 2-6A); the cytoplasmic organelles, in particular the 
mitochondria, remained largely intact. As a basis for comparison a swollen necrotic 
osteoblast is shown in Fig. 2-6B. In contrast to apoptosis there is a total disruption of the 
internal structure of the cell undergoing necrosis whilst the normal morphology of the 
osteoblast is preserved when it is cultured in the presence of IGF-I (Fig. 2-6C). 
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FIG. 2-4. DNA Fragmentation. 
Primary murine osteoblasts or U937 leukemia cells were lysed, and cellular DNA was 
isolated and subjected to gel electrophoresis on a 1% agarose gel. Lane 1, DNA isolated 
from osteoblasts cultured in serum-free medium containing TNF-a (10-10 M) for 24 h. Lane 
2, DNA isolated from osteoblasts cultured in serum-free medium containing staurosporine 
(10-6 M) for 24 h. Lane 3, DNA isolated from osteoblasts cultured in the absence of serum. 
Lanes 4 and 5, U937 cells that were cultured as described for osteoblasts in lanes 1 and 2, 
respectively. Lane 6, U937 cells cultured with FCS. A, DNA size marker (X BstEII digest). 
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FIG. 2-5. In situ DNA labelling by the TUNEL technique. 
Mouse osteoblasts were cultured as described in Materials and Methods in the absence (A) 
or presence (B) of TNF-a (10"10 M). After 48 h the cells were fixed, permeabilized, and 
processed for TUNEL. A, Typical example of osteoblasts showing negligible DNA 
fragmentation; B, cells cultured in the presence of TNF-a show extensive DNA 
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FIG. 2-6. Transmission electron microscopy. 
A, After treatment with TNF-a for 6 h, the chromatin is highly condensed against the 
margins of the nuclei, which contains only an amorphous fibrillar network throughout their 
interior. Cytoplasmic organelles, in particular mitochondria remain intact. B, After 
treatment with sodium nitroprusside (2 mmol/L) for 16 h, necrotic cells could be seen 
which contained swollen nuclei, with few identifiable cytoplasmic organelles. For 
comparison, a normal osteoblast cultured in the presence of IGF-I for 24 h is shown in C. 
Bar = 5.7 µm. 
., ý'. ý ,. 
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Having established that TNF-a induced apoptosis in mouse osteoblasts the effects of 
graded concentrations of this cytokine on PCD in murine osteoblasts was investigated 
using the MTT assay. TNF-a dose-dependently (10"14-10"9 M) decreased the survival of 
primary mouse osteoblasts over a 24 h culture period from a level of survival of 67 ± 2.8% 
at 10"14 M down to 18 ± 1.1 % at 10"9 M (Fig. 2-7). 
2.3.4 Effects of insulin, IGF-1, IGF-2 and bFGF on osteoblast survival in vitro 
To determine the survival effects of different concentrations of insulin and IGFs on 
primary osteoblasts, these cells were cultured in CMRL 1066 serum-free medium with 
thymidine (10"3 M) to prevent proliferation, and survival assessed after 48 h with the MTT 
assay. In the presence of plateau concentrations of insulin, IGF-I, IGF-II or bFGF, about 
two thirds of the cells survived for 2 days (Fig. 2-8 a, b, c and d respectively). The 
concentration that promoted half-maximal survival (the ED5o) was about 10"9 M for IGF-I, 
and 10-8 M for IGF-II as expected if both IGFs promote survival by binding to IGF-I 
receptors (Sara and Hall, 1990). The ED50 for insulin-induced survival was about 10" M 
and the ED5o for bFGF was about 5 ng/ml. 
2.3.5 Effects of multiple factors on osteoblast survival 
Because single factors did not promote 100% survival of osteoblasts, the effects of 
combinations of different GFs on short-term survival were investigated. The combination of 
insulin, IGF-I or IGF-II, for example, did not promote survival better than insulin, IGF-I or 
IGF-II alone (table 2-4). In contrast, a combination of a plateau concentration of bFGF 
with either insulin, IGF-I, or IGF-II produced an additive effect on survival (Fig. 2-8 a, b, c) 
with a maximum of about 75%. A similar effect was seen when a plateau concentration of 
IGF-I was used in combination with graded concentrations of bFGF (Fig. 2-8d) 
Surprisingly, although PDGF did not promote survival on its own, when combined with 
either insulin, IGF-I, or IGF-II survival was enhanced (Fig. 2-9 a, b, c). The combination of 
bFGF and PDGF with IGF-I, did not promote survival better than bFGF with IGF-I (table 
2-4). A similar situation was found with bFGF/PDGF/IGF-II and bFGF/PDGF/insulin 
combinations (table 2-4). There was also no additive effect on survival when several of the 
other GFs such as TGF-ß, EGF, IL-1, IL-11 were used in combination with the IGFs or 
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FIG. 2-7. Effect of TNF-a on osteoblast survival in vitro. 
Mouse osteoblasts were cultured as described in Materials and Methods in the 
presence of increasing concentrations of TNF-a. Vehicle (CMRL-1066 medium) 
was used as a control. After 48 h in culture, cell survival was assessed by the MTT 
cell survival assay. Each point is the mean ± SEM of six wells. TNF-a dose- 
dependently decreased osteoblast survival. 
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FIG. 2-8. Effects of insulin, IGF-I, IGF-II, and bFGF, alone and in combination, on 
osteoblast survival in vitro. 
Mouse osteoblasts were cultured as described in Materials and Methods in the presence of 
increasing concentrations of insulin (a), IGF-1 (b), IGF-2 (c), or bFGF (d). These GFs 
were also added in combination. CMRL-1066 medium without FCS was used as a control. 
After 48 h, cell survival was assessed by the MTT cell survival assay. Each point is the 
mean ± SEM of six wells. The experiment was repeated six times. 
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FIG. 2-9. Effect of PDGF in combination with insulin (A), IGF-1 (B), or IGF-2 (C) 
on osteoblast survival in vitro. 
Mouse osteoblasts were cultured as described in Materials and Methods in the presence 
of increasing concentrations of insulin, IGF-1, or IGF-2, alone or in combination with 
PDGF (10'9 M). Vehicle (CMRL-1066 medium) was used as a control. After 48 h, cell 
survival was assessed by the MTT cell survival assay. Each point is mean ± SEM of six 
wells. Each experiment was repeated three times. 
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TABLE 2-4. Effects of combinations of growth factors and cytokines on osteoblast 
survival 
Treatment % Survival after 48 h 
IGF-I (10'9 M) 52 ±3 
IGF-I (10'9 M) + TGF-ß (10'x' M) 51 ±2 
IGF-I (10'9 M) + EGF (10'9 M) 52 ±4 
IGF-I(10'9M)+IL-la(10" 1) 54±1 
IGF-I (10'9 M) + IL-11 (10'9 M) 50 ±5 
IGF-I (10"9 M) + bFGF (20 ng/ml) 66 ±2 
IGF-I (10"9 M) + bFGF (20 ng/ml) + PDGF (10"9 M) 67 ±I 
IGF-II (10'7 M) 62 ±4 
IGF-II (10'7 M) + TGF-ß (10" 1 M) 60 ±1 
IGF-II(10''M)+EGF(10''M) 63±5 
IGF-II(10'7M)+IL-1a(10") 61 ±3 
IGF-II (10'7 M) + IL-11 (10-9M) 60 ±2 
IGF-II (10"' M) + bFGF (20 ng/ml) 72 ±2 
IGF-II (10"' M) + bFGF (20 ng/ml) + PDGF (10'9 M) 71 ±3 
Insulin (10-6 M) 55 ±4 
Insulin (10-6 M) + TGF-ß (10"' M) 54 ±3 
Insulin (10"6 M) + EGF (10'9 M) 52 ±2 
Insulin (10"6 M) + IL-I a (10" 1) 55 ±I 
Insulin (10'6 M)+IL-11 (10"9M) 56±3 
Insulin (10-6 M) + IGF-I 58 ±4 
Insulin (10'6 M) + IGF-II 57 ±5 
Insulin (10-6 M) + bFGF (20 ng/ml) 67 ±7 
Insulin (10-6 M) + bFGF (20 ng/ml) + PDGF (10'' M) 65 ±4 
Mouse osteoblasts were cultured at a cell density of 10 000 cells per well of a 96 well plate 
in serum free CMRL-1066 medium in the presence of thymidine (10"3 M) and the above growth 
factors. After incubation for 48 h cell survival was assessed by MTT survival assay. The results are 
the mean ± SEM of 12 separate cultures. 
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2.3.6 Effect of OR-3 on survival of mouse osteoblasts promoted by IGF-I and IGF-II 
To determine which receptor was responsible for mediating the effects of the IGFs 
and insulin on osteoblast survival a murine monoclonal antibody, aIR-3 raised against the 
type I IGF receptor, was utilized. This antibody binds specifically to the type I receptor and 
does not cross-react with either the type II IGF or insulin receptor. 
As shown in Fig. 2-10, aIR-3 (1.0 pg/ml) was a potent competitive inhibitor of both 
IGF-I and IGF-II mediated cell survival, indicating that in serum free culture both IGF-I and 
IGF-II mediate their effects on osteoblast survival by interacting with the type I IGF 
receptor. However aIR-3 did not completely inhibit the survival promoting effects of 
insulin, which suggests that insulin may be acting via an interaction with insulin receptors. 
aIR-3 had no effect on bFGF-mediated survival and only partially blocked the bFGF/IGF-I 
combination on osteoblast survival, which suggests that bFGF mediates its effects via an 
interaction with FGF receptors (Fig. 2-10). Finally, aIR3 blocked the action of PDGF/IGF-I 
on osteoblast survival and indicates that PDGF maybe altering the number and/or affinity of 
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FIG. 2-10 Effects of aIR-3 on osteoblast survival. 
Mouse osteoblasts were cultured at a cell density of 10000 cells/well in a 96-well 
plate in the presence of a-IR3 (1 pg/ml) and IGF-I (10"8 M), IGF-II (10'7 M), insulin 
(10"6 M), bFGF (20 ng/ml), bFGF/IGF-I, or PDGF (10"9 M)/IGF-I. Vehicle (CMRL- 
1066 medium) was used as a control. After 48 h in culture, cell survival was assessed 
by the MTT cell survival assay. Data are expressed as the mean ± SEM of six wells. 
P<0.05; * *, P<0.01 (compared with treatment in the absence of aIR3). 
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2.4 DISCUSSION 
This study shows that osteoblast survival in vitro is significantly increased by IGF-I, 
IGF-II, bFGF and insulin. Whilst PDGF was without effect on its own, this GF as well as 
bFGF enhanced the survival promoting effects of the IGFs and insulin although they were 
unable to achieve a 100% survival rate. It is increasingly believed that most normal cell 
deaths in invertebrate and vertebrate development depend on the activation of a suicide 
program in the cells that die (Wyllie and Kerr, 1980; Oppenheim et al., 1990). The findings 
from these in vitro studies indicate that these GFs seem to promote survival by inhibiting 
programmed cell death rather than inducing proliferation as non-radioactive thymidine 
effectively prevented the proliferative effects of the GFs. A variety of other GFs, cytokines 
and osteotropic hormones had no effect on either osteoblast survival or apoptosis. The only 
factor that induced osteoblast apoptosis in this study was the immunoregulatory cytokine, 
TNF-a. In contrast to these results it has been demonstrated using TUNEL that both IL-6 
and PTH suppress apoptosis in both mouse MC3T3-E1 and in human MG63 cells (Jilka et 
al., 1998; 1999). 
The effects of the IGFs on osteoblast survival is in agreement with their activity on 
the survival of oligodendrocytes (Barres et al., 1992) and rat schwann cell precursors 
(Gavrilovic et al., 1995). However, a notable difference between these reports and the 
present study was that the IGFs were capable of promoting a 100% survival rate of 
neuronal-derived cells as opposed to the 60-70% survival of osteoblasts achieved in the 
present study. 
It would appear that insulin can promote survival of osteoblasts by binding to its 
own receptor; because insulin had a significant effect at a 10-8 M concentration, which is 
sufficient to bind to insulin receptors but not IGF-I receptors (Sara and Hall, 1990). This is 
supported by the fact that insulin receptors have been demonstrated on rodent osteoblasts 
and insulin can maintain the growth of these cells at a similar concentration (Hickman and 
McElduff, 1989). Although osteoblasts express type I and II IGF receptors (Slootweg et 
al., 1990; Centrella et al., 1990), the role of the type II receptor in mediating the metabolic 
and proliferative activities of IGF-II are controversial. It is known that the type I IGF 
receptor is recognized by both IGF-I and -II and insulin (Neely et al., 1991) and several 
lines of evidence from this study indicate that the type I IGF receptor is responsible for 
mediating the effects of IGF-I and -II as well as high concentrations of insulin. Firstly the 
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order of potency in stimulating osteoblast survival (IGF-I> IGF-II>insulin) is similar to the 
relative affinities of these hormones for binding to the type I IGF receptor (Rechler et al., 
1980) and is consistent with a common mechanism involving this receptor. Similar 
potencies have been reported for the effects of the IGFs and insulin on other cellular 
activities and the type I IGF receptor seems to mediate the responses in these cell types 
(Jacobs et al., 1986). Secondly, the findings that the combination of IGF-I and IGF-II did 
not enhance the level of osteoblast survival over that produced by IGF-I suggests that the 
type II receptor is not involved in the response. Thirdly, ctIR-3, a monoclonal antibody 
specific for the type 1 IGF receptor, inhibited the survival promoting effects of both IGFs 
and almost prevented those of insulin. The finding in the present study that bFGF increased 
the survival of osteoblasts is similar to the situation for schwann cell precursors (Jessen et 
al., 1994). Recent studies have demonstrated that the calcium binding protein, calbindin- 
D28k is expressed by osteoblasts and suppresses apoptosis by inhibiting caspase-3 activity 
(Bellido et al., 2000). Both IGF-I and FGF induce calbindin-D28k expression and it has been 
suggested that calbindin-D28k may mediate the antiapoptotic effects of IGF-I and FGF on 
osteoblasts (Bellido et al., 2000). 
Although PDGF has been shown to stimulate some cells to make IGF-I (Clemmons, 
1985), this GF inhibits the synthesis of IGF-I and IGF-II by osteoblasts (Gabbitas et al., 
1994). This may explain why PDGF was incapable of inducing osteoblast survival on its 
own. The mechanism underlying the synergy between IGFs and FGFs/PDGF may be due in 
part to the ability of these GFs to modulate type-I IGF receptors. It has been shown for 
example, that bFGF and PDGF increase the number of type-I IGF receptors expressed by 
purified glial cells derived from hypothalamic cultures without affecting receptor affinity 
(Pons and Torres-Aleman, 1992). It is therefore conceivable that in the experiments 
reported here, bFGF/PDGF may increase type-I IGF receptor number or affinity, resulting 
in an enhanced response to IGF-I, IGF-II and insulin. This is supported by the fact that the 
type I receptor antibody, aIR3, prevented the survival enhancing effects of both bFGF/IGF- 
I and PDGF/IGF-I. 
The action of IGFs is known to be regulated by the synthesis and secretion of one of 
six IGF-binding proteins (IGFBPs). Furthermore bFGF has been reported to modulate the 
synthesis of one of the IGFBPs in purified hypothalamic neural crest cell cultures. 
Modulation of these proteins by bFGF/PDGF therefore represents another way in which 
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these GFs might alter cellular responses to IGFs (Pons and Torres-Aleman, 1992; Ernst and 
Rodan, 1990). 
In skeletal tissue osteoblasts express messenger RNA transcripts for IGF-I, IGF-II, 
bFGF and PDGF and the proteins have been shown to influence osteoblast proliferation and 
bone matrix synthesis (Centrella et al., 1992; McCarthy et at, 1989; Globus et al., 1989). 
Furthermore studies on the quantification and characterization of GFs present in human 
bone has revealed that human bone matrix contains multiple GFs including IGF-I, IGF-II, 
TGF-ß, bFGF and PDGF. IGF-II and TGF-ß are the two most abundant GFs present in 
human bone while basic FGF, PDGF and IGF-I are several-fold less abundant (Mohan and 
Baylink, 1991). 
Interestingly TGF-ß was the only GF present in bone matrix which did not have any 
effect on either osteoblast survival or PCD in this study. This is in contrast to the results of 
Jilka et al. (1998) in which TGF-ß promoted survival of the MC3T3-E1 preosteoblastic cell 
line. Osteoblast production of IGF-I and IGF-II is stimulated by TGF-J3 (Linkhart and 
Keffer, 1991) but the absence of a survival promoting effect suggests that this GF is unable 
to induce a single cell to produce enough IGF-I or IGF-II to save itself in microculture. 
The effects of TGF-ß on apoptosis and cell survival are variable and seem to depend upon 
cell phenotype. For example, whilst it induces PCD in a variety of epithelial and myeloid 
cells (Bursch et al., 1993; Taetle et al., 1993), it prevents the process in synovial cells 
(Kawakami et al., 1996), and has no effect on the survival of teratocarcinoma cells 
(Granerus et al., 1995), which is similar to its effect on osteoblasts in this study .A possible 
explanation is unclear although it may relate to the density at which the cells are cultured as 
Mathieu et al., (1995) have found that PCD in vitro exhibits a correlation with this 
parameter. 
Since complete survival of osteoblasts in this study could only be achieved using 
culture medium supplemented with FCS, this would suggest either that unidentified GFs or 
extracellular matrix (ECM) components are responsible for promoting osteoblast survival. 
Among cells that have been shown to require survival factors, in no case is a single 
signalling molecule on its own capable of promoting long-term survival in culture 
(Dohrmann et al., 1986; Sendnter et al., 1991). The significance of the ECM in cell survival 
has recently been demonstrated for endothelial cells which rapidly undergo PCD in the 
absence of integrin mediated adhesion with components of the ECM (Meredith et al., 
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1993). More recently, fibronectin has been shown to be a survival factor for mature 
differentiated rat osteoblasts (Globus et al., 1998). It seems possible that all cells require 
multiple survival factors for long-term survival. 
The effects of inflammatory cytokine TNF-oc on osteoblast apoptosis in this study is 
in accordance with previous studies demonstrating its apoptotic effects in the MC3T3-E1 
cell line (Jilka et al., 1998). Apoptosis in response to TNF-a has been demonstrated in 
several other mammalian cell lines, including the human leukemia cell lines HL-60 and U937 
(Elias et al., 1988) and the murine fibrosarcoma cell lines L929 and WEHI (Fehsel et al., 
1991). 
Whilst biochemical and morphological features of osteoblast apoptosis were 
detected, DNA fragmentation was not detected by agarose gel electrophoresis in cultures 
stimulated with TNF-a. It may be that DNA fragmentation is more apparent in cells which 
have detached from the tissue culture dish, which were not collected in this study or that 
osteoblasts need to be cultured at a lower cell density. DNA fragmentation, however, seems 
not to be an invariable feature of PCD (Lockshin et al., 1991) and condensation of the 
chromatin at the membrane of an apoptotic nucleus is not always associated with activation 
of an endonuclease with subsequent DNA degradation (Oberhammer et al., 1994). TNF-a 
inhibits bone formation and has been found to inhibit collagen synthesis and alkaline 
phosphatase activity in osteoblasts, actions which contrast with those GFs which promote 
osteoblast survival in this study. This suggests that those factors exerting a catabolic action 
on osteoblasts may also induce PCD whilst conversely agents with an anabolic action may 
promote survival. 
95 
3. Autocrine Signals Promote Osteoblast Survival in 
Culture. 
3.1 INTRODUCTION 
Many studies on the control of cell survival have demonstrated that certain 
mammalian cell types have specific survival requirements and require signals from other cell 
types in order to survive, just as cells require signals for cell growth (Baserga, 1985). 
Oligodendrocytes and their precursors require specific growth factors such as IGF-I, IGF-II 
and PDGF (Barres et al., 1992). Colony stimulating factors promote cell survival of 
hematopoietic cells by suppressing apoptosis (Williams et al., 1990) and M-CSF promotes 
osteoclast survival (Fuller et al., 1993). Similarly, developing neurons require neurotrophic 
factors (Levi-Montalcini, 1987). If deprived of their specific survival factors these cells 
seem to die by PCD. In addition other factors such as plasma proteinase inhibitors may be 
important determinants of cell survival (Ikari et al., 2001). 
On the basis of such studies it has been proposed that most mammalian cells are 
programmed to undergo PCD in the absence of survival signals from other cells (Raff, 
1992). In the case of chondrocytes and lens epithelial cells it has been demonstrated that 
these cells can survive in the absence of other cell types, serum and exogenous proteins if 
cultured at high density, but they undergo PCD if cultured in these conditions at low cell 
density (Ishizaki et al., 1993; Ishizaki et al., 1994). It would appear that chondrocytes are 
sensitive to growth factor deprivation and toxic oxygen metabolites derived from molecular 
oxygen, i. e., hydroxyl radicals or hydrogen peroxide although their relative contribution to 
chondrocyte survival remains uncertain. Cartilage is an unusual tissue in that it contains only 
a single cell type and is not innervated, vascularized or penetrated by lymphatic vessels 
(Goss, 1978; Fawcett, 1986). It is possible that chondrocytes have adapted to their 
environment in some manner which has permitted them to survive under these conditions. *over 
In addition to the growth factors discussed in chapter 2 other factors may have 
effects on osteoblast survival. Since bone contains different cell types, survival signals may 
act in a paracrine fashion to effect osteoblast survival. In this study the survival 
requirements of primary osteoblasts are assessed at different cell densities in the absence of 
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Actively metabolizing cells produce quantities of reactive oxygen species that 
lead to oxidative damage to proteins and macromolecules (Cadenas, 1989). Cells have 
evolved complex antioxidant defenses to protect themselves against the harmful effects 
of reactive oxygen species. Such antioxidants include the suithydryl containing amino 
acid cysteine (Cadenas, 1989) that combines with reactive oxygen to form cysteine 
sulfoxide. Cysteine has been shown to have an anti-apoptotic effect in cultures of 
resting chondrocytes which are sensitive to toxic oxygen metabolites (Tschan et al., 
1990). Intracellularly cysteine is utilized for the synthesis of cellular antioxidants such 
as glutathione. Thus addition of cysteine to cell cultures enables it to be utilized for the 
maintenance of cellular antioxidant potential, through direct inactivation of reactive 
oxygen and as an intermediate in the synthesis of glutathione. 
growth factors and cytokines used in chapter 2. The aim was to establish whether osteoblast 
derived survival signals can act in an autocrine fashion to promote the survival of other 
osteoblasts, in a similar manner to chondrocytes and determine the survival requirements of 
these cells in culture. 
3.2 Materials and Methods 
3.2.1 Materials. 
Terminal deoxynucleotidyl transferase, biotinylated dUTP, and streptavidin 
fluorescein were purchased from Boehringer Mannheim GmbH (U. K. ). MTT and all cell 
culture reagents were purchased from Sigma Chemical Co. (St. Louis, MO). The following 
anti-human polyclonal antibodies were purchased from R and D Systems, (Oxon, U. K): IGF- 
I, IGF-II, basic FGF, and PDGF. [3H]-cytidine was purchased from Amersham Int. (U. K. ) 
3.2.2 Methods 
3.2.2.1 Preparation of osteoblasts from neonatal mouse calvaria 
Calvarial osteoblasts were prepared and characterized as described in section 
2.2.2.1. Osteoblasts were cultured in a-MEM containing 10% FBS and antibiotics for 4 
days prior to use. 
3.2.2.2 Preparation of osteoblast conditioned medium 
Osteoblasts were cultured in 96-well tissue culture plates at 100 000 cells/well and 
medium was removed and replaced by fresh CMRL medium every 2 days. The conditioned 
medium was immediately transferred to low density cultures, which were fed with 
conditioned medium every two days. 
3.2.2.3 Fractionation of Conditioned Medium by Ultrafiltration 
1.5 ml of conditioned medium from high density osteoblast cultures was poured into 
the filter cup of a Millipore ultrafiltration unit (molecular mass cutoff 5 kDa), and 
centrifuged at 3,000 g for 45 min at room temperature. The concentrate (1.0 ml) and filtrate 
(0.5 ml) were sterilized by passage through a 0.22 gm millipore filter and immediately 
transferred to low density osteoblast cultures. 
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3.2.2.4 Osteoblast survival assays 
For survival assays, osteoblasts were plated in 100 µl of CMRL-1066 medium with 
1% FCS for 2h to permit adhesion of osteoblasts. Thereafter media was replaced with 
serum free CMRL-1066 medium containing thymidine (10"3 M) to block cell proliferation, 
with or without cysteine or osteoblast conditioned medium (see below). 
The human osteoblastic cell line MG63 was used in some experiments. These cells 
have a well characterized osteoblast phenotype and are frequently used to study the effects 
of cytokines and growth factors in vitro. 
M7T assay. Cell survival was assayed in flat-bottomed 96 well microtitre plates. Cell 
survival was assessed by the MTT assay as described in section 2.2.2.2. 
3.2.2.5 Osteoblast Proliferation assay 
Primary osteoblasts were plated at a density of 10000 cells/well of a 96 well plate and 
cultured for 48 h in CMRL-1066 medium with and without either 10% FCS or 
conditioned media from high density osteoblast cultures in the presence or absence of non- 
radioactive thymidine (10-3 M). Assessment of proliferation in the presence of non- 
radioactive thymidine was performed as described in section 2.2.2.3. 
3.2.2.6 Identification of apoptotic osteoblasts 
(a) TUNEL assay: Apoptosis-induced DNA strand breaks were enzymatically labelled by a 
fluorescein isothiocyanate (FITC) in situ cell-death detection kit (Boehringer Mannheim, 
U. K. ) based on the TUNEL technique which stains individual apoptotic nuclei with green 
fluorescence (Gavrieli et al., 1992). Cells were fixed in 4% paraformaldehyde for 10 min, 
washed in 10 mM Tris-HCI, pH 8.0, and then permeabilized in 0.1% Triton X-100 in 0.1M 
sodium citrate for 5 min on ice. After washing in 10 mM Tris-HCI, pH 8.0 the cells were 
incubated 60 min with TdT and FITC-dUTP at 37°C. After washing in PBS, the cells were 
examined using a Leica fluorescence microscope. 
(b) DNA fragmentation: DNA fragmentation was analyzed by agarose gel electrophoresis 
as described in section 2.2.2.4. Primary mouse osteoblasts were cultured in serum free 
CMRL-1066 medium for 1 or 2 days and DNA extracted from the combined adherent and 
non adherent cell fractions. 
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3.2.2.7 Statistical analysis 
Data are expressed as the means ± SEM of 6 cultures/group. Each experiment was 
repeated three times. Differences between control and treatment groups were determined by 
the Mann-Whitney U test. 
3.3 RESULTS 
3.3.1 Characterization of murine osteoblasts 
Unstimulated cultures of primary mouse osteoblasts were characterized by 
histochemical staining for alkaline phosphatase and intracellular accumulation of cAMP in 
response to PTH. 94.2 ± 2.4% of cells from six separate bone cell preparations were found 
to be strongly positive for alkaline phosphatase. Treatment of primary mouse osteoblast 
cultures with PTH (10"8 M) for 10 min induced a cAMP level of 10.7 ± 1.8 pmollml 
compared with a control level of less than 0.34 pmol/ml. 
3.3.2 Osteoblast survival in Protein-free medium is cell-density dependent 
To study the survival requirements of osteoblasts in culture, osteoblasts prepared 
from calvaria of 2-day-old mice were cultured at various cell densities in serum-free CMRL 
medium containing thymidine (10-3 M) but no added protein in 96-well plates. Cell survival 
was assessed by the MTT assay after various times. Viable cells converted the MTT into a 
dark blue reaction product, while dead cells remained uncoloured. The survival of 
osteoblasts was cell-density dependent: when plated at >2x 104 cells/well, 30% of the cells 
survived for upto 144 h, but when plated at S5x 103 cells/well, all the cells had died by 144 
h (Fig 3-1a). To confirm the hypothesis that the dead osteoblasts were undergoing 
apoptosis rather than necrosis, osteoblasts were examined by TUNEL labelling of nuclei 
with FITC-dUTP. A large proportion of the cells had clear-cut staining indicative of 
chromatin condensation at the nuclear membrane (Fig. 3-2). The occurrence of apoptosis, 
as opposed to necrosis, in primary mouse osteoblasts was confirmed by the demonstration 
of 180 bp DNA fragments, and multimers thereof, in cell extracts (Fig. 3-3). 
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Fig. 3-1 Cell-density dependence of osteoblast survival. 
Primary mouse osteoblasts were cultured at various cell densities in serum-free CMRL-1066 medium 
containing thymidine (10'' M) in 96 well plates in the absence of L-cysteine (A) and in the presence 
of 1mM L-cysteine (B). Cell viability was assessed by MIT assay after 2,6,48,96 and 144 hours. 
Results are expressed as means ± SEM of four experiments. 
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Fig. 3-2. Detection of apoptotic osteoblasts by TUNEL. 
Mouse osteoblasts were cultured in CMRL-1066 medium containing thymidine (l0-' M) 
and 1 mM cysteine at high density (5 x 104 cells/well) or low density (5 x l0; cells/well). 
After 4 days, the cells were fixed with 4% paraformaldehyde, permeabilized by incubation 
with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice, and incubated for 30 min 
with FITC-labelled d-UTP. A, Typical example of osteoblasts showing negligible DNA 
fragmentation; B, cells show intense fluoresence of condensed nuclear chromatin (arrows), 
indicative of cells in the later stages of apoptosis. Bar = 10 µm. 
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Fig. 3-3. Apoptosis of osteoblasts detected by DNA fragmentation. 
Primary mouse osteoblasts were cultured at a density of 5000 cells per well of' 96 well 
plates in CMRL-1066 medium containing thymidine (10"; M), with and without CM from 
high density osteoblast cultures for I or 2 days. DNA was extracted and 5 µg was analyzed 
by electophoresis on a 2% agarose gel. DNA was visualized with ethidium bromide (0.5 
µg/ml). Lanes I and 2, DNA isolated from osteoblasts cultured in the absence of CM from 
high density cultures after I and 2 days respectively. Lanes 3, DNA isolated from 
osteoblasts after 2 days in culture with CM from high density osteoblast cultures. Lane A, 
DNA size marker (OX 174 Hae III digest). 
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3.3.3 Antioxidants prevent osteoblast cell death 
As many inhibitors of apoptosis have antioxidant properties the effects of a variety 
of antioxidants on osteoblast survival were assessed. The addition of cysteine to the culture 
medium greatly enhanced the survival of mouse osteoblasts, especially when cultured at <_ 5 
x 103 cells/well, but only for the first 48 h of culture (Fig. 3-1b). Thereafter, most of the 
cells died with the characteristic features of apoptosis. Cystine also promoted survival, but 
to a lesser extent than cysteine (Table 3-1). The ability of cysteine to promote survival 
apparently depended on the intracellular conversion by glutathione synthase to the 
antioxidant glutathione, as an inhibitor of glutathione synthase, BSO, prevented this effect 
(Table 3-1). Glutathione in reduced form (GSH) was as effective as cysteine, while its 
oxidized form (GSSG) was less effective; neither of their effects were affected by BSO 
(Table 3-1). When superoxide dismutase was added to culture media, cell viability was not 
improved whereas catalase clearly protected the osteoblasts. Superoxide dismutase also had 
no effect in conjunction with catalase (Table 3-1). 
3.3.4 Osteoblasts support one another's survival in culture by secreting survival 
factors that are not antioxidants. 
The finding that osteoblasts survived longer when cultured at high density suggests 
that the cells in high density cultures promote one another's survival through cell-cell 
contact survival factors or by secreting survival-promoting factors. Consistent with the 
latter suggestion, culture medium from high density (105 cells/well) osteoblast cultures 
promoted the survival of low density osteoblast cultures. When osteoblasts were cultured 
at a cell density of 5x104 cells/well in the presence of conditioned medium 63 ± 4% of 
osteoblasts survived after 144 h in culture (Fig. 3-4) compared with a control level of 30 ± 
3% in the absence of conditioned medium (Fig. 3-lA). Addition of cysteine to the 
conditioned medium from high density cultures did not further enhance survival of mouse 
osteoblasts cultured at 5x104 cells/well. Addition of cysteine to the conditioned medium was 
requred to save mouse osteoblasts cultured at <_ 2x104 cells/well (Fig. 3-4). 
When conditioned medium from high density cultures of either mouse or human 
osteoblasts was fractionated by ultrafiltration using a membrane with a molecular mass cut- 
off of 5 kDa, the survival promoting activity was recovered in the concentrate and not in the 
filtrate. When cultured at a cell density of 5x103 in the presence of concentrate 83 ± 5% of 
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osteoblasts survived after 48 h and 47 ± 4% after 144 h compared with a control level of 48 
± 3% for osteoblasts cultured after 48 h and 8± 1% after 144 h in the absence of 
conditioned medium (Fig. 3-5). However, when osteoblasts were cultured in the presence of 
the filtrate only 56 ± 3% survived after 48 h and 13 ± 2% survival was obsurved after 144 
h. This suggested that one or more osteoblast derived growth factors was responsible for 
promoting osteoblast survival. 
TABLE 3-1 Effects of antioxidants on the survival of osteoblasts cultured at low 
density. 
Treatment Conc. (M) % Survival 
Control 30 ± 1.6 
BSO 2x10-4 30 ± 2.2 
Cysteine 10"3 63 ± 1.5 
Cystine 10"3 52 ± 2.1** 
Cysteine + BSO 10"3 + 2x104 34 ± 2.3 
Cystine+BSO 10"3+2x10"4 27±2.6 
GSH 10"3 60 ± 2.4** 
GSH + BSO 10"3 + 2x10-4 57 ± 1.7** 
GSSG 10"3 40 ± 1.1* 
GSSG + BSO 10"3 + 2x104 38 ± 1.0* 
SOD 50U 32 ± 2.0 
Catalase 50 U 56 ± 2.7** 
SOD + Catalase 50 U+ 50 U 58 ± 2.1 ** 
Mouse osteoblasts were cultured for 48 h in CMRL 1066 medium at 5x103 cells per well, 
and their viability was assessed by MTT assay. BSO, buthionine-sulphoximine; GSH, 
reduced glutathione; GSSG, oxidized glutathione; SOD, superoxide dismutase. The results 
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Fig. 3-4. Effects of osteoblast conditioned medium on osteoblast survival. 
Neonatal mouse osteoblasts were cultured at various cell densities in 96-well plates with or 
without I mM cysteine in the presence of conditioned medium from high density (105 
cells/well) osteoblast cultures. MTT assays were performed after 144 hrs. 
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Fig. 3-5. Ultrafiltration of conditioned medium. 
Conditioned medium (CM) was collected from high density cultures (105 cells/well) mouse 
osteoblast cultures and fractionated by ultrafiltration through a membrane that retains 
molecules above 5 kDa molecular weight. The concentrate and the filtrate were immediately 
tested for their ability to promote the survival of mouse osteoblasts in low density (5 x 103 
cells/well) cultures in the presence of 1 mM cysteine. MTT assays were performed after 48 
and 144 hrs. 
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Labelling osteoblast DNA with [3H]-cytidine confirmed that non-radioactive 
thymidine effectively blocked the effects of FCS and conditioned medium from high density 
cultures on osteoblast proliferation (Table 3-2). 
TABLE 3-2 Effects of non-radioactive thymidine (10"3 M) on osteoblast proliferation 
in the presence/absence of either 2% FCS or conditioned medium from high density 
osteoblast cultures. 
Treatment Non-radioactive thymidine dpm 
(+/-) 
Control + 2056 ±234 
Control - 1975 ± 216 
2% FCS + 2213 ± 222 
2%FCS - 14324±654 
CM + 2351±176 
CM - 9865 ± 543 
Primary mouse osteoblasts were cultured at a density of 10,000 cells/well of a 96-well plate 
in CMRL medium with and without non-radioactive thymidine for 48 h. Cells were labelled 
by addition of [3H]-cytidine. CM: conditioned medium from high density osteoblast 
cultures. The results are the mean ± SEM of quadruplicate cultures. 
3.3.5 Effects of neutralizing antibodies to growth factors on osteoblast survival 
To determine which particular growth factors might be responsible for promoting 
osteoblast survival the effects of neutralizing antibodies to those growth factors that are 
produced by osteoblasts were assessed. Antibodies to IGFs-I and -II were capable of 
preventing the survival promoting effects of conditioned medium on low density osteoblast 
cultures whilst antibodies to PDGF and basic FGF were without effect and did not augment 
the inhibitory activity of the IGF antibodies. (Table 3-3). When the various antibodies were 
added to high density MG63 osteoblast cultures in the absence of conditioned medium, a 
similar effect was observed (Table 3-3). 
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Table 3-3 Effects of neutralizing antibodies on the survival promoting effects of 
osteoblast conditioned medium on osteoblasts. 
Survival of Osteoblasts 
Antibody 
Type Cultures + Conditioned medium MG63 Cultures 
Control 8±3 51 ±6 44 ±5 
IGF-I 12±4 12±4** 14±2** 
IGF-II 9±3 14±3** 9±2** 
PDGF 14±4 52±6 46±5 
bFGF 7±3 54±5 51 ±4 
Murine osteoblasts were cultured in 96 well plates at low cell density (5 x 103 cells/well) 
and MG63 osteoblasts were cultured at high cell density (5 x 104 cells/density) for 2 days. 
Conditioned medium from high density MG-63 cultures was added to the low density 
cultures as indicated. Human polyclonal antibodies to bFGF, IGFs -I and -II were added at 
a final concentration of 2 µg/ml and PDGF at 5 jig/ml. The results are the means ± SEM 
of quadruplicate cultures **, P<0.01 significantly different from the control. 
3.4 DISCUSSION 
These studies demonstrate that osteoblasts do not require signals from other cell 
types to survive if cultured at high cell density in the absence of serum, exogenous proteins 
or non-protein molecules. This is similar to survival characteristics of both chondrocytes 
and lens epithelial cells (Tschan et al., 1990; Ishizaki et al., 1993). The studies also show 
that osteoblasts require assistance from other osteoblasts to survive in culture: the cells die 
rapidly when cultured at low cell density, but can be saved by conditioned medium from 
high density osteoblast cultures. The apparent rapid cell death prominent in cells cultured at 
a density on _< 
5x103 cells per well within the first three hours of switching to serum free 
medium may be due to a lack of adhesion resulting from a lack of cell-cell contact survival 
Low Density Low Density cultures High Density 
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factors. The deaths involve activation of an endogenous endonuclease as shown by DNA 
laddering, a characteristic feature of apoptosis (Wyllie et al., 1980b) suggesting that the 
cells die by active PCD. 
The survival of a given cell may be determined by its balance of reactive oxygen 
intermediates (ROI) and antioxidants. The demonstration that a variety of antioxidants that 
scavenge or detoxify ROIs suggests that the latter may be responsible for mediating 
osteoblast death in the low density cultures. 
Since sulfhydryl reagents can act as oxygen radical scavengers (Cadenas, 1989) 
these observations suggested such radicals might be a possible cause of the observed 
cytotoxicity. Oxygen radicals arise from molecular oxygen by one-electron transfer 
reactions. For example, 02-9 and OH " can be formed in the presence of Fe2+ according to: 
02 + Fe 2+ -+ 
02-* + Fe 3+ (1) 
202-0 + 2H+ -ý 02+ H202 (2) 
H202 + Fe 2+ -* OH "+ OH -+ Fe3+ (3) 
Toxic oxygen-derived compounds can be eliminated enzymatically. 02-0 is decomposed by 
superoxide dismutase, and catalase degrades H202 to oxygen and water, thus also 
preventing the production of OH " (formula 3). Both of these enzymes are known to 
protect cells from oxygen toxicity (Cadenas, 1989). These results show that oxygen toxicity 
caused the loss of viable cells in serum-free osteoblast culture. The findings also emphasize 
the importance of H202 or OH ", rather than 02-0. 
Although the results demonstrate that antioxidants are important for the survival of 
osteoblasts in low density cultures (<_ 5x 103 cells/well), they are not enough: extracellular 
signalling molecules are also required. This is supported by the findings that (a) the survival- 
promoting activity in the conditioned medium from high density osteoblast cultures 
collaborates with antioxidants such as cysteine and is associated with molecules that are 
larger than 5 kDa, and (b), this activity is prevented by antibodies to known growth factors. 
While conditioned medium from high density osteoblast cultures does not require 
antioxidants to promote the survival of either mouse or human osteoblasts cultured at 5x 
104 cells/well, it does require antioxidants to promote the survival of osteoblasts cultured at 
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55x 103 cells/well. It can be concluded that osteoblasts, like chondrocytes and many other 
cells require signals from their neighbours in order to avoid PCD, at least in culture. 
Furthermore these signals do not function solely as antioxidants, and osteoblasts themselves 
can secrete such signals. However, the evidence from this study showing that conditioned 
medium from high density osteoblast cultures was unable to achieve a 100% osteoblast 
survival rate, suggests that other factors, possibly cell-to-cell contact factors play a role in 
promoting the survival of osteoblasts cultured at high cell densities. 
Of the neutralizing antibodies to growth factors that were tested, both the IGF-I 
and -II antibodies prevented the survival promoting activity of osteoblast conditioned 
medium. Osteoblasts have been shown to make both these GFs (McCarthy et al., 1989) 
and it seems likely that these GFs promote osteoblast survival in vivo. Whilst these GFs 
stimulate osteoblast proliferation (McCarthy et al., 1989; Ernst and Rodan, 1990), their 
effects on survival and proliferation were distinguished by incorporating non-radioactive 
thymidine into the culture medium which effectively blocked the proliferative effects of the 
conditioned medium. Although bFGF, TGF-ß, PDGF, IGF-I and IGF-II are all present in 
the bloodstream, it is apparent that the paracrine biosynthesis of GFs is more important in 
the modulation of cellular activity (Holly and Wass, 1989). It seems likely that GFs released 
from the extracellular matrix and neighbouring cells are responsible for promoting the 
survival of osteoblasts in bone as they do in vitro. The IGFs have previously been shown to 
be important survival factors during normal tissue development of other cell types such as 
Schwann cells (Delaney et al., 1999) and also in the prevention of cytokine-mediated cell 
death in pancreatic islets (Hill et al., 1999). The IGFs have also been shown to prevent 
apoptosis in many tumour cell lines. It has been demonstrated that IGF-I is the most 
important growth factor present in serum that prevents apoptosis in neuroblastoma cells 
(Van Golen and Feldman, 2000) and this is associated with regulation of the levels of the 
antiapoptotic proteins Bcl-2 and Bcl-XL. IGF-I also protects colon cancer cells from death 
factor-induced apoptosis (Remacle-Bonnet et al., 2000). In contrast to the survival 
promoting effects of IGF-I found in this study, it has been demonstrated that stimulation of 
human osteoblasts with IGF-I induces expression of Fas and subsequently increased their 
susceptibility to Fas-mediated apoptosis when cocultured with FasL+ cells (Kawakami et al., 
1998). It remains to be seen whether IGF-I increases susceptibility to Fas-mediated 
apoptosis in murine osteoblasts. 
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The isolation procedure used in this study will yield osteoblasts at different stages of 
differentiation from osteoprogenitor through to mature osteoblasts. A significant proportion 
of these cells stain strongly for alkaline phosphatase suggesting they are of the 
preosteoblast/osteoblast stage of differentiation. Although it is not certain whether 
osteoprogenitors express IGF-I or IGF-I receptors evidence suggests that genes for 
regulatory proteins such as FGF receptor-I are modulated during progression from late 
osteoprogenitor to preosteoblast and osteoblast stages (Aubin, 1998). Therefore in the 
culture system used in this study these stages may be responsive to the survival promoting 
effects of IGF-I. 
Although no inhibitory activity was found with either bFGF or PDGF neutralizing 
antibodies this does not exclude a role for the involvement of these GFs in vivo. There are 
an increasing number of examples where several distinct extracelluar signalling molecules 
have been shown to collaborate to promote cell survival in culture (Barres et al., 1993), 
presumably reflecting the advantages of combinatorial control. 
Although an assessment was not made as to whether other cells within the bone 
microenvironment can promote the survival of osteoblasts, it has previously been shown 
that lens epithelial cells can promote chondrocyte survival and vice versa (Ishizaki ei al., 
1993). One theoretical advantage of having cells depend on signals from their neighbours 
for survival is that any cell that ends up in an abnormal location would fail to receive the 
survival signals it requires and would consequently die; because cells seem to require a 
combination of signals for sustained survival, at least in culture, a relatively small selection 
of signalling molecules used in different combinations could specifically control the survival 
of many distinct cell types. 
Interestingly, osteoblast apoptosis has been shown to occur in vivo with a frequency 
of - 0.6% (Jilka et al., 1998) and it has been concluded that only about 15% of terminally 
differentiated osteoblasts survive to become osteocytes in vivo (Parfitt, 1990), although 
what activates the death program in these cells remains unknown. An explanation may 
involve the loss of expression of type I IGF receptors by terminally differentiated 
osteoblasts similar to the loss of expression of bFGF receptors by hypertrophic 
chondrocytes (Iwamoto, 1991). 
Osteoblast apoptosis has also been shown to be important in the pathogenesis of 
certain metabolic bone diseases. Studies have shown that exposure to high doses of 
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glucocorticoids such as dexamethasone increase apoptosis of mature osteoblasts and 
osteocytes resulting in glucocorticoid-induced osteoporosis (Weinstein et al., 1998). 
Interestingly, it has been suggested that glucocoticoids antagonize the effects of IGF-I 
(Delaney and Canalis, 1995). Osteoblast apoptosis may also be important in 
postmenopausal osteoporosis since it has been shown that estrogen inhibits osteocyte and 
osteoblast apoptosis (Manolagas et al., 1999). 
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4. The Resorptive Actions of Interleukin-11 On 
Bone in vitro 
4.1 INTRODUCTION 
Bone formation and resorption are coupled through the actions of several locally 
produced growth factors and cytokines. Unlike other cytokines involved in hematopoiesis, 
IL-11 is not produced by monocytes or lymphocytes, but its expression is restricted to 
certain cells of the mesenchymal lineage (Maier et al., 1993). There is evidence to suggest 
that IL-11, like IL-6, is an important osteotropic factor. IL-11 receptor transcripts are 
present in chondroblastic and osteoblastic progenitor cells during mouse embryogenesis 
(Elias et al., 1995). IL-11 is produced by both primary osteoblasts and human osteosarcoma 
SaOS-2 cells in response to bone resorbing agents (Elias et al., 1995; Romas et al., 1996) 
and Girasole et al. (1994) demonstrated that IL-11 dose-dependently stimulates osteoclast- 
like multinucleated cell (OCL) formation in co-cultures of mouse osteoblasts and bone 
marrow cells. They also reported that a monoclonal anti-IL-11 antibody inhibited OCL 
formation induced by several osteotropic factors. 
Bone resorption involves a series of events, the central step being the removal of 
bone matrix by osteoclasts. Osteoblasts play an accessory role in bone resorption by 
releasing matrix metalloproteinases (M vies) that degrade the surface osteoid layer 
(principally type-I collagen), facilitating the access of osteoclasts to the mineralized bone 
(Chambers et al., 1985). Bone resorption is also governed by the recruitment of new 
osteoclasts from progenitor cells of the mononuclear phagocyte system (Suda et al., 1992). 
The mononuclear progenitors are disseminated via the bloodstream and deposited in the 
mesenchyme surrounding the bone rudiments where they proliferate and differentiate into 
(pre)osteoclasts prior to migrating to future resorption sites (Blavier and Delaisse 1995). 
M MPs have been shown to play an important role in 1,25-(OH)2D3-mediated migration and 
fusion of osteoclast precursors (Blavier and Delaisse 1995). 
It is known that prostaglandins (PGs), the cyclo-oxygenase (CO) products of 
arachidonic acid metabolism, are powerful mediators of bone resorption and that a variety 
of agents that stimulate resorption do so by generating PGs in the microenvironment of 
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bone-resorbing cells. More recently products of the 5-lipoxygenase (5-LO) pathway of 
arachidonic acid metabolism, namely 5-hydroxyeicosatetraenoic acid (5-HETE) and the 
peptido-leukotrienes (LTs) LTB4, LTC4, LTD4, and LTE4 have been found to enhance bone 
resorption but their contibution to cytokine-induced resorption has not been established 
(Garcia et al., 1996). Although IL-11 has been shown to stimulate osteoclast formation 
(Girasole et al., 1994), it is not known if the activity of IL-11 is restricted to this stage of 
bone resorption or whether MMPs and products of arachidonic acid metabolism play a role 
in mediating the resorptive activity of IL-11. 
The aims of this study were to use a variety of discriminatory assays to better define 
the mechanisms of action of IL-11 in bone resorption. 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Human recombinant IL-11 and IL-1a were gifts from the Genetics Institute 
(Cambridge, MA) and Dr. J. Saklatvala, Strangeways Research Laboratory (Cambridge, 
UK) respectively. The specific MMP inhibitor, CT 1166 was a gift from Dr. A. Docherty, 
Cell Tech, UK. CT 1166, a concentration-dependent selective inhibitor of gelatinases A and 
B, inhibits MMP activity at a 10'' M concentration (Hill et al., 1995). Modified Biggers 
(BGJ) medium was obtained from Flow Laboratories (Irvine, UK). 4SCaC12 and 14C were 
purchased from Amersham International, Aylesbury, United Kingdom. Indomethacin and a- 
MEM were obtained from Sigma Chemical Company (Poole, Dorset, UK). The 5-LO 
inhibitors, BWA70C and MK886 were gifts from Professor B. Henderson, Eastman Dental 
Institute (UK). BWA70C is a selective inhibitor of the enzyme 5-LO whilst MK886 is a 
selective inhibitor of the 5-LO activating protein (FLAP). The later protein binds to 5-LO 
and is an obligatory participant in the activity of this enzyme. Inhibition of the interaction 
between FLAP and 5-LO blocks the synthesis of lipoxygenase products. Mice (CD-1 strain) 
were purchased from Charles River Breeding Laboratories (U. K. ). 
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4.2.2 Methods 
4.2.2.1 Neonatal calvarial assay 
Bone resorption was assessed by analysing 45 Ca2+ release from cultured neonatal 
mouse calvarial bones (Reynolds and Dingle, 1970). Briefly, 1-day-old mice were injected 
subcutaneously with 0.1 megabecquerels 45CaC12 or 1 megabecquerel 45CaC12 for the kinetic 
studies. After 6 days, the mice were sacrificed and the calvariae were excised and dissected 
into two equal halves and precultured in modified BGJ medium (2 ml) containing 26 mM 
NaHCO3,0.85 mM ascorbic acid, 1.4 mM L-glutamine, 5% FBS (Globepharm, Surrey, 
United Kingdom), and indomethacin (1 µM) for 24 h. Bones were subsequently cultured in 
pairs in fresh modified BGJ medium (2 ml) for up to 8 days with a media change every 2 
days. Mobilization of radioactivity was expressed as the percent release of initial isotope 
(calculated as the sum of radioactivity in medium and bone after culture). To determine 
45Ca2+ release due to passive exchange of isotope, two bones from each litter were 
devitalized by three cycles of freeze-thawing. The percent release from the devitalized bone 
was subtracted from each living bone to give the amount of cell-mediated resorption. 
4.2.2.2 Preparation of osteoblasts from neonatal mouse calvariae 
Calvarial osteoblasts were prepared and characterized as described in section 
2.2.2.1. Cells released by the last two collagenase digestions were washed and grown in 
DMEM containing 10% FBS and antibiotics for 2 days before use. All cultures were 
maintained at 37°C in a humidified atmosphere of 5% C02-95% air. 
4.2.2.3 Preparation of collagen films 
Radiolabelled collagen films were prepared as described previously (Gavrilovic et al, 
1985). Aliquots of 14C-acetylated collagen (rat skin type I; 150 µg in 300 µl of 10 mM 
phosphate buffer, pH 7.4, containing 300 mM NaCl and 0.02% sodium azide) were 
dispensed into tissue culture wells (Linbro, 16 mm diam) and dried at 37°C. 
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4.2.2.4 Preparation of acid-treated serum 
To destroy serum inhibitors of neutral proteinases, aliquots (20 ml) of heat- 
inactivated rabbit serum (Globepharm) were acidified to pH 3.2 with 1M HCl and 
incubated for 35 min at 37°C. The pH was then returned to 7.4 with 1M NaOH. 
4.2.2.5 Culture of osteoblasts on collagen films 
Osteoblasts (1 x 105/well) were settled onto collagen films in 1 ml of DMEM plus 
10% (v/v) FCS, incubated for 16 h at 37°C and washed with serum-free DMEM. Cells were 
then cultured in DMEM (1 ml) supplemented with 5% (v/v) acid-treated rabbit serum as 
described above. Either 1,25-(OH)2D3 or IL-11 alone (final concentration 10'8 M and 10"9 M 
respectively, added in 5 µl of ethanol) or either compound in the presence of the respective 
MAP or arachidonic acid inhibitors were then added to the wells and the cultures 
maintained at 37°C for 48 h. At the end of the culture period the media were centrifuged 
(15 min, 1200xg) to remove any collagen fibrils and radioactivity released during collagen 
degradation quantified by liquid scintillation counting. Residual collagen was digested with 
bacterial collagenase (50 gg/ml) and assayed for radioactivity. Collagenolysis was expressed 
as radioactivity released from the films as a percentage of the total ± SEM. 
4.2.2.6 Isolated osteoclast assay 
The osteoclast bone resorption assay is based on the ability of isolated osteoclasts to 
resorb devitalized cortical bone, dentine, or ivory slices in vitro (Boyde et at, 1984). Ivory 
slices, 200 pm thick, were cut with a low speed water-cooled diamond saw (Isomet, 
Buehler, Coventry, United Kingdom) from a1 cm2 rod. Ivory slices were chosen because 
they are free of vascular systems and pre-existing resorbing surfaces. Osteoclasts were 
prepared from either 2- to 3-day-old mice. After killing the animals, femurs and tibias were 
removed, and osteoclasts were isolated by curetting the bones into 4 ml PBS and agitating 
the cell suspension with a pipette. Larger fragments were allowed to settle for 10 sec before 
500 µl aliquots of the supernatant cell suspension were immediately transferred to 6 wells of 
24 well culture dishes (Costar, Cambridge, MA), each containing a single ivory slice. Cells 
were allowed to settle and attach for 25 min at 37°C. The substrate was then washed free of 
nonadherent cells, and then the various test substances were added to the cultures which 
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were subsequently incubated for 48 h in a humidified atmosphere of 5% C02-95% air at 
37°C in 500 µl a-MEM supplemented with 5% FBS, 2.0 g/L NaHCO3,2 mM L-glutamine, 
100 U/ml penicillin, and 100 µg/ml streptomycin. Due to the variability in the number of 
osteoclasts isolated from each mouse, a single experiment consisted of 6 ivory slices bearing 
the cells from 1 mouse, with 3 slices for each control and test variable. Each experimental 
variable was repeated 4 times. 
At the completion of the 48 h culture period, the cells were removed from the ivory 
slices, which were then stained with toluidine blue to count the resorption lacunae. The 
method used for the precise quantitation of the resorptive capacity involved estimating the 
surface area of the resorption lacunae by image analysis (TC Image, Foster Finlay 
Associates, United Kingdom). To test the indirect responsiveness of osteoclasts to IL-11, 
osteoclasts obtained after a short sedimentation time (25 min) were co-cultured with 
neonatal mouse calvarial osteoblasts (1 x 105 cells/well) for 48 h. Bone resorption was 
quantified as above. 
4.2.2.7 Murine bone marrow cell cultures 
A mouse bone marrow culture system was used to assess osteoclast differentiation 
(Takahashi et al., 1988). 5- to 6-week-old mice were killed by cervical dislocation and the 
femurs and tibias were removed and dissected free of adherent tissue. The epiphyses were 
removed and the marrow cavity was flushed with 1 ml a-MEM using a sterile 30-gauge 
needle. The bone marrow suspension was aspirated up and down with a1 ml pipette and the 
resulting single cell suspension washed 3 times by centrifugation at 300xg. The marrow cells 
were plated in 24-well dishes, with each well containing either a Thermanox coverslip 
(Nunc, Naperville, IL) or a1 cm2 ivory slice, at a density of 2x 106 cells/well in 0.5 ml a- 
MEM containing 10% FBS and 10"' M dexamethasone. The cultures were incubated in the 
presence of IL-11 and/or 1,25-(OH)2D3 (10'8). Cultures were fed every 3 days by replacing 
250 pl culture medium with fresh medium and hormone or vehicle. After 8 days, the 
cultures on the coverslips were stained for TRAP and the number of TRAP-positive 
multinucleated cells (MNCs; three or more nuclei) was counted. The cells were removed 
from the ivory slices after 8 days, and the substrate was stained with toluidine blue and 
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examined for the presence of resorption lacunae by light microscopy. The surface area of 
bone resorption was quantified as before. 
4.2.2.8 Fetal metatarsal long bone assay 
The 3 middle metatarsals of each hindlimb of 17-day-old mouse embryos (day of 
vaginal plug discovery equals day 0 of gestation) were dissected as a triad (Blavier and 
Delaisse, 1995). One triad of each pair was cultured as a control, the other as a test. The 
long bones were cultured without removal of the cartilaginous epiphyses, and care was 
taken not to damage the periosteum-perichondrium. Each triad was cultured in I ml CMRL 
1066 medium supplemented with glutamine (200 mg/1), 10% heat inactivated FCS with and 
without either 1,25-(OH)2D3 (10'8 M) or IL-11 (10'9 M). Media were renewed every day. 
The three metatarsals were placed on a piece of lens paper, itself deposited upon a stainless 
steel grid, which was in turn suspended above the center well of the organ culture dish. The 
culture period was 3 days. 
4.2.2.9 Preparation of tissue sections 
Plastic sections for a detailed characterization of the migration pathway of the 
osteoclasts were prepared as described (Blavier and Delaisse, 1995). Metatarsals were fixed 
in 4% neutral buffered formalin for 18 h at 4°C, and embedded in glycolmethacrylate 
according to the instructions of the "Historesin Embedding Kit" (Reichert-Jung). Sections 
of 3µm were cut with glass knives in a Reichert-Jung microtome (20/50, supercut), stained 
for TRAP and counterstained with haematoxylin (Van de Wijngaert and Burger, 1986). 
4.2.2.10 Histomorphometry 
The number of TRAP-positive cells and their nuclei were determined in 10 evenly 
spaced longitudinal sections per long bone rudiment. According to their location they were 
scored as (a) lying in the developing marrow cavity, that is the area of resorbing calcified 
cartilage surrounded by the thin bone collar; or (b) in the periosteum-perichondrium, that is, 
the soft tissue around the bone rudiment. The few cells lying within the (thin) bone collar 
were equally divided over the two compartments. 
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4.2.2.11 Statistical analysis 
Differences between the control and treatment groups were determined by the 
Mann-Whitney U test. 
4.3 RESULTS 
4.3.1 Effects of IL-11 on calvarial bone resorption 
The neonatal mouse calvarial assay was used to screen for activity modulating 
osteoclast differentiation and function. During an 8-day culture period, IL-11 dose- 
dependently increased the release of 45Ca2+ from calvarial explants with a maximal effect of 
62.5 ± 6.7 % at 5x 10-9 M (Fig 4-IA. ). The EC5o for IL-11 mediated 45Ca2+ release was 10' 
10 M. As shown in Figure 4-1B the kinetics of 45Ca2+ release from calvarial explants as a 
function of time (2,4,6,8 days) demonstrated that the effects of IL-11 were different from 
those of three known resorptive agents namely PTH, 1,25-(OH)2D3 and IL-la. Whilst the 
latter three agents stimulated 45Ca2+ release throughout the culture period, IL-11 (10"9 M) 
had no effect on 45Ca2+ release during the first 2 days of culture, but had a significant 
stimulatory effect during the subsequent culture period (Fig. 4-1B). 
The specific MMP inhibitor, CT1166 (10"7 M) produced a 95.6 ± 6.7% inhibition in 
IL-11 (10-9 M)-stimulated 45 Ca2+ release over an 8 day culture period, whilst the PG 
synthesis inhibitor, indomethacin (10-6 M) produced a 92.7 ± 7.8% inhibition and the LT 
synthesis inhibitor, BWA70C (10-6M) blocked the effects of IL-11 on 45Ca2' release by 
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4.3.2 Effects of IL-11 on the degradation of type-I collagen by mouse osteoblasts 
To assess whether removal of the unmineralized osteoid layer of bone plays a part in 
the bone resorptive activity of IL-11, murine primary osteoblasts were cultured on 14C- 
labelled type I collagen. In unstimulated cultures, there was a 24.1 ± 4.9% release of 14C 
from type-I collagen during a 96 h culture period and IL-11 dose-dependently increased the 
release with a maximum of 58.0 ± 6.2% at a5x 10"9 M concentration (Fig. 4-2A). The ECso 
for IL-11 effects on type-I collagen degradation was 2x 10'10 M. The effects of IL-11 were 
less than those of the osteotropic hormone, 1,25-(OH)2D3 (10-8 M) which induced a 76.5 ± 
7.1% release of 14C after 96 h (Fig. 4-2A). In combination, IL-11 and 1,25-(OH)2D3 
induced an increase in the release of 14C from type I collagen films (91.7 ± 9.4%) over that 
seen with either ligand alone (Fig. 4-2A). The effects of IL-11 (10'9 M) on14C release were 
abrogated by the synthetic MAP inhibitor, CT 1166 (10'7 M), whilst the PG inhibitor, 
indomethacin (10-6 M) and the LT synthesis inhibitor, BWA70C (10'6 M) were without 
effect (Fig. 4-2 B). 
4.3.3 Effects of IL-11 on isolated osteoclast bone resorption 
To ascertain whether activation of mature osteoclasts was responsible for the IL-I 1 
stimulated bone resorption, the effects of IL-i l on mouse osteoclast populations obtained 
after a short (25 min) sedimentation time (which minimizes contamination by non- 
osteoclastic cells and consequent indirect hormonal responses) were examined. Neither IL- 
11 (5 x 10"9 M) nor 1,25-(OH)2D3 (10"g M) alone had any effect on osteoclast lacunar 
resorption (Table 4-1). Similar experiments were performed in which mouse osteoclasts 
obtained after a short (20 min) sedimentation were incubated with primary mouse 
osteoblastic cells. Whilst 1,25-(OH)2D3 (10"8 M) stimulated osteoclast lacunar resorption in 
these co-culture experiments, IL-11 did not increase or decrease osteoclast lacunar 
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FIG. 4-2 Effects of IL-11 and 1,25-(OH)2D3 on the degradation of 14 C-labelled type-I 
collagen films by mouse osteoblasts. 
A. Mouse osteoblasts were cultured at a density of 105 cells/well of a 24-well plate in the 
presence of increasing concentrations of either IL-11 or 1,25-(OH)2D3 for 96 h. The results 
are the mean ± SEM of 6 separate cultures. The percentage release of 14C from the 
control (unstimulated) cultures was 24.1 ± 4.9. B. Effects of inhibition of MMP, PG or LT 
synthesis on the degradation of 14C-labelled type-I collagen films by mouse osteoblasts 
stimulated by either IL-I 1 or 1,25-(OH)2D3. Mouse osteoblasts were cultured as in A. in the 
presence of either IL-1 I (10'9 M) or 1,25-(OH)2D3 (10'8 M) for 96 h. The various ligands 
were added 6h after sedimentation of the osteoblasts. The inhibitory effects of CT 1166 (10' 
6 M) were statistically significant, **P<0.01, compared with the control whilst the inhibitory 
effects of indomethacin (10.6 M), BWA70C (10-6 M) and MK886 (10-6 M) were not 
statistically significant compared to the control. 
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TABLE 4-1. Effects of IL-11 and 1,25-(OH)2D3 on lacunar resorption by isolated 
osteoclasts and by osteoclasts cocultured with osteoblasts. 
Treatment No. of pits/ivory slice Surface area of resorption/ 
ivory slice (µm2) 
OC 16.7 ± 3.1 4186 ± 815 
OC + IL-11 19.2 ± 4.5 4214 ± 971 
OC + 1,25-(OH)2D3 20.3 ± 4.2 4695 ± 761 
OC + OB 43.7 ± 9.7 11,034 ± 2016 
OC + OB + IL-11 47.2 ± 11.3 10,709 ± 3169 
OC + OB + 1,25-(OH)2D3 175.0 ± 30.1 63,616 ± 12132 
Mouse osteoclasts (OC) were sedimented onto ivory slices for 25 min and cultured alone or 
in the presence of mouse osteoblasts (OB). IL-11 and 1,25-(OH)2D3 were added to the 
cultures once the cells had attached to the substrate. After incubation for 48 h in the 
presence of either IL-11 (10"9 M) or 1,25-(OH)2D3 (10'8 M), the resorption was quantified 
by image analysis. Each mean ± SEM represents 12 ivory slices from four separate 
experiments. The number of TRAP positive multinucleated osteoclasts per slice was 24.3 t 
6.2 and the mean surface area of the pits was 305.7 ± 125 µm2. 
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4.3.4 Effects of IL-11 on TRAP-positive MNC formation in bone marrow cultures 
To determine the possible involvement of IL-11 in the regulation of TRAP-positive 
MNC generation, IL-11 was added to the cultures separately or in combination with 1,25- 
(OH)2D3. In the absence of 1,25-(OH)2D3, IL-11 dose-dependently increased the formation 
of TRAP-positive MNC (Fig. 4-3A). The EC5o for IL-11 effects on TRAP-positive MNCs 
was 3x 10"11 M. Maximal TRAP-positive MNC formation occurred at a concentration of 
10-9 M. The numbers of TRAP-positive MNC formed in 16 independent cultures treated 
with IL-11 (10"9 M) was 136.7 ± 22.3 (Fig. 4-3A). IL-11 was not as effective as 1,25- 
(OH)2D3 (10"8 M) in generating TRAP-positive MNC (179.7 ± 27.8). However, IL-11 had 
an additive effect on TRAP-positive MNC formation when added in combination with 1,25- 
(OH)2D3 (226.6 ± 36.7). 
4.3.5 Effects of IL-11 on bone resorption in marrow cultures 
The cultures in which TRAP-positive MNC were generated in the presence of IL-11 
had the ability to form resorption pits when cultured on an ivory substratum (Fig 4-4). Since 
IL-11 did not enhance the resorptive activity of mature osteoclasts compared to 
unstimulated cultures (Table 4-1) this indicates that the IL-11-mediated resorption in the 
marrow cultures reflects the effects of IL-11 on osteoclast formation. Therefore the effects 
of IL-11 on resorption in the marrow cultures were quantified. When marrow mononuclear 
cells were cultured on ivory slices for 8 days, IL-11 induced a dose-dependent increase in 
the surface area of resorption compared with the control cultures (Fig. 4-3B). The EC5o for 
the effects of IL-1 I on lacunar resorption was 2x 10'" M and a maximal effect occurred at 
a concentration of 10"9 M (Fig. 4-3B). The 5-LO inhibitors, BWA70C and MK886 
produced a dose-dependent inhibition in IL-11-mediated resorption with a maximum of 
-50% at 10'6 M (Fig 4-3C). The PG synthesis inhibitor, indomethacin produced a greater 
inhibition with a maximum of 83.6 ± 9.7% at the same concentration (Fig. 4-3C). Complete 
inhibition was only achieved using a combination of both types of inhibitor. The MMP 
inhibitor, CT1166 (10-6 M) produced a 28.9 ± 8.7% inhibition in the resorptive activity of 
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FIG. 4-3 Effects of IL-11 on the formation of TRAP-positive MNCs. 
A. Mouse marrow cells were cultured with increasing concentrations of IL-11 for 8 days. 
Data are expressed as the mean ± SEM of 6 cultures from 2 experiments. B. Effects of IL- 
I1 on bone resorption. Bone marrow cells were cultured on ivory slices for 10 days in the 
presence of increasing concentrations of IL-11. Lacunar resorption was quantified by image 
analysis. Data are expressed as the mean ± SEM of four cultures from two experiments. C. 
Effects of inhibition of PG, LT and MMP synthesis on IL-11 stimulated lacunar resorption. 
Murine bone marrow cells were cultured on ivory slices for 10 days and stimulated by IL-11 
(10"9 M). IL-11, CT1166, BWA70C and MK886 were added to the cultures 8h after 
sedimentation of the marrow cells. The inhibitory effects of CT1166, BWA70C, MK886, 
and indomethacin were statistically significant, *, P<0.05; * *, P 0.01 compared with the 
control. Lacunar resorption was quantified by measuring the surface area of the lacunae by 
Image Analysis. Data are expressed as the mean ± SEM of four cultures from 2 
experiments. 
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Fig. 4-4 Scanning electron micrograph of resorption pits. 
Bone marrow cells were cultured on ivory slices and cultured in the presence of IL-11 as 
described in Materials and Methods. After 8 days ivory slices were removed and processed 
for scanning electron microscopy. Slices show large resorption lacunae. Magnification X 
900. 
126 
4.3.6 Effects of IL-11 on osteoclast migration and fusion in 17-day-old metatarsal 
rudiments 
The effects of IL-11 and 1,25-(OH)2D3 on osteoclast migration and fusion were 
investigated in non-invaded 17-day-old metatarsal bone rudiments after 3 days of culture by 
means of histomorphometry after TRAP staining. After 3 days of culture a maximal number 
of mature osteoclasts have been formed and are present in the primitive marrow cavity 
(Scheven et al., 1986). Culturing for a longer period gradually diminishes osteoclast 
numbers, which is most likely the result of less available calcified matrix due to resorption 
(Baron et al., 1986). When the cultures are started at day 0, cell and nuclei counts are 
similar, showing that the majority of TRAP-positive cells are mononucleated (Fig. 4-5). 
Upon culture there is a progressive increase in the number of cells and nuclei per metatarsal 
as described previously (Blavier and Delaisse, 1995). The increase is larger for nuclei than 
for cell numbers, showing that the TRAP-positive cells become multinucleated (Fig. 4-5). 
These observations are compatible with a continuous differentiation of TRAP-negative 
precursors into TRAP-positive cells, and with the concept that multinucleated osteoclasts 
are generated by fusion of TRAP-positive cells (Baron et al., 1986). Fig. 4-5 shows the 
effect of 3 days of continuous treatment with either IL-11 (10"9 M) or 1,25-(OH)2D3 (10"8 
M) on the migration kinetics of the maturing osteoclasts to the mineralized matrix, as 
evaluated from the counts of the total number of TRAP-positive cells and their nuclei in 
serial sections of a number of metatarsals. In the 1,25-(OH)2D3 treated cultures there is a 
significantly greater increase in the number of TRAP-positive cells and nuclei per 
metatarsal as compared to the control cultures. Culture with 1,25-(OH)2D3 leads also to an 
increase numbers of TRAP-positive cells and of nuclei in the mineralized matrix; the 
proportion of nuclei in the matrix increases from 0 to 43 for the control cultures and from 0 
to 116 for the 1,25-(OH)2D3 treated cultures (Fig. 4-5). In contrast, although IL-11 (10'9 
M) induced an increase in the number of TRAP-positive cells and their nuclei, the cells were 
prevented from invading the mineralized matrix (Fig. 4-5). In Fig. 4-6 histological sections 
of 17-day-old fetal mouse metatarsal are shown after 3 days in culture with and without IL- 
11. In the IL-11-treated metatarsal explant (Fig. 4-6A) TRAP-positive multinucleated 
osteoclast precursors (arrows) are still confined periosteum whereas in the untreated 
explant TRAP-positive cells have invaded the mineralized matrix (Fig. 4-6B). 
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Fig. 4-5. Effects of IIr11 and 1,25-(OH)2D3 on the migration of TRAP-positive cells in 
metatarsal explants. 
Metatarsals were obtained from 3 litters of 17-day-old fetal mice. The metatarsal triads of 
the left limb were cultured with either IL-11 (10'9 M) or 1,25-(OH)2D3 (10'8 M) and those 
of the corresponding right limbs were cultured under control conditions for 3 days. The 
number of TRAP-positive cells and their nuclei localized inside and outside the calcified 
cartilage (cc) were counted. Counts inside the cc are shown to the right of the `0' axis and 
those within the periosteum are shown to the left. Each bar (left and right) expresses thus 
the total number in one metatarsal. Counts at day 0 and 3 are the means ± SEM of 12 and 






Fig. 4-6. Light micrographs of 17-day-old fetal metatarsal rudiments. 
17-day-old fetal metatarsal rudiments were cultured for 3 days in medium with IL-11 (10-9 
M; A) and control medium (B). In the IL-I I treated rudiment (A), large TRAP-positive 
cells are present in the periosteum (arrow), but no TRAP-positive cells have invaded the 
mineralized center, which is not resorbing. In the control rudiment (B), several TRAP- 
positive cells (arrows) have entered the rudiment. Mineralized matrix is being resorbed in 
the centre of the bone. Bar = 50 pm. 
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4.4 DISCUSSION 
This investigation looks at the mechanism of action of IL-I I on bone resorption 
using a variety of discriminatory in vitro culture systems representing different aspects of 
the resorptive cascade. As there is strong evidence for the involvement of both MMPs and 
products of arachidonic acid metabolism in the resorption of bone their contribution to the 
resorptive activity of IL-I I has been determined. 
The effects of IL-11 on bone resorption were initially assessed using neonatal 
calvarial explants that comprise a hetereogenous cell population which includes mature 
osteoclasts and their precursors. These explants enable one to simultaneously screen for 
activity influencing several steps in the resorption cascade, including osteoblast-mediated 
osteoid degradation, osteoclast recruitment and osteoclast activity. Demonstration that IL- 
11 was without effect on bone resorption for the first 2 days of culture compared to the 
osteotropic agents PTH, IL-1 and 1,25-(OH)2D3 suggested that the mechanism by which 
IL-11 modulates bone resorption may be restricted to specific steps in the process and that 
the cytokine may not directly stimulate osteoclast resorptive activity. This was investigated 
using selective assays representative of the different steps in the bone resorption cascade. 
The study demonstrates that IL-11 (i) stimulates osteoblast-mediated type I collagen 
degradation and osteoclast formation, (ii) inhibits the migration of (pre)osteoclasts to future 
resorption sites and (iii) has no effect on the activity of mature osteoclasts. Furthermore, 
the use of selective inhibitors has shown that the CO and 5-LO products of arachidonic 
acid metabolism play a part in the osteoclastogenic activity of IL-11 and that MMPs are 
involved in mediating osteoblast degradation of the unmineralized osteoid layer of bone in 
response to IL-11. 
Cytokines exert their pleiotropic effects by interacting with specific cell surface 
receptors (Kishimoto et al., 1994). Osteoblasts express transcripts for the complete IL-11 
receptor which consists of two components: a unique ligand-binding chain (IL-11 Ra) (Yin 
et al., 1992) and a non-ligand binding, signal transducing chain (gp 130) (Yin et al., 1993). 
The results with the selective MMIP inhibitor, CT 1166, indicate that the interaction of IL- 
11 with its receptors on osteoblasts enhances the synthesis of MMPs that are responsible 
for the degradation of type I collagen. This upregulation in osteoblast MMP production is 
similar to that induced by several osteotropic factors, including IL-1, PTH and 1,25- 
(OH)2D3, which also cause osteoblasts to degrade type I collagen (Hill et al., 1995; Meikle 
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et al., 1992). Therefore, it appears that the increase in MMP activity is a common 
denominator among the bone-resorbing actions of several agents. Osteoblasts are a source 
of IL-11 (Elias et al., 1995; Romas et al., 1996) and upon stimulation by several 
osteotropic agents, including PTH, 1,25-(OH)2D3, and IL-1, the expression of IL-11 and 
the signal transducing component of the IL-11 receptor, gp130 in osteoblasts is enhanced 
(Romas et al., 1996). These observations suggest that IL-11 may play a central role in 
osteoblast-mediated type I collagen degradation and that the regulation of gp130 by certain 
osteotropic agents may modulate the sensitivity of osteoblasts to IL-11. 
Although IL-11 receptor transcripts have been demonstrated in mature osteoclasts 
(Romas et al., 1996), the inability of IL-I1 to stimulate bone resorption even when 
osteoclasts were cocultured with osteoblasts suggests that the IL-11 receptor is not 
involved in this aspect of osteoclast activity. However, the demonstration that IL-11 
stimulates osteoclast formation and prevents the migration of (pre)osteoclasts to resorption 
sites suggests that the receptor may play a role in these aspects of the resorption cascade. 
IL-11 has recently been shown to increase expression of RANKL in cultures of primary 
mouse osteoblasts which explain the effects of IL-i l on osteoclast generation (Horwood et 
al., 1998). 
PGs are produced in bone by many cells, especially osteoblasts, and production is 
stimulated by a variety of cytokines derived from macrophages or hemopoietic cells within 
the bone marrow microenvironment (Feyan et al., 1984). In the present study an important 
role for PGs in IL-11-mediated osteoclast formation has been demonstrated which confirms 
a recent report (Girasole et al., 1994). However based upon the effects of two selective 
lipoxygenase inhibitors, BWA70C and MK886 the findings from this study indicate that 
lipoxygenases also contribute to the osteoclastogenic activity of IL-11. The IC50 values for 
the inhibitors are in accord with the reported potency of these compounds and so the results 
would appear to be due to the selective inhibitory activity of the compounds and not to non- 
specific effects. The fact that two mechanistically distinct classes of lipoxygenase inhibitor 
can block bone resorption induced by IL-11 reinforces the fact that these enzymes are 
induced by this particular osteolytic cytokine. At present it is not certain as to which 
particular lipoxygenase products of arachidonic acid metabolism are responsible for 
mediating the effects of IL-11 on osteoclast formation due to the instability and short half- 
life of the products (Keppler, 1992). Interestingly, a role for leukotriene B4 in 
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osteoclastogenesis has recently been shown in murine bone marrow cultures (Garcia et al., 
1996). Whilst PGs have been shown to mediate the bone resorptive activity of a variety of 
cytokines, this is the first indication that the 5-LO products of arachidonic acid metabolism 
might also play a role in the osteolytic activity of a pleiotropic cytokine. 
The ability of IL-11 to induce osteoclast development when added to cultures of 
bone marrow cells by itself contrasts with the related cytokine, IL-6 whose biological 
activities are also mediated by the gp130 signal transducer (Taga et al., 1989). IL-6 
induction of osteoclast differentiation, however, is dependent on the presence of soluble IL- 
6 receptors (Tamura et al., 1993) and is mediated by IL-6 receptors expressed on 
osteoblastic cells rather than osteoclast progenitors (Udagawa et al., 1995). The ability of 
IL-11 to induce osteoclast differentiation on its own may be due to the presence of IL-I1 
receptors on osteoclasts or because osteoblasts express a sufficient levels of functional IL- 
11 receptors. 
Osteoclast formation is induced by at least three different mechanisms (Suda et al., 
1992). The first mechanism is the PTH, IL-1, PGE2 axis which is mediated by signaling 
involving cAMP. The second mechanism is 1,25-(OH)2D3 induced osteoclast formation, 
which is mediated by the vitamin D receptor but independent of cAMP. The gp130 signal, 
activated by cytokines such as IL-11, IL-6 and LIF is an additional and important pathway 
of osteoclast formation. Interestingly IL-1 1 may contribute in part to osteoclast formation 
induced by some osteotropic agents because antibodies to either gp130 or IL-11 inhibit the 
osteoclastogenic effects of PTH, IL-1, PGE2, and 1,25-(OH)2D3 (Romas et al., 1996; 
Girasole et al., 1994). Furthermore these agents stimulate IL-11 production in cocultures of 
osteoblasts and bone marrow cell cultures (Romas et al., 1996; Girasole et al., 1994). 
In this study it has been shown that 1,25-(OH)2D3 increases the number of TRAP- 
positive cells that migrate from the periosteum to mineralized matrix in the center of the 
rudiments where they excavate a primitive marrow cavity. 1,25-(OH)2D3 increased the 
number of TRAP cells in the bone center as well as the excavation of a marrow cavity. Both 
phenomena, accumulation of cells in the resorbing center and cell fusion imply cell 
movement. In contrast IL-11 prevented the migration of TRAP-positive osteoclasts to 
future resorption sites without effecting their fusion into multinucleated cells. An 
accumulation of TRAP-positive cells in the periosteum accompanies the blockage of 
migration, thus indicating that the generation of TRAP-positive cells is not prevented. The 
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failure of (pre)osteoclast invasion of the mineralized matrix cannot be ascribed to an 
antiproliferative effect of IL-11 as the cells responsible for resorption have already reached 
a post-proliferative stage at the onset of the cultures, as shown by irradiation (Scheven et 
al., 1986). 
It is highly unlikely that PG synthesis is involved in the inhibitory effects of IL-11 on 
osteoclast migration, since PGs stimulate resorption in fetal long bones, which implies that 
osteoclast migration is enhanced by PGs. The inhibitory activity of IL-11 on (pre)osteoclast 
migration may be due to an alteration in the balance between MMPs and their natural 
inhibitors, the tissue inhibitor of metalloproteinases (TIMPs), as some modulators of this 
balance, such as TNF-a, TGF-ß and LIF (Murphy and Reynolds, 1993) have been found to 
interfere with the migration of (pre)osteoclasts into the mineralized matrix of metatarsal 
rudiments (Van der Pluijm et al., 1991; Dieudonne et al., 1991; Van Beek et al., 1993). In 
support of this concept it has recently been demonstrated that an MMP inhibitor prevented 
the migration of (pre)osteoclasts induced by 1,25-(OH)2D3 and that migrating osteoclasts 
express gelatinase B (MAP-9) (Blavier and Delaisse, 1995), a proteinase involved in 
several processes where cells invade connective tissues, including wound healing, ovulation, 
tumour invasion and metastases. Furthermore high levels of TIMP have been detected in the 
periosteum of developing bones (Nomura et al., 1989) and within isolated osteoclasts (Hill 
et al., 1994). Thus TIMP may restrict the migration of (pre)osteoclasts directly or indireclty 
by limiting the lysis of the periosteum to focal points. Interestingly IL-11 stimulates the 
production of TIMP in chondrocytes and synoviocytes thereby limiting connective tissue 
degradation (Maier et al., 1993). 
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5. Expression and Function of Members of the ADAMs 
Family of Proteins in Bone Cells. 
5.1 INTRODUCTION 
It is well established that multinucleated osteoclasts are formed by fusion of 
mononuclear osteoclast precursors derived from hematopoietic progenitor cells (Nijweide et 
al., 1986) and that osteoclastogenesis critically involves cell-cell interactions between 
osteoclast precursors and osteoblasts (Takahashi et al., 1988). The precise repertoire of 
proteins and cellular mechanisms involved in these cell-cell interactions and subsequent 
events leading to cellular fusion are not fully elucidated. A role for integrins and non- 
integrin cellular adhesion molecules in the processes leading to osteoclast formation has 
been well established. E-cadherin is expressed by mouse and human osteoclasts and 
neutralization of E-cadherin function decreases the number of osteoclasts formed in bone 
marrow cultures (Mbadaviele et al., 1995). Furthermore, synthetic RGD peptides have been 
shown to inhibit fusion of mononuclear osteoclast precursors (van der Pluijm et al., 1994) 
thus implicating the integrin class of adhesion molecules in osteoclast formation. 
Recently, members of the ADAM family of membrane bound glycoproteins have 
been cloned, characterized and shown to have a multiple domain structure consisting of a 
metalloproteinase domain, a disintegrin-like domain, a cysteine rich domain, a 
transmembrane region and an intracellular domain (Wolfsberg and White, 1996). To date 30 
members of this family have been isolated and implicated in a number of important cell-cell 
and cell-matrix interactions. ADAM-15 (metargidin) has been shown to interact via its 
disintegrin domain with the av03 integrin expressed on chinese hamster ovary cell lines 
(Zhang et al., 1998) and with the av(3l integrin on haemopoietic cells (Nath et al., 1999). 
The cysteine rich domain of recombinant human ADAM-12 has also been shown to 
promote cellular adhesion in a number of human tumour cell lines (Iba et al., 1999), whilst 
the disintegrin domain of ADAM-12 has been found to interact with the a9ßß integrin in an 
RGD-independent manner (Eto et al., 2000). 
The cysteine rich domains of ADAM-1 (fertilin a) and ADAM-12 contain a short 
hydrophobic stretch of approximately 30 amino acids, which bears homology to fusion 
peptides present in viruses. ADAM-1 forms a heterodimer with ADAM-2 (fertilin ß) and 
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has been shown, using blocking antibodies and synthetic peptides, to be involved in sperm- 
egg binding and subsequent fusion (Myles et al., 1994; Almeida et al., 1995). Yagami- 
Hiromasa et al. (1995) cloned ADAM-12 (meltrin-a) from C2C12 muscle cells and 
demonstrated using antisense RNA that ADAM-12 is involved in myoblast fusion. In 
addition ADAM-9 (meltrin-y) and ADAM-19 (meltrin-ß) were cloned and may be involved 
in fusion events. ADAM-12 and ADAM-19 have been shown to be expressed in 
osteoblastic cells and it has been speculated that they may be involved in osteoblast 
differentiation (Inoue et al., 1998). 
The aims of this study were firstly to investigate the expression of ADAMs-9, -12 
and -19 in (1) primary mouse osteoblasts by RT-PCR and (2) in isolated osteoclasts and in 
the 17-day-old embryonic mouse metatarsal model by in situ hybridization. Secondly, to 
assess the function of ADAM-12 using bioassays of osteoclast formation and osteoblast 
differentiation. 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Recombinant human RANKL was from Insight Biotechnology Ltd. (Middlesex, 
UK) and recombinant murine M-CSF was from R&D Systems Ltd. (Abingdon, Oxon, 
UK). Recombinant glutathione-S-transferase (GST) and all chemicals and cell culture 
reagents were purchased from Sigma. CD-1 mice were purchased from Charles Rivers. The 
plasmid pGEX-2T was a generous gift from Dr. A. Waseem (Department of Craniofacial 
development, Guy's hospital) and the plasmids pcDNA-3 and pSPAP (secreted placental 
alkaline phosphatase) were obtained from Dr. A. Sunters (Craniofacial development, Guy's 
hospital). 
5.2.2 Methods 
5.2.2.1 Extraction of total RNA 
Total RNA was prepared from osteoblasts using an RNA isolation kit (Stratagene, 
UK) according to the manufacturer's instructions. Briefly RNA was isolated using acid 
guanidinium thiocyanate-phenol chloroform extraction and precipitated using isopropanol 
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and sodium acetate (0.2 M; pH 4.0). Total RNA was recovered by centrifugation at 10000 
xg for 20 min at 4°C, washed with 75% ethanol, and dissolved in nuclease-free water. 
5.2.2.2 RT-PCR procedure 
Oligonucleotide PCR primers were designed using Designer PCR (Research 
Genetics, UK) from previously published sequence data shown in Table 6-1 and synthesized 
by Life Technologies, UK. 
Table 5-1. Oligonucleotide RT-PCR primer sequences for mouse ADAMs 
Primer Sequence Expected Product 
Length (base pair) 
F 5'-ACAGCGAAGGAGTGTGAGGTGG-3' 188 
ADAM 9 
R 5'-GGGCAGAACTGAGAGGAACCG-3' 
F 5'-CCTGGTGAGCATCCTGTGTCTG-3' 241 
ADAM 12 
R 5'-GCATTTCAGCGAGTGCCTGTC-3' 
F 5'-GAGGAGGAAGGGGAAGGTGAC-3' 189 
ADAM 19 
R 5'-GCCAGGGAAGCAATGACAGTT-3' 
F 5'-CCACGAGAAATATGACAAC-3' 222 
GAPDH 
R 5'-GATGCAGGGATGATGTTC-3' 
F 5'-CAGGCATTGTGATGGACTCCG-3' 186 
p-ACTIN 
RT-PCR reactions were performed using the GeneAmp rT1h Reverse Transcriptase 
RNA PCR Kit (Perkin Elmer, USA) and a Stratagene Robocycler Gradient 96 PCR 
machine (Stratagene, UK). Briefly, 20 µl reverse transcription (RT) reactions were prepared 
from a master mix consisting of 1 .0 mM MnC12,200 µM each of 
dGTP, dATP, dTTP and 
dCTP and 5 units of rTth. To each 20 µl RT reaction was added 250 ng of total RNA and 
reverse primer (15 pmol). Each reaction was overlaid with mineral oil and incubated at 
70°C for 15 min. Following RT the reactions were held at 4°C and 100 µl PCR-reactions 
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prepared by addition of a master mix consisting of chelating buffer and MgC12 (final 
concentration 1.5 mM). To each 100 µl PCR reaction was added the matching forward 
primer (15 pmol) and the reaction overlaid with mineral oil. PCR mixtures were incubated 
at 95°C for 3 min followed by 35 cycles at 94°C (melting temperature) for 1.0 min, 55°C 
(annealing temperature) for 1.5 min and 72°C (primer extension) for 1.0 min. A final step 
was performed at 94°C for 1.0 min, 55°C for 1.5 min and 72°C for 10.0 min. RT-PCR 
products were analyzed by electrophoresis on a 2.0% agarose gel in Tris-Acetate-EDTA 
buffer (TAE) containing ethidium bromide (0.5 gg/ml). Band size was checked against 
molecular weight standards (0X174 Hae III digest). 
5.2.2.3 Cloning of RT-PCR products in pGEM-T 
RT-PCR products were electrophoresed on 1.5% low melting point agarose gels in 
Tris-Acetate-EDTA (TAE; Appendix 1). The expected DNA fragments were excised and 
purified from a TAE gel using QlAquick gel extraction kit (Qiagen GmbH, Germany). The 
authenticity of the sequences was verified by automated sequencing (Advanced 
Biotechnology Centre, Imperial College of Science, Technology and Medicine, UK). The 
fresh PCR products were ligated to pGEM-T vector (Promega, Southampton, UK) using 
T4 DNA ligase (Promega), and then transformed to high efficiency JM109 E. coli. 
Recombinant clones were selected for on Luria-Bertani (LB) medium containing ampicillin 
(100 pg/ml), isopropylthio-ß-D-galactoside (0.5 mM) and 5-bromo-4-chloro-3-indolyl-ß-D- 
galactoside (X-gal; 80 gg/ml). E. coil were cultured overnight in 250 ml of LB broth 
containing ampicillin (100 p. g/ml) and plasmid DNA was extracted using a method based on 
Qiagen Maxiprep DNA purification (Qiagen). Plasmids were linearized with Ncol and Spel 
for synthesis of Digoxigenin-11-UTP labelled riboprobes. 
5.2.2.4 Preparation of MMP-9 probe 
The probe for MlvfP-9 was a generous gift from Karl Tryggvason (Karolinska 
Institute, Sweden) and consisted of a 323 base pair fragment cloned into the Sma I/EcoRI 
site of plasmids pSP64/65. The plasmids were transformed to competent JM109 E. coli and 
recombinant clones selected for on LB medium containing ampicillin (100 pg/ml). E. coli 
were then cultured in 250 ml of LB broth containing ampicillin (100 gg/ml) and plasmid 
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DNA extracted using a method based on Qiagen Maxiprep DNA purification (Qiagen). 
Plasmids were linearized with BamHl for synthesis of Digoxigenin-11-UTP riboprobes. 
5.2.2.5 Preparation of riboprobes 
For in situ hybridization, digoxigenin-11-UTP labelled sense and antisense 
riboprobes were synthesized from linearized template plasmids using a DIG RNA labelling 
kit (Boehringer Mannheim, Mannheim, Germany) according to the manufacturer's 
instructions. The sense RNA strand was used as a negative control for each probe. Before 
use riboprobes were heated at 85 °C for 5 min. 
5.2.2.6 In situ hybridization 
Paraformaldehyde (PFA)-fixed sections were deparaffinized in histoclear and 
rehydrated through a graded series of alcohols. The slides were postfixed in fresh 4% PFA, 
washed in phosphate buffered saline (PBS), 0.1 M HCl, PBS, distilled H20, then Tris 
buffer/CaC12 (20 mM Tris-HCI, pH 7.4,2 mM CaC12). The slides were incubated with 10 
µg/ml proteinase K in the same buffer for 15 min and washed with PBS. After washing, 
postfixation was carried out in 4% PFA for 10 min. Further washes in PBS and 0.1 M 
triethanolamine (pH 8.0) were followed by acetylation in 0.25% acetic acid, 0.1 M 
triethanolamine (pH 8.0) for 20 min. Slides were then washed in PBS. Prehybridization was 
performed using hybridization buffer (50% formamide, 5X SSC(0.3 M NaCl and 0.03 M 
sodium citrate), 5X Denhardt's solution, 250 pg/ml tRNA) for 3h at room temperature. 
Hybridization was carried out under coverslips using 50 µl of hybridization solution with 
the digoxigenin-labelled probe and incubated at 50°C overnight. Excess probe was removed 
by incubating in 5X SSC for 5 min at 50°C, 0.2X SSC for 1h at 50°C and 100 mM Tris 
HCl pH 7.5,150 mM NaCl for 5 min at room temperature. Slides were incubated with 10% 
normal sheep serum for 1h at room temperature and detection performed using alkaline 
phosphatase labelled sheep anti-DIG Fab fragments (Boehringer Mannheim). Unbound 
antibody was removed by washing in 100 mM Tris HCl pH 7.5,150 mM NaCl for 15 min 
and signal detected by incubating in 50 mM Tris-HCl pH 9.5,100 mM NaCl, 50 mM MgCl2 
buffer containing nitroblue tetrazolium (340 p. g/ml), 5-bromo-4-chloro-3-indoyl phosphate 
(175 µg/ml) and levamisole (1 mM) overnight. The reaction was stopped by washing with 
10 mM Tris-HC1 (pH 8.0) and 1 mM EDTA. 
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5.2.2.7 Oligodeoxynucleotides (ODNs) 
The ODNs used for antisense studies were purchased from Biognostik (Gattlingen, 
Germany) and were phosphorothioated and purified by HPLC. The sequences, 
corresponding to the first 24 bases from the methionine start site, were: GCGCCGCGCCGG 
GCGCTCTGCCAT (antisense, AS-ODN) and ATGGCAGAGCGCCCGGCGCGGCGC 
(sense, S-ODN). A scrambled ODN (Scr-ODN) consisting of the same base composition as 
the antisense ODN had the following sequence: GCCGGCGCCGCGCGTCCGTTACCG. A 
search of the NCBI BLAST database revealed no homolgy to any other mouse gene. For 
assessment of uptake of ODN a fluorescene-isothiocyanate labelled ODN (FITC-ODN) 
having the same base composition as the AS-ODN was added to cultures. 
5.2.2.8 Generation of GST/ADAM-12 cysteine rich domain fusion protein 
A cDNA corresponding to amino acids 551-657, encoding the cysteine rich domain 
of mouse ADAM-12, was generated by RT-PCR from total RNA isolated from primary 
mouse osteoblasts using the following primers: forward primer, 5'-GGATCCCCGTG- 
TCAGGGCGTGGAT-3' and reverse primer, 5'-GGATCCCTTGTGAACGCCGAAGACA- 
C-3'. The forward primer and reverse primer contained a BamHl for ligation. The DNA 
fragment corresponding to the cysteine rich domain was excised and purified from a 2% 
TAE gel using QlAquick gel extraction kit (Qiagen GmbH, Germany). The cDNA fragment 
bearing full length ADAM-12 cysteine rich domain was ligated into the BamHl site of 
pGEX-2T expression vector using T4 DNA ligase and transformed into the JM109 strain of 
E. coli. Recombinant clones were selected on LB medium as described in section 5.2.2.4. 
Plasmids containing the cysteine rich domain of ADAM-12 were subjected to automated 
sequencing to confirm the authenticity of the sequence and the correct reading frame for 
expression of the fusion protein. Plasmids were transformed into the BL21 strain of 
E. coli. for production of recombinant protein (Al2cys). Synthesis of the glutathione-S- 
transferase (GST)/ADAM-12 cysteine rich domain fusion protein was induced in a 500 ml 
culture of BL21 bacteria by addition of fresh IPTG to a concentration of 0.1 mM. After 
incubation for 4h at 37°C the bacterial culture was centrifuged at 2000xg and resuspended 
in 50 ml of tween lysis buffer (TLB; Appendix 1). The fusion protein was extracted by 
sonication and purified using glutathione sepharose (Amersham Pharmacia) according to the 
manufacturer's instructions. The concentration of Al2cys was quantified using the BCA 
protein assay (Pierce Chemical Co., Rockford, USA). The quality of the purified protein 
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was determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis SDS-PAGE 
on a 12% gel followed by Coomassie brilliant blue staining (Appendix 1) . 
5.2.2.9 Construction of ADAM-12 antisense constructs 
The cDNA fragment bearing full length ADAM-12 cysteine rich domain was ligated 
into the BamHl site of pcDNA-3 expression vector using T4 DNA ligase and transformed 
into the JM109 strain of E. coli. The orientation of the insert was confirmed by restriction 
enzyme digestion with Kpnl. Plasmids containing the insert in the reverse/antisense 
orientation (AS/A12) and plasmids containing the insert in the forward/sense orientation 
(S/A12) were used for transfection of primary mouse osteoblasts. 
5.2.2.10 Preparation of osteoblasts from neonatal mouse calvariae 
Osteoblasts were prepared and characterized as described in section 2.2.2.1. 
5.2.2.11 Osteoblast differentiation assay 
Primary mouse osteoblasts were seeded at a density of 2x 104 cells/well of a 24-well 
plate. After 24 h osteoblasts were cotransfected with either of the following: AS/A12 and 
pSPAP, S/A12 and pSPAP, pcDNA-3 and pSPAP, pSPAP or mock transfection with no 
DNA. SPAP can be assayed for in the culture medium and used as a reporter of transfection 
efficiency (Cullen and Hallim, 1992). Transfections were performed using effectene 
transfection reagent (Qiagen) according to the manufacturer's instructions. After 24 h the 
DNA complexes were removed and replaced with 0.5 ml a-MEM + 10% FBS containing 
10 mM ß-glycerophosphate and 5 pg/ml ascorbic acid. The medium was changed after 3 
days and assayed for SPAP (Appendix 1), thereafter medium was changed every 3 days and 
cultures were maintained for 14 days. 
For quantitation of bone nodules von Kossa staining was performed. Cultures were 
rinsed with cold PBS and fixed in 10% neutral buffered formalin (Appendix 1) for 15 min, 
rinsed with distilled water and then stained with 2.5% silver nitrate solution for 30 min at 
room temperature. Culture plates were rinsed with distilled water before the addition of 
sodium carbonate formaldehyde (5% Na2CO3,20% formaldehyde) for 5 min. After rinsing 
the nodules were stained for alkaline phosphatase as described in section 2.2.2.1. The 
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percent mineralization was assessed by counting the number of occurences of von Kossa- 
positive (black) nodules where the presence of nodules coincided with intercepts on a grid 
5.2.2.12 Generation of osteoclasts 
Bone marrow assay 
Osteoclasts were generated from the bone marrow of 5- to 6-week-old mice to 
assess the effects of AS-ODN on osteoclast formation. Bone marrow was isolated as 
described in section 4.2.2.7 and plated in 24-well plates at a cell density of Ix 106 cells per 
well in 0.5 ml ct-MEM containing 10% FBS and 10'8 M 1,25-(OH)2D3 with or without an 
ivory slice. ODNs were added at the beginning of culture and medium was changed every 
two days with addition of ODNs at each medium change. Osteoclast formation was 
assessed by counting the number of TRAP-positive multinucleated cells with over two 
nuclei after 8 days in culture. 
Spleen cell assay 
Spleen cell suspensions were prepared from spleens of 5- to 6-week old CD1 mice 
by injection of a-MEM containing 10% FBS into the spleens followed by mechanical 
dissagregation of the remaining tissue with a scalpel blade. The suspension was washed 
twice by centrifugation at 300xg for 7 min and resuspended in a-MEM containing 10% 
FBS. Spleen cells were plated in 24-well plates at a cell density of 1x 106 cells per well in 
0.5 ml of a-MEM containing 10% FBS, M-CSF (10 ng/ml) and RANKL (40 ng/ml). 
Cultures were fed every 2 days by replacing 400 µl of culture medium with fresh medium 
containing 10% FBS, M-CSF and RANKL. Ater 7 days osteoclast formation was assessed 
by counting the number of TRAP-positive multinucleated cells with over two nuclei. 
Culture of M-CSF selected bone marrow cells 
Bone marrow cells were isolated from 5- to 6-week old CD1 mice to assess the 
effects of recombinant A12cys on osteoclast formation. Bone marrow cells were isolated as 
described in section 4.2.2.7. The resulting bone marrow suspension was resuspended in a- 
MEM containing 10% FBS, and incubated for 24 h in the presence of M-CSF (10 ng/ml) at 
a density 5x 105 cells/nil in a 75 cm2 flask. After 24 h the non-adherent population was 
harvested, washed once by centrifugation at 300xg, and resuspended in a-MEM +10% FBS 
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containing 10 ng/ml M-CSF and 40 ng/ml RANIKL at a concentration of 5x105 cells/mi. 
This suspension was added (1x105 cells/well) to the wells of a 48-well plate with or without 
an ivory slice. To each well was added Al2cys, recombinant GST as a control or vehicle. 
Isolation of mature osteoclasts 
Mature osteoclasts were prepared as described in section 4.2.2.6. For in situ 
hybridization studies bone marrow suspensions of 6-day-old mice were sedimented onto 
22mm diameter glass coverslips coated with rat tail type I collagen 50 µg/ml (Becton 
Dickinson) and cultured for 3h at 37°C. Non-adherent cells were washed from the 
coverslips with a-MEM and the adherent cells fixed with 4% PFA for 10 min. For 
assessment of lacunar resorption bone marrow suspensions were plated onto ivory slices in 
96-well plates and cultured as described in section 4.2.2.6. 
5.3 RESULTS 
5.3.1 RT-PCR analysis of total RNA extracted from primary mouse osteoblasts 
Oligonucleotide primers specific for ADAM-9, -12 and -19 were used for RT-PCR 
analysis of gene expression in primary mouse osteoblasts. As depicted in figure 5-1, RT- 
PCR analysis revealed expression of ADAM-9, -12 and -19 in unstimulated osteoblasts and 
the RT-PCR products amplified were of the predicted size. To determine whether 
expression of either ADAM -9, or -12 or -19 is up-regulated by osteotropic hormones, 
semi-quantitative RT-PCR was performed on osteoblasts stimulated with PTH (10-8 M) for 
3,6 and 24 h. As shown in figure 5-1, expression of ADAM-12 appears to be up-regulated 
by treatment with PTH with a slight increase in expression over 24 h of stimulation. 
Expression of ADAM-19 also appears to be up-regulated with an increase in expression 
after 3h stimulation with PTH. Analysis of ADAM-9 by semiquantitative RT-PCR showed 













Fig. 5-1. RT-PCR analysis of ADAMs in mouse osteoblasts. 
Primary mouse osteoblasts were cultured as described in materials and methods and ttal 
RNA isolated. RT-PCR was performed with primers specific for ADAM-9, -12 and-19. 
Each RT-PCR reaction also contained primers for GAPDH (ADAM-9 and -19) or ß-Actin 
(ADAM-12) as a positive control. PCR was performed for 30 cycles and 10 Al analyzed by 
gel electrophoresis on a 2% agarose gel. Lane 1, analysis of RNA isolated from 
unstimulated osteoblasts. Lane 2 RNA isolated from osteoblasts stimulated with PTH for 3 
h. Lane 3 RNA isolated from osteoblasts stimulated with PTH for 6 h. Lane 4 RNA 
isolated from osteoblasts stimulated with PTH for 24 h. A, DNA size marker (OX174 
HaeIII digest). 
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5.3.2 Expression of ADAMs in osteoclasts 
The expressions of ADAM-9, -12 and 19 in osteoclasts were investigated initially by 
in situ hybridization studies on isolated osteoclasts sedimented for a period of 3h on type I 
collagen coated glass coverslips (Fig. 5-2). Osteoclasts exhibited a weak signal when 
hybridized with the ADAM-12 DIG-labelled antisense riboprobe (Fig. 5-2C). For 
comparison osteoclasts hybridized with the corresponding sense riboprobe are shown in 
figure 5-2D. Expression of ADAMs-9 and -19 were not detected in any of the cultures. 
To establish a role for ADAMs in the formation and activity of osteoclasts in 17- 
day-old fetal mouse metatarsals, in situ hybridizations were performed with DIG-labelled 
riboprobes for ADAM-9, -12 and -19. Metatarsal explants cultured for 3 days in the 
presence of 1,25-(OH)2D3 exhibited formation of MM'-9-positive osteoclasts within the 
calcified cartilage (cc) as shown by in situ hybridization (Fig. 5-3G) and subsequent 
resorption of the cc. mRNA for ADAM-12 was detected in both mononuclear cells and 
multinucleated osteoclast-like cells within the cc (Fig. 5-3 C). 
5.3.3 Role of ADAM-12 in osteoblast differentiation 
To investigate the role of ADAM-12 in osteoblast differentiation, primary mouse 
osteoblasts were transiently transfected with either an antisense or sense construct to 
ADAM-12 in the mammalian expression vector pcDNA-3. Since no antibodies were 
available to establish whether ADAM-12 protein levels were decreased, the efficiency of the 
transfection had to be monitored using pSPAP as a reporter. Figure 5-4B shows the 
presence of SPAP in medium from cultures of osteoblasts that had been cotransfected with 
the antisense/sense constructs and pSPAP. After 14 days culture in the presence of ß- 
glycerophosphate and ascorbic acid osteoblast cultures had developed large mineralized 
bone nodules as assessed by the presence of von Kossa positive deposits within the nodules 
(Fig. 5-4). Cultures also stained strongly for alkaline phosphatase (Fig 5-4). Quantitation of 
bone nodules expressed as percent mineralization revealed little difference between cultures 
transfected with AS/A12 (10.0% ± 2.0), S/A12 (11.0% ± 1.4) and mock transfection with 
no DNA (10.2% ± 1.0). Transfection of cultures with pSPAP alone also had no effect on 











Fig. 5-2. In situ hybridization of ADAMs in isolated osteoclasts. 
Osteoclasts were prepared as described in Materials and Methods and cultured on rat tail 
type I collagen coated coverslips. Coverslips were hybridized with A, ADAM-9 antisense 
riboprobe; B, ADAM-9 sense riboprobe; C, ADAM-12 antisense riboprobe; D, ADAM-12 
sense riboprobe; E, ADAM-19 antisense riboprobe; F, ADAM-19 sense riboprobe. G, 
osteoclasts hybridized with MMP-9 antisense and H, MMP-9 sense. Bar = 50 µm. 
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Fig. 5-3. In situ hybridization of ADAMS in metatarsals explants. 
Metatarsal explants were dissected and cultured as described in section 4.2.2.8. Sections 
were hybridized with A, ADAM-9 antisense riboprobe; B, ADAM-9 sense riboprobe; C, 
ADAM- 12 antisense riboprobe; D, ADAM- 12 sense riboprobe; E, ADAM- 19 antisense 
riboprobe; F, ADAM-19 sense riboprobe. G, section hybridized with MMP-9 antisense and 
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FIG. 5-4. Effect of A12/AS construct on osteoblast differentiation. 
Primary mouse osteoblasts were cultured in 24-well plates and transfected as described in 
Materials and Methods. A, After 14 days cultures were stained by the von Kossa method and by 
alkaline phosphatase. B, Culture medium was assayed for SPAP 3 days after transfection. C, The 
presence of mineralized nodules was assessed after 14 days. Results for SPAP levels and % 
mineralization are expressed as mean ± SEM of 8 wells from 2 separate experiments. 
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5.3.4 Effect of AS-ODN on lacunar resorption by isolated osteoclasts 
In order to establish whether ADAM-12 has a role in lacunar resorption by mature 
osteoclasts ODNs were added to osteoclasts isolated from the femurs and tibias of 6-day- 
old CD 1 mice. In this study ODNs were used at a concentration of 5 4M based on a 
previous investigation by Inui et al. (1996) on inhibition of lacunar resorption by cathepsin 
K antisense ODNs. Uptake of ADAM-12 antisense ODNs by isolated osteoclasts was 
confirmed by addition of a FITC-labelled ODN (5 µM) having the same base composition 
as the AS-ODN. Figure 5-5A shows an osteoclast, cultured on a type I collagen coated 
glass coverslip in the presence of FITC-conjugated ODN for 24 h, and exhibiting intense 
fluorescence in the cytoplasm and nuclei. 
The effect of ADAM-12 AS-ODN on lacunar resorption by isolated osteoclasts was 
investigated by the pit formation assay on ivory slices. Quantification of the surface area 
resorbed showed that AS-ODN had little effect on lacunar resorption by isolated osteoclasts 
with only a 15% decrease compared with the sense and scrambled controls (Fig. 5-5B). 
5.3.5 Effect of AS-ODN on osteoclast formation 
To investigate the role of ADAM-12 in osteoclast formation, ODNs were added to 
mouse bone marrow cultures stimulated with 1,25-(OH)2D3 (10'8 M). In the absence of 
ODN these cultures developed large MNC-osteoclast like cells that were TRAP-positive 
(78 ± 14 MNCs/well; figure 5-6A). Addition of S-ODN (100 nM) and Scr-ODN (100 nM) 
had little effect on formation of MNCs in these cultures (68 ± 8; 64 ±9 MNCs/well 
respectively). Addition of AS-ODN however resulted in a significant decrease in the number 
of MNCs formed per well compared to the control, S-ODN, and Scr-ODN. 
The effect of AS-ODN formation was also investigated in an alternative assay for 
osteoclast formation which utilizes spleen cells as the source of haematopoietic precursors 
stimulated with M-CSF (10 ng/ml) and RANKL (40 ng/ml). Addition of M-CSF and 
RANKL to this assay obviates the need for osteoblasts in osteoclast formation. In the 
absence of ODNs or in the presence of S-ODN and Scr-ODN, spleen cell cultures 
developed large numbers of TRAP-positive MNCs (97 ± 11,100 ± 10 and 95 ±9 
MNCs/well respectively). Addition of AS-ODN, however, resulted in only a minor 


















Fig. 5-5. Effects of oligodeoxynucleotides on lacunar resorption by isolated mouse 
osteoclasts. 
Mouse osteoclasts were sedimented onto ivory slices for 25 min and cultured in the 
presence of ADAM-12 specific oligodeoxynucleotides (5 µM). A, Culture in the presence 
of FITC labelled ODN demonstated uptake of ODN by osteoclasts as revealed by intense 
fluorescence in the cytoplasm and nuclei. Bar = 50 4m B, After incubation for 24 h, 
resorption was quantified by image analysis. Data are expressed as mean ± SEM of 12 
slices from 3 separate experiments. Disruption of ADAM-12 expression had a minimal 



























FIG. 5-6. Effects of oligodeoxynucleotides on formation of TRAP-positive MNCs. 
A, Mouse bone marrow cells stimulated with 1,25-(OH)2D3 (10'8 M) were cultured in the 
presence of ODNs (100 nM) for 8 days. In the presence of AS-ODN to ADAM-12 there 
was an inhibition in TRAP-positive MNC formation compared with bone marrow cells 
cultured in the presence of S- and Scr-ODNs. Data are expressed as mean ± SEM of 6 wells 
from 3 experiments. B, Mouse spleen cells stimulated with M-CSF (10 ng/ml) and RANKL 
(40 ng/ml) were cultured in the presence of ODNs (100 nM) for 8 days. AS-ODN to 
ADAM-12 had only a minimal effect on formation of TRAP-positive MNCs compared with 
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5.3.6 Effect of A12/cys on osteoclast formation 
It has been proposed that the cysteine rich domain of ADAM-12 may be involved in 
cellular fusion based on the existence of a sequence similar to the potential fusion peptide of 
rubella virus (Yagami-Hiromasa et al., 1995). If the cysteine rich domain is involved in an 
aspect of osteoclast formation then addition of recombinant A12/cys to osteoclast formation 
assays may compete with endogenous ADAM-12 for binding to its target thereby, acting as 
a mimetic in a similar way to RGD containing peptides. A12/cys was expressed in this study 
as a fusion protein with GST in E. coli. The fusion protein was purified from bacterial 
extracts on Glutathione-sepharose and buffer exchanged against 10 mM Tris pH 7.4. 
Analysis of the fusion protein by SDS-PAGE showed that the fusion protein migrated at an 
expected molecular weight of approximately 40 kDa (Fig. 5-6A). To investigate whether 
the cysteine rich domain of ADAM-12 is involved in fusion of osteoclast precursors, M- 
CSF dependent bone marrow cells (MDBM) stimulated with M-CSF (10 ng/ml) and 
RANKL (40 ng/ml) were cultured in the presence recombinant A12/cys (10'8 M) or 
recombinant GST (10'8 M) as a control. This assay was chosen due to its greater potential 
to form large numbers of TRAP-positive MNCs with characteristics of osteoclasts (Fig. 5- 
6B and Q. Addition of recombinant GST to MDBM cell cultures had no effect on 
formation of TRAP-positive MNCs (Fig. 5-7B) or on resorptive activity of osteoclasts 
generated in this assay (Fig. 5-7C). However, addition of A12/cys resulted in a significant 
inhibition of both osteoclast formation (37 ± 10 MNCs/well) and osteoclast resorptive 



























FIG. 5-7. Effects of A12/cys on osteoclast formation. 
A12/cys was purified on GST sepharose and buffer exchanged with 10 mM Tris. Cl pH 7.4 
A, SDS-PAGE of recombinant A12/cys, run under reducing conditions, used to investigate 
osteoclast formation. Lane 1, molecular weight markers; lanes 2-3 cysteine rich domain 
GST fusion protein of mouse ADAM-12. M-CSF dependent bone marrow cells were 
cultured in 48-well plates and stimulated with M-CSF (10 ng/ml) and RANKL (40 ng/ml). 
Recombinant A12/cys was added at a concentration of 10"8 M. As a control recombinant 
GST was added to some wells at a concentration of 10-8 M. Control wells received vehicle 
(5 µl 10 mM Tris. C1 pH 7.4). Addition of A12/cys significantly reduced TRAP-positive 
MNC formation B and resorption C. The results are the mean ± SEM of 24 separate 
cultures from 3 separate experiments. The inhibitory effect was statistically significant, 
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5.4 Discussion 
Members of the ADAM family of matrixins have been implicated in a variety of 
important cellular processes including neurogenesis, protein ectodermal shedding, basement 
membrane degradation, cell to cell binding and fusion, and cell to matrix interactions 
(Blobel et al., 1992; Yagami-Hiromasa et al., 1995; Fambrough et at., 1996; Rooke et al., 
1996; Moss et at., 1997 and Black et al., 1997). Previous studies have shown that ADAM- 
12 plays a critical role in fusion of C2C12 myoblast cells (Yagami-Hiromasa et at., 1995). 
Furthermore, both ADAM-12 and ADAM-19 were shown to be most abundantly expressed in 
adult bone, and in neonatal muscle (Yagami-Hiromasa et al., 1995). Since formation of 
osteoclasts also involves cellular fusion these observations raised the possibility that ADAM 
9,12 and 19 may be expressed in cells of the osteoclast lineage and may therefore be 
involved in the fusion process of these cells. 
The results of this study demonstrate that in bone, the major cell type expressing 
ADAMs -9, -12 and -19 is the osteoblast, and that ADAM-12 is upregulated upon 
stimulation of primary osteoblasts with PTH. These results are consistent with those of 
Inoue et al. (1998) who have demonstrated expression of ADAMs -9, -12, -15 and -19 in 
primary osteoblasts and upregulation of expression of ADAMs -12 and -19 upon 
stimulation with 1,25-(OH)2D3. It remains to be shown whether ADAM-9 and -12 are 
expressed at the protein level: no antibodies were available for this study. The significance 
of expression of ADAM-9, -12 and -19 by osteoblasts in unclear, as the processes of 
osteoblast cell differentiation and maturation do not require multinucleation. The fact that 
all 3 ADAMs, namely ADAM-9, -12 and -19 were expressed in non-fusing cells may 
suggest the possibility that they serve a different function in osteoblasts. The results of 
Inoue et al. (1998) show that ADAM-12 and ADAM-19 are regulated in a differentiation- 
associated manner in the mouse osteoblastic cell line MC3T3E1 implying a role in 
osteoblast differentiation. It has been shown IGFBP-5 levels in culture supernatants of 
differentiating MC3T3-E1 cells decrease during differentiation which is associated with a 97 
kDa proteinase which was not an MMP (Thraikill et al., 1995). It has subsequently been 
shown that a soluble form of human ADAM-12 (ADAM 12-S; Loechel et al., 1998) can 
bind and cleave IGFBP-3 and -5 (Shi et al., 2000; Loechel et al., 2000). In this study 
transfection of primary mouse osteoblasts with antisense constructs against ADAM-12 had 
no effect on differentiation of osteoblasts and formation of bone nodules. It may be that the 
disruption of expression of ADAM-12 in this assay is compensated for by ADAM-19 or 
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another member of the ADAM family. It remains to be seen whether disruption of ADAM- 
19 alone or in combination with ADAM-12 has any effect on osteoblast differentiation. 
A more likely function for ADAMs -9, -12, -19 and -15 in osteoblasts is to promote 
cell-cell and cell-matrix interactions. Interestingly, ADAM-9 has recently been shown to 
function as an adhesion protein by binding the a(35 integrin in a non RGD dependent 
fashion (Zhou et al., 2001). Similarly ADAM-15 has been shown to bind to the avß3 
integrin (Nath et al., 1999). The aß3 integrin has been shown to be expressed in osteoclasts 
(Nesbitt et at., 1993) and thus ADAM-9 and -15 may promote osteoblast-osteoclast 
interactions. ADAM-12 has been shown to interact with the a9ß1 integrin in a non RGD 
dependent fashion via its disintegrin domain (Eto et al., 2000) although expression of c 51 
integrin in bone cells has not been shown. 
The demonstration of ADAM-12 expression in isolated osteoclasts suggests that this 
proteinase may be involved in an aspect of the bone resorption cascade. Previous studies 
have shown that MM's and cysteine proteinases are key proteolytic enzymes in the 
degradation of the organic matrix of bone (Hill et al., 1994a; 1994b). In this study addition 
of ADAM-12 AS-ODN to cultures of primary isolated osteoclasts produced only a 15% 
decrease in lacunar resorption by isolated osteoclasts. This suggests that ADAM-12 is not a 
key player in the degradation of the organic matrix. By comparison a similar study by Inui et 
al. (1996) demonstrated a 50% reduction in lacunar resorption upon disruption of cathepsin 
K by ODNs. The metalloproteinase domain of ADAM-12 has been shown to be catalytically 
active by using the trapping mechanism of a2-macroglobulin to assay for protease activity 
(Loechel et al., 1998). At present no physiological substrate for membrane-bound ADAM- 
12 has yet been identified although ADAM 12-S can cleave IGFBP-5 and this interaction 
has been shown to be inhibited by TIMP-3 (Loechel et al., 2000). Only ADAM-10 has been 
shown to have proteolytic activity against an ECM protein being able to degrade type IV 
collagen (Millichip et al., 1998) as well as a non ECM protein, myelin basic protein 
(Howard et al., 1996). It seems that the metalloproteinase domain of catalytically active 
ADAM proteinases are predominantly involved in proteolytic shedding of membrane bound 
cytokines and growth factors (Schlondorff and Blobel, 1999). Interestingly, recent studies 
have shown that ADAM-9 is involved in the processing of heparin binding EGF-like growth 
factor (Izumi et al., 1998) and ADAM-19 is involved in the processing of neuregulin 
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(Shirakabe et al., 2001). It seems likely that ADAM-12 may be involved in the protein 
ectodomain shedding. 
The findings that ADAM-12 is expressed in osteoclasts of cultured 17-day-old fetal 
mouse metatarsal suggest that ADAM-12 may play a role in migration of osteoclast 
precusors and formation of multinucleated osteoclasts. These results are consistent with 
previous studies by Abe et al. (1999) demonstrating expression of ADAM-12 in osteoclasts 
generated in bone marrow cultures. Disruption of ADAM-12 expression in this study using 
antisense ODNs led to an inhibition of osteoclast formation in the bone marrow assay. 
These results are consistent with previous findings by Abe et al. (1999). However, antisense 
ODNs had little effect on osteoclast formation in cultures of spleen cells treated with 
RANKL and M-CSF. Since the spleen ce1VRANKL/M-CSF assay for osteoclast generation 
has no mesenchymal/osteoblastic cells present, these results suggest a role for ADAM-12 in 
mediating a cell-cell interaction between osteoblasts and osteoclast precursors which is an 
essential pre-requisite for osteoclast formation. Another possibility is that treatment of 
spleen cells with RANKL and M-CSF may alter the expression of ADAM family members 
such that disruption of ADAM-12 is compensated for by other family members. 
Interestingly, ADAM-8 has also been shown to be expressed in haemopoietic cells and 
demonstrated to be a novel osteoclast stimulating factor (Choi et al., 2001). Previous 
studies have suggested that ADAM-12 may be directly involved in the process of cellular 
fusion (Yagami-Hiromassa et al., 1995) consistent with the presence of a potential 
hydrophobic fusion peptide sequence within the cysteine rich domain. Results from this 
study on the effect of addition of recombinant Al 2/cys to cultures of MDBM cells suggest 
that the cysteine rich domain may have a pivotal role in osteoclast formation. Such a role 
may involve a cell-cell interaction between osteoclast precursors which is a prerequisite for 
fusion. Recent studies using recombinant human ADAM-12 cysteine rich domain have 
shown that it supports cell adhesion through syndecans (Iba et al., 2000). 
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6. Effects of Serine Proteinase inhibitors on Bone 
Resorption In Vitro 
6.1 INTRODUCTION 
Bone resorption involves the removal of both the mineral and organic constituents 
of bone matrix. Osteoclasts are the cells principally responsible for this process which 
occurs in the subosteoclastic resorption zone (SORZ), a specialized extracellular 
compartment bounded by the ruffled border of the cell and the mineralized bone matrix 
(Baron, 1989). Osteoclasts acidify the SORZ leading to dissolution of mineral (Blair et a!., 
1989) while the organic matrix is believed to be degraded by lysosomal cysteine proteinases, 
matrix metalloproteinases and also serine proteinases. 
The plasminogen activators (PAs), uPA and tPA, are serine proteinases (SPs) that 
catalyze the conversion of the proenzyme plasminogen into a broad spectrum serine- 
protease, plasmin. The plasmin thus generated can either directly or indirectly, via activation 
of latent MMPs, promote the degradation of all components of the extracellular matrix in 
vitro (Mignatti and Rifkin, 1993; Murphy et al., 1992). This latter activity may be relevant 
to the physiological process involved in osteoclast migration. With regard to a possible 
involvement of the SPs in bone turnover, plasminogen has been shown to be present in 
extracellular matrices (Knudsen et al., 1986). Furthermore osteoblasts produce PAs in 
response to agents that promote bone resorption (Fukumoto et al., 1992; Allan and Martin, 
1995) and most recently it has been suggested that SPs are involved in the degradation of 
non-collagenous proteins of bone (Daci et al., 1999). Although these results support the 
notion that the PA/plasmin system might be involved in bone resorption results from other 
studies suggest a limited role (Leloup et al., 1994; 1996). Since plasminogen is the most 
abundant and best defined substrate for PAs and that its activation by PAs results in the 
generation of plasmin (Vassalli et al., 1991), the importance of plasmin activity to the 
normal sequence of events that leads to osteoclastic bone resorption was investigated in this 
study. 
The aim of this study was to assess the contribution of the PA/plasmin system to the 
different aspects of the bone resorption cascade using selective inhibitors of SPs in 
combination with a variety of in vitro models that are specific for the various aspects of the 
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resorption process. Furthermore an assessment was made of the expression of the SPs and 
their natural inhibitors in these model systems by RT-PCR and in situ hybridization. 
6.2 MATERIALS AND METHODS 
6.2.1 Materials 
Cell culture reagents and the SP inhibitors, aprotinin and a2-antiplasmin were 
purchased from Sigma Chemical Co. (Poole, Dorset, UK). The specific gelatinase inhibitor, 
CT1399 was a gift from Dr A Docherty, CellTech, UK. 45CaC12,14C and 'H-amino acid 
mixture were purchased from Amersham International (Aylesbury, United Kingdom). 
Enzymes and reagents for RT-PCR were purchased as a kit from Perkin Elmer Biosystems 
(California, USA). The cysteine proteinase inhibitor Ep453 was a generous gift from Dr. M. 
Murata (Research Centre, Taisho Pharmaceuticals, Saitama, Japan) and inhibits the activities 
of cathepsins B, L, S and K. 
6.2.2 Methods 
6.2.2.1 Neonatal calvarial assay 
Bone reorption was assessed by analysing 45Ca2+ release from neonatal mouse 
calvarial bones as described in section 4.2.2.1. The bones were precultured for 24 h in 
CMRL-1066 medium (2 ml) containing 5% acid-treated rabbit serum and indomethacin 
(1µM). Bones were subsequently cultured in pairs in fresh CMRL-1066 medium (2 ml) 
containing 5% FBS and stimulated with either PTH or 1,25-(OH)2D3 (10'8 M) for upto 4 days 
with media change every 2 days in the presence or absence of SP inhibitor. Release of 4SCa2+ 
was determined as described in section 4.2.2.1. 
6.2.2.2 Isolated osteoclast assay 
The isolated osteoclast assay was carried out as described in section 4.2.2.6. Ivory 
slices were incubated for 24 h in 500 . Ll a-MEM supplemented with 5% FBS, 2. Og/liter 
NaHCO3,2mM L-glutamine, 100U/ml penicillin and 100µg/m1 streptomycin. Cultures 
were stimulated with IL-la (10'1° M) in the presence or absence of SP inhibitor, the MMP 
inhibitor CT1399 or Ep453. 
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6.2.2.3 Osteoclast formation assay 
Osteoclasts were generated in a coculture system consisting of bone marrow of 5- to 
6-week-old mice and primary osteoblasts. Primary mouse osteoblasts were plated at a 
density of 2x 104 cells/well of a 24-well plate in a-MEM containing 10% FBS and cultured 
overnight. Bone marrow was isolated as described in section 4.2.2.7 and added at a cell 
density of 1x 106 cells per well in 0.5 ml a-MEM containing 10% FBS and 10'8 M 1,25- 
(OH)2D3. Osteoclast formation was assessed by counting the number of TRAP-positive 
multinucleated cells with over two nuclei after 8 days in culture. 
6.2.2.4 Fetal metatarsal long bone assay 
Osteoclast migration was assessed using 17-day-old fetal metatarsals prepared as 
described in section 4.2.2.8. The metatarsal explants were cultured for 3 days and then fixed 
in 4% paraformaldehyde overnight at 4°C. Specimens were then washed in PBS, decalcified 
in 5% EDTA overnight, dehydrated through a graded series of ethanol and embedded in 
paraffin. Sections of 5 µm were cut, transferred to sialinised glass slides (Sigma) and dried 
at 50°C overnight. 
6.2.2.5 Histomorphometry 
The number of TRAP-positive cells and their nuclei were determined in 10 evenly 
spaced longitudinal sections per long bone rudiment. According to their location they were 
scored as (a) lying in the developing marrow cavity, that is the area of resorbing calcified 
cartilage surrounded by the thin bone collar; or (b) in the periosteum-perichondrium, that is, 
the soft tissue around the bone rudiment. The few cells lying within the (thin) bone collar 
were equally divided over the two compartments. 
6.2.2.6 Preparation of osteoblasts from neonatal mouse calvariae 
Calvarial osteoblasts were prepared and characterized as previously described in 
section 2.2.2.1 
6.2.2.7 Preparation of collagen films and acid-treated serum 
Radiolabelled collagen films were prepared by the method described previously in 
section 4.2.2.3. Acid-treated serum was prepared as described in section 4.2.2.4 
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6.2.2.8 Culture of osteoblasts on collagen films 
Osteoblasts (1 x 105/well) were settled onto collagen films in 1 ml of DMEM plus 
10% (v/v) FCS, incubated for 16 h at 37°C and washed with serum-free DMEM. Cells were 
then cultured in DMEM (1 ml) supplemented with 5% (v/v) acid-treated rabbit serum as 
described above. Either 1,25-(OH)2D3 (10-8 M) alone or 1,25-(OH)2D3 plus either aprotinin 
or CT1399 was then added to the wells and the cultures maintained at 37°C for 48 h. The 
basal release of 14C by unstimulated osteoblasts was subtracted from the 1,25-(OH)2D3- 
stimulated release in the presence and absence of inhibitors to give the corrected values for 
stimulated lysis. At the end of the culture period the media were centrifuged (15 min, 
1200xg) to remove any collagen fibrils and radioactivity released during collagen 
degradation quantified by liquid scintillation counting. Residual collagen was digested with 
bacterial collagenase (50 pg/ml) and assayed for radioactivity. Collagenolysis was expressed 
as radioactivity released from the films as a percentage of the total ± SEM. 
6.2.2.9 Formation of 3H-labelled extracellular bone matrix 
The murine calvaria-derived cell line, MC3T3-E1, is a well characterized osteoblast 
culture system providing a suitable model of osteogenesis analogous to in vivo bone 
formation (Sudo et al., 1983). When cultured in medium containing ascorbic acid, these 
cells have been shown to express phenotypic markers characteristic of mature osteoblasts 
including alkaline phosphatase, osteocalcin, osteopontin, type I collagen synthesis and 
formation of an extracellular collagenous matrix (Kurihara et al., 1986; Boyan et al., 1989; 
Quarles et al., 1992). 
Extracellular bone-like matrix was produced as described by Ronday et al. (1997). 
MC3T3-E1 cells were plated at a density of 1x 104 cells/well on collagen-coated 24-well 
plates (Becton Dickinson, MA, USA) and cultured in a-MEM supplemented with 10% 
FBS, 50 µg/ml ascorbic acid. After 4-5 days, when the cultures had reached confluence and 
the formation of an extracellular matrix had started, fresh medium was added containing I 
iCi/ml 3H amino acid mixture (Amersham International, Aylesbury, UK) to create a non- 
mineralized radiolabelled extracellular bone matrix. The radiolabelled medium was changed 
every 72 h. After 14 days, cells were lysed with 0.5 ml/well of Triton X-100 (0.5% v/v in 
PBS). The cytoskeleton was removed by 25 mM NH4OH treatment and 1mM 
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phenylmethylsulphonyl fluoride (0.5 ml/well) treatment was used to block proteinase 
activity. Matrices were washed with H2O and 75% (vlv) ethanol to remove unincorporated 
3H-radiolabelled amino acids, dried and stored at -20°C. 
6.2.2.10 Bone matrix degradation assay 
To assay for matrix degradation, osteoblasts were plated onto the matrices at a 
density of 1x 105 cells/well in culture medium with and without specific proteinase 
inhibitors. All culture media were supplemented with 10% acid-treated FBS to maintain cell 
viability. Aprotinin or CT-1399 each at a concentration of 10'5 M were added to different 
wells. After 72 h incubation, the media were removed and the extent of degraded 3H- 
radiolabelled matrix released into the medium was determined by liquid scintillation 
counting. The remaining matrix was degraded with 0.25% (w/v) trypsin, 0.1% (w/v) 
collagenase in PBS for 1h at 37°C, and the amount of radioactivity in the matrix similarly 
assessed. Matrix degradation was expressed as 3H released in the medium as a percentage 
of the total amount of 3H released by the cells during the 72 h culture period, plus that 
solubilized from the remaining matrix by trypsin/collagenase treatment. 
6.2.2.11 Extraction of total RNA 
Total RNA was prepared as described in section 5.2.2.1. The RNA pellet was 
solubilised in diethyl pyrocarbonate (DEPC)-treated water, and the concentration of the 
RNA was determined spectrophotometrically (Ultrospec III, Pharmacia, St. Albans, UK). 
6.2.2.12 RT-PCR procedure 
Synthetic oligonucleotide sequences specific for tPA, uPA, uPAR, PAI-l, PAI-2 
and PN-1 were synthesized by Life Technologies Ltd. (Paisley, UK) using previously 
published sequence data (Yang et al., 1997) and shown in Table 1. The housekeeping gene 
GAPDH was used as a positive control for the RT-PCR methodology. 
6.2.2.13 RT-PCR and preparation of probes 
RT-PCR was performed as described in section 5.2.2.2 under the same conditions. 
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RT-PCR products were analysed by gel electrophoresis on a 2% agarose gel. The DNA 
fragment corresponding to tPA was excised from the gel and cloned into pGEM-T as 
described in section 5.2.2.3. 
The probe for uPA was a generous gift from Dr. J. D. Vassalli (University of 
Geneva) and consisted of a 660 base pair fragment cloned into the PstI/HindlII site of 
plasmids pSP64. The plasmids were transformed to competent JM109 E. coli and 
recombinant clones selected for on LB medium containing ampicillin (100 µg/ml). E. coli 
were then cultured in 250 ml of LB broth containing ampicillin (100 . tg/ml) and plasmid 
DNA extracted using a method based on Qiagen Maxiprep DNA purification (Qiagen). 
Plasmids were linearized with BamHl for synthesis of Digoxigenin-11-UTP riboprobes. 
In situ hybridization was performed as described in section 5.2.2.6. 
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Table 6-1. Oligonucleotide RT-PCR primer sequences for mouse PAs. 























6.2.2.14 Statistical Analysis 
Data are expressed as the mean ± SEM. Differences between control and treatment groups 
were determined by the Mann-Whitney U test. *, **, *** significantly different from control 
at P< 0.05, P<0.01 and P<0.001 respectively. 
6.3 RESULTS 
6.3.1 Calvarial bone resorption 
To determine the role of SPs in bone resorption, a neonatal calvarial assay was 
used. This assay simultaneously screens for activities influencing various aspects of the bone 
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resorption process including osteoclast formation and activity. A comparison of the effects 
of the SP inhibitors aprotinin and a2-antiplasmin on 45Caa+ release from prelabelled calvarial 
explants was initially carried out. As shown in figure 6-1, each SP inhibitor dose- 
dependently inhibited 45Ca2+ release, in the range 10-'0 to 10"5 M. During the 2 days of 
culture aprotinin and a2-antiplasmin produced approximately a 50% inhibition of 43Ca2+ 
release at a concentration of 10-5 M. In contrast the MAP inhibitor CT1399 produced a 
more complete inhibition of 45Ca2+ release (76 ± 7%) at a concentration of 10's M. 
To determine whether the inhibitory effect was reversible a recovery experiment was 
carried out. Calvarial bones were treated with PTH (10"9 M) and either aprotinin (10'5 M) or 
a2-antiplasmin (10"5 M) for the first 48 h and then cultured in the presence of PTH only for 
48-96 h. The inhibitory effects of the compounds seen during the initial culture period were 
subsequently lost (Table 6-2). PTH-stimulated release of 45 Ca2+ returned to levels observed 
without addition of inhibitors during the 0-48 h culture period. 
6.3.2 Osteoclast pit formation on ivory slices 
The direct effect of the inhibitors on osteoclast function was investigated in an 
isolated osteoclast pit assay. Both the number of pits formed and their plan area were 
quantitated. Figure 6-2 shows that aprotinin did not prevent osteoclast resorption on ivory 
slices, producing only a 2% inhibition in pit number and 5% inhibition in surface area 
resorbed. In contrast a CP inhibitor, Ep453 (10" M), produced significant inhibition of 
osteoclast activity of approximately 80% for both number of pits and the surface area 
resorbed. Similarly, the MMP inhibitor CT1399 produced a significant decrease in 
osteoclast activity of approximately 45% for pit number and surface area resorbed. 
6.3.3 Osteoclast formation in vitro 
A coculture system, comprising murine bone marrow cells and primary osteoblasts 
stimulated with 1,25-(OH)2D3 was used to assess the effects of the SPs on osteoclast 
formation. Maximal numbers of osteoclasts, identified as TRAP +ve MNC were formed by 
1,25-(OH)2D3 at a concentration of 10 M. The addition of either aprotinin (10" M), or a2- 
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Fig. 6-1. Effects of SP inhibitors on PTH-stimulated release of 45Ca2+ from calvarial 
bones after a 48 h incubation period. 
The results are expressed as percentage inhibition of PTH-stimulated 4SCa2' release which 
was arbitrarily set to 100%. Each value is the mean ± SEM of 5 pairs of bones. The 
inhibitory effects of aprotinin (10"g-10"S M) and a2-antiplasmin (10'$-10'5 M) were 
statistically significant (*p<0.05, **p<0.01). The percentage release of 4SCa2+ from PTH 
stimulated bones was 25.6 ± 4.3 (aprotinin) and 23.6 ± 3.6 (a2-antiplasmin). Both inhibitors 
dose-dependently inhibited release of 45Ca2+. 
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Table 6-2 Recovery from the inhibitory effects of aprotinin and a2-antiplasmin on the 
PTH stimulated release of 45Ca2+ from mouse calvarial bones in culture. 
Treatment Cell-mediated 45Ca2+ release (%) 
0-48 h 49-96 h 0-48 h 49-96 h 
PTH PTH 17.2 ± 2.1 13.3 ± 2.6 
PTH + aprotinin PTH 9.1 ± 1.5 * 15.2 ± 2.1 
PTH + a2-antiplasmin PTH 8.3 ± 2.3 * 12.6 ± 1.6 
Values are means ± SEM for five calvarial bones prelabelled with 0.37 Mbq 45Ca2+. PT!!, 
aprotinin and a2-antiplasmin were added at final concentrations of 10"9 M, 10"5 M, 10-5 M 
and 10"5 M respectively. *Significantly different from PTH alone at (P<0.05). 
Table 6-3 The effects of SP inhibtors on TRAP +ve MNC formation 
Treatment Number of TRAP-positive MNCs 
per well 
1,25-(OH)2D3 65 ± 12 
1,25-(OH)2D3 + CT1399 69 ±8 
1,25-(OH)2D3 + Aprotinin 73 ± 13 
1,25-(OH)2D3 + a2-antiplasmin 62 ± 10 
Mouse bone marrow cells were cultured as described in Materials and Methods in the 
presence of 1,25-(OH)2D3 (10'$ M). Aprotinin, a2-antiplasmin or CT1399 were added at a 
concentration of 10 M at the beginning of the culture. After 8 days the cultures were 
stained for TRAP and the number of TRAP +ve MNCs with over 2 nuclei counted. Results 
are expressed as mean ± SEM of 6 wells from 2 experiments. 
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Fig. 6-2 Effects of proteinase inhibitors on the number and the total surface area of 
mouse osteoclast lacunae. 
Each value is the percentage inhibition of osteoclast lacunar resorption arbitrarily set to 
100%. The values represent the means ± SEM from five individual experiments representing 
15 slices for each variable. The number and surface area of pits on the Ep453 and CT1399 
treated slices were significantly different from control (*P< 0.05 and **P< 0.01). The 
number of lacunae in the control cultures was 1021 (Ep453), 1293 (CT1399) and 879 
(aprotinin). 
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6.3.4 Osteoclast migration and fusion 
The role of the PA/plasmin system on osteoclast migration and fusion was examined 
in noninvaded 17-day-old fetal metatarsal rudiments after 3 and 6 days of culture by means 
of histomorphometry after TRAP staining. 
The effects of the proteinase inhibitors on the number of TRAP+ve cells in both the 
periosteum and mineralized matrix was determined at the beginning of the experiment and 
after 3 and 6 days of culture (Fig. 6-3). As the TRAP+ve cells were often multinucleate, 
especially in the excavating marrow cavity, both TRAP cell profiles and nuclei were 
counted. The SP inhibitor aprotinin produced a significant reduction of approximately 55% 
in the invasion of the mineralized matrix by TRAP+ve cells after 3 days with a concomitant 
accumulation of TRAP+ve cells in the periosteum, thus showing that the SP inhibitors do 
not stop the formation of new TRAP+ve cells. A similar situation was found for the number 
of nuclei per TRAP+ve cell. However after 6 days culture with aprotinin the numbers of 
TRAP+ve cells and nuclei per TRAP+ve cell were similar to the control cultures (Fig. 6-3). 
In contrast the MMP inhibitor CT1399 completely prevented the invasion of the mineralized 
matrix by TRAP+ve cells after 3 days with a concomitant increase in the number of 
TRAP+ve cells in the periosteum. After 6 days CT1399 still produced a significant 
reduction in the migration of TRAP+ve cells although its effects were incomplete (Fig. 6-3). 
None of the inhibitors appeared to effect the intrinsic ability of cells to fuse. 
6.3.5 Degradation of bone-like matrix 
To determine whether the PA system is involved in the degradation of non- 
mineralized bone matrix, primary osteoblasts were cultured on 3H-labelled bone-like matrix 
produced by MC3T3-E1 cells. Mouse osteoblasts cultured for 48 h in the absence of serum 
produced neither basal nor 1,25-(OH)2D3-stimulated matrix breakdown, but the stimulated 
osteoblasts produced a 3-fold increase in matrix degradation when plasminogen was added 
to the cultures. Plasminogen-dependent matrix breakdown was significantly inhibited by the 
SP inhibitors, aprotinin (10 M) and a2-antiplasmin (10 M). Furthermore plasminogen- 
dependent breakdown was inhibited by the MMP inhibitor, CT1399 (10`6 M). 
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Fig. 6-3. Effects of proteinase inhibitors on the migration of TRAP+ve cells in 
metatarsal explants. 
Metatarsals were obtained from 3 litters of 17-day-old fetal mice. The metatarsal triads of 
the left limb were cultured in control conditions with 1,25-(OH)2D3 and those of the 
corresponding right limbs were cultured in the presence of 1,25-(OH)2D3 and either 
CT1399 (10-6 M) or aprotinin (10'6 M) for the indicated times. The number of TRAP+ve 
cells and their nuclei localized inside and outside the calcified cartilage (cc) were counted. 
Counts inside the cc are shown to the right of the `0' axis and those within the periosteum 
are shown to the left. Each bar (left and right) expresses thus the total numbers in one 























Fig. 6-4. Effects of proteinase inhibitors on the degradation of non-mineralized bone 
matrix. 
Primary mouse osteoblasts were cultured for 48 h on 3H-labelled extracellular matrices and 
stimulated with 1,25-(OH)2D3 (10-8 M) in the presence of 5% serum, in serum-free medium 
or in serum-free medium supplemented with 5 pg/ml plasminogen. Aprotinin (10'5 M), a2- 
antiplasmin (10"s M) or CT1399 (10-6 M) were added to cultures containing 5 µg/ml of 
plasminogen. The results are expressed as percentage degradation of 3H-labelled bone 
matrix. Each bar represents the mean ± SEM of 6 wells. Aprotinin, a2-antiplasmin, and 
CT1399 inhibited degradation of 3H-labelled bone matrix that was statistically significant 
compared to the control (**P<0.01). 
169 
EE serum-free + 5µg/ml 22 plasminogen 
6.3.6 Degradation of type I collagen films 
To confirm a role for the PA system in the degradation of type I collagen, primary 
osteoblasts were cultured on 14C-labelled type I collagen films for 48 h. Aprotinin dose- 
dependently inhibited 1,25-(0H)2D3-stimulated collagen breakdown by mouse osteoblasts 
(Fig. 6-5). CT1399 produced a complete inhibition whilst the SP inhibitors only produced 
about a 55% reduction in type I collagenolysis. 
6.3.7 Expression of PAs and their inhibitors in osteoblasts 
RT-PCR analysis was used to establish expression of mRNA for the PAs and their 
inhibitors in unstimulated and PTH-stimulated cultures of primary mouse osteoblasts using 
specific oligonucleotide primers. RT-PCR analysis showed that osteoblasts express mRNA 
transcripts for tPA, uPA and the type-I receptor for uPA, uPAR-I (Fig. 6-6). RT-PCR 
analysis using primers for the serine proteinase inhibitors showed expression of PAM and 
the broad spectrum inhibitor PN-I. The PCR products were of the correct size and the 
authenticity of the sequences was verified by automated sequencing. RT-PCR of mRNA 
isolated from PTH-stimulated osteoblasts revealed no difference in expression pattern of the 
PAs and their inhibitors. The primers for PAI-2 generated PCR fragments between 194 and 
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Fig. 6-5. Effects of proteinase inhibitors on the degradation of 14C-labelled type I 
collagen films by mouse osteoblasts. 
Primary mouse osteoblasts were stimulated by 1,25-(OH)2D3 (10"8 M) after 72 hours. The 
results are expressed as percentage inhibition of 1,25-(OH)2D3-stimulated 14C release, which 
was arbitrarily set to 100%. Each point is the mean ± S. E. M. of six wells. The inhibitory 
effects of CT1399 (10-8-10"5 M) and aprotinin (10"8_10'1 M) were statistically significant 
*P<0.05, **P<0.01 compared with control. The percentage release of isotope by 
1,25(OH)2D3-stimulated mouse osteoblasts was 64.7 ± 5.9 which was obtained after 
subtracting the unstimulated release of isotope (23.7 ± 3.7). 
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Fig. 6-6. RT-PCR of PAs and their inhibitors osteoblasts. 
Primary mouse osteoblasts were cultured as described in materials and methods in 75 cm2 
tissue culture flasks in the presence or absence of 10-5 M PTH. Total RNA was isolated and 
RT-PCR performed with primers specific for: tPA, uPA, uPARI, PAI-1, PAI-2 and PNI. 
The housekeeping gene GAPDH was used as a positive control. PCR was performed for 35 
cycles in a 100 µl reaction and 10 µl analyzed by gel electrophoresis on a 2% agarose gel. 
A, DNA size marker. No difference was observed in the pattern of mRNA expression 
between unstimulated and PTH-stimulated mouse osteoblasts. 
172 
6.3.8 Expression of PAs in osteoclasts 
Expression of mRNA for tPA and uPA were investigated initially by in situ 
hybridization studies on osteoclasts isolated from the long bones of 6-day-old mice. Bone 
cell suspensions were plated directly onto type I collagen coated glass coverslips in 300 µ1 
of a-MEM and cultured for 3h to adhere. Figure 6-7A shows a typical multinuceate 
osteoclast showing expression of tPA mRNA. For comparison the sense probe for tPA was 
used as a negative control and showed negligible hybridization to tPA mRNA. Osteoclasts 
cultured on type I collagen also exhibited expression of uPA as shown in figure 6-7C. 
Osteoclasts hybridized with the sense probe as a comparison exhibited only a weak signal 
compared with the antisense probe. Since MMP-9 is expressed at high levels in osteoclasts 
this was used as a positive control and as a marker for osteoclasts. As shown in figure 6-7D 
osteoclasts exhibited a strong signal when hybridized with the MMP-9 antisense riboprobe. 
The sense probe, used as a negative control did not hybridized with MW-9 mRNA (Fig. 6- 
7E). 
In order to assess whether tPA and uPA mRNA is expressed in migrating 
osteoclasts in situ hybridization was performed on sections of 17-day-old fetal mouse 
metatarsals using DIG-labelled riboprobes. Hybridization of tPA antisense probe to tPA 
mRNA produced a very weak signal that was barely detectable, in multinucleated and in 
some mononuclear cells, present in the calcified cartilage, indicating very low expression of 
tPA. (Fig. 6-8A). As a negative control hybridizations were performed with the sense 
riboprobe which did not hybridize to mRNA and produced no signal (Fig. 6-8B). In contrast 
hybridization with the uPA antisense probe produced a stonger signal in cells within the 
calcified cartilage indicating the presence mRNA for uPA (Fig. 6-8C). MIvIP-9 has been 
shown to be important in osteoclast migration in 17-day-old metatarsals (Blavier and 
Delaisse, 1995). To confirm the presence of osteoclasts within the calcified cartilage 
adjacent sections were hyridized with MAP-9 antisense riboprobe. As can be seen in figure 
6-8E numerous MMP-9 positive osteoclasts were present at the level of calcified cartilage. 
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Fig. 6-7. In situ hybridization of tPA and uPA in isolated osteoclasts. 
Osteoclasts were prepared as described in Materials and Methods and cultured on rat tail 
type I collagen coated coverslips. Coverslips were hybridized with A, tPA antisense 
riboprobe; B, tPA sense riboprobe; C, uPA antisense riboprobe; D, uPA sense riboprobe; 
E, osteoclasts hybridized with MMP-9 antisense and F, MMP-9 sense. Bar = 50 µm. 
Osteoclasts exhibited expression of tPA and uPA when hybridized with the respective 
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Fig. 6-8. In situ hybridization studies of tPA and uPA in 17-day-old fetal mouse 
metatarsals. 
Metatarsal explants were dissected and cultured as described in Materials and Methods. 
Sections were hybridized with A, tPA antisense riboprobe; B, tPA sense riboprobe; C, uPA 
antisense riboprobe; D, uPA sense riboprobe; E, adjacent section hybridized with MMP-9 
antisense riboprobe; F, MMP-9 sense riboprobe. Metatarsal explants exhibited a weak 
signal when hybridized with tPA antisense riboprobe and exhibited expression of uPA in 
cells which also exhibit expression of MMP-9. Bar = 50 µm. 
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6.4 Discussion 
The data presented in this study demonstrate that the PA/plasmin system plays a role 
in the bone resorption cascade. Using selective proteinase inhibitors this study has shown 
that the PA/plasmin system is involved in the migration of osteoclasts to future resorption 
sites and is also involved in osteoblast-mediated degradation of type I collagen, whilst the 
PA/plasmin system is not involved in either osteoclast formation nor osteoclast resorptive 
activity. Furthermore the expression of various components of the PA/plasmin system in 
primary mouse osteoblasts and osteoclasts has been demonstrated. 
Aprotinin is a small extremely stable peptide that reacts rapidly with plasmin to form 
high-affinity complexes (with a kd of 10"9-10"1° M). In contrast to a2-antiplasmin and a, 
antitrypsin, the main inhibitor present in plasma, aprotinin also inhibits plasmin when it is 
bound to the plasminogen/plasmin surface receptors (Stephens et al., 1989 Bizik et al., 
1990) found on many cell types (Mignatti et al., 1986). 
The neonatal murine calvarial bone resorption assay reflects mainly post-mitotic 
events, namely the fusion of preosteoclasts, the activation of fully developed mature 
osteoclasts and osteoblast degradation of collagen fibrils whilst it is virtually independent of 
proliferation of osteoclast progenitors. This probably explains why the SP inhibitors, 
aprotinin and a2-antiplasmin were less effective at preventing calvarial resorption than the 
MMP inhibitor, CT1399, since SP activity is limited to osteoblast-mediated degradation of 
the osteoid layer in this culture system. 
It is widely believed that prior to osteoclastic resorption, the bone surface is freed of 
a thin investing layer of non-mineralized collagen fibrils. Although, osteoblast-derived 
MMPs, in particular collagenase, have been implicated in this process, it has been suggested 
that the PA/plasmin system may also be involved in this process (Thomson et al., 1989). 
The findings that osteoblast-mediated degradation of both type I collagen and bone-like 
matrix is dependent on the presence of plasminogen and that the SP inhibitor, aprotinin 
partially prevented osteoblast-mediated degradation of these substrates supports the 
concept that the PA/plasmin system is involved in this aspect of the bone resorption 
process. Consistent with a role for the PA/plasmin system in osteoid degradation it has been 
shown that degaradation of nonmineralized matrix by cocultures of osteoblasts and 
osteoclasts is decreased by combined inactivation of uPA and tPA genes (Daci et al., 1999). 
Furthermore, the demonstration in this study that osteoblasts express tPA and uPA is in 
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accordance with previous studies that have shown that a variety of bone resorbing agents 
upregulate PA activity in osteoblasts (Hamilton et al., 1984; 1985). Although the precise 
mechanism of action of the PA/plasmin system in collagen degradation has not been 
demonstrated in this study it is known that plasmin will activate MMPs, particularly 
prostromelysin-1 and -2. In concert, plasmin and stromelysins then activate other osteoblast 
derived MMPs (Meikle et al., 1992) in particular collagenase and gelatinase B (Murphy and 
Knauper, 1997) which may be directly responsible for the type I collagen degradation (Hill 
et al., 1995). 
The finding from this study that aprotinin prevented the migration of osteoclasts 
from the periosteum to the mineralized matrix in 17-day-old fetal metatarsals is similar to 
findings of Hoekman et al. (1992) who demonstrated that tPA stimulated osteoclastic 
resorption in these explants an event that is indicative of osteoclast migration to the calcified 
matrix. Furthermore, the results presented here demonstrate expression of uPA in fetal 
metatarsal explants by in situ hybridisation. Leloup cat al. (1994) also demonstrated that 
uPA is the main PA present in extracts of cultured fetal mouse metatarsals. Although, 
Leloup et al. (1994) reported that inhibitors of plasmin did not influence metatarsal bone 
resorption they found that when the explants were cultured in serum depicted of plasmin 
inhibitors there was enhanced bone resorption suggesting that the PA/plasmin system may 
be involved. Furthermore LeLoup et al., (1996) subsequently demonstrated that in mice 
with an inactivated uPA gene, bone resorption was reduced at the commencement of 
culture in the metatarsal explants whereas inactivation of the tPA gene had no effect on 
bone resorption in fetal metatarsal explants. A combined inactivation of both uPA and tPA 
in these studies did not further inhibit bone resorption at the commencement of culture. 
The inhibitory activity of aprotinin against the invasion of preosteoclasts and the 
degradation of type I collagen by osteoblasts is comparable with the inhibitory activity of 
aprotinin in several other culture models in which it contributed to establish the role of the 
PA/plasmin system in either invasion or the degradation of extracellular matrices (Mignatti 
et al., 1986; Cajot et al., 1989; Quax et al., 1991). 
The expression of tPA and uPA has been identified in osteoclasts both at the 
message level by RT-PCR (Yang et a!., 1997), and at the protein level by 
immunocytochemistry (Grills et al., 1990). Furthermore Yang et a!. (1997) demonstrated 
expression of uPAR1, by in situ hybridisation, in osteoclasts cultured at p116.9 although at 
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pli 7.3 little expression was observed. however, results from this study demonstrate that 
aprotinin had no inhibitory effect on ostcoclast lacunar resorptivc activity suggests that, at 
least under these iii vitro conditions used in this study, the PAlplasmin system is not directly 
involved in this aspect of the resorption cascade. These findings are consistent with the 
results reported by Daci et al. (1999) in which osteoclasts derived from mice with a 
combined inactivation of both uPA and tPA were still able to resorb dentine. Also 
Hoekman et al. (1992) found that tPA had no effect on bone resoprtion in 17-day-old fetal 
radii that contain mature osteoclasts. Nonetheless, there are several potential roles for the 
osteoclast derived PAs in bone. These include the activation of latent protcases (Kwaan, 
1992), activation of latent growth factors (Martin el al., 1993; Lalou el al., 1994), and a 
nonproteolytic role as a mitogenic agent (Kirchheimer et a!., 1987; Rabbani et al., 1990). 
The activation of various proenzymes by the PA system in osteoclasts, including enzymes 
that degrade extracellular matrix proteins such as prostromelysin and procollagenase, could 
aid in the resoprtion of bone (Delaisse and Vaes, 1992). Thus, since there are various 
proteolytic enzymes that appear to have overlapping functions in the activation of 
proenzymes or paracrine factors involved in bone resorption, the PA system may be one of 
several redundant mechanisms involved in this process. Another function of the PA system 
in osteoclasts may be to activate paracrine factors involved in the regulation of bone 
remodelling (Martin et a!., 1993). Plasmin has been shown to dissociate IGF-l from its 
binding protein in human osteosarcoma cells and to activate the IL-1ß precursor and latent 
TGF-ß (Martin et al., 1993; Kwaan, 1992). 
In this study aprotinin and a2-antiplasmin had no effect on formation of TRAP +ve 
MNCs. Similarly, Daci et al. (1999) reported that cocultures of primary osteoblasts and 
bone marrow cells from wild type mice were able to generate TRAP +ve MNCs in the 
presence of aprotinin. Also cocultures of primary mouse osteoblasts and bone marrow cells 
derived from mice with an inactivation of uPA, tPA or a combined inactivation of both were 
capable of forming TRAP +ve MNCs when stimulated with 1,25-(O11)2D3 (Daci et al. 
1999). 
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7. Conclusions and Considerations for Future Work 
7.1 Osteoblast Survival 
The results from this investigation provide new insights into the cellular mechanisms 
by which certain growth factors present in bone matrix, notably the IGFs, FGF and I'DGF 
may co-operatively effect osteoblast survival. The findings from chapter 2 demonstrate that 
bone matrix derived growth factors, IGF-I and IGF-II, increased osteoblast survival in vitro 
and this was synergistically enhanced by PDGF and bFGF. The importance of FGF in 
osteoblast survival and bone development is highlighted by craniosynostosis disorders in 
which there is premature closure of the cranial sutures. This has been proposed to be a 
result of an inhibition of osteoblast apoptosis (Rice et al., 1999) due to defective FGF 
signalling. Human craniosynostosis disorders have been linked to mutations in the FGF 
receptor-1 and -2 genes (Muenke and Schell, 1995). Interestingly osteoblasts derived from 
patients with syndromic craniosynostosis have been shown to inhibit the apoptotic rate of 
normal human osteoblasts through the production of soluble factors (Dry el a!., 2001). In 
contrast to the results presented in this thesis it has been shown that FGF can also induce 
apoptosis in osteoblast cultures undergoing differentiation in the presence of ascorbic acid 
and ß-glycerophosphate (Mansukhani et al., 2000). 
The importance of IGF-I in vivo has been demonstrated by targeted overexprcssion 
of IGF-I in osteoblasts of transgenic mice (Zhao et al., 2000). In these mice there was 
increased trabecular bone volume without an increase in osteoblast number. Although this 
increase in trabecular bone volume was ascribed to increased osteoblast activity, IGF-I may 
also have increased osteoblast survival. It has been shown that glucocorticoids also decrease 
levels of IGF-I (Delaney and Canalis, 1995). Thus in glucocorticoid induced osteoporosis 
decreased bioavailability of IGF-I may effect osteoblast activity and survival. The main 
focus of future work will involve elucidating the signal transduction pathways by which 
these locally produced growth factors increase osteoblast survival. This may then provide a 
target for therapeutic drugs to mimic the actions of these growth factors thereby increasing 
osteoblast lifespan and subsequent bone mass. 
Recently it has been shown that the plasma proteinase inhibitors al -proteinase 
inhibitor, al-antichymotrypsin and a2-macroglobulin act as antiapoptotic factors for human 
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vascular smooth muscle cells (Ikari et al., 2001). Given that the combinations of growth 
factors investigated in the course of this thesis was insufficient to achieve a level osteoblast 
survival comparable to survival in the presence of serum it would have been interesting to 
investigate the role of proteinase inhibitors on osteoblast survival. Other protcinase 
inhibitors have recently been shown to be important determinants of cell survival; of 
particular interest is the demonstration that TIMP-3 promoted apoptosis in smooth muscle 
cells (Bond et al., 2000). This activity was associated with the metalloproteinase inhibiting 
activity of TIMP-3. TIMP-3 exhibits a unique ability to inhibit members of the ADAM 
family (Amour et al., 1998; Amour et al., 2000; Kashiwagi et al,, 2001) and inhibition of 
proteolytic shedding by TIMP-3 may effect cell survival. The serine proteinase inhibitor, 
PAI-2, may be important in protecting cells from TNF-induced apoptosis at inflammatory 
sites (Dickinson et al., 1995) since it has been shown that HeLa cells overexpressing PAI-2 
are protected from cell death induced by TNF. 
Cell-cell contact may also be important to osteoblast survival. Expression of N- 
cadherin has been demonstrated in immortalized human neonatal calvarial cells and 
expression of N-cadherin was upregulated by FGF-2 (Debiais cal al., 2001). Furthermore N- 
cadherin-mediated cell-cell interactions in melanoma cells inactivate the proapoptotic factor 
BAD (Li et al., 2001). Whether a similar mechanism operates in osteoblasts remains to be 
investigated. 
Although the results from this investigation show that antioxidants promote 
osteoblast survival in vitro the importance of reactive oxygen species to osteoblast survival 
in vivo is uncertain. It has been shown in vitro that TRAP can generate reactive oxygen 
species and that cells overexpressing TRAP produce higher amounts of intracellular reactive 
oxygen species (Halleen et al., 1999). Antioxidants thus may be important in protecting 
osteoblasts from reactive oxygen species produced by osteoclasts during bone remodelling. 
Interestingly, it has been demonstrated that human fetal osteoblasts produce glutathione 
peroxidase and selenoproteins which possess antioxidant properties (Dreher et al., 1998). 
Production of TNFa by T-cells has been shown to play a key role in bone loss 
associated with rheumatoid arthritis and TNFa is also important in the pathogensis of bone 
loss associated with tumour osteolysis and periodontal disease. The findings presented in 
chapter 2 that TNF-a promotes osteoblast apoptosis may further contribute to the current 
understanding of the mechanisms involved in these diseases. Indeed, it has been shown that 
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culture supernatants from activated T-cells induced apoptosis in primary human osteoblasts 
and that the bisphosphonate, etidronate, inhibited the production of pro-apoptotic factors by 
T-cells (Abe et al., 2000). 
7.2 Importance of IIr11 in bone cell function 
Studies in chapter 4 highlight the importance of IL-I 1 as a cytokine that influences 
osteoblast activity and osteoclast formation and function. Although IL-11 may play a role in 
normal bone metabolism, the importance of IL-11 as a cytokine that stimulates osteoclast 
formation may be more relevant to pathological conditions characterized by bone loss. 
Previous studies have implicated IL-11 as an important cytokine in tumour promoted 
osteolysis. The human melanoma cell line, A375M, and the breast cancer cell line, MDA- 
MB-23 1, have been shown to form osteolytic bone metastases in vivo and both cell lines 
produce IL-11 by themselves and stimulate IL-11 production from osteoblasts (Morinaga et 
al., 1997). The results from chapter 4 may be relevant to understanding cellular mechanisms 
involved in recruitment of osteoclasts in osteolytic bone diseases. Furthermore, the 
stimulation of osteoblast mediated osteoid degradation by IL-I1 may exacerbate 
progression of tumour osteolysis by predisposing mineralized bone surfaces to bone 
resorption by osteoclasts. IL-11 may also be involved in mechanisms of bone remodelling in 
osteoarthritis and rheumatoid arthritis since osteoblasts and bone marrow stromal cells from 
patients with these diseases constitutively secrete IL-11 (Lisignoli et al., 2000). Kim et al. 
(1997) demonstrated that IL-1 stimulates the production of IL-11 by human bone marrow 
stromal cells, raising the possibility that IL-11 may play a key role in bone loss associated 
with estrogen deficiency. However, stimulation of IL-11 by IL-1 was not inhibited 17 ß- 
estradiol suggesting that IL-1l may play only a minor role in bone resorption in estrogen 
deficiency. 
The observation that IL-11 stimulates osteoblast-mediated type I collagen 
degradation indicate that IL-1I may play a major role in regulating MMP expression in 
osteoblasts. Further studies will be required to 
identify which MMPs are expressed by 
mouse osteoblasts in response to IL-11 and whether this cytokine 
is responsible for 
enhancing osteoblast M1VIP synthesis in response to stimulation 
by PTH, IL-1, and 1,25- 
(OH)2D3. Interestingly, IL-6 with sIL-6R has been shown to stimulate mRNA expression of 
Mop-2, -3, -9 and -13 in cultured mouse calvaria 
(Kusano et al., 1998). In the same study 
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IL-1 also increased expression of these MMPs but to a greater extent. Future work will also 
be neccessary to establish whether IL-11 regulates the expression of members of the 
ADAM family in mouse calvarial osteoblasts. 
Although osteoclasts have been shown to express IL-11 receptor transcripts (Romas 
et al., 1996) the results presented in chapter 4 show that IL-11 did not stimulate bone 
resorption by isolated osteoclasts. Other investigators have shown that IL-11 does not 
influence osteoclast survival and antibody to gp130 does not effect lacunar resorption by 
osteoclasts. Interestingly the data presented in chapter 4 suggests that IL-1 I may alter the 
balance between MMPs and TIlVIPs. Future investigations will investigate the regulation of 
MMP/TIMP expression in bone cells by IL-11 to determine whether an alteration in this 
balance is responsible for matrix degradation. It will also be interesting to determine 
whether IL-11 effects the expression of members of the plasminogen activator/inhibitor 
pathway, which may also be important in osteoclast migration in the 17-day-old fetal 
metatarsal model employed in this study. 
The precise involvement of IL-11 in normal bone remodelling will be revealed by 
generating knockout mice. Mice with a targeted mutation in the IL-11 receptor display 
normal hematopoiesis although the effects on bone turnover have not been studied 
(Nandurkan et al., 1997). 
7.3 Role of ADAMs and serine proteinases in bone cells 
The data presented in chapter 5 demonstrates a role for ADAM-12 in the formation 
of osteoclasts. Furthermore, the requirement of ADAM proteins in osteoclast formation 
provides a useful target for intervention by therapeutic agents in the treatment of 
pathological disease states leading to bone loss. The addition of ODNs to bone marrow 
cultures had an inhibitory effect on osteoclast formation. Furthermore, recombinant 
ADAM-12 cysteine rich domain/GST fusion protein inhibited osteoclast formation from 
MDBM cells stimulated with RANKL and M-CSF. To eliminate any possibility that the 
inhibitory effect was due to the cysteine rich domain being fused to GST further 
investigations will need to be performed using purified A12/cys that has been cleaved from 
the GST using thrombin agarose. It would have been interesting to have performed pulse 
experiments by adding A12/cys at different stages of culture to see what effect this 
had on 
osteoclast formation. Construction of a mutant cysteine rich 
domain by deleting the 
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hydrophobic sequence or introducing point mutations by oligonucleotide-site directed 
mutagenesis may prove useful in elucidating which region of the cysteine rich domain is 
responsible for its biological activity. 
It has been demonstrated that recombinant disintegrin/cysteine-rich domain of 
mouse ADAM-12 is an active cell adhesion domain by supporting adhesion to C2C12 
myoblasts and to NIH 3T3 fibroblasts (Zolkiewska, 1999). Other studies have shown that 
the recombinant disintegrin domain on its own can bind to a9ß1 integrin (Eto et al., 2000) 
and recombinant cysteine-rich domain binds to syndecans (Iba et al., 2000) and IGFBP-3 
(Shi et al., 2000) in the case of human ADAM 12-S. The main focus for future work will 
involve construction of expression libraries representative of MDBM cells or osteoblasts 
and screening them with biotinylated disintegrin, cysteine-rich or disintegrin/cysteine-rich 
domain to identify potential targets for these domains. It would also be interesting to add 
recombinant disintegrin domain to bioassays for osteoclast formation to see if it also has an 
inhibitory effect. 
A number of questions remain to be answered with regard to the role of ADAMs 
proteins in osteoclast formation. Although the results from this study demonstrate a role for 
ADAM-12 in osteoclast formation it is not clear whether ADAM-12 is involved in cell 
fusion per se or whether it is involved in a pre-fusion step. Such a pre-fusion activity may 
involve mediating a cell-cell interaction between osteoclast precursors or between 
osteoblasts and osteoclast precursors. Interestingly osteoblasts express syndecans -2 and -4 
(Modrowski et al., 2000); thus one possible scenario is an interaction between osteoblasts 
and ADAM-12 expressed on osteoclast precursors. Although expression of ADAM-9 was 
not demonstrated by in situ hybridization other investigators have shown expression of 
ADAM-9 in osteoclasts by RNAse protection assay (Inoue et al., 1998). Also, the cysteine 
rich domain of ADAM-9 contains a hydrophobic fusion peptide sequence. It may be that 
ADAM-12 interacts with other ADAM family members such as ADAM-9 or ADAM-19 in 
a similar way to the heterodimerization that occurs between ADAM-1 and ADAM-2 to 
form fertilin. In such a case one ADAM would mediate cell-cell adhesion between 
osteoclast precursors whilst the other ADAM would mediate fusion of the plasma 
membranes. To investigate this it will be necessary to do immunoprecipitation and western 
blotting with antibodies specific for different ADAM family members. 
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Disruption of ADAM-12 expression in cultures of primary mouse osteoblasts had no 
effect on osteoblast differentiation as assayed by mineralized nodule formation. It is 
intrigueing that previous studies have shown that human ADAM 12-S can regulate IGFBP- 
3 and -5 levels in pregnancy serum (Shi ei al., 2000; Loechel et al., 2000). Also IGFBP-5 is 
degraded in conditioned medium from differentiating MC3T3-E1 cells by a 97 kDa protease 
that is not an MMP (Thraikill el al., 1995). Although mouse ADAM 12-S has not been 
cloned it is conceivable that membrane bound ADAM-12 could be shed from the plasma 
membrane. It would be interesting to see if IGFBP-5 is degraded in conditioned medium of 
osteoblasts transfected with ADAM-12 antisense constructs. Regulation of IGFBP levels by 
ADAMs would provide a cellular mechanism for influencing the bioavailability of IGFs to 
osteoblasts and thus affecting osteoblast proliferation and survival. 
Addition of antisense oligodeoxnucleotides specific for ADAM-12 had little effect 
on osteoclast activity as assessed by lacunar resorption. Although no assessment of 
osteoclast survival was made in these cultures, it seems unlikely that disruption of ADAM- 
12 by antisense oligodeoxynucleotides effects osteoclast survival. It would be interesting to 
assess the effects of disruption of other ADAMs such as ADAM-9 and -19 on osteoclast 
survival. Since TEMP-3 preferentially inhibits proteolytic shedding by members of the 
ADAM family it would be interesting to investigate the effect TIMP-3 on survival of mature 
osteoclasts and on osteoclast generation. 
Although the results presented here demonstrate expression of ADAM-12 in 17- 
day-old metatarsals; specific inhibitors of ADAM-12 will be required to investigate whether 
ADAM-12 is involved in osteoclast migration in this in vitro system. It seems more likely 
that serine proteinases may be more important in osteoclast migration. The findings from 
chapter 6 demonstrate that inhibitors of serine proteinases inhibit osteoclast migration over 
three days in mouse metatarsal explants, thus implicating the PA/plasmin pathway in 
osteoclast migration. The findings from chapter 6 also demonstrate a role for the 
PA/plasmin pathway in the degradation of nonmineralized matrix. However in vivo studies 
demonstrate that mice deficient in uPA and tPA have no obvious skeletal defects suggesting 
that the PA/plasmin system is not a key player in bone remodelling (Leloup et al., 1996; 
Daci et al., 1999). Future work will focus on regulation of expression of plasminogen 
activators and their natural inhibitors PAI-I and PAI-II in 17-day-old metatarsals. 
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It seems that proteinases other than PAs may have a critical role in bone remodelling 
as suggested by genetic disorders giving rise to an abnormal bone phenotype. Mutations in 
the cathepsin K gene have been linked to pycnodysostosis, characterized by osteosclerosis 
(Ho et al., 1999). More recently, mutations of MMP-2 in consanguineous families have 
been shown to cause osteolyses characterized by crippling arthritic changes and marked 
osteoporosis (Martignetti et al., 2001). The mechanism by which MMP-2 deficiency results 
in an osteolytic disorder in these cases is unclear but may involve defective bone formation 
resulting from incomplete extracellular matrix degradation. 
185 
8. REFERENCES 
Abe, E., Ishimi, Y., Jin, C. H., Hong, M. H., Sato, T., Suda, T. (1991) Granulocyte- 
macrophage colony-stimulating factor is a major macrophage fusion factor present in 
conditioned medium of concanavalin A-stimulated spleen cell cultures. J. Immunol. 
147: 1810-1815. 
Abe, E., Mocharia, H., Yamate, T., Taguchi, Y., Manolagas, S. C. (1999) Meltrin-a, a 
fusion protein involved in multinucleated giant cell and osteoclast formation. Calcif. Tissue 
Int. 64: 508-515. 
Abe, E., Yamamoto, M., Taguchi, Y., Lecka-Czernik, B., O'Brien C. A., Economides, 
A. N., Stahl, N., Jilka, R. L., Manolagas, S. C. (2000) Essential requirement of BMPs-2/4 
for both osteoblast and osteoclast formation in murine bone marrow cultures from adult 
mice: antagonism by noggin. J. Bone Miner. Res. 15(4): 663-673. 
Abe, Y., Kawakami, A., Nakashima, T., Ejima, E., Fujiyama, K., Kiriyama, T. et at. 
(2000) Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic 
factor(s) produced by activated T cells. Journal of Laboratory & Clinical Medicine. 
136(5): 344-354. 
Adams AE. Abu-Amer Y. Chappel J. Stueckle S. Ross FP. Teitelbaum SL. Suva W. 
(1999) 1,25 dihydroxyvitamin D3 and dexamethasone induce the cyclooxygenase 1 gene in 
osteoclast-supporting stromal cells. J. Cell. Biochem. 74(4): 587-595. 
Adams, J. M., Cory, S. (1998) The Bcl-2 protein family: arbiters of cell survival. [Review] 
[60 refs] Science. 281(5381): 1322-1326. 
Akatsu, T., Takahashi, N., Debari, K., Morita, I., Murota, S., Nagata, N., Takatani, 
0., Suda, T. (1989a) Prostaglandins promote osteoclastlike cell formation by a mechanism 
involving cyclic adenosine 3', 5'-monophosphate in mouse bone marrow cell cultures. J. 
Bone Miner. Res. 4(1): 29-35. 
Akatsu, T., Takahashi, N., Udagawa, N., Sato, K., Nagata, N., Moseley, J. M., Martin, 
T. J., Suda, T. (1989b) Parathyroid hormone (PTH)-related protein is a potent stimulator 
of osteoclast-like multinucleated cell formation to the same extent as PTH in mouse 
marrow cultures. Endocrinology 125(1): 20-27. 
Akatsu, T., Takahashi, N., Udagawa, N., Imamura, K., Yamaguchi, A., Sato, K., 
Nagata, N., Suda, T. (1991) Role of prostaglandins in interleukin-l-induced bone 
resorption in mice in vitro. J. Bone Miner. Res. 
6(2): 183-189. 
Al-Humidan, A., Ralston, S. H., Hughes, D. E., Chapman, K, Aarden, L., Russell, 
R. G. G., Gowen, M. (1991) Interleukin-6 does not stimulate bone resorption in neonatal 
mouse calvariae. J. Bone Miner. Res. 6: 3. 
186 
i, 
Allan, E. H., Hamilton, J. A., Medcalf, R. L., Kubota, M., Martin, T. J. (1986) Cyclic 
AMP-dependent and -independent effects on tissue-type plasminogen activator activity in 
osteogenic sarcoma cells; evidence from phosphodiesterase inhibition and parathyroid 
hormone antagonists. Biochim. Biophys. Acta. 888: 199-207. 
Allan, E. H., Hilton, D. J., Brown, M. A., Evely, RS., Yumita, S., Metcalf, D., Gough, 
N. M., Ng, K. W., Nicola, N. A., Martin, T. J. (1990) Osteoblasts display receptors for and 
responses to leukemia-inhibitory factor. J. Cell. Physiol. 145: 110-119. 
Allan, E. H., Zeheb, R., Gelehrter, T. D., Heaton, J. H., Fukumoto, S., Yee, J. A., 
Martin, T. J. (1991) Transforming growth factor beta inhibits plasminogen activator (PA) 
activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and 
protein in rat osteoblast-like cells. J. Cell. Physiol. 149: 34-43. 
Allan, E. H., Martin, T. J. (1995) Prostaglandin E2 regulates production of plasminogen 
activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary 
cultures of rat calvarial osteoblasts. J. Cell. Physiol. 165: 521-529. 
Almeida, E. A., Huovila, A. P., Sutherland, A. E., Stephens, L. E., Calarco, P. G., Shaw, 
L. M., Mercurio, A. M., Sonnenberg A., Primakoff, P., Myles DG. et at. (1995) Mouse 
egg integrin alpha 6 beta 1 functions as a sperm receptor. Cell 81(7): 1095-1104. 
Amour, A., Slocombe, P. M., Webster, A., Butler, M., Knight, C. G., Smith, B. J., 
Stephens, P. E., Shelley, C., Hutton, M., Knauper, V., Docherty, A. J., Murphy, G. 
(1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 
435(1): 39-44. 
Amour A. Knight CG. Webster A. Slocombe PM. Stephens PE. Knauper V. Docherty 
Al Murphy G. (2000) The in vitro activity of ADAM-10 is inhibited by TIMP-1 and 
TIMP-3. FEBS Lett. 473(3): 275-279. 
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., 
Roux, E. R., Teepe, M. C., DuBose, RF., Cosman, D., Galibert, L. (1997) A homologue 
of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. 
Nature 390(6656): 175-179. 
Angel, P., Baumann, I., Stein, B., Delius, H., Rahmsdorf, H. J., Herrlich, P. (1987) 12- 
O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated 
by an inducible enhancer element located in the 5'-flanking region. Mol. Cell. Biol. 
7(6): 2256-2266. 
Angel, P., Karin, M. (1991) The role of Jun, Fos and the AP-1 complex in cell- 
proliferation and transformation. [Review] [276 refs] Biochim. Biophys. Acta. 1072(2- 
3): 129-157. 
Apte, S. S., Mattel, M-G., Olsen, B. R. (1994) Cloning of the cDNA encoding human 
tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to 
chromosome 22. Genomics 19: 86-90. 
187 
Asahina, I., Sampath, T. K., Nishimura, I., Hauschka, P. V. (1993) Human osteogenic 
protein-1 induces both chondroblastic and osteoblastic differentiation of osteoprogenitor 
cells derived from newborn rat calvaria. J. Cell Biol. 123(4): 921-933. 
Ashkenazi, A., Dixit, V. M. (1998) Death receptors: signaling and modulation. Science 
281: 1305-1308. 
Athanasou, N. A., Quinn, J., McGee, J. O. (1987) Leukocyte common antigen is present 
on osteoclasts. J. Pathol. 153: 121-126. 
Athanasou, N. A., Quinn, J. (1990) Immunophenotypic differences between osteoclasts 
and macrophage polykaryons: immunohistological distinction and implications for 
osteoclast ontogeny and function. J. Clin. Pathol. 43: 997-1003. 
Aubin, J. E. (1998) Advances in the osteoblast lineage. [Review] Biochemistry & Cell 
Biology. 76(6): 899-910. 
Banyai, L., Varadi, A., Patthy L. (1998) Common evolutionary origin of the fibrin- 
binding structures of fibronectin and tissue-type plasminogen activator. FEBS Lett. 
163(1): 37-41. 
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Vojvodic, IT., Richardson, W. D., 
Raff, M. C. (1992) Cell death and control of cell survival in the oligodendrocyte lineage. 
Cell 70: 31-46. 
Barres, B. A., Schmid, R., Sendtner, M., Thoen, H., Raff, M. C. (1993) Multiple 
extracelluar signals are required for long-term oligodendrocyte survival. Development 
118: 283-295. 
Barnathan, E. S., Kuo, A., Van der Keyl, H., McCrae, KR., Larsen, G. R., Cines, D. B. 
(1988) Tissue-type plasminogen activator binding to human endothelial cells. Evidence for 
two distinct binding sites. J. Biol. Chem. 263(16): 7792-7799. 
Baron, R, Neff, L., Van, P. T., Nefussi, J.., Vignery, A. (1986) Kinetic and 
cytochemical identification of osteoclast precursors and their differentiation into 
multinucleated osteoclasts. Am. J. Pathol. 122: 363-378. 
Baron, R. (1989) Molecular mechanisms of bone resorption by the osteoclast. [Review] 
[66 refs] Anatomical Record. 224(2): 317-324. 
Barton, B. E., Mayer, R. (1989) IL-3 induces differentiation of bone marrow precursor 
cells to osteoclast-like cells. J. Immunol. 143(10): 
3211-3216. 
Baserga, R. (1985) The Biology of Cell Reproduction. Harvard University Press, 
Cambridge, MA. 
188 
Bautista, C. M., Baylink, D. J., Mohan, S. (1991) Isolation of a novel insulin-like growth 
factor (IGF) binding protein from human bone: a potential candidate for fixing IGF-II in 
human bone. Biochem. Biophys. Res. Commun. 183: 1153-1158. 
Bellido, T., Stahl, N., Farrugella, T. J., Borda, V., Yancapoulos, G. D., Manolagas, S. C. 
(1996) Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, 
oncostatin M, and ciliary neurotrophic factor in bone marrow stromaUosteoblastic cells. J. 
Clin. Invest. 97: 431-437. 
Bellido, T., Huening, M., Raval-Pandya, M., Manolagas, S. C., Christakos, S. (2000) 
Calbindin-D28k is expressed in osteoblastic cells and suppresses their apoptosis by 
inhibiting caspase-3 activity. J. Biol. Chem. 275(34): 26328-26332. 
Bellows, C. G., Aubin, J. E. (1989) Determination of numbers of osteoprogenitors present 
in isolated fetal rat calvaria cells in vitro. Developmental Biology (Orlando). 133(1): 8-13. 
Beresford, J. N., Joyner, C. J., Devlin, C., Triffitt, J. T. (1994) The effects of 
dexamethasone and 1,25-dihydroxyvitamin D3 on osteogenic differentiation of human 
marrow stromal cells in vitro. Archives of Oral Biology. 39(11): 941-947. 
Bertolini, D. R., Nedwin, G. E., Bringman, T. S., Smith, D. D., Mundy, G. R. (1986) 
Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour 
necrosis factors. Nature 319(6053): 516-518. 
Bertolini, D. R., Strassmann, G. (1991) Differential activity of granulocyte-macrophage 
and macrophage colony-stimulating factors on bone resorption in fetal rat long bone organ 
cultures. Cytokine 3: 421-427. 
Bigg, H. F., Shi, Y. E., Liu, Y. E., Steffensen, B., Overall, C. M. (1997) Specific, high 
affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal 
hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the 
COOH-terminal domain in a similar manner to TIMP-2. J. Biol. Chem. 272(24): 15496- 
15500. 
Biggers, J. D., Whitten, W. V., and Whittingham, D. G. (1971) The culture of mouse 
embryo in vitro. In: Daniel JC (ed) Methods in Mammalian Embryology Freeman 
Publications, San Francisco, CA 86-116. 
Birkedal-Hansen, H., Moore, W. G. I., Bodden, M. K., Windsor, L. J., Birkedal-Ilansen, 
B., DeCarlo, A., Engler, J. A. (1993) Matrix metalloproteinases: a review. Crit. Rev. Oral 
Biol. Med. 4: 197-250. 
Bizik, J., Lizonova, A., Stephens, R. W., Grofova, M., Vaheri, A. (1990) Plasminogen 
activation by t-PA on the surface of human melanoma cells in the presence of alpha 2 
macroglobulin. Cell Regulation 1: 895-905. 
189 
Black, R., Rauch, C., Kozlosky, C., Peschon, J., Slack, J., Wolfson, M., Castner, B., 
Stocking, K, Reddy, P., Srinivasan, S. (1997) A metalloproteinase disintegrin that 
releases tumour necrosis factor alpha from cells. Nature 385: 729-733. 
Blair, H. C., Teitelbaum, S. L., Ghiselli, R., Gluck, S. (1989) Osteoclastic bone resorption 
by a polarized vacuolar proton pump. Science 245(4920): 855-857. 
Blavier, L., Delaisse, J. M. (1995) Matrix metalloproteinases are obligatory for migration 
of preosteoclasts to the developing marrow cavity of primitive long bones. J. Cell Sci. 108: 
3649-3659. 
Blobel, C. P., Wolfsberg, T. G., Turck, C. W., Myles, D. G., Primakoff, P., White, J. M. 
(1992) A potential fusion peptide and an integrin ligand domain in a protein active in 
sperm-egg fusion [see comments]. Nature 356(6366): 248-252. 
Bolander, M. E., Young, M. F., Fisher, L. W. Yamada, Y., Termine, J. D. (1988) 
Osteonectin cDNA sequence reveals potential binding regions for calcium and 
hydroxyapatite and shows homologies with both a basement membrane protein (SPARK) 
and a serine proteinase inhibitor (ovomucoid). Proc. Natl. Acad. Sci. USA 85(9): 2919-23. 
Bond, M., Murphy, G., Bennett, M. R, Amour, A., Knauper, V., Newby, A. C., Baker, 
A. H. (2000) Localization of the death domain of tissue inhibitor of metalloproteinase-3 to 
the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity. J. 
Biol. Chem. 275(52): 41358-41363. 
Bonfoco, E., Krainc, D., Ankarcrona, M., Nicotera, P., Lipton, S. A. (1995) Apoptosis 
and necrosis: two distinct events induced, respectively, by mild and intense insults with N- 
methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc. Natl. Acad. 
Sci. USA 92: 7162-7166. 
Boone, T. C., Johnson, M. J., De Clerck, Y. A., Langley, K. E. (1990) cDNA cloning and 
expression of a metalloproteinase inhibitor related to tissue inhibitor of metalloproteinases. 
Proc. Natl. Acad. Sci. USA 87: 2800-2804. 
Boonekamp, P. M., van der Wee-Pals, L. J., van Wijk-van Lennep, M. M., Thesing, 
C. W., Bijvoet, O. L. (1986) Two modes of action of bisphosphonates on osteoclastic 
resorption of mineralized matrix. Bone & Mineral 1(1): 27-39. 
Bord, S., Horner, A., Hembry, R. M., Reynolds, J. J., Compston, J. E. (1996) Production 
of collagenase by human osteoblasts and osteoclasts in vivo. Bone 19(1): 35-40. 
Bord, S., Horner, A., Hembry, RM., Compston, J. E. (1998) Stromelysin-1 (MMP-3) 
and stromelysin-2 (MMP-10) expression in 
developing human bone: potential roles in 
skeletal development. Bone 23(1): 7-12. 
190 
Bossard, M. J., Tomaszek, T. A., Thompson, S. K., Amegadzie, B. Y., Hanning, C. R., 
Jones, C., Kurdyla, J. T., McNulty, D. E., Drake, F. H., Gowen, M., Levy, M. A. (1996) 
Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, 
and substrate identification. J. Biol. Chem. 271(21): 12517-12524. 
Bouillon, R (1990) Diabetic bone disease. Calcif. Tissue Int. 49: 155-160. 
Boyan, B. D., Schwartz, Z., Bonewald, L. F., Swain, L. D. (1989) Localization of 1,25- 
(OH)2D3-responsive alkaline phosphatase in osteoblast-like cells (ROS 17/2.8, MG 63, 
and MC3T3E1) and growth cartilage cells in culture. J. Biol. Chem. 264(20): 11879-11886. 
Boyce, B. F., Aufdemorte, T. B., Garrett, it, Yates, A. J. P., Mundy, G. R. (1989) Effects 
of interleukin-1 on bone turnover on normal mice. Endocrinology 125: 1142. 
Boyde, A., Ali, N. N., Jones, S. J. (1984) Resorption of dentine by isolated osteoclasts in 
vitro. Br. Dent. J. 156: 216-220. 
Bromme, D., Okamoto, K. (1995) Human cathepsin 02, a novel cysteine protease highly 
expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue 
distribution. Biological Chemistry Hoppe-Seyler 376(6): 379-384. 
Bruckner, P., Horler, I., Mendler, M., Houze, Y., Winterhalter, K. H., Eich-Bender, 
S. G., Spycher, M. A. (1989) Induction and prevention of chondrocyte hypertrophy in 
culture. J. Cell Biol. 109: 2537-2545. 
Bunn, P. A., Schecter, G. P., Jaffe, E., Blayney, D., Young, R. C., Mathews, M. J., 
Blatner, W., Broder, S., Robert-Guroff, M., Gallo, RC. (1983) Clincal course of 
retrovirus-associated T-cell lymphoma in the United States. New Engl. J. Med. 309: 257- 
269. 
Burger, E. H., Van der Meer, J. W., van de Gevel, J. S., Gribnau, J. C., Thesingh, G. W. 
van Furth, R. (1982) In vitro formation of osteoclasts from long-term cultures of bone 
marrow mononuclear phagocytes. J. Exp. Med. 156(6): 1604-1614. 
Burgess, T. L., Qian, Y., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., 
Hsu, H., Boyle, W. J., Dunstan, C. R, Hu, S., Lacey, D. L. (1999) The ligand for 
osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biology 145(3): 527- 
538. 
Burleigh, M. C., Barrett, A. J., Lazarus, G. S. (1974) Cathepsin B1. A lysosomal enzyme 
that degrades native collagen. Biochem. J. 137(2): 387-398. 
Burleigh, M. C., Werb, Z., Reynolds, J. J. (1977) Evidence that species specificity and 
rate of collagen degradation are properties of collagen, not collagenase. Biochim. Biophys. 
Acta. 494(1): 198-208. 
191 
Bursch, W., Oberhammer, F., Jirtle, R. L., Askari, M., Sedivy, M, Grasl-Kraupp, B., 
Purchio, A. F., Schulte-Hermann, R (1993) Transforming growth factor-beta 1 as a 
signal for induction of cell death by apoptosis. Brit. J. Cancer 67: 531-536. 
Butler, G. S., Will, H., Atkinson, S. J., Murphy, G. (1997) Membrane-type-2 matrix 
metalloproteinase can initiate the processing of progelatinase A and is regulated by the 
tissue inhibitors of metalloproteinases. European Journal of Biochemistry. 244(2): 653-657. 
Butler, G. S., Apte, S. S., Willenbrock, F., Murphy, G. (1999) Human tissue inhibitor of 
metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A 
and B. Regulation by polyanions. J. Biol. Chem. 274(16): 10846-10851. 
Cadenas, E. (1989) Biochemistry of oxygen toxicity. Annu. Rev. Biochem. 58: 79-110. 
Cajot, J. F., Schleuning, W. D., Medcalf, R. L., Baurat, J., Testuz, J., Liebermann, L., 
Sordat, B. (1989) Mouse L cells expressing human prourokinase-type plasminogen 
activator: Effects on extracellular matrix degradation and invasion. J. Cell Biol. 109: 915- 
925. 
Canalis, E. (1981) Effect of platelet-derived growth factor on DNA and protein synthesis 
in cultured rat calvariae. Metabolism 30: 970. 
Canalis, E., Centrella, M., McCarthy, T. (1988) Effects of basic fibroblast growth factor 
on bone formation in vitro. J. Clin. Invest. 79: 52. 
Canalis, E., Pash, J., Gabbitas B., Rydziel, S., Vaeghese, S. (1993a) Growth factors 
regulate the synthesis of insulin-like growth factor I in bone cell cultures. Endocrinology 
133: 33-38. 
Canalis, E., Pash, J., Varghese, S. (1993b) Skeletal growth factors. Crit. Rev. Eukaryot. 
Gene Expr. 3: 155-166. 
Canalis, E. (1993c) Systemic and local factors and the maintenance of bone quality. 
Calcif. Tissue Int. 53 (Suppl 1): S90-S92. 
Canalis, E. (1998) Inhibitory actions of glucocorticoids on skeleton growth: Is local 
insulin-like growth factor Ito blame? Endocrinology 139: 3041-3042. 
Cao, Z., Xiong, M., Takeuchi, T., Kurama, T., Goeddel, D. V. (1996) TRAF 6 is a signal 
transducer for interleukin 1. Nature 383: 443-446. 
Celeste, A. J., lannazzi, J. A., Taylor, R. C., Hewick, R. M., Rosen, V., Wang, E. A., 
Wozney, J. M. (1990) Identification of transforming growth factor beta family members 
present in bone-inductive protein purified from bovine bone. Proc. Natl. Acad. Sci. USA 
87(24): 9843-9847. 
192 
Centrella, M., McCarthy, T. L., Canalis, E. (1987) Transforming growth factor beta is a 
bifunctional regulator of replication and collagen synthesis in osteoblast-enriched cell 
cultures from fetal rat bone. J. Biol. Chem. 262: 2869. 
Centrella, M., McCarthy, T. L., Cannalis, E. (1990) Receptors for insulin- like growth 
factors I and II in osteoblast-enriched cultures from fetal rat bone. Endocrinology 126: 39- 
44. 
Centrella, M., McCarthy, T. L., Kusmic, W. F., Canalis, E. (1992) Isoform specific 
regulation of platelet-derived growth factor activity and binding in osteoblast-enriched 
cultures from fetal rat bone. J. Clin. Invest. 89: 1076-1084. 
Cerretti, D. P., DuBose, RF., Black, R. A., Nelson, N. (1999) Isolation of two novel 
metalloproteinase-disintegrin (ADAM) cDNAs that show testis-specific gene expression. 
Biochem. Biophys. Res. Commun. 263(3): 810-815. 
Chambers, T. J., Magnus, C. J. (1982) Calcitonin alters behaviour of isolated osteoclasts. 
J. Pathol. 136(1): 27-39. 
Chambers, T. J., Revell, P. A., Fuller, K., Athanasou, N. A. (1984) Resorption of bone by 
isolated rabbit osteoclasts. J. Cell Sci. 66: 383-399. 
Chambers, T. J., McSheehy, P. M., Thomson, B. M., Fuller, K. (1985a) The effect of 
calcium-regulating hormones and prostaglandins on bone resorption by osteoclasts 
disaggregated from neonatal rabbit bones. Endocrinology 116(1): 234-239. 
Chambers, T. J., Fuller, K., McSheehy, P. M., Pringle, J. A. (1985b) The effects of 
calcium regulating hormones on bone resorption by isolated human osteoclastoma cells. J. 
Pathol. 145(4) 297-305. 
Chambers, T. J., Darby, J. A., Fuller, K. (1985c) Mammalian collagenase predisposes 
bone surfaces to osteoclastic resorption. Cell Tiss. Res. 241: 67-675. 
Chambers, T. J., Owens, J. M., Hattersley, G., Jat, P. S., Noble, M. D. (1993) Generation 
of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA58 transgenic 
mouse. Proc. Natl. Acad. Sci. USA. 90(12): 5578-5582. 
Chantry, A., Gregson, N. A., Glynn, P. (1989) A novel metalloproteinase associated with 
brain myelin membranes. Isolation and characterization. J. Biol. Chem. 264(36): 21603- 
21617. 
Cheng, S. L., Shen, V., Peck, W. A. (1991) Regulation of plasminogen activator and 
plasminogen activator inhibitor production by growth factors and cytokines in rat calvarial 
cells. Calcif. Tissue Int. 49(5): 321-327. 
Chenu, C., Pfeilschifter, J., Mundy, G. R., Roodman, G. D. (1988) Transforming growth 
factor beta inhibits formation of osteoclast-like cells in long term human marrow cells. 
Proc. Natl. Acad. Sci. USA 85: 5683. 
193 
Choi, S. J, Han, J., Roodman, G. D. (2001) ADAM8: A Novel Osteoclast Stimulating 
Factor. J. Bone Miner. Res. 16(5): 814-822. 
Clemmons, D. R. (1985) Variables controling the secretion of a somatomedin-like peptide 
by cultured porcine smooth muscle cells. Circ. Res. 56: 418-426. 
Cole AA. Chubinskaya S. Schumacher B. Huch K. Szabo G. Yao J. Mikecz K. Hasty 
KA. Kuettner KE. (1996) Chondrocyte matrix metalloproteinase-8. Human articular 
chondrocytes express neutrophil collagenase. J. Biol. Chem. 271(18): 11023-11026. 
Collier, I. E., Wilhelm, S. M., Eisen, A. Z., Marmer, B. L., Grant, G. A., Seltzer, J. L., 
Kronberger, A., He, C. S., Bauer, E. A., Goldberg, G. I. (1988) H-ras oncogenc- 
transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease 
capable of degrading basement membrane collagen. J. Biol. Chem. 263(14): 6579-6587. 
Collins, D. A., Chambers, T. J. (1991) Effect of prostaglandins El, E2, and F2 alpha on 
osteoclast formation in mouse bone marrow cultures. J. Bone Miner. Res. 6(2): 157-164. 
Collins, D. A., Chambers, T. J. (1992) Prostaglandin E2 promotes osteoclast formation in 
murine hematopoietic cultures through an action on hematopoietic cells. J. Bone Mincr. 
Res. 7(5): 555-561. 
Cowell, S., Knauper, V., Stewart, M. L., D'Ortho, M. P., Stanton, II., IIembry, R. M., 
Lopez-Otin, C., Reynolds, J. J., Murphy, G. (1998) Induction of matrix 
metalloproteinase activation cascades based on membrane-type 1 matrix metal loproteinasc: 
associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem. J. 331 (Pt 
2): 453-458. 
Croucher, P. I., Wang, F., Hargreaves, P. G. (1999) Interleukin-6 receptor shedding: a 
possible role for members of the ADAM family. Biochem. Soc. Transactions 27: 224-228. 
Cubellis, M. V., Andreasen, P., Ragno, P., Mayer, M., Dano, K., Blasi F. (1989) 
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc. 
Natl. Acad. Sei. 86(13): 4828-4832. 
Cubellis, M. V., Wun, T. C., Blasi, F. (1990) Receptor-mediated internalization and 
degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9(4): 1079- 
1085. 
Cullen, B. R, Malim, M. H. (1992) Secreted placental alkaline phosphatase as a eukaryotic 
reporter gene. Methods Enzymol. 216: 362-368. 
Daci, E., Udagawa, N., Martin, T. J., Bouillon, R., Carmeliet, G. (1999) The role of the 
plasminogen system in bone resorption in vitro. 
J. Bone Miner Res. 14(6): 946-952. 
Dallas, D. J., Genever, P. G., Patton, A. J., Millichip, M. I., McKie, N., Skerry, T. M. 
(1999) Localization of ADAM10 and Notch receptors in bone. Bone 25(1): 9-15. 
194 
Datta, H. K., Rathod, H., Manning, P., Turnbull, Y., McNeil, C. J. (1996) Parathyroid 
hormone induces superoxide anion burst in the osteoclast: evidence for the direct 
instantaneous activation of the osteoclast by the hormone. J. Endocrinology 149(2): 269- 
275. 
Debiais, F., Lemonnier, J., Hay, E., Delannoy, P., Caverzasio, J., Marie, P. J. (2001) 
Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase 
C and Src-kinase pathways in human calvaria osteoblasts. J. Cell. Biochem. 81(1): 68-81. 
Decker, R. S. (1976) Influence of thyroid hormones on neuronal death and differentiation 
in larval Rana pipiens. Dev. Biol. 49: 101-118. 
Degli-Esposti, M., Dougall, W., Smolak, P., Waugh, J., Smith, C., and Goodwin, It. 
(1997) The novel receptor TRAIL-R4 induces NF-KB and protects against TRAIL- 
mediated apoptosis, yet retains an incomplete death domain. Immunity 7: 13. 
Delaisse, J. M., Eeckhout, Y., Vaes, G. (1984) In vivo and in vitro evidence for the 
involvement of cysteine proteinases in bone resorption. Biochem. Biophys. Res. Commun. 
125: 441-447. 
Delaisse, J. M., Boyde, A., Maconnachie, E., All, N. N., Sear, C. H., Eeckhout, Y., Vacs, 
G., Jones, S. J. (1987) The effects of inhibitors of cysteine-proteinases and collagenase on 
the resorptive activity of isolated osteoclasts. Bone 8(5): 305-313. 
Delaisse, J. M., Vaes, G. (1992) Mechanisms of mineral solubilization and matrix 
degradation in osteoclastic bone resorption. In: Biology and physiology of the osteoclast 
(Rifkin, B. R. & Gay, C. V., eds), pp 289-314. CRC Press, Boca Raton. 
Delaisse, J. M., Eeckhout, Y., Neff, L., Francois-Gillet, C., Henriet, P., Su, Y., Vacs, G., 
Baron, P. (1993) (Pro)collagenase (matrix metalloproteinase-1) is present in rodent 
osteoclasts and in the underlying bone-resorbing compartment. J. Cell Sci. 106(Pt 4): 1071- 
1082. 
Delany, A. M., Canalis, E. (1995) Transcriptional repression of insulin-like growth factor I 
by glucocorticoids in rat bone cells. Endocrinology 136(11): 4776-4781. 
Delaney, C. L., Cheng, H. L., Feldman, E. L. (1999) Insulin-like growth factor-I prevents 
caspase-mediated apoptosis in Schwann cells. J Neurobiol 41(4): 540-548. 
Dempster, D. W., Moonga, B. S., Stein, L. S., Horbert, W. R., Antakly, T. (1997) 
Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis. 
Journal of Endocrinology 154(3): 397-406. 
Dickinson, J. L., Bates, E. J., Ferrante, A., Antalis, T. M. (1995) Plasminogen activator 
inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an 
alternate biological function. J. Biol. Chem. 270(46): 27894-27904. 
195 
Dietrich, J. W., Goodson, J. M., Raisz, L. G. (1975) Stimulation of bone resorption by 
various prostaglandin in organ culture. Prostaglandins. 10(2): 231-240. 
Dieudonne, S. C., Foo, P., Van Zoelen, E., Buger, E. H. (1991) Inhibiting and stimulating 
effects of TGFP on osteoclastic bone resorption in fetal mouse bone organ cultures. J. Bone 
Miner. Res. 6: 479-487. 
Dobnig, H., Turner, R. T. (1995) Evidence that intermittent treatment with parathyroid 
hormone increases bone formation in adult rats by activation of bone lining cells. 
Endocrinology. 136(8): 3632-3638. 
Docherty, A. J. P., Lyons, A., Smith, B. J., Wright, E. M., Stephens, P. E., Harris, T. J. R., 
Murphy, G., Reynolds, J. J. (1985) Sequence of human tissue inhibitor of 
metalloproteinases and its identity to erythroid potentiating activity. Nature 318: 66-69. 
Dohrmann, U., Edgar, D., Thoenea, H. (1986) Muscle-derived factors that support 
survival and promote outgrowth from embryonic chick spinal motor neurons in culture. 
Dev. Biol. 118: 209-221. 
d'Ortho, M-P., Will, H., Atkinson, S., Butler, G. S., Messant, A., Gavrilovic, J., Smith, 
B., Timpl, R., Zardi, L., Murphy, G. (1997) Membrane-type matrix metalloproteinases I 
and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix 
metalloproteinases. Eur. J. Biochem. 250: 751-757. 
Dragovich, T., Rudin, C. M., Thompson, C. B. (1998) Signal transduction pathways that 
regulate cell survival and cell death. [Review] [62 refs] Oncogene 17(25): 3207-3213. 
Drake, F. H., Dodds, R. A., James, I. E., Connor, J. R., Debouck, C., Richardson, S., 
Lee-Rykaczewski, E., Coleman, L., Rieman, D., Barthlow, R., Hastings, G., Gowen, 
M. (1996) Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human 
osteoclasts. J. Biol. Chem. 271(21): 12511-12516. 
Dranoff, G., Crawford, A. D., Sadelain, M., Ream, B., Rashid, A., Bronson, R. T., 
Dickersin, G. R., Bachurski, C. J., Mark, E. L., Whitsett, J. A., Mulligan, R. C. (1994) 
Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary 
homeostasis. Science 264: 713-716. 
Dreher, I., Schutze, N., Baur, A., Hesse, K., Schneider, D., Kohrle, J., Jakob, F. (1998) 
Selenoproteins are expressed in fetal human osteoblast-like cells. Biochem. Biophys. Res. 
Commun. 245(1): 101-107. 
Dressler, K. A., Mathias, S., Kolesnick, P. N. (1992) Tumour necrosis factor-a activates 
the sphingomyelin signal transduction pathway in a cell-free system. Science 255: 1715- 
1718. 
196 
Dry, G. M., Yasinskaya, Y. I., Williams, J. K., Ehrlich, G. D., Preston, R. A., IIu, F. Z. 
Gruss, J. S., Ellenbogen, R. G., Cunningham, M. L. (2001) Inhibition of apoptosis: a 
potential mechanism for syndromic craniosynostosis. Plastic & Reconstructive Surgery. 
107(2): 425-432. 
DuBois, RN., Awad, J., Morrow, J., Roberts, L. J., Bishop, P. R. (1994) Regulation of 
eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming 
growth factor-alpha and phorbol ester. J. Clin. Invest. 93: 493-498. 
Ducy, P., Desbois, C., Boyce, B., Pinero, G., Story, B., Dunstan, C., Smith, E., 
Bonadio, J., Goldstein, S., Gundberg, C., Bradley, A., Karsenty, G. (1996) Increased 
bone formation in osteocalcin-deficient mice. Nature. 382(6590): 448-452. 
Ducy, P., Zhang, R., Geoffroy, V., Ridall, AL., Karsenty, G. (1997) Osf2/Cbfal: a 
transcriptional activator of osteoblast differentiation. Cell 89(5): 747-754. 
Duke, R. C., Cohen, J. J. (1986) IL-2 addictions: withdrawal of growth factor activates a 
suicide program in dependent T-cells. Lympokine Res. 5: 289-299. 
Edwards, M., Sarma, U., Flanagan, A. M. (1998) Macrophage colony-stimulating factor 
increases bone resorption by osteoclasts disaggregated from human fetal long bones. Bonc 
22(4): 325-359. 
Eisenberg, S. P., Evans, RJ., Arend, W. P., Verderber, E., Brewer, M. T., Ilannum, 
C. H., Thompson, R. C. (1990) Primary structure and functional expression from 
complementary DNA of a human interleukin-1 receptor antagonist. Nature 343: 341. 
Elias, J. A., Tang, W., Horowitz, M. (1995) Cytokine and hormonal stimulation of human 
osteosarcoma interleukin-11 production. Endocrinology 136: 531-542. 
Elias, L., Moore, P. B., Rose, S. M. (1988) Tumour necrosis factor induced DNA 
fragmentation in HL60 cells. Biochem. Biophys. Res. Commun. 157: 963-969. 
Ellis, RE., Yuan, J., Horvitz, H. R. (1991) Mechanisms and functions of cell death. Ann. 
Rev. Cell Biol. 7: 663-698. 
Ernst, M., Rodan, G. A. (1990) Increased activity of insulin-like growth factor (IGF) in 
osteoblastic cells in the presence of growth hormone (GH): positive correlation with the 
presence of the GH-induced IGF binding. Endocrinology 127: 807-814. 
Eto, K., Puzon-McLaughlin, W., Sheppard, D., Sehara-Fujisawa, A., Zhang, X. P., 
Takada, Y. (2000) RGD-independent binding of integrin alpha9betal to the ADAM-12 
and -15 disintegrin domains mediates cell-cell 
interaction. J. Biol. Chem. 275(45): 34922- 
34930. 
197 
Everts, V., Delaisse, J. M., Korper, W., Niehof, A., Vaes, G., Beertsen, W. (1992) 
Degradation of collagen in the bone-resorbing compartment underlying the osteoclast 
involves both cysteine-proteinases and matrix metalloproteinases. J. Cell. Physiol. 
150(2): 221-231. 
Everts, V., Delaisse, J. M., Korper, W., Beertsen, W. (1998) Cysteine proteinases and 
matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone. J. Bone 
Miner. Res. 13: 1420-1430. 
Fambrough, D., Pan, D., Rubin, G. M., Goodman, C. S. (1996) The cell surface 
metalloprotease/disintegrin Kuzbanian is required for axonal extension in Drosophila. 
Proc. Natl. Acad. Sci. USA. 93(23): 13233-13238. 
Fawcett, D. W. (1986) A textbook of Histology. 11th cd WB Saunders Company, 
Philadelphia, PA. 
Fehsel, K., Kolb-Bachofer, V., Kolb, H. (1991) Analysis of TNF-alpha-induced DNA 
strand breaks at the single cell level. Am. J. Pathol. 139: 251-254. 
Felix, R., Elford, P. R., Stoerckle, C., Cecchini, M., Wetterwald, A., Trechsel, U., 
Fleisch, H., Stadler, B. M. (1988) Production of hemopoietic growth factors by bone tissue 
and bone cells in culture. J. Bone Miner. Res. 3: 27-36. 
Felix, R., Fleisch, H., Elford, P. R. (1989) Bone-resorbing cytokines enhance release of 
macrophage colony-stimulating activity by the osteoblastic cell MC3T3-E1. Calcif. Tissue 
Int. 44(5): 356-360. 
Felix, R., Cecchini, M. G., Hofstetter, W., Guenther, H. L., Fleisch, H. (1990a) 
Production of granulocyte-macrophage (GM-CSF) and granulocyte colony-stimulating 
factor (G-CSF) by rat clonal osteoblastic cell population CRP 10/30 and the immortalized 
cell line IRC 10/30-mycl stimulated by tumour necrosis factor. Endocrinology 128: 661- 
667. 
Felix, R., Cecchini, M. G., Hofstetter, W., Elford, P. R., Stutzer, A., Fleisch, H. (1990b) 
Impairment of macrophage colony-stimulating factor production and lack of resident bone 
marrow macrophages in the osteopetrotic op/op mouse. J. Bone Miner. Res. 5(7): 781-789. 
Felix, R., Cecchini, M. G., Fleisch, H. (1990c) Macrophage colony stimulating factor 
restores in vivo bone resorption in the op/op osteopetrotic mouse. 
Endocrinology. 
127(5): 2592-2594. 
Ferguson MA. Williams AF. (1988) Cell-surface anchoring of proteins via glycosyl- 
phosphatidylinositol structures. [Review] 
[194 refs] Ann. Rev. Biochem. 57: 285-320. 
Feyan, J. H. M., Van der Wilt, G., Moonen, P., DiBon, A., Nijweide, P. J. (1984) 
Stimulation of arachidonic acid metabolism in primary cultures of osteoblast-like cells by 
hormones and drugs. Prostaglandins 28: 213-220. 
198 
Fixe, P., Praloran, V. (1997) Macrophage colony-stimulating-factor (M-CSF or CSF-1) 
and its receptor: structure-function relationships. [Review] European Cytokine Network. 
8(2): 125-136. 
Flanagan, A. M., Horton, M. A., Dorey, E. L., Collins, D. A., Evely, R. S., Moseley, J. M., 
Firkin, F. C., Chambers, T. J., Helfrich, M. H., Martin, T. J. (1992) An assessment of the 
ability of human bone marrow cultures to generate osteoclasts. Int. J. Exp. Path. 73(3): 387- 
401. 
Flanagan, A. M., Stow, M. D., Williams, R (1995) The effect of interleukin-6 and soluble 
interleukin-6 receptor protein on the bone resorptive activity of human osteoclasts 
generated in vitro. Journal of Pathology 176(3): 289-297. 
Fleischmann, A., Hafezi, F., Elliott, C., Reme, C. E., Ruther, U., Wagner, E. F. (2000) 
Fra-1 replaces c-Fos-dependent functions in mice. Genes & Development 14(21): 2695- 
2700. 
Fraser, J. D., Otawara, Y., Price, P. A. (1988) 1,25-Dihydroxyvitamin D3 stimulates the 
synthesis of matrix gamma-carboxyglutamic acid protein by osteosarcoma cells. Mutually 
exclusive expression of vitamin K-dependent bone proteins by osteoblastic cell lines. J. 
Biol. Chem. 263(2): 911-916. 
Friedenstein, A. J., Chailakhyan, RK., Gerasimov, U. V. (1987) Bone marrow 
osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell & 
Tissue Kinetics. 20(3): 263-72. 
Freije, J. M., Diez-Itza, I., Balbin, M., Sanchez, L. M., Blasco, %, Tolivia, J., Lopez- 
Otin, C. (1994) Molecular cloning and expression of collagenase-3, a novel human matrix 
metalloproteinase produced by breast carcinomas. J. Biol. Chem. 269(24): 16766-16773. 
Fromigue, 0., Marie, P. J., Lomri, A. (1998) Bone morphogentic protein-2 and 
transforming growth factor-ß2 interact to modulate human bone marrow stromal cell 
proliferation and differentiation. J. Cell. Biochem. 68: 411-426. 
Fukumoto, S., Allan, E. H., Yee, J. A., Gelehrter, T. D., Martin, T. J., (1992) 
Plasminogen activator regulation in osteoblasts: parathyroid hormone inhibition of type-1 
plasminogen activator inhibitor and its mRNA. J. Cell. Physiol. 152: 346-355. 
Fukumoto, S., Allan, E. H., Martin, T. J., (1994) Regulation of plasminogen activator 
inhibitor-1 (PAI-1) expression by 1,25-dihydroxyvitamin D-3 in normal and malignant rat 
osteoblasts. Biochim. Biophys. Acta. 1201: 223-228. 
Fulton, A., and Chong, Y. (1992) The role of macrophage TNF-oc in the induction of 
sublethal tumour cell DNA damage. Carcinogenesis 13: 77-81. 
Fuller, K., Chambers, T. J. (1989a) Bone matrix stimulates osteoclastic differentiation in 
cultures of rabbit bone marrow cells. J. Bone Miner. Res. 4(2): 
179-183. 
199 
Fuller, K., Chambers, T. J. (1989b) Effect of arachidonic acid metabolites on bone 
resorption by isolated rat osteoclasts. J. Bone Miner. Res. 4(2): 209-215. 
Fuller, K., Owens, J. M., Jagger, C. J., Wilson, A., Moss, R, Chambers, T. J. (1993) 
Macrophage colony-stimulating factor stimulates survival and chemotactic behaviour in 
isolated osteoclasts. J. Exp. Med. 178: 1733-1744. 
Fuller, K., Owens, J. M., Chambers, T. J. (1995a) Macrophage inflammatory protein-1 
alpha and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts. 
J. Immunol. 154(11): 6065-6072. 
Fuller, K., Chambers, T. J. (1995b) Localisation of mRNA for collagenase in osteocytic, 
bone surface and chondrocytic cells but not osteoclasts. J. Cell Sci. 108 (Pt 6): 2221-2230. 
Fuller, K., Wong, B., Fox, S., Choi, Y., Chambers, T. J. (1998) TRANCE is necessary 
and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. 
Med. 188(5): 997-1001. 
Fuller, K., Lean, J. M., Bayley, K. E., Wani, M. R, Chambers, T. J. (2000) A role for 
TGFbeta(1) in osteoclast differentiation and survival. J. Cell Sci. 113(13): 2445-2453. 
Gabbitas, B., Pash, J., Canalis, E. (1994) Regulation of insulin-like growth factor II 
synthesis in bone cell cultures. Endocrinology 135: 84-89. 
Gack, S., Vallon, R., Schaper, J., Ruther, U., Angel, P. (1994) Phenotypic alterations in 
fos-transgenic mice correlate with changes in Fos/Jun-dependent collagenase type I 
expression. Regulation of mouse metalloproteinases by carcinogens, tumor promoters, 
cAMP, and Fos oncoprotein. J. Biol. Chem. 269(14): 10363-10369. 
Galibert, L., Tometsko, M. E., Anderson, D. M., Cosman, D., Dougall, W. C. (1998) The 
involvement of multiple tumour necrosis factor receptor (TNFR)-associated factors in the 
signalling mechanism of receptor activator of NF-KB, a member of the TNFR superfamily. 
J. Biol. Chem. 273: 34120-34127. 
Gao, Y., Morita, I., Maruo, N., Kubota, T., Murota, S., Aso, T. (1998) Expression of 
IL-6 receptor and GP130 in mouse bone marrow cells during osteoclast differentiation. 
Bone 22: 487-493. 
Garcia, C., Boyce, B., Gilles, J., Dallas, M., Qiao, M., Mundy, G., Bonewald, L. (1996) 
Leukotriene B4 stimulates bone resorption both in vitro and in vivo. J. Bone Miner. Res. 
11: 1619-1627. 
Garnero, P., Borel, 0., Byrjalsen, I., Ferreras, M., Drake, F. H., McQueney, M. S., 
Foged, N. T., Delmas, P. D., Delaisse, J. M. (1998) The collagenolytic activity of cathcpsin 
K is unique among mammalian proteinases. J. Biol. 
Chem. 273(48): 32347-32352. 
200 
Garrett, I. R., Guise, T. A., Bonewald, L. F., Chizzonite, R., Mundy, G. R. (1993) 
Evidence that interleukin-1 exerts its effects on bone resorption via the 80 kilodalton 
interleukin-1 receptor. Calcif. Tissue Int. 52(6): 438-441. 
Gavrieli, Y., Sherman, Y., Ben-Sasson, S. A. (1992) Idetification of programmed cell 
death in situ via specific labelling of nuclear DNA fragmentation. J. Cell Biol. 119: 493- 
501.31. 
Gavrilovic, J., Reynolds, J. J., Murphy, G. (1985) Inhibition of type I collagen film 
degradation by tumour cells using a specific antibody to collagenase and the specific tissue 
inhibitor of metalloproteinases (TIMP). Cell Biology International Reports. 9(12): 1097- 
1107. 
Gavrilovic, J., Brennan, A., Mirsky, it, Jessen, K. (1995) Fibroblast growth factors and 
insulin growth factors combine to promote survival of rat Schwane cell precursors without 
induction of DNA synthesis. J. Neuro. Sci. 7: 77-85.41. 
Girasole, G., Jilka, R. L., Passeri, G., Boswell, S., Boder, G., Williams, D. C., 
Manolagas S. C. (1992) 17 beta-estradiol inhibits interleukin-6 production by bone 
marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the 
antiosteoporotic effect of estrogens. J. Clin. Invest. 89: 883-891. 
Girasole, G., Passeri, G., Jilka, ILL., Manolagas, S. C. (1994) Interleukin-11: A new 
cytokine critical for osteoclast development. J. Clin. Invest. 93: 1516-1524. 
Gitelman, S. E., Kobrin, M. S., Ye, J. Q., Lopez, A. R., Lee, A., Derynck, R. (1994) 
Recombinant Vgr-1BMP-6-expressing tumors induce fibrosis and endochondral bone 
formation in vivo. [Journal Article] J. Cell Biol. 126(6): 1595-1609. 
Globus, RK., Plouet, J., Gospadarowicz, (1989) Cultured bovine bone cells synthesizc 
basic fibroblast growth factor and store it in their extracellular matrix. Endocrinology 
124: 1539-1547. 
Globus, RK., Doty, S. B., Lull, J. C., Holmuhamedov, E., Humphries, M. J., Damsky, 
C. H. (1998) Fibronectin is a survival factor for differentiated osteoblasts. J. Cell Sci. 
111: 1385-93. 
Gohel, A., McCarthy, M., Gronowicz, G. (1999) Estrogen prevents glucocorticoid- 
induced apoptosis in osteoblasts in vivo and in vitro. Endocrinology 140: 5339-5347. 
Goldberg, G. I., Marmer, B. L., Grant, G. A., Eisen, A. Z., Wilhelm, S., He, C. S. (1989) 
Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of 
metalloproteases designated TIMP-2. Proc. Natl. Acad. Sci. USA 86(21): 8207-8211. 
Goss, R. J. (1978) The Physiology of Growth. Academic Press, New York. 
201 
Goto, T., Tsukuba, T., Kiyoshima, T., Nishimura, Y., Kato, K., Yamamoto, K., 
Tanaka, T. (1993) Immunohistochemical localization of cathepsins B, D and L in the rat 
osteoclast. Histochemistry 99(5): 411-414. 
Gouin, F., Couillaud, S., Cottrel, M., Godard, A., Passud, N., Heymann, D. (1999) 
Presence of leukemia inhibitory factor (LIF) and LIF-receptor chain (gpl90) in osteoclast. 
like cells cultured from human giant cell tumour of bone. Ultrastructural distribution. 
Cytokine 11: 282-289. 
Gowen, M., Wood, D. D., Ihrie, E. J., McGuire, M. K. B., Russell, R. G. R. (1983) An 
interleukin 1 like factor stimulates bone resorption in vitro. Nature 306: 378 
Gowen, M., Lazner, F., Dodds, R., Kapadia, It, Feild, J., Tavaria, M., Bertoncello, I., 
Drake, F., Zavarselk, S., Tellis, I., Hertzog, P., Debouck, C., Kola, I. (1999) Cathepsin 
K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not 
demineralization. J. Bone Miner. Res. 14(10): 1654-1663. 
Granerus, M., Schofield, P., Bierke, P., Engsrom, W. (1995) Growth factors and 
apoptosis in development. The role of insulin-like growth factor I and TGF-beta I in 
regulating cell growth and cell death in a human teratocarcinoma derived cell line. Int. J. 
Dev. Biol. 39: 759-764. 
Greene, J., Wang, M., Liu, Y. E., Raymond, L. A., Rosen, C., Shi, Y. E. (1996) 
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J. 
Biol. Chem. 271: 30375-30380. 
Greenblatt, M., and Elias, L. (1992) The type B receptor for tumour necrosis factor alpha 
mediates DNA fragmentation in HL60 and U937 cells and differentiation in HL-60 cells. 
Blood 80: 1339-1346. 
Grigoriadis, A. E., Wang, Z. Q., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, II. A. 
Wagner, E. F. (1994) c-Fos: a key regulator of osteoclast-macrophage lineage 
determination and bone remodeling. Science 266(5184): 443-448. 
Grills, B. L., Gallagher, J. A., Allan, E. H., Yumita, S., Martin, T. J. (1990) Identification 
of plasminogen activator in osteoclasts. J. Bone Miner. Res. 5: 499-505. 
Grzesik, W. J., Robey, P. G. (1994) Bone matrix RGD glycoproteins: immunolocalization 
and interaction with human primary osteoblastic bone cells in vitro. J. Bone Miner. Res. 
9(4): 487-496. 
Gulbins, E., Bissonnette, R., Mahboubi, A., Martin, S., Nishioka, W., et al. (1995) 
FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway, 
Immunity 2: 341-351. 
Hagenaars, C. E., Kawilarang-de Haas, E. W., van der Kraan, A. A., Spooncer, E., 
Dexter, T. M., Nijweide, P. J. (1991) Interleukin-3-dependent hematopoietic stem cell lines 
capable of osteoclast formation in vitro. J. Bone Miner. Res. 6(9): 947-954. 
202 
Hajjar, K. A. (1991) The endothelial cell tissue plasminogen activator receptor. Specific 
interaction with plasminogen. J. Biol. Chem. 266: 21962-21970. 
Halleen, J. M., Raisanen, S., Salo, J. J., Reddy, S. V., Roodman, G. D., Hentunen, T. A., 
Lehenkari, P. P., Kaija, H., Vihko, P., Väänänen, H. K. (1999) Intracellular 
fragmentation of bone resorption products by reactive oxygen species generated by 
osteoclastic tartrate-resistant acid phosphatase. J. Biol. Chem. 274(33): 22907-22910. 
Hamilton, J. A., Lingelbach, S. R., Partridge, N. C., Martin, T. J. (1984) Stimulation of 
plasminogen activator in osteoblast-like cells by bone-resorbing hormones. Biochcm. 
Biophys. Res. Commun. 122: 230-236. 
Hamilton JA. Lingelbach S. Partridge NC. Martin TJ. (1985) Regulation of 
plasminogen activator production by bone-resorbing hormones in normal and malignant 
osteoblasts. Endocrinology. 116: 2186-2191. 
Hammar, S. P., Mottet, N. K. (1971) Tetrazolium salt and electron microscopic studies of 
cellular degeneration and necrosis in the interdigital areas of the developing chick limb. J. 
Cell Sci. 8: 229-251. 
Hannink, M., Donoghue, D. J., (1989) Structure and function of platelet-derived growth 
factor (PDGF) and related proteins. Biochim. Biophys. Acta. 989: 1. 
Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Ileimdal, P. L., 
Armes, L. G., Sommer, A., Eisenberg, S. P., Thompson, R. C. (1990) Interleukin-1 
receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343: 336 
Hattersley, G., Dorey, E., Horton, M. A., Chambers, T. J. (1988) Human macrophage 
colony stimulating factor inhibits bone resorption by osteoclasts disaggregated from rat 
bone. J. Cell. Physiol. 137: 199-203. 
Hattersley, G., Chambers, T. J. (1989a) Calcitonin receptors as markers for osteoclastic 
differentiation: correlation between generation of bone-resorptive cells and cells that 
express calcitonin receptors in mouse bone marrow cultures. Endocrinology 125: 1606- 
1612. 
Hattersley, G., Chambers, T. J. (1989b) Generation of osteoclasts from hemopoictic cells 
and a multipotential cell line in vitro. J. Cell. Physiol. 140(3): 478-482. 
Hattersley, G., Chambers, T. J. (1990) Effects of interleukin 3 and of granulocyte. 
macrophage and macrophage colony stimulating 
factors on osteoclast differentiation from 
mouse hemopoietic tissue. J. Cell. Physiol. 142(1): 201-209. 
Hattersley, G., Kerby, J. A., Chambers, T. J. (1991) Identification of osteoclast 
precursors in multilineage hemopoietic colonies. 
Endocrinology 128(1): 259-262. 
203 
Hauschka, P. V., Mavrakos, A. E., lafrate, M. D., Doleman, S. E., Klagsbrun, M. (1986) 
Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on 
heparin sepharose. J. Biol. Chem. 261: 12665-12674. 
Heath, J. K., Atkinson, S. J., Meikle, M. C., Reynolds, J. J. (1984) Mouse osteoblasts 
synthesize collagenase in response to bone resorbing agents. Biochim. Biophys. Acta. 
802: 151-154. 
Heath, J. K., Saklatvala, J., Meikle, M. C., Atkinson, S. J., Reynolds, J. J. (1985) Pig 
interleukin 1 (catabolin) is a potent stimulator of bone resorption in vitro. Cacif. Tissue Int. 
37: 95. 
Henriet, P., Rousseau, G. G., Eeckhout, Y. (1992) Cloning and sequencing of mouse 
collagenase cDNA. Divergence of mouse and rat collagenases from the other mammalian 
collagenases. FEBS Lett. 310(2): 175-178. 
Heymann, D., Gouin, F., Guicheux, J., Munevar, J. C., Godard, A., Daculsi, G. (1997) 
Upmodulation of multinucleated cell formation in long-term human bone marrow cultures 
by leukemia inhibitory factor (LIF). Cytokine 9: 46-52. 
Hill, D. J., Petrik, J., Arany, E., McDonald, T. J., Delovitch, T. L. (1999) Insulin-like 
growth factors prevent cytokine-mediated cell death in isolated islets of Langerhans from 
pre-diabetic non-obese diabetic mice. J. Endocrinol. 161: 153-165. 
Hill, P. A., Reynolds, J. J., Meikle, M. C. (1993) Inhibition of stimulated bone resorption 
in vitro by TIMP-1 and TIMP-2. Biochim. Biophys. Acta. 1177(1): 71-74. 
Hill, P. A., Buttle, D. J., Jones, S. J., Boyde, A., Murata, M., Reynolds, J. J., Meikle, 
M. C. (1994a) Inhibition of bone resorption by selective inactivators of cysteine 
proteinases. J Cell Biochem 56: 118-130. 
Hill, P. A., Murphy, G., Docherty, A. Hembry, it, Millican, T., Reynolds, J., Meikle, 
M. C. (1994b) The effects of selective inhibitors of matrix metalloproteinases (MMPs) on 
bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J. Cell 
Sci. 107: 3055-3064. 
Hill, P. A., Reynolds, J. J., Meikle, M. C. (1995a) Osteoblasts mediate insulin-like growth 
factor-I and -II stimulation of osteoclast formation and function. Endocrinology 
136(1): 124-131. 
Hill, P. A., Docherty, A., Bottomly, K., O'Connell, J., Morphy, J., Reynolds, J. J., 
Meikle, M. C. (1995b) Inhibition of bone resorption in vitro by selective inhibitors of 
gelatinase and collagenase. Biochem. J. 308: 167-175. 
Hickman, J., McElduff, A. (1989) Insulin promotes growth of the cultured rat 
osteosarcoma cell line UMR-106-01: an osteoblast-like cell. Endocrinology 124: 701-706. 
204 
Ho, N., Punturieri, A., Wilkin, D., Szabo, J., Johnson, M., Whaley, J., Davis, J., 
Clark, A., Weiss, S., Francomano, C. (1999) Mutations of CTSK result in 
pycnodysostosis via a reduction in cathepsin K protein. J. Bone Miner. Res. 14(10): 1649- 
1653. 
Hock, J. M., Centrella, M., and Canalis, E. (1988) Insulin-like growth factor I has 
independent effects on bone matrix formation and cell replication. Endocrinology 122: 254. 
260. 
Hoekman, K., Lowik, C. W. G. M., van de Ruit, M., Bijvoet, O. L. M., Verheijen, J. I1., 
Papapoulos S. E. (1992) The effect of tissue type plasminogen activator on osteoclastic 
resoprtion in embryonic mouse long bone explants: a possible role for the growth factor 
domain of tPA. Bone and Mineral 17: 1-14. 
Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., Khosla, S. (1998) 
Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, 
bone morphogenetic protein-2, and cytokines. Biochem. Biophys. Res. Commun. 
250(3): 776-781. 
Hofbauer, L. C., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., Khosla, S. 
(1999) Interleukin- 1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate 
osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25(3): 255-259. 
Holly, J. M. P., Wass, J. A. H. (1989) Insulin-like growth factors: autocrine, paracrine or 
endocrine? New perspectives of the somatomedin hypothesis in the light of recent 
development. J. Endocrinol. 122: 611-618. 
Holtrop, M. E. (1975) The ultrastructure of bone. Annals of Clinical & Laboratory 
Science. 5(4): 264-271. 
Holtrop, M. E., King, G. J. (1977) The ultrastructure of the osteoclast and its functional 
implications. Clinical Orthopaedics and Related Research 123: 177-196. 
Hooft van Huijsduijnen R. (1998) ADAM 20 and 21; two novel human testis-specific 
membrane metalloproteases with similarity to fertilin-alpha. Gene 206(2): 273-82. 
Horne, W. C., Neff, L., Chatterjee, D., Lomri, A., Levy, J. B., Baron, R. (1992) 
Osteoclasts express high levels of pp60c-src in association with intracellular membranes. J. 
Cell Biology 119(4): 1003-10013. 
Horowitz, M. C., Coleman, D. L., Flood, P. M., Kupper, P. S., Jilka, R. L. (1989) 
Parathyroid hormone and lipopolysaccharide induce murine osteoblast-like cells to secrete 
a cytokine indistinguishable from granulocyte-macrophage colony-stimulating factor. J. 
Clin. Invest. 83: 149-157. 
Norwood, N. J., Elliott, J., Martin, T. J., Gillespie, M. T. (1998) Osteotropic agents 
regulate the expression of osteoclast 
differentiation factor and osteoprotegerin in 
osteoblastic stromal cells. Endocrinology 139(11): 
4743-4746. 
205 
Horwood, N. J., Elliott, J., Martin, T. J., Gillespie, M. T. (2001) IL-12 alone and in 
synergy with IL-18 inhibits osteoclast formation in vitro. J. Immunol. 166(8): 4915-4921. 
Howard, E. W., Bullen, E. C., Banda, M. J. (1991) Preferential inhibition of 72- and 92- 
kDa gelatinases by tissue inhibitor of metalloproteinases-2. J. Biol. Chem. 266(20): 13070- 
13075. 
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, 
H. L., Elliott, G., Kelley, M. J., Sarosi, I., Wang, L., Xia, X. Z., et al. (1999) Tumor 
necrosis factor receptor family member RANK mediates osteoclast differentiation and 
activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96(7): 3540-3545. 
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, G. D., 
Mundy, G. R. and Boyce B. F. (1995) Bisphosphonates promote apoptosis in murine 
osteoclasts in vivo and in vitro. J. Bone Miner. Res. 10: 1478-1487. 
Hughes, D. E., Aihua, D., Tiffee, J. C., Li, H. H., Mundy, G. R. and Boyce, B. F. (1996) 
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-ß. Nat. Mcd. 2: 1132- 
1136. 
Hurley, M. M., Lee, S. K., Raisz, L. G., Bernecker, P., Lorenzo, J. (1998) Basic fibroblast 
growth factor induces osteoclast formation in murine bone marrow cultures. Bone 
22(4): 309-316. 
Hynes, R. O. (1992a) Integrins: versatility, modulation, and signaling in cell adhesion. 
[Review] Cell. 69(1): 11-25. 
Hynes, R. O. (1992b) Specificity of cell adhesion in development: the cadherin 
superfamily. [Review] Current Opinion in Genetics and Development. 2(4): 621-624. 
Iba, K., Albrechtsen, R., Gilpin, B. J., Loechel, F., Wewer, U. M. (1999) Cysteine-rich 
domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am. J. Pathol. 
154(5): 1489-1501. 
Ikari, Y., Mulvihill, E., Schwartz, S. M. (2001) alpha 1-Proteinase inhibitor, alpha 1- 
antichymotrypsin, and alpha 2-macroglobulin are the antiapoptotic factors of vascular 
smooth muscle cells. J. Biol. Chem. 276(15): 11798-11803 
Inaoka, T., Bilbe, G., Ishibashi, 0., Tezuka, K, Kumegawa, M., Kokubo, T. (1995) 
Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase 
predominantly expressed in bone. Biochem. 
Biophys. Res. Commun. 206(1): 89-96. 
Inoue D. Reid M. Lum L. Kratzschmar J. Weskamp G. Myung YM. Baron R. Blobel 
CP. (1998) Cloning and initial characterization of mouse meltrin beta and analysis of the 
expression of four metalloprotease-disintegrins 
in bone cells. J. Biol. Chem. 273(7): 4180- 
4187. 
206 
Inui, T., Ishibashi, 0., Inaoka, T., Origane, Y., Kumegawa, M., Kokubo, T., 
Yamamura, T. (1997) Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic 
bone resorption. J. Biol. Chem. 272(13): 8109-8112. 
Ishizaki, Y., Voyvodic, J. T., Burne, J. F., Raff, M. C. (1993) Control of lens epithelial 
cell survival. J. Cell Biol. 121: 899-908. 
Ishizaki, Y., Burne, J. F., Raff, M. C. (1994) Autocrine signals enable chondrocytes to 
survive in culture. J. Cell Biol. 126: 1069-1077. 
Ishmi, Y., Miyaura, C., Jin, C. H., Akatsu, T., Abe, E., Nakamura, Y., Yamaguchi, A., 
Yoshiki, S., Matsuka, T., Hirano, T., Kishismoto, T., Suda, T. (1990) IL-6 is produced 
by osteoblasts and induces bone resorption. J. Immunol. 145: 3297. 
Iwamoto, M., Shimazu, A., Nakashima, K., Suzuki, F., Kato, Y. (1991) Reduction in 
basic fibroblast growth factor receptor is coupled with terminal differentiation of 
chondrocytes. J. Biol. Chem. 266: 461-467. 
Izumi, Y., Hirata, M., Hasuwa, H., Iwamoto, R., Umata, T., Miyado, K., Tamal, Y., 
Kurisaki, T., Sehara-Fujisawa, A., Ohno, S., Mekada, E. (1998) A metalloprotcase- 
disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced 
ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. 
EMBO J 17(24): 7260-7272. 
Jacobs, KR., Cook, S., Siroboda, M. E., Van Wyk, J. J. (1986) Interaction of monoclonal 
antibodies aIR-1 and aIR-3 with insulin and somatomedin-C receptors. Endocrinology 
118: 223-226. 
Jacobson, M. D., Burne, J. F., Raff, M. C. (1994) Programmed cell death and Bcl-2 
protection in the absence of a nucleus. EMBO J. 13: 1899-1910. 
James, I. E., Marquis, R. W., Blake, S. M., Hwang, S. M., Gress, C. J., Ru, Y., Zembryki, 
D., Yamashita, D. S., McQueney, M. S., Tomaszek, T. A., Oh, H. J., Gowen, M., Veber, 
D. F., Lark, M. W. (2001) Potent and selective cathepsin L inhibitors do not inhibit human 
osteoclast resorption in vitro. J. Biol. Chem. 276(15): 11507-11511. 
Jessen, KR., Brennan, A., Morgan, L., Mirsky, It, Kent, A., Hasimoto, Y., 
Gavrilovic, J. (1994) The Schwann cell precursor and its fate: a study of cell death and 
differentiation during gliogenesis in rat embryonic nerves. Neuron 12: 509- 527. 
Jilka, R. L., Weinstein, ILS., Bellido, T., Parfitt, A. M., Manolagas, S. C. (1998) 
Osteoblast Programmed Cell Death (Apoptosis): Modulation by growth factors and 
cytokines. J. Bone Miner. Res. 13: 793-802. 
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., Manolagas, S. C. 
(1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid 
hormone. J. Clin. Invest. 104(4): 439-446. 
207 
Jimi, E., Shuto, T., Koga, T. (1995) Macrophage colony-stimulating factor and 
interleukin-la maintain the survival of osteoclast-like cells. Endocrinology 136: 808-811. 
Jimi, E., Shuto, T., Ikebe, T., Jingushi, S., Hirata, M., Koga, T. (1996) Basic fibroblast 
growth factor inhibits osteoclast-like cell formation. J. Cell. Physiol. 168: 395-402. 
Jimi, E., Nakamura, I., Ikebe, T., Akiyama, S., Takahashi, N., Suda, T. (1998) 
Activation of NFx-B is involved in the survival of osteoclasts promoted by interleukin-1. J. 
Biol. Chem. 273: 8799-8805. 
Jimi, E., Nakamura, I., Duong, L. T., Ikebe, T., Takahashi, N., Rodan, G. A., Suda, T. 
(1999) Interleukin 1 induces multinucleation and bone-resorbing activity in osteoclasts in 
the absence of osteoblasts/stromal cells. Exp. Cell Res. 247: 84-93. 
Kakegawa, H., Nikawa, T., Tagami, K., Kamioka, H., Sumitani, K., Kawata, T., 
Drobnic-Kosorok, M., Lenarcic, B., Turk, V., Katunuma, N. (1993) Participation of 
cathepsin L on bone resorption. FEBS Lett. 321(2-3): 247-250. 
Kalu, D. N. (1990) Proliferation of tartrate-resistant acid phosphatase positive 
multinucleate cells in ovariectomized animals. Proceedings of the Society for Experimental 
Biology & Medicine. 195: 70-74. 
Kalu, D. N., Liu, C. C., Salerno, E., Hollis, B., Echon, R., Ray, M. (1991a) Skeletal 
response of ovariectomized rats to low and high doses of 17 beta-estradiol. Bone & 
Mineral. 14: 175-187. 
Kalu, D. N., Salerno, E., Liu, C. C., Echon, It, Ray, M., Garza-Zapata, M., Hollis, 
B. W. (1991b) A comparative study of the actions of tamoxifen, estrogen and progesterone 
in the ovariectomized rat. Bone & Mineral. 15: 109-123. 
Kameda, T., Miyazawa, Y., Mori, T., Yuasa, M., Shiokawa, Y., Nakamura, II. 9 Mano, 
H., Hakeda, Y., Kameda, A. and Kumegawa, M. (1996) Vitamin K2 inhibits osteoclastic 
bone resorption by inducing osteoclast apoptosis. Biochem. Biophys. Res. Commun. 
220: 515-519. 
Kameda, T., Mano, H., Yuasa, T., Mori, Y., Miyazawa, K., Shiokawa, M., Nakamaru, 
Y., Hiroi, E., Hiura, K., Kameda, A., Yang, N. N., Hakeda, Y. and Kumegawa, M. 
(1997) Estrogen inhibits bone resorption by directly inducing apoptosis of the bone- 
resorbing osteoclasts. 186: 489-495. 
Kashiwagi, M., Tortorella, M., Nagase, H., Brew, K. (2001) TIMP-3 is a potent inhibitor 
of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem. 
276(16): 12501-12504. 
Kasperk, C., Wergedal, J. E., Mohan, S., Long, D. L., Lau, K. H. W., Baylink, D. J. 
(1990) Interactions of growth factors present in bone matrix and bone cells: Effects on 
DNA synthesis and alkaline phosphatase. Growth Factors 3: 147. 
208 
Kawakami, A., Eguchi, K., Matsuoka, N., Tsuboi, M., Kawabe, Y., Aoyagi, T., 
Nagataki, S. (1996) Inhibition of Fas antigen-mediated apoptosis of rheumatoid synovial 
cells in vitro by transforming growth factor beta 1. Arthritis & Rheumatism 39(8): 1267-76. 
Kawakami, A., Nakashima, T., Tsuboi, M., Urayama, S., Matsuoka, N., Ida, II., 
Kawabe, Y., Sakai, H., Migita, K., Aoyagi, T., Nakashima, M., Maeda, K., Eguchi, K. 
(1998) Insulin-like growth factor I stimulates proliferation and fas-mediated apoptosis of 
human osteoblasts. Biochem. Biophys. Res. Com. 247: 46-51. 
Kawasaki, K., Gao, Y. H., Uokose, S., Kaji, Y., Nakamura, T., Suda, T., Yoshida, K., 
Taga, T., Kishimoto, T., Kataoka, H., Yuasa, T., Norimatsu, H., Yamaguchi, A. (1997) 
Osteoclasts are present in gpl30-deficient mice. Endocrinology 138: 4959-4965. 
Kawata, A., Mikuni-Takagaki, Y. (1998) Mechanotransduction in stretched osteocytcs- 
temporal expression of immediate early and other genes. Biochem. Biophys. Res. 
Commun. 246(2): 404-408. 
Keppler, D. (1992) Leukotrienes: Biosynthesis, transport, inactivation and analysis. Rev. 
Phys. Biochem. Pharmacol. 121: 2-23. 
Kerby, J. A., Hattersley, G., Collins, D. A., Chambers, T. J. (1992) Derivation of 
osteoclasts from hematopoietic colony-forming cells in culture. J. Bone Miner. Res. 
7(3): 353-362. 
Kerr, J. F. R., Wyllie, A. H., Currie, A. R. (1972) Apoptosis: a basic biological 
phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26: 239-257. 
Kim, G. S., Kim, C. H., Choi, C. S., Park, J. Y., Lee, K. U. (1997) Involvement of different 
second messengers in parathyroid hormone- and interleukin-1-induced interleukin-6 and 
interleukin-11 production in human bone marrow stromal cells. J. Bone Miner. Res. 
12(6): 896-902. 
Kircheimer, J. C., Wojta, J., Christ, G., Binder, B. R. (1987) Proliferation of a human 
epidermal tumor cell line stimualted by urokinase. FASEB J. 1: 125-128. 
Kirschke, H., Kembhavi, A. A., Bohley, P., Barrett, A. J. (1982) Action of rat liver 
cathepsin L on collagen and other substrates. Biochem. J. 201(2): 367-372. 
Kishimoto, T., Taga, T., Akira, S. (1994) Cytokine signal transduction. Cell 76: 253-262. 
Kitajima, I., Toshihiro, N., Takeshi, I., Ikuko, T., Koichi, K., Toshihiro, 0., Takeshi, 
T., Yasuko, S., Kazuhiro, A. and Ikuro, M. (1996a) Induction of apoptosis in murine 
clonal osteoblasts expressed by human T-cell 
leukemia virus type I tax by NF-KB and 
TNF-a. J. Bone Miner Res. 11: 200-210. 
Kitajima, I., Soejima, Y., Takasaki, I., Beppu, H., Tokioka, T., and Maruyama, I. 
(1996b) Ceramide-induced nuclear translocation of NF-KB is a potential mediator of 
the apoptotic response to TNF-a in murine clonal osteoblasts. 
Bone 19: 263-270. 
209 
Kitamura, H., Hawata, H., Takahashi, F., Higuchi, Y., Furuichi, T., Ohkawa, H. 
(1995) Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 
transgenic mice. Acellular relationship among hematopoietic cells, osteoblasts, and 
osteoclasts mediated by stromal cells in bone marrow. Am. J. Pathol. 147: 1682-1692. 
Knauper, V., Will, H., Lopez-Otin, C., Smith, B., Atkinson, S. J., Stanton, II., 
Hembry, RM., Murphy, G. (1996) Cellular mechanisms for human procollagenase-3 
(MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are 
able to generate active enzyme. J. Biol. Chem. 271(29): 17124-17131. 
Knauper, V., Cowell, S., Smith, B., Lopez-Otin, C., O'Shea, M., Morris, Ii., Zardi, L., 
Murphy, G. (1997) The role of the C-terminal domain of human collagenase-3 (MMP-13) 
in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of 
metalloproteinase interaction. J. Biol. Chem. 272(12): 7608-7616. 
Knudsen, B. S., Silverstein, R. L., Leung, L. L., Harpel, P. C., Nachman, R. L. (1986) 
Binding of plasminogen to extracellular matrix. J. Biol. Chem. 261(23): 10765-10771. 
Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., 
Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Morinaga, T., 
Higashio, K., Martin, T. J., Suda, T. (2000) Tumor necrosis factor alpha stimulates 
osteoclast differentiation by a mechanism independent of the ODFIRANKL-RANK 
interaction. J. Exp. Med. 191(2): 275-286. 
Koide, M., Murase, Y., Yamato, K, Noguchi, T., Okahashi, N., Nishihara, T. (1999) 
Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin. 
1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2. 
Biochem. Biophys. Res. Commun. 259(1): 97-102. 
Komori T. Yagi H. Nomura S. Yamaguchi A. Sasaki K. Deguchi K. Shimizu Y. 
Bronson RT. Gao YH. Inada M. Sato M. Okamoto R. Kitamura Y. Yoshiki S. 
Kishimoto T. (1997) Targeted disruption of Cbfal results in a complete lack of bone 
formation owing to maturational arrest of osteoblasts. Cell 89(5): 755-764. 
Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., et al. (1999) 
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node 
organogenesis. Nature 397: 315-323. 
Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishlyama, S., Salto, 
S., Inoue, K., Kamatani, N., Gillespie, M. T., Martin, T. J., Suda, T. (1999) IL-17 in 
synovial fluids from patients with rheumatoid arthritis 
is a potent stimulator of 
osteoclastogenesis. J. Clin. Invest. 103(9): 1345-1352. 
Kream, B., Smith, M., Canalis, E., Raisz, L. (1985) Characterization of the effect of 
insulin on collagen synthesis in fetal rat bone. Endocrinology 116: 296-302. 
210 
Kurihara, N., Ishizuka, S., Kiyoki, M., Haketa, Y., Ikeda, K., Kumegawa, M. (1986) 
Effects of 1,25-dihydroxyvitamin D3 on osteoblastic MC3T3-E1 cells. Endocrinology 
118(3): 940-947. 
Kurihara, N., Suda, T., Miura, Y., Nakauchi, H., Kodama, H., Hiura, K., Ilakeda, Y., 
Kumegawa, M. (1989) Generation of osteoclasts from isolated hematopoietic progenitor 
cells. Blood 74: 1295-1302. 
Kusano, K., Miyaura, C., Inada, M., Tamura, T., Ito, A., Nagase, II., Kamoi, K., 
Suda, T. (1998) Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by 
interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone 
resorption. Endocrinology 139(3): 1338-1345. 
Kwaan, H. C. (1992) The plasminogen-plasmin system in malignancy. Cancer Metasis 
Rev. 11: 291-311. 
Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. -, Burgess, T., et al. 
(1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and 
activation. Cell 93(2): 165-176. 
Lader, C. 5., Flanagan, A. M. (1998) Prostaglandin E2, Interleukin la, and Tumour 
Necrosis Factor-a increase human osteoclast formation and bone resorption in vitro. 
Endocrinology 139: 3157-3164. 
Lalou, C., Silve, C., Rosato, R., Segovia, B., Bonoux, M. (1994) Interactions between 
insulin-like growth factor-I and the system of plasminogen actoivators and their inhibitors 
in the control of IGF-binding protein 3 production and proteolysis in human osteosarcoma 
cells. Endocrinology 135: 2318-2326. 
Langenbach, R., Morham, S. G., Tiano, H. F., Loftin, C. D., Ghanayem, B. I., Chulada, 
P. C., Mahler, J. F., Lee, C. A., Goulding, E. H., Kluckman, K. D. (1995) Prostaglandin 
synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and 
indomethacin-induced gastric ulceration. Cell. 83(3): 483-492. 
Leco, K. J., Apte, S. S., Taniguchi, G. T., Hawkes, S. P., Khokha, R,, Schultz, G. A., 
Edwards, D. R. (1997) Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA 
isolation and expression in adult mouse tissues. FEBS Lett. 401: 213-217. 
Lee, S. K., Goldring, S. R, Lorenzo, J. A. (1995) Expression of the calcitonin receptor in 
bone marrow cell cultures and in bone: a specific marker of the differentiated osteoclast 
that is regulated by calcitonin. Endocrinology. 136(10): 4572-4581. 
Lefebvre, V., Peeters-Joris, C., Vaes, G. (1990) Modulation by interleukin 1 and tumor 
necrosis factor alpha of production of collagenase, tissue inhibitor of metalloproteinases 
and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochim. 
Biophys. Acta. 1052(3): 366-378. 
211 
Leloup, G., Delaisse, J. M., Vaes, G. (1994) Relationship of the plasminogen 
activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal 
metatarsal bones. J. Bone Miner. Res. 9(6): 891-902. 
Leloup, G., Lemoine, P., Carmeliet, P., Vaes, G. (1996) Bone resorption and response to 
calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator 
or of their type 1 inhibitor. J. Bone Miner. Res. 11: 1146-1157. 
Lenaers-Claeys, G., Vaes, G. (1979) Collagenase, procollagenase and bone resorption. 
Effects of heparin, parathyroid hormone and calcitonin. Biochim. Biophys. Acta. 
584(3): 375-388. 
Levi-Montalcini, R. (1987) The nerve growth factor: 35 years later. EMBO J. 6: 1145- 
1154. 
Levy, J., Murray, E., Manolagas, S., Olefsky, J. (1986) Demonstration of insulin 
receptors and modulation of alkaline phosphatase activity by insulin in rat osteoblastie 
cells. Endocrinology 119: 1786-1792. 
Li, G., Satyamoorthy, K., Herlyn, M. (2001) N-cadherin-mediated intercellular 
interactions promote survival and migration of melanoma cells. Cancer Research. 
61(9): 3819-3825. 
Linkhart, T. A., Jennings, J. C., Mohan, S., Wakley, G. K., Baylink, D. J. (1986) 
Characterization of mitogenic activities extracted from bovine bone matrix. Bone 7: 479. 
Linkhart, T. A., Keffer, M. J. (1991) Differential regulation of insulin-like growth factor-I 
(IGF-II) release from cultured neonatal mouse calvariaby parathyroid hormone, 
transforming growth factor-ß and 1,25 dihydroxyvitamin D3. Endocrinology 128: 1511- 
1518. 
Lisignoli, G., Piacentini, A., Toneguzzi, S., Grassi, F., Cocchini, B., Ferruzzi, A., 
Gualtieri, G., Facchini, A. (2000) Osteoblasts and stromal cells isolated from femora in 
rheumatoid arthritis (RA) and osteoarthritis (OA) patients express IL-11, leukaemia 
inhibitory factor and oncostatin M. Clinical & Experimental Immunology 119(2): 346-353. 
Littlewood-Evans, A., Kokubo, T., Ishibashi, 0., Inaoka, T., Wlodarski, B., 
Gallagher, J. A., Bilbe, G. (1997) Localization of cathepsin K in human osteoclasts by in 
situ hybridization and immunohistochemistry. Bone 20(2): 81-86. 
Lockshin, RA., Zakeri, Z. (1991) Programmed cell death and apoptosis. IN: Tomei 
LD, Cope FO (eds) Apoptosis: The Molecular Basis of Cell Death. Cold Spring 
Harbour Laboratory Press, Cold Spring Harbour, pp 47-60. 
Loechel, F., Gilpin, B. J., Engvall, E., Albrechtsen, R., Wewer, U. M. (1998) Human 
ADAM 12 (meltrin alpha) is an active metalloprotease. J. Biol. Chem. 273(27): 16993- 
16997. 
212 
Loechel, F., Overgaard, M. T., Oxvig, C., Albrechtsen, R., Wewer, U. M. (1999) 
Regulation of human ADAM 12 protease by the prodomain. Evidence for a functional 
cysteine switch. J. Biol. Chem. 274(19): 13427-13433. 
Loechel, F., Fox, J. W., Murphy, G., Albrechtsen, R, Wewer, U. M. (2000) ADAM 12-S 
cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem. Biophys. Res. 
Commun. 278(3): 511-515. 
Lomago, M. A., Yeh, W. C., Sarosi, I., et al. (1999) TRAF 6 deficiency results in 
osteopetrosis and defective interleukin-1, CD40 and LPS signaling. Genes Dcv. 13: 1015- 
1024. 
Lotz, M., Setarah, M., Kempis, J. V., and Schwarz, H. (1996) The nerve growth 
factor/tumour necrosis factor receptor family. J. leukocyte Biol. 60: 1-7. 
Lunn, C. A., Fan, X., Dalie, B., Miller, K., Zavodny, P. J., Narula, S. K., Lundell, D. 
(1997) Purification of ADAM 10 from bovine spleen as a TNFalpha convertase. FEES 
Lett. 400(3): 333-335. 
Lyons, RM., Gentry, L. E., Purchio, A. F., Moses, H. L. (1990) Mechanism of activation 
of latent recombinant transforming growth factor beta 1 by plasmin. J. Cell Biol. 
110(4): 1361-1367. 
MacDonald BR. Mundy GR. Clark S. Wang EA. Kuehl TJ. Stanley ER. Roodman 
GD. (1986) Effects of human recombinant CSF-GM and highly purified CSF-1 on the 
formation of multinucleated cells with osteoclast characteristics in long-term bone marrow 
cultures. J. Bone Miner. Res. 1(2): 227-233. 
MacDonald, B. R., Takahashi, N., McManus, L. M., Holahan, J., Mundy, G. R., 
Roodman, G. D. (1987) Formation of multinucleated cells that respond to osteotropic 
hormones in long term human bone marrow cultures. Endocrinology 120(6): 2326-2333. 
Maciewicz, R. A., Etherington, D. J., Kos, J., Turk, V. (1987) Collagenolytic cathepsins 
of rabbit spleen: a kinetic analysis of collagen degradation and inhibition by chicken 
cystatin. Collagen & Related Research. 7(4): 295-304. 
Maciewicz, R. A., Wotton, S. F. (1991) Degradation of cartilage matrix components by the 
cysteine proteinases, cathepsins B and L. Biomed. Biochim. Acta 50(4-6): 561-564. 
Maier, 1L Gann, V., Lotz, M. (1993) Interleukin-11, an inducible cytokine in human 
articular chondrocytes and synoviocytes, stimulates the production of tissue inhibitor of 
metalloproteinases. J. Biol. Chem. 268: 21527-21532. 
Manolagas, S. C., Weinstein, R. S., Bellido, T., Bodenner, D. L. (1999) Opposite effects 
of estrogen on the life span of osteoblasts/osteocytes versus osteoclasts in vivo: an 
explanation of the imbalance between formation and resorption in estrogen deficiency. J. 
Bone Miner. Res. 14: S169. (Abstr. ) 
213 
Mansukhani, A., Bellosta, P., Sahni, M., Basilico, C. (2000) Signaling by fibroblast 
growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations 
blocks mineralization and induces apoptosis in osteoblasts. J. Cell Biol. 149(6): 1297-1308. 
March, C. J., Mosley, B., Larsen, A., Cerretti, D. P., Braedt, G., Price, V., Gillis, S., 
Henney, C. S., Kronheim, S. R, Grabstein, K. et al. (1985) Cloning, sequence and 
expression of two distinct interleukin-1 complementary DNAs. Nature 315(6021): 641-647. 
Marks, S. C., Lane, P. W. (1976) Osteopetrosis, a new recessive skeletal mutation on 
chromosome 12 of the mouse. J. Hered. 67: 11-18. 
Marks, S. C., Popoff, S. N. (1988) Bone cell biology: the regulation of development, 
structure and function in the skeleton. [Review] Am. J. Anat. 183(1): 1-44. 
Martignetti, J. A., Al Aqeel, A., Al Sewairi, W., Boumah, C. E., Kambouris, M., Al 
Mayouf, S., Sheth, K. V., Al Eid, W., Dowling, 0., Harris, J., Glucksman, M. J., 
Bahabri, S., Meyer, B. F., Desnick, R. J. (2001) Mutation of the matrix metalloproteinase 
2 (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nature Genetics 
28(3): 261-265. 
Martin, T. J., Allan, E. H., Fukumoto, S. (1993) The plasminogen activator and inhibitor 
system in bone remodelling. Growth Reg. 3: 209-214. 
Mathieu, C., Jozan, S., Mazars, P., Come, M. G., Moisand, A., Valette, A. (1995) 
Density-dependent induction of apoptosis by transforming growth factor-beta 1 in a human 
ovarian carcinoma cell line. Exp. Cell Res. 216: 13-20. 
Matrisian LM. (1992) The matrix-degrading metalloproteinases. [Review] [50 refs] 
Bioessays 14(7): 455-463. 
Matsumoto, H. N., Tamura, M., Denhardt, D. T., Obinata, M., Noda, M. (1995) 
Establishment and characterization of bone marrow stromal cell lines that support 
osteoclastogenesis. Endocrinology 136(9): 4084-4091. 
Mbalaviele, G., Chen, H., Boyce, B. F., Mundy, G. R., Yoneda, T. (1995) The role of 
cadherin in the generation of multinucleated osteoclasts from mononuclear precursors in 
murine marrow. J. Clin. Invest. 95(6): 2757-2765. 
McCarthy, T. L., Centrella, M., Canalis, E. (1989) Parathyroid hormone enhances the 
transcript and polypeptide levelsof insulin-like growth factor I in osteoblast enriched 
cultures from fetal rat bone. Endocrinology 124: 1247-1253. 
McSheehy, P. M. J., Chambers, T. J. (1986) Osteoblastic cells mediate osteoclastic 
responsiveness to parathyroid hormone. Endocrinology 118: 824-828. 
McSheehy, P. M., Chambers, TJ. (1987) 1,25-Dihydroxyvitamin D3 stimulates rat 
osteoblastic cells to release a soluble factor that 
increases osteoclastic bone resorption. J. 
Clin. Invest. 80(2): 425-429. 
214 
Mee, A. P., Hoyland, J. A., Braidman, I. P., Freemont, A. J., Davies, M., Mawer, E. B. 
(1996) Demonstration of vitamin D receptor transcripts in actively resorbing osteoclasts in 
bone sections. Bone 18: 295-299. 
Meikle, M. C., Bord, S., Hembry, R. M., Compston, J., Croucher, P., Reynolds, J. 
(1992) Human osteoblasts in culture synthesize collagenase and other matrix 
metalloproteinases in response to osteotropic hormones and cytokines. J. Cell Sei. 
103: 1093-1099. 
Meikle, M. C., Bord, S., Hembry, R. M., Reynolds, J. J. (1994) Rabbit calvarial 
osteoblasts in culture constitutively synthesize progelatinase-A, and TIMP-1 and TIMP-2. 
Biochim. Biophys. Acta. 1224(1): 99-102. 
Meikle, M. C., Bord, S., Hembry, R. M., Reynolds, J. J. (1995) The synthesis of 
collagenase, gelatinase-A (72 kDa) and -B (95 kDa), and TIMP-1 and -2 by human 
osteoblasts from normal and arthritic bone. Bone 17(3): 255-260. 
Meredith, J. E., Fazeli, B., Schwartz, M. (1993) The extracellular matrix as a cell survival 
factor. Mol. Biol. Cell 4: 953-961. 
Merry, D. E., Korsmeyer, S. J. (1997) Bcl-2 gene family in the nervous system. [Review] 
[180 refs] Ann. Rev. Neurosci. 20: 245-267. 
Metcalf, D. (1984) The colony stimulating factors. In "The Hemapoictic Colony 
Stimulating Factors". pp. 55-96 Elsevier, Amsterdam. 
Metcalf, D., Gearing, D. P. (1989) A myelosclerotic syndrome in mice engraficd with cells 
producing high levels of leukemia inhibitory factor (LIF). Leukemia 3: 847-852. 
Mignati, P., Robbins, E., Rifkin, D. B. (1986) Tumour invasion through the human 
amniotic membrane: Requirement for a proteinase cascade. Cell 47: 487-498. 
Mignatti, P., Rifkin, D. B. (1993) Biology and biochemistry of proteinases in tumor 
invasion. [Review] [306 refs] Physiological Reviews. 73(1): 161-95. 
Minkin, C. (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a markcr 
for osteoclast function. Calcif. Tissue Internat 34: 285-290. 
Millichip, M. I., Dallas, D. J., Wu, E., Dale, S., McKie, N. (1998) The metallo-disintcgrin 
ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. 
Biochem. Biophys. Res. Commun. 245(2): 594-598. 
Miyauchi, A., Alvarez, J., Greenfield, E. M., Teti, A., Grano, M., Colucci, S., 
Zambonin-Zallone, A., Ross, F. P., Teitelbaum, S. L., Cheresh, D., et al. (1991) 
Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates 
immediate cell signals in osteoclasts. J. Biol. Chem. 266(30): 20369-20374. 
215 
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., et al. (1998) 
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. 
Biochem. Biophys. Res. Commun. 247: 610-615. 
Mochizuki, H., Hakeda, Y., Wakatsuki, N., Usul, N., Akashi, S., Sato, T., Tanaka, K., 
Kumegawa, M. (1992) Insulin-like growth factor-I supports formation and activation of 
osteoclasts. Endocrinology 131(3): 1075-1080. 
Modrowski, D., Basle, M., Lomri, A., Marie, P. J. (2000) Syndecan-2 is involved in the 
mitogenic activity and signaling of granulocyte-macrophage colony-stimulating factor in 
osteoblasts. J. Biol. Chem. 275(13): 9178-9185. 
Mohan, S., Jennings, J. C., Linkhart, T. A., Baylink, D. J. (1988) Primary structure of 
human skeletal growth factor: homology with human insulin-like growth factor-1I. 
Biochim. Biophys. Acta. 966(1): 44-55. 
Mohan, S., Baylink, D. J. (1991) Bone growth factors. Clin. Orthop. 263: 30-48. 
Mohan, S., Baylink, D. J. (1993) Characterization of the IGF regulatory system in bonc. 
Adv. Exp. Med. & Biology 343: 397-406. 
Montero, A., Okada, Y., Tomita, M., Ito, M., Tsurukaml, H., Nakamura, T., 
Doetschman, T., Coffin, J. D., Hurley, M. M. (2000) Disruption of the fibroblast growth 
factor-2 gene results in decreased bone mass and bone formation. J. Clin. Invest. 
105(8): 1085-1093. 
Morinaga, Y., Fujita, N., Ohishi, K., Tsuruo, T. (1997) Stimulation of intcrlcukin-11 
production from osteoblast-like cells by transforming growth factor-beta and tumor ccll 
factors. Int. J. Cancer. 71(3): 422-428. 
Morinaga, Y., Fujita, N., Ohishi, K., Zhang, Y., Tsuruo, T. (1998) Suppression of 
interleukin-1 1 -mediated bone resorption by cyclooxygenase inhibitors. J. Cell. Physiol. 
175: 247-254. 
Mosman, T. (1983) Rapid colorimetric assay forcellular growth and survival: application 
to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63. 
Moss, M. L., Jin, S. L., Milla, M. E., Bickett, D. M., Burkhart, W., Carter, ILL., et al. 
(1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis 
factor-alpha. Nature 385(6618): 733-736. 
Muenke, M., Schell, U. (1995) Fibroblast-growth-factor receptor mutations in human 
skeletal disorders. [Review] [50 refs] Trends in Genetics. 11(8): 308-313. 
Murgo, A. J., Fried, J., Burchenal, D., Vale, K. L., Strife, A., Woodcock, T., Young, 
C. W., Clarkson, B. D. (1980) Effects of thymidine and thymidine plus 5-iluorouracil on 
the growth kinetics of a lymphoid cell line. Cancer Res. 40: 1543-1549. 
216 
Murphy, G., Bretz, U., Baggiolini, M., Reynolds, J. J. (1980) The latent collagenase and 
gelatinase of human polymorphonuclear neutrophil leucocytes. Biochem. J. 192(2): 517- 
525. 
Murphy, G., Hembry, R. M., McGarrity, A. M., Reynolds, J. J., Henderson, B. (1989) 
Gelatinase (type IV collagenase) immunolocalization in cells and tissues: use of an 
antiserum to rabbit bone gelatinase that identifies high and low Mr forms. J. Cell Sci. 
92(3): 487-495. 
Murphy, G., Cockett, M. I., Ward, R. V., Docherty, A. J. (1991) Matrix metalloproteinase 
degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the 
activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated 
metalloproteinase (PUMP). Biochem. J. 277 (Pt 1): 277-279. 
Murphy, G., Ward, It, Gavrilovic, J., Atkinson, S. (1992) Physiological mechanisms 
for metalloproteinase activation. Matrix Supplement. 1: 224-230. 
Murphy, G., Reynolds, J. J. (1993a) Extracellular matrix degradation. In "Connective 
Tissue and Its Heritable Disorders: Molecular, Genetic and Medical Aspects" (Royce PM, 
Steinmann B, eds), 1st ed, pp 287-316, Wiley-Liss, New York. 
Murphy, G., Segain, J-P., O'Shea, M., Cockett, M., Ioannou, C., Lefebvre, 0., 
Chambon, P., Basset, P. (1993b) The 28-kDa N-terminal domain of mouse stromelysin-3 
has the general properties of a weak metalloproteinase. J. Biol. Chem. 268: 15435-15441. 
Murphy, G., Knauper V. (1997) Relating matrix metalloproteinase structure to function: 
Why the hemopexin domain? Matrix Biology 15: 511-518. 
Murrills, RJ., Shane, E., Lindsay, R., Dempster, D. W. (1989) Bone resorption by 
isolated human osteoclasts in vitro: effects of calcitonin. J. Bone Miner. Res. 4(2): 259-268. 
Musashi, M., Yang, Y. C., Paul, S. R, Clark, S. C., Ogawa, M. (1991a) Direct and 
synergistic effects of interleukin-11 on murine hemopoiesis in culture. Proc. Nat. Acad. 
Sci. USA. 88: 765-769. 
Musashi, M., Clark, S. C., Sudo, T., Urdal, D. L., Ogava, M. (1991b) Synergistic 
interactions between interleukin-11 and interleukin-4 in support of proliferation of 
primitive haematopoietic progenitors of mice. Blood 78: 1448-1451. 
Myles, D. G., Kimmel, L. H., Blobel, C. P., White, J. M., Primakoff, P. (1994) 
Identification of a binding site in the disintegrin domain of fertilin required for sperm-egg 
fusion. Proc. Natl. Acad. Sci. USA. 91(10): 4195-4198. 
Nagata, S. (1997) Apoptosis by death factor. Cell 88: 355-365. 
Nagase H. (1995) Human stromelysins 1 and 2. Methods Enzymol. 248: 449-470. 
217 
Nagase, H., Woessner, F. (1999) Matrix metalloproteinases. J. Biol. Chem. 274: 21491- 
21494. 
Nakagawa, N., Yasuda, H., Yano, K., Mochizuki, Si., Kobayashi, N., Fujimoto, I1., 
Yamaguchi, K., Shima, N., Morinaga, T., Higashio, K. (1999a) Basic fibroblast growth 
factor inhibits osteoclast formation induced by lalpha, 25-dihydroxyvitamin D(3) through 
suppressing the production of osteoclast differentiation factor. Biochem. Biophys. Res. 
Commun. 265(1): 45-50. 
Nakagawa, N., Yasuda, H., Yano, K, Mochizuki, Si., Kobayashi, N., Fujimoto, IL, 
Shima, N., Morinaga, T., Chikazu, D., Kawaguchi, H., Higashio, K. (1999b) Basic 
fibroblast growth factor induces osteoclast formation by reciprocally regulating the 
production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in 
mouse osteoblastic cells. Biochem. Biophys. Res. Commun. 265(1): 158-163. 
Nandurkar, H. H., Robb, L., Tarlinton, D., Barnett, L., Kontgen, F., Begley, C. G. 
(1997) Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display 
normal hematopoiesis. Blood 90(6): 2148-2159. 
Nath, D., Slocombe, P. M., Stephens, P. E., Warn, A., Hutchinson, G. R, Yamada, 
KM.,, Docherty, A. J., Murphy, G. (1999) Interaction of metargidin (ADAM-15) with 
alphavbeta3 and alpha5betal integrins on different haemopoietic cells. J. Cell Sci. 
112(4): 579-587. 
Neely, E. K., Beckers, M. W., Oh, Y., Cohen, P., Rosenfield, R. G. (1991) Insulin-likc 
growth factor receptors. Acta. Paediatr. Scand. [Suppl] 372: 116-123. 
Nijweide, P. J., Burger, E. H., Feyen, J. H. (1986) Cells of bone: proliferation, 
differentiation, and hormonal regulation. [Review] [235 refs] Physiological Reviews. 
66(4): 855-886. 
Nesbitt, S., Nesbitt, A., Helfrich, M., Horton, M. (1993) Biochemical characterization of 
human osteoclast integrins: Osteoclasts express avß3, a2ß 1, and avß 1 integrins. J. Biol. 
Chem. 268: 16737-16745. 
Neufeld, G., Gospodarowicz, D. (1986) Basic and acidic fibroblast growth factors interact 
with the same cell surface receptors. J. Biol. Chem. 261: 5631-5637. 
Neuhaus, H., Beltenhausen, B., Bilinski, P., Simon, D., Guenet, J., Gossler, A. (1994) 
Et12, a novel putative type-1 cytokine receptor expressed during mouse embryogenesis at 
high levels in skin and cells with skeletogenic potential. Dev Biol 166: 531-542. 
Nicholson, G. C., Moseley, J. M., Sexton, P. M., Mendelsohn, F. A., Martin, T. J. (1986) 
Abundant calcitonin receptors in isolated rat osteoclasts. biochemical and autoradiographic 
characterization. J. Clinical Invest. 78: 355. 
218 
Nomura, S., Hogan, B. L., Wills, A., Heath, J., Edwards, D. (1989) Developmental 
expression of tissue inhibitor of metalloproteinase (TIMP) RNA. Development 105: 575- 
583. 
Nunez, G., Benedict, M. A., Hu, Y., Inohara, N. (1998) Caspases: the proteases of the 
apoptotic pathway. [Review] [130 refs] Oncogene 17(25): 3237-3245. 
Oberhammer, F., Fritisch, G., Schmied, M., Pavelka, M., Printz, D., Purchlo, T., 
Lassman, H., Schulte, L., Herman, R (1993) Condensation of chromatin at the 
membrane of an apoptotic nucleus is not associated with the activation of an endonuciease. 
J. Cell Sci. 104: 317-326. 
Ohsaki, Y., Takahashi, S., Scarcez, T., Demulder, A., Nishihara, T., Williams, It, 
Roodman, G. D. (1992) Evidence for an autocrine/paracrine role for interleukin-6 in bone 
resorption by giant cells from giant cell tumors of bone. Endocrinology 131(5): 2229-2234. 
Okada, Y., Naka, K., Kawamura, K., Matsumoto, T., Nakanishi, I., Fujimoto, N., 
Sato, H., Seiki, M. (1995) Localization of matrix metalloproteinase 9 (92-kilodalton 
gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implications for bone 
resorption. Lab. Invest. 72(3): 311-322. 
Oldberg, A., Jirskog-Hed, B., Axelsson, S., Heinegard, D. (1989) Regulation of bone 
sialoprotein mRNA by steroid hormones. J. Cell Biology 109(6): 3183-3186. 
Okahashi, N., Nakamura, I., Jimi, E., Koide, M., Suda, T., Nishihara, T. (1997) 
Specific inhibitors of vacuolar H(+)-ATPase trigger apoptotic cell death of osteoclasts. J. 
Bone Miner. Res. 12(7): 1116-1123. 
Oppenheim, R. W., Prevette, D., Tytell, M., Homma, S. (1990) Naturally occurring 
and induced neuronal death in the chick embryo in vivo requires protein and RNA 
synthesis: evidence for the role of cell death genes. Dev. Biol. 138: 104-113. 
Oppenheim, R. W. (1991) Cell death during development of the nervous system. Annu. 
Rev. Neurosci. 14: 3602-361035. 
Oreffo, R. O. C., Bonewald, L., Sayedin, S. M., Rosen, D., Mundy, G. R., (1989) 
Inhibition of osteoclastic bone resorption by growth factors. J. Bone Miner. Res. 4: S 154. 
Orlinick, J., and Chao, M. (1998) TNF-related ligands and their receptors. Cellular 
Signalling. 10(8): 543-551. 
Oursler, M. J., Collin-Osdoby, P., Anderson, F., Li, L., Webber, D., Osdoby, P. 
(1991a) Isolation of avian osteoclasts: improved techniques to preferentially purify viable 
cells. J. Bone Miner. Res. 6(4): 375-385. 
219 
Oursier, M. J., Cortese, C., Keeting, P., Anderson, M. A., Bonde, S. K., Riggs, B. L., 
Spelsberg, T. C. (1991b) Modulation of transforming growth factor-beta production in 
normal human osteoblast-like cells by 17 beta-estradiol and parathyroid hormone. 
Endocrinology. 129: 3313-3320. 
Owen, T. A., Aronow, M., Shalhoub, V., Barone, L. M., Wilming, L., Tassinari, M. S., 
Kennedy, M. B., Pockwinse, S., Lian J. B., Stein, G. S. (1990) Progressive development of 
the rat osteoblastic phenotype in vitro: reciprocal relationships in expression of genes 
associated with osteoblast proliferation and differentiation during formation of the bone 
extracellular matrix. J. Cellular Physiol. 143(3): 420-430. 
Owens, J. M., Gallagher, A. C., Chambers, T. J. (1996) IL-10 modulates formation of 
osteoclasts in murine hemopoietic cultures. J. Immunol. 157(2): 936-940. 
Pacifici, R., Rifas, L., Teitelbaum, S., Slatopolsky, E., McCracken, R., Bergfeld, M., 
Lee, W., Avioli, L. V., Peck, W. A. (1987) Spontaneous release of intcrlcukin 1 from 
human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc. Natl. 
Acad. Sei. USA 84: 4616-4620. 
Parfitt, A. M. (1990) Bone forming cells in clinical conditions. In: Hall BK (ed. ) Bone, 
Vol 1: The Osteoblast and Osteocyte. Telford Press and CRC Press, Boca Raton, FL, 
U. S. A.., pp. 351-429. 
Pan, G., Ni, J., Wei, Y., Yu, G., Gentz, R., and Dixit, V. (1997) An antagonist dccoy 
receptor and a death domain-containing receptor for TRAIL. Science 277: 815. 
Paul, S. R., Bennett, F., Calvetti, J. A., Kelleher, K., Wood, C. R., O'Hara, R. M., Leary, 
A. C., Sibley, B., Clark, S. C., Williams, D. A., Yang, Y. C. (1990) Molecular cloning of a 
cDNA encoding interleukin-11, a stromal cell-derived lymphopoietic and haemopoietic 
cytokine. Proc. Nat. Acad. Sei. (Wash. ) 87: 7512-7516. 
Pei, D. (1999) Identification and characterization of the fifth membrane-type matrix 
metalloproteinase MT5-MMP. J. Biol. Chem. 274: 8925-8932. 
Peschon, J. J., Slack, J. L., Reddy, P., Stocking, K. L., Sunnarborg, S. W., Lee, D. C. et 
al. (1998) An essential role for ectodomain shedding in mammalian development. Science. 
282(5392): 1281-1284. 
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., Bellido, 
T. (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and 
calcitonin J Clin Invest. 104: 1363-1374. 
Poli, V., Balena, it, Fattori, E., Markatos, A., Yamamoto, M., Tanaka, II., Ciliberto, 
G., Rodan, G. A., Costantini, F. (1994) Interleukin-6 deficient mice are protected from 
bone loss caused by estrogen depletion. EMBO J. 13: 1189-1196. 
220 
Pons, S., Torres-Aleman, I. (1992) Basic fibroblast growth factor modulates insulin-like 
growth factor-I and its receptor and its binding protein in hypothalamic cell cultures. 
Endocrinology 133: 2271-2278. 
Price, P. A., Baukol, S. A. (1980) 1,25-Dihydroxyvitamin D3 increases synthesis of the 
vitamin K-dependent bone protein by osteosarcoma cells. J. Biol. Chem. 255(24): 11660- 
11663. 
Primakoff, P., Myles, D. G. (2000) The ADAM gene family: surface proteins with 
adhesion and protease activity. [Review] [47 refs] Trends in Genetics 16(2): 83.87. 
Puente, X. S., Pendas, A. M., Llano, E., Velasco, G., Lopez-Otis, C. (1996) Molecular 
cloning of a novel membrane-type matrix metalloproteinase from a human breast 
carcinoma. Cancer Res. 56(5): 944-949. 
Pun, K., Lau, P., Ho, P., (1989) The characterization, regulation and function of insulin 
receptors on osteoblast-like clonal osteosarcoma cell line. J. Bone Miner. Rcs. 4: 853-862. 
Qi, H., Rand, M. D., Wu, X., Sestan, N., Wang, W., Rakic, P., Xu, T., Artavanis- 
Tsakonas, S. (1999) Processing of the notch ligand delta by the mctalloprotcasc 
Kuzbanian. Science 283(5398): 91-94. 
Qu, Q., Harkonen, P. L. Väänänen, H. K. (1999) Comparative effects of estrogen and 
antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J. Ccll. 
Biochem. 73: 500-507. 
Quarles, L. D., Yohay, D. A., Lever, L. W., Caton, R., Wenstrup, R. J. (1992) Distinct 
proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro 
model of osteoblast development. J. Bone Miner. Res. 7(6): 683-692. 
Quax, P. H. A., Pedersen, N., Masucci, M. T., Weening-Verhoeff, E. J. D., Dano, K., 
Verheijen, J. H., Blasi, F. (1991) Complementation between urokinase-producing and 
receptor-producing cells in extracellular matrix degradation. Cell regulation 2: 793-803. 
Quinn, J. M., Elliott, J., Gillespie, M. T., Martin, T. J. (1998) A combination of osteoclast 
differentiation factor and macrophage-colony stimulating factor is sufficient for both 
human and mouse osteoclast formation in vitro. Endocrinology. 139(10): 4424-4427. 
Rabbani, S. A., Desjardins, J., Bell, A. W., Banville, D., Mazar, A., ltenkin, J. 
Goltzman, D. (1990) An amino-terminal fragment of urokinase isolated from a prostate 
cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem. Biophys. Res. 
Commun. 173: 1058-1064. 
Raff, M. C. (1992) Social controls on cell survival and cell death. Nature (Lond. ). 356: 
397-400. 
Raisz, L. G. (1965) Bone resorption in tissue culture. Factors influencing the response to 
parathyroid hormone. J. Clin. Invest. 44: 103-116. 
221 
Raisz, L. G., Trummel, C. L., Holick, M. F., DeLuca, H. F. (1972) 1,25- 
dihydroxycholecalciferol: a potent stimulator of bone resorption in tissue culture. Science 
175(23): 768-769. 
Ralston, S. H., Russell, RG., Gowen, M. (1990) Estrogen inhibits release of tumor 
necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J. 
Bone Miner. Res. 5: 983-988. 
Rebout, P., Pelletier, J-P., Tardif, G., Cloutier. J-M., Martel-Pelletier, J. (1996) The 
new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but 
not by synoviocytes. A role in osteoarthritis. J. Clin. Invest. 97: 2011-2019. 
Rechter, M. M., Zapf, J., Nissley, S. P., Froesch, E. R., Moses, A. C., Podskalny, J. M., 
Schilling, E. E., Humbel, RE. (1980) Interactions of insulin-like growth factors I and 11 
and multiplication-stimulating activity with receptor and serum carrier proteins. 
Endocrinology 107: 1451-1459.37. 
Reid, I. R., Lowe, C., Cornish, J., Skinner, S. J. M., Hilton, D. J., Wilson, T. A., Gearing, 
D. P., Martin, T. J. (1990) Leukemia inhibitory factor: a novel bone-active cytokinc. 
Endocrinology 126: 1416-1420. 
Remacle-Bonnet, M. M., Garrouste, F. L., Heller, S., Andre, F., Marvaldl, J. L., 
Pommier, G. J. (2000) Insulin-like growth factor I protects colon cancer cells from death 
factor-induced apoptosis by potentiating tumour necrosis factor alpha-induced mitogcn. 
activated protein kinase and nuclear factor kappaB signalling pathways. Cancer Res. 
60(7): 2007-2017. 
Reponen, P., Sahlberg, C., Munaut, C., Thesleff, I., Tryggvason, K. (1994) High 
expression of 92-kD type IV collagenase (gelatinase B) in the osteoclast lineage during 
mouse development. J. Cell Biol. 124: 1091-1102. 
Reynolds, J. J., Dingle, J. T. (1968) The induction and inhibition of bone resorption in 
vitro. Calcif. Tissue Res. Suppl: 50-50a. 
Reynolds, J. J., Dingle, J. T. (1970) A sensitive in vitro method for studying the induction 
and inhibition of bone resorption. Calc. Tiss. Res. 4: 339-349. 
Reynolds, J. J., Meikle, M. C. (2000) Mechanisms of connective tissue matrix destruction 
in periodontitis. [Review] [99 refs] Periodontology 14: 144-157. 
Riancho, J. A., Zarrabeitia, M. T., Mundy, G. R., Yoneda, T., Gonzalez-Macias, J. 
(1993) Effects of interleukin-4 on the formation of macrophages and osteoclast-like cells. 
J. Bone Miner. Res. 8(11): 1337-1344. 
Rice, D. P., Kim, H. J., Thesleff, I. (1999) Apoptosis in murine calvarial bone and suture 
development. European Journal of Oral Sciences. 107(4): 265-275. 
222 
Richards, C. D., Langdon, C., Deschamps, P., Pennica, D., Shaughnessy, S. G. (2000) 
Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukemia 
inhibitory factor, cardiotrophin-1 and interleukin-6: synergy with dexamethasone. 
Cytokine 12(6): 613-621. 
Rickard, D. J., Sullivan, T. A., Shenker, B. J., Leboy, P. S., Kazhdan, I. (1994) Induction 
of rapid osteoblast differentiation in rat bone marrow stromal cell culture by 
dexamethasone and BMP-2. Dev. Biol. 161: 218-228. 
Rifas, L., Halstead, L. R., Peck, W. A., Avioli, L. V., Welgus, H. G. (1989) Human 
osteoblasts in vitro secrete tissue inhibitor of metalloproteinases and gelatinase but not 
interstitial collagenase as major cellular products. J. Clin. Invest. 84(2): 686-694. 
Rifas, L., Fausto, A., Scott, M. J., Avioli, L. V., Welgus, H. G. (1994) Expression of 
metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like 
cells: differentiation is associated with repression of metalloproteinase biosynthesis. 
Endocrinology 134(1): 213-221. 
Rifkin, D. B., Moscatelli, D. (1989) Recent developments in the cell biology of basic 
fibroblast growth factor. J. Cell. Biol. 109: 1-6. 
Robey, P. G., Young, M. F., Fisher, L. W., McClain, T. D. (1989) Thrombospondin is an 
osteoblast-derived component of mineralized extracellular matrix. J. Cell Biology, 
108(2): 719-727. 
Robey, P. G. (1996) Vertebrate mineralized matrix proteins: structure and function. 
[Review] Connective Tissue Res. 35(1-4): 131-6. 
Rodan, S. B., Wesolowski, G., Yoon, K., Rodan, G. A. (1989) Opposing effects of 
fibroblast growth factor and pertussis toxin on alkaline phosphatase, osteopontin, 
osteocalcin, type I collagen mRNA levels in ROS 17/2.8 cells. J. Biol. Chem. 264: 19934- 
19941. 
Ronday, H. K., Smits, H. H., Quax, P. H., van der Pluijm, G., Lowik, C. W., Breedveld, 
F. C., Verheijen, J. H. (1997) Bone matrix degradation by the plasminogen activation 
system. Possible mechanism of bone destruction in arthritis. Br. J. Rheumatol. 36(1): 9-15. 
Romas, E., Udagawa, N., Zhou, H., Tamura, T., Sato, M., Taga, T., Hilton, D., Suda, 
T., Ng, K. W., Martin, T. J. (1996) The role of gp 130-mediated signals in osteoclast 
development: Regulation of interleukin-11 production by osteoblasts and distribution of its 
receptor in bone marrow cells. J. Exp. Med. 183: 2581-2591. 
Rooke, J., Pan, D., Xu, T., Rubin, G. M. (1996) KUZ, a conserved metalloprotease- 
disintegrin protein with two roles in Drosophila neurogenesis. Science. 273(5279): 1227- 
1231. 
Rouleau, M. F., Mitchell, J., Goltzman, D. (1988) In vivo distribution of parathyroid 
hormone receptors in bone: evidence that a predominant osseous target cell is not the 
mature osteoblast. Endocrinology 123(1): 187-191. 
223 
Saftig, P., Hunziker, E., Wehmeyer, 0., Jones, S., Boyde, A., Rommerskirch, W., 
Moritz, J. D., Schu, P., von Figura, K. (1998) Impaired osteoclastic bone resorption leads 
to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA 95(23): 13453- 
13458. 
Sagane, K., Yamazaki, K., Mizui, Y., Tanaka, I. (1999) Cloning and chromosomal 
mapping of mouse ADAM11, ADAM22 and ADAM23. Gene 236(1): 79-86. 
Santana, P., Pena, L. A., Haimovitz-Friedman, A., Martin, S., Green, D. (1996) Acid 
sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation- 
induced apoptosis. Cell 86: 189-199. 
Sara, V. R., Hall, K. (1990) Insulin-like growth and their binding proteins. Physiol. Rev. 
70: 591-614. 
Sarma, U., Flanagan, A. M. (1996) Macrophage colony-stimulating factor induces 
substantial osteoclast generation and bone resorption in human bone marrow cultures. 
Blood 88(7): 2531-2540. 
Sasaki, T., Ueno-Matsuda, E. (1993) Cysteine-proteinase localization in osteoclasts: an 
immunocytochemical study. Cell & Tissue Research. 271(1): 177-179. 
Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., Seiki, M. 
(1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells [see 
comments]. Nature 370(6484): 61-65. 
Sato, H., Seiki, M. (1996) Membrane-type matrix metalloproteinases (MT-MMPs) in 
tumor metastasis. J. Biochem. (Tokyo) 119: 209-215. 
Sato, T., del Carmen Ovejero, M., Hou, P., Heegaard, A. M., Kumegawa, M., Foged, 
N. T., Delaisse, J. M. (1997) Identification of the membrane-type matrix metalloproteinasc 
MT1-MMP in osteoclasts. J. Cell Sci. 110(5): 589-596. 
Scheven, B. A., Kawilarang-de Haas, E. W., Wassenaar, A. M., Nijweide, P. J. (1986a) 
Differentiation kinetics of osteoclasts in the periosteum of embryonic bones in vivo and in 
vitro. Anat. Rec. 214: 418-423. 
Scheven, B. A., Visser, J. W., Nijweide, P. J. (1986b) In vitro osteoclast generation from 
different bone marrow fractions, including a highly enriched haematopoietic stem cell 
population. Nature 321(6065): 79-81. 
Schlondorff, J., Blobel, C. P. (1999) Metalloprotease-disintegrins: modular proteins 
capable of promoting cell-cell interactions and triggering signals by protein-ectodomain 
shedding. [Review] [157 refs] J. Cell Sci. 112(Pt 21): 3603-3617. 
Schneider, G. B., Relfson, M. (1988) The effects of transplantation of granulocyte- 
macrophage progenitors on bone resorption in osteopetrotic rats. 
J. Bone Miner. Res. 
3: 225-232. 
224 
Sells Galvin, R. J., Gatlin, C. L., Horn, J. W., Fuson, T. R. (1999) TGF-beta enhances 
osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M- 
CSF. Biochem. Biophys. Res. Commun. 265(1): 233-239. 
Sendnter, M., Arakawa, Y., Stockli, K. A., Kreutzberg, G. W., Theonen, 11. (1991) 
Effect of ciliary neurotrophic factor (CNTF) on motor neuron survival. J. Cell Sci. Suppl. 
15: 103-109. 
Seyedin, S. M., Thomas, T. C., Thompson, A. Y., Rosen, D. M., Piez, K. A. (1985) 
Purification and characterization of two cartilage-inducing factors from bovine 
demineralized bone. Proc. Natl. Acad. Sci. USA 82: 2267-2271. 
Shapiro SD. (1998) Matrix metalloproteinase degradation of extraccllular matrix: 
biological consequences. [Review] [51 refs] Current Opinion in Cell Biology. 10(5): 602- 
608. 
Sheridan, J., Marsters, A., Pitti, P., Gurney, A., Skubatch, M., Baldwin, I)., 
Ramakrishnan, L., Gray, C., Baker, K., Wood, W., Goddard, A., Godowski, P., and 
Ashkenazi, A. (1997) Control of TRAIL-induced apoptosis by a family of signalling and 
decoy receptors. Science 277: 818. 
Shevde, N. K., Bendixen, A. C., Dienger, K. M., Pike, J. W. (2000) Estrogens suppress 
RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism 
involving c-Jun repression. Proc. Natl. Acad. Sci. USA 97: 7829-7834. 
Shi, G. P., Chapman, H. A., Bhairi, S. M., DeLeeuw, C., Reddy, V. Y., Weiss, S. J. (1995) 
Molecular cloning of human cathepsin 0, a novel endoproteinase and homologue of rabbit 
OC2. FEBS Lett. 357(2): 129-134. 
Shi, Z., Xu, W., Loechel, F., Wewer, U. M., Murphy, L. J. (2000) ADAM 12, a 
disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J. 
Biol. Chem. 275(24): 18574-18580. 
Shinar, D. M., Sato, M., Rodan, G. A. (1990) The effect of hemopoietic growth factors on 
the generation of osteoclast-like cells in mouse bone marrow cultures. Endocrinology. 
126(3): 1728-1735. 
Shirakabe, K., Wakatsuki, S., Kurisaki, T., Fujisawa-Sehara, A. (2001) Roles of 
Meltrin beta /ADAM19 in the processing of neuregulin. J. Biol. Chem. 276(12): 9352- 
9358. 
Shuto, T., Kukita, T., Hirata, M., Jimi, E., Koga, T. (1994) Dexamethasone stimulates 
osteoclast-like cell formation by inhibiting granulocyte-macrophage colony-stimulating 
factorproduction in mouse bone marrow cultures. Endocrinology 134: 1121-1126. 
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., et al. 
(1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. 
Cell 89(2): 309-319. 
225 
Slater, M., Patava, J., Kingham, K., Mason, R. S. (1994) Modulation of growth factor 
incorporation into ECM of human osteoblast-like cells in vitro by 17 beta-estradiol. Am. J. 
Physiol. 267: E990-1001. 
Slootweg, M. C., Hoogerbrugge, C. M., de Poorter, T. L., Duursma, S. A., van Buul- 
Offers, S. C. (1990) The presence of classical insulin-like growth factor (IGF) type-I and 
type-II receptors on mouse osteoblasts: autocrine/paracrine growth effects of IGFs. J. 
Endocrinol. 125: 271-277. 
Smith, W. L. (1992) Prostanoid biosynthesis and mechanisms of action. [Review] Am. J. 
Physiol. 263(2 Pt 2): F181-91. 
Sonoda, Y., Yang, Y. C., Wong, G. G., Clark, S. C., Ogawa, M. (1988) Analysis in 
serum-free culture of the targets of recombinant human hemopoietic growth factors: 
interleukin 3 and granulocyte/macrophage-colony-stimulating factor are specific for early 
developmental stages. Proc. Natl. Acad. Sci. USA 85(12): 4360-4364. 
Soriano, P., Montgomery, C., Geske, R, Bradley, A. (1991) Targeted disruption of the 
c-src proto-oncogene leads to osteopetrosis in mice. Cell. 64(4): 693-702. 
Stephens, R. W., Pollanen, J., Tapiovaara, H., Leung, K. C., Sim, P. S., Salonen, E. M., 
Ronne, E., Behrendt, N., Dano, K., Vaheri, A. (1989) Activation of pro-urokinase and 
plasminogen on human sarcoma cells: A proteolytic system with surface bound reactants. J 
Cell Biol. 108: 1987-1995. 
Stewart, P. J., Stern, P. H. (1986) Effects of the antiestrogens tamoxifen and clomiphcnc 
on bone resorption in vitro. Endocrinology 118(1): 125-131. 
Stroh, C., Schulze-Osthoff, K. (1998) Death by a thousand cuts: an ever increasing list of 
caspase substrates. [Review] [52 refs] Cell Death & Differentiation 5(12): 997-1000. 
Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A., Goldberg, G. I. 
(1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of 
the activated form of the membrane metalloprotease. J. Biol. Chem. 270(10): 5331-5338. 
Suda, T., Takahashi, N., Martin, T. J. (1992) Modulation of osteoclast differentiation. 
Endoc. Rev. 13: 66-88. 
Suzuki, H., Nakamura, I., Takahashi, N., Ikuhara, T., Matsuzaki K., Isogal, Y., Iiori, 
M., Suda, T. (1996) Calcitonin-induced changes in cytoskeleton are mediated by a signal 
pathway associated with protein kinase A in osteoclasts. Endocrinology 137: 4684-4690. 
Taetle, M. Payne, C., Dos Santos, B., Russell, M., Segarini, P. (1993) Effects of 
transforming growth factor-beta 1 on growth and apoptosis of human acute myelogenous 
leukemia cells. Cancer Res 54: 3386-3393. 
226 
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, T., Matsuda, T., Ilirano, T., 
Kishimoto, T. (1989) Interleukin-6 triggers the association of its receptor with a possible 
signal transducer, gp130. Cell 58: 513-581. 
Takahashi, N., Mundy, G. R., Roodman, G. D. (1986) Recombinant human interferon- 
gamma inhibits formation of human osteoclast-like cells. [Journal Article] J. Immunol. 
137(11): 3544-3549. 
Takahashi, N., Yamana, H., Yoshiki, S., Roodman, G. D., Mundy, G. R., Jones, S. J., 
Boyde, A., Suda, T. (1988a) Osteoclast-like cell formation and its regulation by 
osteotropic hormones in mouse bone marrow cultures. Endocrinology 122: 1373-1382. 
Takahashi, N., Akatsu, T., Sasati, T., Nicholson, G. C., Moseby, J. M., Martin, T. J., 
Suda, T. (1988b) Induction of calcitonin receptors by 1,25 dihydroxyvitamin D, in 
osteoclast-like multinucleated cells formed from mouse bone marrow cells. Endocrinology 
123: 1504-1510. 
Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., 
Martin, T. J., Suda, T. (1988c) Osteoblastic cells are involved in osteoclast formation. 
Endocrinology 123: 2600-2602. 
Takahashi, N., Udagawa, N., Akatsu, T., Tanaka, II., Shionome, M., Suda, T. (1991) 
Role of colony-stimulating factors in osteoclast development. J. Bone Miner. Rcs. 
6(9): 977-985. 
Takai, H., Kanematsu, M., Yano, K., Tsuda, E., Higashlo, K., Ikeda, K., Watanabe, 
K., Yamada, Y. (1998) Transforming growth factor-beta stimulates the production of 
osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J. Biol. 
Chem. 273(42): 27091-27096. 
Takeuchi, Y., Kodama, Y., Matsumoto, T. (1994) Bone matrix dccorin binds 
transforming growth factor-beta and enhances its bioactivity. J. Biol. Chcm. 
269(51): 32634-32638. 
Takino, T., Sato, H., Shinagawa, A., Seiki, M. (1995) Identification of the second 
membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta 
cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J. 
Biol. Chem. 270(39): 23013-23020. 
Tanaka, S., Takahashi, N., Udagawa, N., Sasaki, T., Fukul, Y., Kurokawa, T., Suda, 
T. (1992) Osteoclasts express high levels of p60c-src, preferentially on ruffled bordcr 
membranes. FEBS Lett. 313(1): 85-89. 
Tanaka, M., Suda, T., Haze, K., Nakamura, N., Sato, K., Kimura, F., Motoyoslhi, K., 
Mizuki, M., Tagawa, S., Ohga, S., et at (1996) Fas ligand in human serum. Nature Mcd. 
2: 317-322. 
227 
Tang, B. L., Hong, W. (1999) ADAMTS: a novel family of proteases with an ADAM 
protease domain and thrombospondin 1 repeats. [Review] [15 refs] FEBS Lett. 445(2- 
3): 223-225. 
Tamura, T., Udagawa, N., Takahashi, N., Miyaura, C., Tanaka, S., Yamada, Y., 
Koishihara, Y., Ohsugi, Y., Kumaki, K., Taga, T., Kishmoto, T., Suda, T. (1993) 
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc. Nat. 
Acad. Sci. USA 90: 11924-11928. 
Tartaglia, L. A., Goeddel, D. V. (1992) Two TNF receptors. [Review] [30 refs] 
Immunology Today. 13(5): 151-153. 
Tartaglia, L. A., Ayres, T. M., Wong, G. H. W., Goeddel, T. V. (1993) A novel domain 
within the 55 kd TNF receptor signals cell death. Cell 74: 845-853. 
Tashjian, A. H., Jr., Wright, D. R, Ivey, J. L., Pont, A. (1978) Calcitonin binding sites in 
bone: relationships to biological responses and "escape". Recent Prog. Horm. Res. 34: 285. 
Tashjian, A. H., Jr., Hohmann, E. L., Antoniades, H. N., Levine, L. (1982) Platelet- 
derived growth factor stimulates bone resorption via a prostaglandin-mediated mechanism. 
Endocrinology 111: 118. 
Tashjian, A. H., Voekel, E. F., Lazzaro, M., Singer, J. R., Roberts, A. B., Derynk, R., 
Winkler, M. E., Levine, L. (1985) Alpha and beta human transforming growth factors 
stimulate prostaglandin production and bone resorption in cultured mouse calvaria. Proc. 
Natl. Acad. Sci. USA 82: 4535. 
Tashjian, A. H., Jr., Voelkel, E. F., Lazzaro, M., Goad, D., Bosma, T., Levine, L. (1987) 
Tumour necrosis factor-alpha (cachectin) stimulates bone resorption in mouse calvaria via 
a prostaglandin-mediated mechanism. Endocrinology 120: 2029-2035. 
Teramura, M., Kobayashi, S., Hoshino, S., Oshimi, K., Mizoguchi, If., (1992) 
Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 79: 327-331. 
Testa, N. G., Allen, T. D., Lajtha, L. G., Onions, D., Jarret, O. (1981) Generation of 
osteoclasts in vitro. J. Cell Sci. 47: 127-137. 
Tezuka, K., Tezuka, Y., Maejima, A., Sato, T., Nemoto, K., Kamioka, If., IIakeda, Y., 
Kumegawa, M. (1994a) Molecular cloning of a possible cysteine proteinasc 
predominantly expressed in osteoclasts. J. Biol. Chem. 269(2): 1106-1109. 
Tezuka, K., Nemoto, K., Tezuka, Y., Sato, T., Ikeda, Y., Kobori, M., Kawashima, II., 
Eguchi, H., Hakeda, Y., Kumegawa, M. (1994b) Identification of matrix 
metalloproteinase 9 in rabbit osteoclasts. J. Biol. Chem. 269(21): 15006-15009. 
Thomas, D. M., Hards, D. K., Rogers, S. D., Ng, K. W., Best, J. D. (1996) Insulin receptor 
expression in bone. J. Bone Miner. Res. 11: 1312-1320. 
228 
Thomson, B. M., Saklatvala, J., Chambers, T. J. (1986) Osteoblasts mediate interleukin I 
stimulation of bone resorption by rat osteoclasts. J. Exp. Med. 164(1): 104-112. 
Thomson, B. M., Mundy, G. R, Chambers, T. J. (1987) Tumor necrosis factors alpha and 
beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J. Immunol. 
138(3): 775-779. 
Thomson, B. M., Atkinson, S. J., McGarrity, A. M., Hembry, R. M., Reynolds, J. J., 
Meikie, M. C. (1989) Type I collagen degradation by mouse calvarial ostcoblasts 
stimulated with 1,25-dihydroxyvitamin D-3: evidence for a plasminogen-plasmin- 
metalloproteinase activation cascade. Biochim. Biophys. Acta 1014(2): 125-132. 
Thrailkill, K. M., Quarles, L. D., Nagase, H., Suzuki, K., Serra, D. M., Fowlkes, J. L. 
(1995) Characterization of insulin-like growth factor-binding protein 5-degrading proteases 
produced throughout murine osteoblast differentiation. Endocrinology 136(8): 3527-3533. 
Tomida, M., Yamamoto-Yamaguchi, Y., Hozumi, M. (1984) Purification of a factor 
inducing differentiation of mouse myeloid leukemic M1 cells from conditioned medium of 
mouse fibroblast L929 cells. J. Biol. Chem. 259: 10978-10982. 
Tondravi, M. M., McKercher, S. R., Anderson, K., Erdmann, J. M., Quiroz, M., Maki, 
R, Teitelbaum. S. L. (1997) Osteopetrosis in mice lacking haematopoietic transcription 
factor PU. 1. Nature. 386(6620): 81-84. 
Tracy, RP., Shull, S., Riggs, B. L., Mann, K. G. (1988) The osteonectin family of 
proteins. [Review] Int. J. Biochem. 20(7): 653-660. 
Tschan, T., Hoerler, I., Houze, Y., Winterhalter, K. H., Richter, C., Bruckner, P. 
(1990) Resting chondrocytes in culture survive without growth factors, but are sensitive to 
toxic oxygen metabolites. J. Cell. Biol. 111: 257-260. 
Tsuji, K., Lyman, S. D., Sudo, T., Clark, S. C., Ogawa, M. (1992) Enhancement of 
murine hematopoiesis by synergistic interactions between steel factor (ligand for c-kit), 
interleukin-11, and other early acting factors in culture. Blood 79: 2855-2860. 
Tsukii, K., Shima, N., Mochizuki, S., Yamaguchi, K, Kinosaki, M., Yano, K., 
Shibata, 0., Udagawa, N., Yasuda, H., Suda, T., Higashio, K. (1998) Osteoclast 
differentiation factor mediates an essential signal for bone resorption induced by I 
alpha, 25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the 
microenvironment of bone. Biochem. Biophys. Res. Commun. 246(2): 337-341. 
Udagawa, N., Takahashi, N., Akatsu, T., Sasaki, T., Yamaguchi, A., Kodama, II., 
Martin, T. J., Suda, T. (1989) The bone marrow-derived stromal cell lines MC3T3- 
G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse 
spleen cells. Endocrinology 125(4): 1805-1813. 
229 
Udagawa, N., Takahashi, N., Katagiri, T., Tamura, T., Wada, S., Findlay, D., Martin, 
T., Hirota, H., Taga, T., Kishimoto, T., Suda, T. (1995) IL-6 induction of osteoclast 
differentiation depends upon IL-6 receptors expressed on osteoblast cells, but not on 
osteoclast progenitors. J. Exp. Med. 182: 1461-1468. 
Udagawa, N., Horwood, N. J., Elliott, J., Mackay, A., Owens, J., Okamura, 11., 
Kurimoto, M., Chambers, T. J., Martin, T. J., Gillespie, M. T. (1997) Interleukin-18 
(Interferon-y-inducing factor) is produced by osteoblasts and acts via 
granulocyte/macrophage colony-stimulating factor and not via interferon-y to inhibit 
osteoclast formation. J. Exp. Med. 185(6): 1005-1012. 
Väänänen, H. K. (1984) Immunohistochemical localization of carbonic anhydrase 
isoenzymes I and II in human bone, cartilage and giant cell tumor. Histochemistry. 
81(5): 485-487. 
Väänänen, H. K., Karhukorpi, E. K., Sundquist, K., Wallmark, B., Roininen, I., 
Hentunen, T., Tuukkanen, J., Lakkakorpi, P. (1990) Evidence for the presence of a 
proton pump of the vacuolar H(+)-ATPase type in the ruffled borders of osteoclasts. J. Cell 
Biology. 111(3): 1305-1311. 
Väänänen, H. K., Horton, M. (1995) The osteoclast clear zone is a specialized cell- 
extracellular matrix adhesion structure. J. Cell Sci. 108: 2729-2732. 
Van Beek, E., Van der Wee-Pals, L., De Ruit. M., Nijweide, P., Papapoulos, S., Lowik, 
C. (1993) Leukemia inhibitory factor inhibits osteoclastic resorption, growth, 
mineralization and alkaline phosphatase activity in fetal mouse metacarpal bones in 
culture. J. Bone Miner. Res. 8: 191-198. 
van der Pluijm, G., Most, W., Van der Wee-Pals, L., de Groot. H., Papapoulos, S., 
Lowik, C. (1991) Two distinct effects of recombinant human tumour necrosis factor-a on 
osteoclast development and subsequent resorption of mineralized matrix. Endocrinology 
129: 1596-1604. 
van der Pluijm, G., Mouthaan, H., Baas, C., de Groot, H., Papapoulos, S., Lowik, C. 
(1994) Integrins and osteoclastic resorption in three bone organ cultures: differential 
sensitivity to synthetic Arg-Gly-Asp peptides during osteoclast formation. J. Bone Miner. 
Res. 9(7): 1021-1028. 
van der Rest, M., Garrone, R. (1991) Collagen family of proteins. FASEB Journal. 
5(13): 2814-23. 
van de Wijngaert, F. P., Burger, E. H. (1986) Demonstration of tartrate-resistant and 
phosphatase in un-decalcified glycolmethacrylate-embedded mouse bone: a possible 
marker for (pre) osteoclast identification. J. Histochem. Cytochem. 34: 1317-1323. 
Van Golen, C. M., Feldman, E. L. (2000) Insulin-like growth factor I is the key growth 
factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J. 
Cell. Physiol. 182: 24-32. 
230 
Vandenabeele, P., Declercq, W., Beyaert, R, Fiers, W. (1995) Two tumour necrosis 
factor receptors: structure and function. Trends Cell Biol. 5: 392-399. 
van't Hof, R. J., Ralston, S. H. (1997) Cytokine-induced nitric oxide inhibits bone 
resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast 
activity. J. Bone Miner. Res. 12(11): 1797-1804. 
van Zonneveld, A. J., Veerman, H., Pannekoek, H. (1986) On the interaction of the 
finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition 
of kringle-2 binding to fibrin by epsilon-amino caproic acid. J. Biol. Chem. 
261(30): 14214-14218. 
Verheij, M., Bose, IL, Lin, X. H., Yao, B., Jarvis, W. D., et al. (1996) Requirement for 
ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380: 75-79. 
Villanova, I., Townsend, P. A., Uhlmann, E., Knolle, J., Peyman, A., Amling, M., 
Baron, R., Horton, M. A., Teti, A. (1999) Oligodeoxynucleotide targeted to the alphav 
gene inhibits alphav integrin synthesis, impairs osteoclast function, and activates 
intracellular signals to apoptosis. J. Bone Miner. Res. 14(11): 1867-1879. 
Vink-van Wijngaarden, T., Birkenhager, J. C., Kleinekoort, W. M., van den Bemd, 
G. J., Pols, H. A., van Leeuwen, JP. (1995) Antiestrogens inhibit in vitro bone resorption 
stimulated by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogs EB 1089 and 
KH1060. Endocrinology 136(2): 812-815. 
Votta, B. J., Bertolini, D. R. (1994) Cytokine suppressive anti-inflammatory compounds 
inhibit bone resorption in vitro. Bone 15(5): 533-538. 
Wang, Z. Q., Ovitt, C., Grigoriadis, A. E., Mohie-Steinlein, U., Ruther, U., Wagner, 
E. F. (1992) Bone and haematopoietic defects in mice lacking c-fos. Nature 360(6406): 741- 
745. 
Wani, M. R, Fuller, K., Kim, N. S., Choi, Y., Chambers, T. (1999) Prostaglandin E2 
cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic 
activation of differentiation, cell spreading, and fusion. Endocrinology 140(4): 1927-1935. 
Weinstein, RS., Jilka, RL., Parfitt, A. M., Manolagas, S. C. (1998) Inhibition of 
osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by 
glucocorticoids. J. Clin. Invest. 102: 274-282. 
Weir, E. C., Lowik, C. W., Paliwal, I., Insogna, K. L. (1996) Colony stimulating factor-1 
plays a role in osteoclast formation and function in bone resorption induced by parathyroid 
hormone and parathyroid hormone-related protein. J. Bone Miner. Res. 11(10): 1474-1481. 
Welgus, H. G., Campbell, E. J., Bar-Shavit, Z., Senior, RM., Teitelbaum, S. L. (1985) 
Human alveolar macrophages produce a fibroblast-like collagenase and collagenase 
inhibitor. J. Clin. Invest. 76(1): 219-224. 
231 
Wergedal, J. E., Mohan, S., Lundy, M., Baylink, D. J. (1990) Skeletal growth factor and 
other growth factors known to be present in bone matrix stimulate proliferation and protein 
synthesis in human bone cells. J. Bone Mineral Res. 5(2): 179-186. 
Westermarck, J., Kahari, V. M. (1999) Regulation of matrix metalloproteinase 
expression in tumor invasion. [Review] [115 refs] FASEB J. 13(8): 781-792. 
Wiktor-Jedrzejczak, W., Bartocci, A., Ferrante, A. W. Jr., Ahmed-Ansari, A., Sell, 
K. W., Pollard, J. W., Stanley, E. R. (1990) Total absence of colony-stimulating factor 1 in 
the macrophage-deficient osteopetrotic (op/op) mouse [published erratum appears in Proc 
Nat! Acad Sci USA 1991 Jul 1; 88(13): 5937]. Proc. Natl. Acad. Sci. USA 87(12): 4828- 
4832. 
Wiktor-Jedrzejczak, W., Urbanowska, E., Szperl, M. (1994) Granulocyte-macrophage 
colony-stimulating factor corrects macrophage deficiencies, but not osteopetrosis, in the 
colony-stimulating factor- l-deficient op/op mouse. Endocrinology 134: 1932-1935. 
Wiley, S., Schooley, K., Smolak, P., Din, W., Huang, C., Nichol, J., Sutherland, G., 
Davis Smith, T., Rauch, C., Smith, C., Goodwin, R., (1995) Identification and 
characterization of a new member of the TNF family that induces apoptosis. Immunity 
3: 673. 
Wilhelm, S. M., Collier, I. E., Marmer, B. L., Eisen, A. Z., Grant, G. A., Goldberg, G. I. 
(1989) SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase 
which is identical to that secreted by normal human macrophages [published erratum 
appears in J Biol Chem 1990 Dec 25; 265(36): 22570]. J. Biol. Chem. 264(29): 17213- 
17221. 
Willenbrock, F., Murphy, G. (1994) Structure-function relationships in the tissue 
inhibitors of metalloproteinases. Am. J. Respir. Crit. Care. Med. 150: S 165-S 170. 
Williams, GT., Smith, CA., Spooner, E., Dexter, TM., Taylor, DR (1990) 
Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. 
Nature (Lond. ). 343: 76-78. 
Wolfsberg, T. G., Straight, P. D., Gerena, RL., Huovila, A. P., Primakoff, P., Myles, 
D. G., White, J. M. (1995) ADAM, a widely distributed and developmentally regulated 
gene family encoding membrane proteins with a disintegrin and metalloprotease domain. 
Dev. Biol. 169(1): 378-383. 
Wolfsberg, T. G., White. J. M. (1996) ADAMs in fertilization and development. [Review] 
[63 refs] Dev. Biol. 180(2): 389-401. 
Wolfman, N. M., Hattersley, G., Cox, K., Celeste, A. J., Nelson, R., Yamaji, N., Dube, 
J. L., DiBlasio-Smith, E., Nove, J., Song, J. J., Wozney, J. M., Rosen, V. (1997) Ectopic 
induction of tendon and ligament in rats by growth and differentiation factors 5,6, and 7, 
members of the TGF-beta gene family. J. Clin. Invest. 100(2): 321-330. 
232 
Wong, B. R., Josien, It, Lee, S. Y., Sauter, B., Li, H. L., Steinman, RM., Choi, Y., 
(1997) TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new 
TNF family member predominantly expressed in T cells, is a dendritic cell-specific 
survival factor. J. Exp. Med. 186(12): 2075-2080. 
Wozney, J. M., Rosen, V., Celeste, A. J., Mitsock, L. M., Whitters, M. J., Kriz, R. W., 
Hewick, RM., Wang, E. A. (1988) Novel regulators of bone formation: molecular clones 
and activities. Science 242: 1528-1534. 
Wozney, J. M. (1989) Bone morphogenetic proteins. Progress in Growth Factor Research 
1: 267-280. 
Wucherpfennig, A. L., Li, Y. P., Stetler-Stevenson, W. G., Rosenberg, A. E., Stashenko, 
P. (1994) Expression of 92 kD type N collagenase/gelatinase B in human osteoclasts. J. 
Bone Miner. Res. 9(4): 549-556. 
Wun, T. C., Schleuning, W. D., Reich, E. (1982) Isolation and characterization of 
urokinase from human plasma. J. Biol. Chem. 257(6): 3276-3283. 
Wyllie, A. H, (1980a) Glucocorticoid-induced thymocyte apoptosis is associated with 
endogenous endonuclease activation. Nature 284: 555. 
Wyllie, A. H., Kerr, J. F. R., Currie, A. R. (1980b) Cell death: the significance of 
apoptosis. Int. Rev. Cytol. 68: 251-307. 
Yagami-Hiromasa, T., Sato, T.,, Kurisaki, T., Kamijo, K., Nabeshima, Y., Fujisawa- 
Sehara, A. (1995) A metalloprotease-disintegrin participating in myoblast fusion [see 
comments]. Nature 377(6550): 652-656. 
Yamasaki, K., Taga, T., Hirata, Y., Yawata, H., Kawanishi, Y., Seed, B., Taniguchi, 
T., Hirano, T., Kishimoto, T. (1988) Cloning and expression of the human interleukin-6 
(BSF-2/IFN beta 2) receptor. Science 241(4867): 825-828. 
Yang, J. N., Allan, E. H., Anderson, G. I., Martin, T. J., Minkin, C. (1997) Plasminogen 
activator system in osteoclasts. J. Bone Miner. Res. 12(5): 761-768. 
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S. I., Yano, K., Fujise, N., et al. 
(1998a) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): 
a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 
139(3): 1329-1337. 
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K, Kinosaki, M., Mochizuki, S., et 
al. (1998b) Osteoclast differentiation factor is a ligand for osteoprotegerin/ 
osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. 
Acad. Sci. USA 95: 3597-3602. 
233 
Yee, J. A., Yan, L., Dominguez, J. C., Allan, E. H., Martin, T. J. (1993) Plasminogen- 
dependent activation of latent transforming growth factor beta (TGF beta) by growing 
cultures of osteoblast-like cells. J. Cell. Physiol. 157(3): 528-534. 
Yin, T., Miyazawa, K., Yang, Y. (1992) Characterization of interleukin 11 receptor and 
protein tyrosine kinase phosphorylation induced by interleukin 11 in mouse 3T3-L1 cells. 
J. Biol. Chem. 267: 8347-8351. 
Yin, T., Taga, T., Tsang, L., Yasukawa, K., Yang, Y. (1993) Involvement of IL-6 signal 
transducer gpl30 in IL-11 mediated signal transduction. J. Immunol. 151: 2555-2561. 
Yoshida, H., Hayashi, S., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., 
Sudo, T., Shultz, L. D., Nishikawa, S. (1990) The murine mutation osteopetrosis is in the 
coding region of the macrophage colony stimulating factor gene. Nature 345(6274): 442- 
444. 
Yuan, R., Primakoff, P., Myles, D. G. (1997) A role for the disintegrin domain of 
cyritestin, a sperm surface protein belonging to the ADAM family, in mouse sperm-egg 
plasma membrane adhesion and fusion. J. Cell Biol. 137(1): 105-112. 
Zhao, G., Monier-Faugere, M. C., Langub, M. C., Geng, Z., Nakayama, T., Pike, J. W., 
Chernausek, S. D., Rosen, C. J., Donahue, L. R., Malluche, H. H., Fagin, J. A., Clemens, 
T. L. (2000) Targeted overexpression of insulin-like growth factor I to osteoblasts of 
transgenic mice: increased trabecular bone volume without increased osteoblast 
proliferation. Endocrinology 141(7): 2674-2682. 
Zhang, X. P., Kamata, T., Yokoyama, K., Puzon-McLaughlin, W., Takada, Y. (1998) 
Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, 
ADAM-15) with integrin alphavbeta3. J. Biol. Chem. 273(13): 7345-7350. 
Zhang, Z., Chen, J., Jin, D. (1998) Platelet-derived growth factor (PDGF)-BB stimulates 
osteoclastic bone resorption directly: the role of receptor beta. Biochem. Biophys. Res. 
Commun. 251(1): 190-194. 
Zhou, M., Graham, it, Russell, G., Croucher, P. I. (2001) MDC-9 (ADAM-9/Meltrin 
gamma) functions as an adhesion molecule by binding the alpha(v)beta(5) integrin. 
Biochem. Biophys. Res. Commun. 280(2): 574-580. 
Zhu, G. Z., Lin, Y., Myles, D. G., Primakoff, P. (1999) Identification of four novel 
ADAMs with potential roles in spermatogenesis and fertilization. Gene 234(2): 227-237. 
Zolkiewska, A. (1999) Disintegrin-like/cysteine-rich region of ADAM 12 is an active cell 
adhesion domain. Exp. Cell Res. 252(2): 423-431. 
234 
9. Appendices 
9.1 Appendix 1 
9.1.1 Tyrodes Solution 
KCl 200 mg/L 
NaC1 800 mg/L 
NaHCO3 1 g/L 
NaH2PO4. H20 50 mg/L 
The above chemicals were dissolved in 800 ml of deionized water and the pH adjusted to 
7.4 with 1M NaOH. The solution was then made up to 1L with deionized water. 
9.1.2 Phosphate Buffered Saline 
NaCl 8.0 g/L 
KCl 0.2 g/L 
Na2HPO4 1.44 g/L 
KH2PO4 0.24 g/L 
The above chemicals were dissolved in 800 ml of deionized water and the pH adjusted to 
7.4. The solution was then made up to 1L with deionized water. 
9.1.3 Preparation of 50x Tris-Acetate-EDTA 
Tris base 242 g/L 
Glacial acetic acid 57. lml/L 
0.5 M EDTA 100 ml/L 
Tris base was dissolved in 800 ml of deionized water and the glacial acetic acid and EDTA 
added. The buffer was made up to 1. OL with deionized water. 
9.1.4 Tween Lysis Buffer 
N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES) 13.02 g/L 
Ethylenediaminetetraacetic acid (EDTA) 0.37 g/L 
Ethylene glycol-bis(2-aminoethyl)-N, N, N', N'-tetraacetic acid (EGTA) 0.95 g/L 
NaCl 8.76 g/L 
Dithiothreitol (DTT) 0.15 g/L 
Tween-20 1.0 ml/L 
NaF 0.04 g/L 
Na3VO4 0.02 gIL 
HEPES was dissolved in 800 ml of deionised water and the pH adjusted to pH 8.0 with 1 
M NaOH. The other chemicals were then added, the pH checked and the solution made up 
to 1L with deionised water. 
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9.1.5 Reagents for SDS-PAGE electrophoresis 
9.1.5.1 Preparation of Resolving gel buffer (1.5 M Tris. Cl pH 8.8) 
Tris base 181.5 g/L 
Tris base was dissolved in 800 ml of deionized water and the pH adjusted to 8.8 with 10 M 
HCI. The buffer was then made up to 1L with deionized water. 
9.1.5.2 Preparation of Stacking gel buffer (0.5 M Tris. Cl pH 6.8) 
Tris base 60.5 g/L 
Tris base was dissolved in 800 ml of deionised water and the pH adjusted to 6.8 with 10 M 
HCI. The buffer was then made up to 1L with deionized water. 







The above chemicals were dissolved in 1L of deionized water 
9.1.5.4 Preparation of 3x sample buffer (10 ml) 
1M Tris. HCl pH 6.8 1.85 ml 
10% SDS 0.6 g 
10% Bromophenyl blue 75 µl 
Glycerol 3.0 ml 
2-Mercaptoethanol 300 µl 
The above chemicals were combined in a fume cupboard and the volume made up to 10 ml 
with deionized water. 
9.1.5.5 Preparation of coomassie blue destain solution 
Methanol 200 mUL 
Acetic acid 100 ml/L 
Deionized water 700 mUL 
9.1.5.6 Preparation of 12% resolving gel 
30% (w/v) Acrylamide: 0.8% (w/v) Bis-acrylamide stock (37.5: 1) 8.4 ml 
Resolving gel buffer 5.0 ml 
Deionized water 6.25 ml 
10% SDS 200 µl 
N, N, N', N'-Tetramethylethylenediamine (TEMED) 9.0 µl 
10% Ammonium persulphate (APS) 200 µl 
The acrylamide (National Diagnostics Ltd, Hull, UK), resolving gel buffer, SDS and water 
were combined in a universal. TEMED and APS were added and the mixture pipetted 
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between glass plates of the SDS-PAGE apparatus followed by addition of water saturated 
isobutanol. The gel was allowed to polymerise for 1h and the isobutanol washed off. 
9.1.5.7 Preparation of stacking gel 
30% (w/v) Acrylamide: 0.8% (w/v) Bis-acrylamide stock (37.5: 1) 0.7 ml 
Stacking gel buffer 1.25 ml 
Deionized water 2.95 ml 
10% SDS 50 µl 
TEMED 5.0 µl 
10% APS 50 µl 
The above chemicals were combined in a universal. After washing away the water 
saturated isobutanol from the resolving gel the stacking gel was pipetted on top followed 
by insertion of the comb. 
9.1.6 Assay for secreted placental alkaline phosphatase 
9.1.6.1 Preparation of diethanolamine (DEA) buffer 
1M diethanolamine 105.4 g/L 
0.28 M NaCl 16.36 g/L 
0.5 M MgC12.6H20 0.102 g/L 
The above chemicals were dissolved in 800 ml of deionized water and the pH adjusted to 
9.85 with concentrated HCI. The solution was made up to 1L with deionized water. 
9.1.6.2 Preparation of 20x p-nitrophenylphosphate (PNPP, 100 mM) 
PNPP (742 mg; Sigma) was dissolved in 20 ml of DEA buffer and stored at -20°C 
protected from light. For the assay 1X PNPP (5 mM) was prepared in DEA buffer and 1 
ml added to 50 p1 of medium sample that had been heat inactivated at 65°C for 45 min. 
The absorbance was measured at 405 nm when a yellow colour had developed. SPAP 
activity was expressed in units where 1 unit is defined as the amount of SPAP that will 
hydrolyse 1.0 nmol of p-nitrophenylphosphate per minute. 
9.1.7 Preparation of neutral buffered formalin 
Formaldehyde 100 ml 
Na2HPO4 16 g 
NaH2PO4. H2O 4g 
Na2HPO4 and NaH2PO4. H2O were dissolved in 900 ml of deionized water and 
formaldehyde added to 1 L. 
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9.2 Appendix 2 
9.2.1 Publications arising from this research 
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Tumber, A., Meikle, M. C., Hill, P. A. (2000) Autocrine signals promote osteoblast 
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